Developing a non-invasive treatment for twin-twin transfusion syndrome using high intensity focused ultrasound in an animal model by Shaw, Caroline Jayne
1 
 
TITLE PAGE 
DEVELOPING A NON-INVASIVE TREATMENT  
FOR TWIN-TWIN TRANSFUSION SYNDROME  
USING HIGH INTENSITY FOCUSED ULTRASOUND  
IN AN ANIMAL MODEL 
 
A thesis submitted for the degree of 
Doctor of Philosophy 
of 
Imperial College London 
by 
Caroline Jayne Shaw 
 
Institute of Reproductive and Developmental Biology 
Imperial College London 
 
Submitted July 2017 
  
2 
 
ABSTRACT 
 
High Intensity Focused Ultrasound (HIFU) is a non-invasive, non-ionising technology which can 
selectively occlude blood vessels.  In Twin-Twin Transfusion Syndrome (TTTS), anastomotic 
placental vessels in a shared placenta allow uneven blood distribution between the twins.  
Despite advances in prenatal and neonatal care, TTTS remains the leading cause of death and 
disability in twins.  Invasive fetoscopic laser can divide anastomoses, with risks of miscarriage, 
placental haemorrhage, extreme prematurity or second trimester rupture of membranes.  
Fetoscopic laser has undergone improvements in technology and therapeutic protocols over 
two decades, but it still does not consistently improve survival or decrease severe neurological 
morbidity in surviving twins.  Hence, it is only used in severe cases, where benefits outweigh 
risks, and over 16-18 weeks gestation, after chorion and amnion fusion.  This represents an 
unmet clinical need, which could be addressed by ultrasound-guided HIFU (USgHIFU).  
Selective occlusion of placental vessels using HIFU has not been described.  Ultrasound 
identification of placental vascular anastomoses in humans is described, but is not in routine 
clinical use.  Therefore, we tested the efficacy and safety of using USgHIFU as a non-invasive 
method of placental vascular occlusion in the pregnant sheep. 
An iterative study design in six animal groups was used. Treatment protocols for ultrasound 
guidance and HIFU delivery were developed in three animal groups.  The efficacy and rates of 
associated direct and indirect iatrogenic harm of each version of the protocol was tested in 
another three animal groups, using invasive and non-invasive measures. 
Overall, transdermal USgHIFU occluded 97% of target placental vessels in the most developed 
treatment protocol.  This persisted for 21 days and showed evidence of permanent vessel 
occlusion by fibrosis obliterans.  This was achieved without significant adverse events, although 
maternal skin (2%), uterine (1%) and fetal skin burns (1%) were observed.  There were no long-
term effects (up to 21 d) of the technique based on assessment of maternal and fetal 
cardiovascular, metabolic, endocrine and obstetric outcomes, or evidence of fetal compromise. 
This study is proof of principle that USgHIFU can be used to occlude placental vessels in the 
pregnant sheep.  There is a low rate of direct iatrogenic harm and no evidence of indirect harm 
associated with the technique.  As such, this supports the concept of future translational studies 
to develop USgHIFU as a treatment for TTTS in humans. 
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GLOSSARY OF TECHNICAL TERMS 
 
Attenuation  In ultrasound physics, (acoustic) attenuation describes the loss of 
energy from the ultrasound wave as it passes through a viscous 
medium, in our situation, overlying tissues.  This is specific to the 
frequency of the ultrasound wave. 
CamDAS  The name of a portable, customised data acquisition system, which 
samples the output of invasive arterial pressure transducers and flow 
probes, to transmit information about heart rate, arterial pressure and 
flow to a visual interface. 
C-STAR A ratio devised for this study.  It relates the 2D ultrasound 
appearance of the cross-sectional area containing the target blood 
vessel to a simplified cross-sectional area that is exposed to the focal 
zones of all HIFU exposures in a HIFU exposure series.  A ratio of 1 
indicates the areas are of equal size.  If the ratio is <1, the area 
around the target vessel is larger than the HIFU treatment area; if the 
ratio is >1, the opposite is true. 
Drive voltage  A nominal setting on our customised HIFU system, which was 
directly adjusted by the operator to deliver more or less ultrasound 
energy to the target vessel.  It is measured in dBm, a unit which 
describes the power ratio (e.g. electrical to acoustic) of the measured 
power to one milliwatt.  
Focal zone  The region in which the intensity (incident energy per unit area) of 
HIFU is high enough to produce tissue damage. Also called the HIFU 
focus. 
Free field intensity  The amount of ultrasound energy (per unit area) which would reach 
the HIFU focus if there were no energy losses along the path of the 
ultrasound beam. 
HIFU exposure series Refers to a sequence of HIFU exposures with the same exposure 
characteristics, placed so that individual lesions are joined into a 
linear track. 
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Hyperecho  An ultrasound finding of an area of tissue in which the echoes are 
stronger than the surrounding, similar, tissue.  In HIFU research, de 
novo development of hyperecho is recognised to denote an area of 
tissue heating. 
In situ intensity  An estimated amount of ultrasound energy (per unit area) which is 
delivered to the HIFU focus.  It is equal to free field intensity minus 
the estimated energy losses due to acoustic attenuation of the tissue 
in the path of the ultrasound beam. 
Lesion  An area of tissue destruction resulting from exposure to HIFU 
energy. 
Targeting error  A discrepancy between the placement of the HIFU focal zone and 
the intended vascular target resulting from incorrect planning of the 
HIFU exposure series (operator error), defined for this study only. 
Technical error  A failure of the HIFU system to deliver the HIFU exposure series as 
planned (system error), defined for this study only. 
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CHAPTER 1: INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The text in sections 1.1 and 1.2 of this chapter is substantially based on a previously published 
paper, Shaw et al. 2014 (1).  
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1.1 Twin to Twin Transfusion Syndrome 
1.1.1 Background 
Twin to Twin Transfusion Syndrome (TTTS) is an important condition in fetal medicine which 
affects between 10-15% of monochorionic diamniotic (MCDA) twins (2, 3), and is the most 
important underlying cause of death and handicap in monochorionic twins (4).  MCDA twins are 
considered high risk pregnancies due to the incidence of this and other complications (3), and 
prenatal surveillance for sonographic evidence of TTTS is more intense than for singleton or 
dichorionic twin pregnancies (5). 
TTTS is a complication only found in pregnancies where fetuses share a placenta, usually 
monochorionic twins or dichorionic triplets.  It results from unequal sharing of blood supply 
between twins due to placental vascular anastomoses, present in 95% monochorionic 
placentae (6, 7) which allow “vascular steal”.  This is a description of unbalanced blood flow 
between the circulations of each fetus (8), leading to a relative over- and under-perfusion of the 
recipient and donor twin respectively.  Placental vascular anastomoses may form between the 
placental arterial vessels of donor twin and recipient twin, the arterial and venous systems, or 
the venous and venous systems (Figure 1.1).    
 
Figure 1.1: Placental vascular anastomoses.   
Schematic representation of potential placental vascular anastomoses in a monochorionic placenta.  AAA: arterio-
arterial anastomoses, AVA: arterio-venous anastomoses, VVA: veno-venous anastomoses. 
Fifty percent of monochorionic placentae contain arterio-arterial anastomoses (AAA); 25% 
contain veno-venous anastomoses (VVA); 5% contain arterio-venous anastomoses (AVA) and 
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5% contain no anastomoses at all.  AAAs and VVAs are superficial and allow bidirectional flow, 
giving the potential to correct the imbalance of the circulations according to the pressure 
differential between the circulations of donor and recipient twins.  AVAs are deeper, with 
exchange occurring at the capillary level within a placental lobule, and only allow flow in a single 
direction, from artery to vein, i.e. from high pressure to low. The diameter of AVAs quoted in 
published literature is between 0.9 – 2.1 mm (9).  Although they can form in either direction 
(donor to recipient and recipient to donor), this unidirectional flow is believed to give rise to the 
unbalanced blood flow distribution between the twins’ circulations found in TTTS (10).  AVAs 
allow deoxygenated blood flow to be shunted from the umbilical arterial flow returning from the 
donor twin to the placental bed, into the umbilical venous flow travelling from the placental bed 
to the recipient twin.  This additional blood volume remains in the recipient twin’s circulation 
unless restored to the donor circulation by the action of AAAs, VVAs or AVAs flowing in an 
opposing direction in the placental bed.  The overall sum of blood flow via these anastomoses 
determines whether the placental circulation is balanced or unbalanced, and the size and 
direction of the vascular steal. 
 
1.1.2 Diagnosis 
As a result of the progressive vascular steal, the donor twin will become under-perfused as its 
circulating volume is reduced.  It will begin by making physiological changes appropriate to its 
volume depleted status, such as activation of the renin-angiotensin system and renal 
conservation of fluid, leading to oliguria and oligohydramnios.  As the circulating volume 
reduces further these changes become pathological with the fetus centralising blood flow, 
ultimately leading to fetal death. 
Conversely the recipient twin will be over-perfused and hypervolaemic, and will begin making 
physiological changes to offload excess circulating volume, releasing atrial natriuretic peptide 
(ANP), becoming polyuric and leading to polyhydramnios.  As the circulating volume increases 
further the fetus will start to show signs of congestive cardiac failure due to the volume overload 
and ultimately become hydropic leading to fetal death. 
Some of the sequence of changes that take place as TTTS progresses can be monitored via 
prenatal ultrasound and was standardised into a classification system by Quintero.  Under this 
system there is grading of disease progression as assessed by ultrasound from mild (stage I-II) 
to severe (stage III-IV) with in utero death of one or both fetuses being stage V (Table 1.1) (11).   
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Table 1.1: Quintero staging of TTTS. 
Ultrasound-based staging of TTTS, derived from Quintero et al. 1999 (11). Key: + denotes that the criteria is met, - 
denotes that the criteria is not met. 
It is difficult to define the natural history of each Quintero stage of TTTS as the ultrasound 
staging system was introduced in response to the need for a uniform classification of disease to 
use with invasive treatments, amniocentesis and fetoscopic laser.  Prior to this, cases were 
typically divided into hydropic (stage IV) and non-hydropic (stage I-III) groups when reporting 
observational data or the outcome of treatments, and the capability for regular ultrasound 
surveillance is a relatively recent event.  However some retrospective analyses have been 
published of TTTS cases with no intervention or with amnio-drainage only (which may prolong 
the pregnancy by reducing uterine stretch, improving survival rates with regard to gestation age 
at delivery but does not alter the underlying disease pathology) which gives an idea of the 
heterogeneity of the disease process (Table 1.2) (12). 
 
 
Stage
Amniotic fluid 
discordance
Absent 
bladder in 
Donor twin
Abnormal fetal 
Doppler 
studies
Fetal hydrops Fetal demise
I + - - - -
II + + - - -
III + + + - -
IV + + + + -
V + + + + +
DVP <2cm 
donor;
A/REDF in 
Umbilical 
artery;
Ascites;
DVP >8cm 
recipient
Reveresed 'a 
wave' in 
ductus 
venosus;
Collection of 
fluid in 2+ 
fetal cavities
Pulsatile 
umbilical 
venous flow.
Details of 
ultrasound 
criteria
One or both 
fetuses
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Table 1.2: Natural history of disease progression and mortality in TTTS.   
The numbers represent the percentage of pregnancies in which TTTS will improve, remain stable or worsen, based 
on TTTS stage at diagnosis.  It also shows the percentage of pregnancies which will end in fetal death before 
delivery, at any gestation (in utero death) or perinatal death (death before delivery at over 24/40 or within 7 days of 
delivery) based on TTTS stage at diagnosis.  Data derived from Dickinson et al. 2004 (12). 
This demonstrates that although more advanced stage of disease at diagnosis gives a higher 
overall risk of perinatal death, delivering an individual prognosis based on stage of disease at 
diagnosis is far from simple.  To this end, many groups have attempted to define features which 
may quantify the risk of progressive TTTS and perinatal death.  AAAs may be protective against 
developing TTTS, although their presence or absence is not conclusive.  VVAs have been 
suggested to contribute to co-twin rates of death and neurological damage by allowing sudden 
changes in venous return to create profound hypotension in the surviving co-twin in the event of 
intrauterine fetal death, usually of the donor twin. 
 
1.1.3 Treatment 
The results of the multicentre Eurofetus study, a randomised control trial comparing amnio-
drainage with fetoscopic laser for treatment of TTTS, published in 2004, established fetoscopic 
laser (after 2 decades of development) as the optimum therapy in treatment of TTTS (13).  This 
started a proliferation of centres providing fetoscopic laser, studies reporting incremented 
technique developments, and affected pregnancies managed by this invasive method.   
Fetoscopic laser seeks to ablate the placental anastomoses, essentially separating the fetal 
circulations, and halting any further vascular steal, though it cannot reverse or redistribute the 
blood flow distribution imbalance that has already occurred.  Amnio-drainage seeks to reduce 
the risk of preterm labour secondary to polyhydramnios and uterine stretch, particularly at pre-
viable or extremely premature gestational ages, but does not alter the underlying disease 
pathology.   The potential disadvantage of fetoscopic laser is that while both are invasive 
techniques, there is a larger calibre instrument introduced into the intrauterine space with 
Stage at 
Diagnosis
Spontaneous 
regression or 
resolution
Stable 
disease
Progressive 
disease
In-utero death
Perinatal 
death
Stage I 27.30% 27.30% 31.80% 18.20% 22.70%
Stage II 53.30% 6.70% 40.00% 13.30% 30.00%
Stage III 21.70% 47.80% 30.40% 26.10% 45.70%
Stage IV 12.50% 62.50% 25.00% 25.00% 56.20%
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fetoscopic laser, for a longer duration, leading to a higher complication rate (14).  Direct 
complications of breaching the intrauterine space include amniotic fluid leakage, placental 
haemorrhage, chorioamnionitis, miscarriage or extreme prematurity, and damage to adjacent 
fetal or maternal structures. 
The Eurofetus trial showed that, especially in severe disease, these higher risks due to 
intrauterine invasion were offset by the more complete treatment of disease in terms of overall 
survival.  Compared to amnio-drainage, fetoscopic laser demonstrated higher survival rates of 
at least one twin to six months of age, and thereafter was recommended as the gold standard of 
care for cases of TTTS stage III-IV.  Only Quintero stage III and IV disease was considered for 
treatment by fetoscopic laser, as in stage I and II disease the overall risk of perinatal death was 
found to be less than the risk of fetal demise from the procedure.   
However, a 2014 Cochrane review found no difference for overall death between pregnancies 
treated with fetoscopic laser versus amnio-drainage: RR 0.87, 95% CI 0.55-1.38.  This meta-
analysis included data from only two trials, Eurofetus and NIHCD (15), 182 pregnancies and 
364 fetuses.  Neither was there any difference in babies alive with major neurological 
abnormality at 6 years treated by amnio-drainage versus fetoscopic laser: RR 0.97, 95% CI 
0.34-2.77.  There was, however a reduction in neurodevelopmental delay in children alive at 6 
years when treated with fetoscopic laser: RR 1.57 95% CI 1.05-2.34.  There was no difference 
between techniques for: rates of death of one or both twins; preterm labour or rupture of 
membranes rates within 48 hours of the procedure; the incidence of intraventricular 
haemorrhage grade III/IV, the need for mechanical ventilation after delivery or blood transfusion 
within 48 hours of delivery (15).  For this reason, fetoscopic laser can still be recommended to 
pregnancies affected by TTTS to reduce developmental delay, with the caveat that it will not 
alter survival or rates of major neurological abnormality. 
Additionally, complications of fetoscopic laser do not result solely from invasion of the 
intrauterine space.  The “deep” nature of AVAs means that they are not readily visible for 
identification via the fetoscope on the surface of the placenta as AAA and VVA are; rather 
unpaired vessels with a difference in blood colouration are seen to perforate the placental 
surface and an anastomosis at the capillary level is assumed.  There is also no real-time 
method of confirming that complete ablation of all anastomoses has occurred at the time of 
surgery. Colour Doppler studies post fetoscopic laser treatment describe between 5-30% 
residual anastomoses, which may result in residual disease in up to 16% of treated cases and is 
associated with lower rate of survival and neurologically intact infants (16).   
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Alternatively, smaller calibre residual anastomoses can result in Twin Anaemia-Polycythaemia 
Syndrome (TAPS).  Iatrogenic TAPS is more common after ablation than spontaneously (13% 
vs. 5%) (2, 17) suggesting that it is within the same disease spectrum as recurrent TTTS.  While 
TAPS has much better outcomes than TTTS it can still result in the need for postnatal 
transfusion and exchange transfusion, elevated bilirubin levels and ischaemic events in the 
polycythaemic twin, entailing an increased perinatal hospital stay for the twins and an additional 
burden on neonatal services.   
Attempts to reduce the level of residual anastomoses have been made by trialling an alternative 
to selective vessel fetoscopic laser (SVFL): SVFL followed by placental bipartition.  In this 
technique the shared area of the placenta is identified and all tissue along that line is ablated, 
with visible vessels occluded first to reduce the risk of haemorrhage, and then the remaining 
tissue bipartition to create a functionally dichorionic placenta and ideally occluded any 
unidentified smaller or deeper vessels (18).  Recurrence rates appear to be lower (around 5%), 
and the incidence of TAPS is also reduced with this technique.  However, in a meta-analysis of 
531 cases using the new technique, there is no improvement in survival, no significant 
prolongation of gestation, no reduction in severe morbidity or difference in long-term 
neurodevelopmental injury compared to SVFL alone (19). 
 
  
Chapter 1: Introduction 
37 
 
1.2 High Intensity Focused Ultrasound 
1.2.1 Background 
High intensity focused ultrasound (HIFU) is a clinical therapeutic technique which uses high 
frequency sound waves (usually, 1-10 MHz), generated by a piezoelectric ceramic transducer 
outside the body.  HIFU is a non-invasive alternative to surgery, in that it has the potential to 
destroy targeted tissues, without damaging adjacent tissue, as invasive surgical techniques do. 
The ultrasonic energy generated can be tightly focused and accurately placed to produce 
localised tissue destruction (referred to as lesions) at depth.  HIFU uses a focused source to 
converge the ultrasonic energy into a tissue volume distant from the transducer.  This region is 
called the focal zone or focus, and is the only position in which the ultrasound intensity (incident 
energy per unit area) should be high enough to produce changes in the structure of the tissue, 
and create a lesion.  The tissue in the path along which the ultrasound waves pass is ideally 
exposed to energies too low to produce damage.  The lesions formed are ellipsoid in shape, 
reflecting the shape of the focal region of the beam, and are typically 1-2mm in diameter 
(orthogonal to the direction of sound travel) and 8-15mm in length (parallel to the direction of 
sound travel). To destroy larger, clinically relevant, volumes of tissue, this small focal zone is 
moved systematically throughout the target region by electronic or mechanical means to form a 
line or a grid of lesions (Figure 1.2).  The use of diagnostic imaging allows non-invasive 
identification of the target and monitoring of response. 
 
Figure 1.2: Non-invasive set-up of HIFU transducer to produce tissue lesions at depth. 
Reproduced from Shaw et al. 2014 (1) 
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HIFU energy can pass through different tissue layers en route to the target.  Providing regions 
of bone and air are avoided relatively little energy should be lost at each tissue interface. The 
main energy loss is due to attenuation (absorption and scatter) within the tissue layers. The 
amount of ultrasound energy generated by the transducer is known as the free field intensity, 
which can be measured, whereas the amount which reaches the target tissue is known as the in 
situ intensity, which is by necessity an estimated value based on assessment of energy losses, 
calculated from the free field intensity and energy losses to acoustic attenuation.  Alternative 
techniques such as radio frequency ablation (RFA), laser photocoagulation and microwave 
energy have poor tissue penetration so use invasive methods to destroy deep tissue, but deliver 
a more predictable amount of energy to the tissue when properly calibrated and controlled.   
HIFU exposure can be continuous (primarily used to induce heating) or pulsed, which may 
better exploit acoustic cavitation and reduce the need for tissue heating to produce tissue 
damage (20).   
Ultrasound can be converted to thermal energy mainly via a variety of molecular relaxation 
processes which occur following ultrasound excitation. When temperatures in excess of 56oC 
are maintained for ≥ 2 s (21, 22) this causes coagulative necrosis due to protein denaturation, 
cellular destruction (22) and tissue stiffening (23).  Coagulative necrosis is a form of unplanned 
cell death in response to a cellular insult, where tissue architecture is characteristically 
preserved, cells retain their outline while their proteins coagulate, and metabolic activity ceases 
(24).  In soft tissue, HIFU lesions are characterised histologically by a necrotic centre and a rim 
of functionally impaired cells (lacking glycogen stores) which fade to ghost outlines leaving a 
sharp rim between affected and unaffected tissues 48 hours after exposure, with the lesion 
encapsulated by granulation tissue (25).  Detachment of cells from their basement membrane 
and each other is also observed (26) with evidence of a strong acute inflammatory response 
and remodelling in a chronic inflammatory response, involving cellular regeneration, 
proliferation, migration and removal of debris lasting up to three months (20).   
Applying pulses of HIFU can cause rapid changes in tissue pressure, described as the peak 
rarefaction pressure amplitude (PRPA). There is a threshold PRPA for each tissue at which 
acoustic cavitation occurs, where gas or liquid filled cavities form, usually at points of 
“weakness”, such as interfaces between different tissue layers or fluid filled structures (27).  
These bubbles oscillate and exert shear stresses on the surrounding tissue or may expand 
rapidly and collapse, destroying surrounding tissue structure, in a technique known as 
histotripsy. This mechanism does not rely on tissue heating to work (20).  Histology of tissue 
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subjected to histotripsy reveals emulsification, and regions filled with acellular debris produced 
by mechanical fractionation of the tissue (28).  
As of 2017, HIFU is an approved method of treatment for uterine fibroids, breast, renal, liver, 
pancreatic, prostate and thyroid cancers, ablation of brain tissue in essential tremor and 
Parkinson’s disease, and treatment of pain from bony metastases (29).  However, these are all 
applications of HIFU which involve targeted soft tissue ablation, rather than specific occlusion of 
blood vessels.  Purely vascular applications – such as treatment of peripheral arterial disease or 
arterio-venous malformations in the brain – remain in the conceptual or preclinical stages of 
development. 
 
1.2.2 Vascular Specific HIFU 
The first specific attempts to produce HIFU mediated vascular occlusion were in 1972 and relied 
upon visual targeting of surface vessels, the auricular artery in rabbits (30).  Since then, HIFU 
has been demonstrated produce a number of vascular changes when applied to blood vessels, 
suggesting more than one possible mechanisms by which blood flow can be occluded.  Each 
research group also used different strategies to attempt to occlude vessels, so the ideal method 
of producing selective vascular occlusion is far from apparent from this review of the body of 
published work.  There is a lack of consistent reporting of methodology and outcomes, and as 
such there is no consensus which can be reached as to the most successful exposure 
characteristics for vascular occlusion. 
The results of this systematic review of are provided in Table 1.3 and Table 1.4 (1). In summary, 
the effect of HIFU energy on blood vessels can be to: 
(i) produce occlusion or arteries and veins by obliteration of the vascular lumen (31-43); 
(ii) occlude arteries or veins by generation of persistent thrombus within the lumen 
leading to fibrosis obliterans (30, 34, 36, 39, 42); 
(iii) produce vascular spasm and reduction in blood flow (34, 37, 38, 40, 41, 44-46). 
Exposure of blood vessels can also lead to: 
(i) arterial rupture (31, 32, 37, 38, 47); 
(ii) no change in blood flow seen or impairment in vascular function reported (48-50).    
HIFU has also been used to demonstrate haemostasis of experimentally punctured arteries and 
veins, by sealing the defect or producing occlusive thrombus (51-56).   
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The majority of studies use continuous HIFU designed to induce vessel heating (Table 1.3), 
although a smaller number used pulsed HIFU to maximise generation of thrombus without 
heating (Table 1.4).  There is a wide range of in situ intensities described, 0.025 – 8.8 kW.cm-2, 
with the majority clustering around 2.0-4.5 kW.cm-2.  The duration of exposure varies widely, 
0.5-720 s, with most of studies using 5 – 20 s. 
There is a single case report of successful treatment in human pregnancy: a TRAP sequence 
where HIFU was applied to the insertion of the umbilical cord of the acardiac fetus (43). This 
study did not demonstrate whether selective vascular occlusion or localised soft tissue 
destruction at the cord insertion point (the established clinical method used by RFA) was 
performed in the acardiac twin.  It is therefore unclear if a vascular-specific or a soft-tissue 
specific exposure protocol resulted in division of the fetal circulations, although the ultrasound 
images previously published (57) suggest the latter.  This study used an unknown number of 10 
s HIFU exposures, in an unknown pattern, at 4.6 kW.cm-2 in situ intensity to achieve its effect, 
which persisted for 20 weeks until delivery of the surviving twin. 
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Table 1.3:  Systematic review HIFU vascular occlusion (continuous HIFU).  
Summary of the continuous HIFU exposure characteristics used in the 23 studies included in the systematic review, and their associated vascular outcomes.  
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Fallon (1972) Rabbit Auricular Artery 12 28 0.7 - 1.0 Yes Visual 25-1500 1 125 1 0.5-720
38.5-
66.7
NR X - o o - - o 72 hrs
Dog Unspec. vein 19 - NR Yes A-mode NR 3 NR multiple NR NR NR - - o - - - o
Immediate 
sacrifice
Man Varicose leg veins 11 - NR Yes Visual NR 3 NR multiple NR NR NR - - o - - - o
Immediate 
sacrifice
Yang (1992) Rabbit Aorta, IVC 24 - NR
Surgical 
exposure
Visual 1500 4 NR 20 5
68.8-
80.1
NR X - - - X X o 6 months
Delon-Martin (1995) Rat Femoral vein 6 - 1.5
Surgical 
exposure
A-mode 167 7.31 20 4-7 3 <45 X o - o o - - - 28 days
Hynyen (1996) Rabbit Femoral art., vein 19 26 1.0 - 1.3 Yes MRI 4400-8800 1.49 NR 5-8 1 NR o o - - - o o - 14 days
Hynyen (1996b) Rabbit Renal artery 9 - 0.6 Yes MRI 2800, 6500 1.5 NR 12-16 10 64 o o - - - o o - 7 days
Vaezy (1997) Rabbit
Liver 
microvasculature*
8 27 <0.5 No Visual 3000 3.3 40 1 1-2 59-86 o o o X o - - o
Immediate 
sacrifice
Vaezy (1998) Pig Muscular Arteries* 5 41 3-10 No Visual 3100 3.5 55 1 10-20 NR NR X o o o o - o
Immediate 
sacrifice
Martin (1999) Pig Muscular Arteries* 3 89 3-10 No Doppler 2000 3.5 55 1 5-20 NR NR X o - - - o -
Immediate 
sacrifice
Vaezy (1999) Pig Muscular Arteries 4 76 3-10 No Doppler 3000 3.5 55 1 17-25 NR NR o o o o - - o
Immediate 
sacrifice
Rivens (1999) Rat Femoral art., vein 10 - 0.5-1.5
Surgical 
exposure
Visual 4660 1.7 150 1 2 NR NR o o - - - o -
Immediate 
sacrifice
Denbow (2000) Rat Femoral art., vein 16 - 0.5-1.5
Surgical 
exposure
Visual 1690-4660 1.7 150 1 5 NR NR o - - - - o -
Immediate 
sacrifice
800 1 1 5-10 46 NR X - - - - - -
Immediate 
sacrifice
10,000 3 1 5-10 98 NR o - - - - - o 12 days
Hwang (2003) Rabbit Auricular Vein* 15 - 1.0 Yes Visual 750 3.9 35 1-3 3 NR NR o o o o - - o 28 days
Ishikawa (2003) Rat Femoral artery 23 - 0.5 Yes Doppler 530-2750 3.3 NR 1 5 98 NR o - o o o - o 3 days
Nizard (2004) Sheep Uterine Artery 7 - NR No Doppler NR 1.05 100 6-7 8-10 NR • X - - o o - o NR
Zderic (2006) Rabbit Femoral Artery 25 - 1.5 No Visual 3000 9.6 25 Multiple 5-10 NR NR o o o o - - o 60 days
Ichizuka (2007) Rabbit Umbilical artery 11 - 0.4-0.8 Yes Doppler 1400-5500 2.26 70 3-15 5 NR NR o - o o - X o
Immediate 
sacrifice
Ichihara (2007) Rabbit Renal artery 8 - 0.5 Yes Doppler 4000 2.2 60 2-10 5 NR NR o - - - o o o 7 days
Ichizuka (2012) Human (in utero) Umbilical artery 1 - NR Yes Doppler 2300 1.71 NR NR 10 NR NR X - - - - - - 3 weeks
Okai (2013) Human (in utero) Umbilical artery 1 - NR Yes Doppler 4600 1.71 60 multiple 10 NR NR o - - - - - - 20 weeks
van Breugel (2015) Human Tibial AVM 1 5 NR Yes MRI NR NR NR 5 8.3 - 19.5 62 - 81 NR o - - - - - - 13 months
Ichizuka (2016) Rabbit Renal artery, vein 3 NR NR Yes Doppler 1940 1.1 60 NR 10 NR NR o - - - - - -
Immediate 
sacrifice
18 36
Key:   o: Vascular effect observed      X: Vascular effect not observed     -:Vascular effect not reported/investigated   *: lacerated vessels   NR: not reported
0.5 NR NR NR
Schultz-Haakh (1989)
Fujiwara (2002) Rat Femoral artery 
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Table 1.4:  Systematic review HIFU vascular occlusion (pulsed HIFU).  
Summary of the pulsed HIFU exposure characteristics used in the 5 studies included in the systematic review, and their associated vascular outcomes. 
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Mahoney 
(2000)
Rabbit
Auricular 
artery, vein
22 - 1.0 Yes Visual NR 4-37
0.68-
2.02
5-20 10 10-180 NR o o - - - o o o 3 hours -
Hwang 
(2006)
Rabbit
Auricular 
Vein
16 - 1.0 Yes Visual NR 1-9 1.17 1 NR 1-120 NR o X - o o - - o I hour UCA
Yang 
(2009)
Rat
Aorta, 
Femoral 
Artery
9 - 1 No Doppler 578-1734 NR 1 1 50 6 29-30 o X X X X o X X
Immediate 
Sacrifice
UCA
Hwang 
(2010)
Rabbit
Auricular 
Vein
21 - 1 Yes Visual 23 9 1.17 NR NR 60 NR o o - o o - X X 14 days
UCA + 
Fibrinogen
Kim (2017) Worm
Ventral 
blood 
vessel
NR 6-20 NR Yes Visual NR NR
1.1-
3.3
1-10 NR 1-600 NR - o - - - - o -
Immediate 
Sacrifice
-
Key:   o: Vascular effect observed      X: Vascular effect not observed     -:Vascular effect not reported/investigated      NR: not reported
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The heterogeneity of these results demonstrates that describing the properties of delivered 
energy alone is not predictive of the outcome in blood vessels. In some studies, vascular 
occlusion has been successful at lower energy levels where only non-occlusive endothelial or 
vascular wall damage has been reported and at higher levels where vascular rupture would be 
expected.  This may be explained by blood vessels forming part of a biological system, with 
multiple anatomical, physiological, mechanical, thrombotic and inflammatory responses to the 
absorption of ultrasound energy. 
Neither coagulative necrosis nor tissue emulsification alone are likely to be effective 
mechanisms of vascular occlusion. HIFU can destroy soft tissue microvasculature by 
coagulative necrosis even when not deliberately targeted at the vessels, occluding vessels up to 
a diameter of 0.5 mm (58), working with limited efficacy on lacerated vessels of 0.5-2.5 mm and 
being ineffective on vessels >2.5 mm (54).  However, both damaged (59) and undamaged (26) 
un-occluded blood vessels are often seen surrounding soft tissue HIFU lesions, resulting in 
circumferential haemorrhage (60), with greater haemorrhage in more vascular regions (61).  
Changes suggestive of coagulative necrosis are also seen in vessel walls exposed to HIFU 
without loss of structure or function (48, 54).  In emulsified tissue there are also margins which 
demonstrate circumferential haemorrhage around the lesioned area (62).  Pulsed HIFU has 
been shown to produce oedema and disruption of the extracellular matrix and collagen fibrils of 
vessels, without occlusion (48, 54, 63), acoustic cavitation in tissue is associated with 
unintended vascular rupture (27, 64) and may therefore be used to increase vascular 
permeability. 
1.2.3 Proposed mechanisms of HIFU mediated vascular occlusion 
1.2.3.1 Heating and tissue fusion 
Arteries and veins have a common basic structure comprising the tunica intima, an inner layer 
of endothelium on a basement membrane.   The tunica media is an intermediate layer of 
smooth muscle, thicker in arteries than veins and absent in capillaries. The tunica adventitia is 
an external supportive layer and may be continuous with surrounding collagenous connective 
tissue, absent in capillaries.  Arteries also contain elastin layers (65).  Capillaries, arterioles and 
venules (d ≤0.3 mm) comprise tissue microvasculature.   Theoretical modelling of vascular 
thermal damage suggests that the first vessel changes are caused by thermal denaturation and 
shrinkage of collagen fibres while vessel integrity is maintained by elastic laminae, if present, 
and smooth muscle (66). 
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Tissue fusion is a common method of therapeutic vascular occlusion.  The vessel is 
mechanically compressed and occluded, while energy is converted to heat at the point of 
occlusion, which seals the vessel closed by tissue fusion.  Tissue fusion requires partial 
denaturation of collagen (and elastin if present) such that the fractured structure can reform 
bonds outside the laminar structure (bridging), effectively fusing the many layers of the vessel 
wall together.  Arteries and veins become more difficult to occlude by tissue fusion as their 
diameter, lumenal blood flow or pulse pressure increases.  Collagen is a prominent feature of 
the tunica media and adventitia.  Heating collagen to above its denaturation threshold of 62-
67oC (67) unravels its rope-like structure.  Collagen undergoes isovolumetric shrinkage of up to 
60% of its length when heated above this threshold, the majority of which occurs within 1 
second (68).  Such vessel shrinkage has been demonstrated ex vivo where the luminal cross-
sectional area of a non-perfused vessel was reduced by up to 96% (69, 70), although this effect 
is much less pronounced in perfused vessels in vivo (45).  Heating of collagen beyond this 
threshold leads to hyalinisation and fracturing of its structure, which contributes to tissue 
stiffness, and is a possible explanation for why vessels subjected to multiple HIFU exposures 
stiffen and become prone to rupture (52).  During the initial phase of heating (<1 s) collagen is 
able to form bridging bonds to other partially denatured collagen fibres and fuse tissue (71).  
However, the free ends of collagen must be physically adjacent to form bridging bonds, usually 
requiring a form of external compression. Capillaries, arterioles and venules have sufficiently 
narrow lumen that a combination of collagen shrinkage and cellular dehydration will result in 
vessel collapse and coagulation with minimal attendant cell damage or haemorrhage (72), the 
likely mechanism of HIFU-mediated microvascular destruction.   
Vascular occlusion does not invariably result from heating a vessel.  Heating to temperatures 
above 100oC with laser or diathermy, where the water in cells vaporises and ruptures cellular 
membranes, produces a weak coagulum of denatured cells, collagen debris and carbonised 
tissue, unable to withstand physiological blood pressure (73), and can cause vascular rupture 
due to vessel wall necrosis and elastin destruction (74).  A similar tissue vaporisation is seen in 
HIFU tissue emulsification, although tissue carbonisation is less likely to occur as desiccated 
tissue cannot propagate ultrasound, and further heating does not occur beyond this point.  
Successful vascular occlusion by collagen fusion occurs in temperature range 73-87oC (75), 
while temperatures below 54oC caused no structural changes in collagen (75).   
The electrothermal bipolar vessel sealing system is approved for clinical occlusion of arteries 
(diameter ≤6 mm) and veins (diameter ≤12 mm) (76).  It uses mechanical compression 
combined with electrical heating to cause collagen bridging between vessel walls (77).  The 
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resultant occlusion has a burst pressure well in excess of physiological pressures (78).   The 
system is computer controlled, monitoring electrical impedance to allow careful control of the 
energy supplied and prevent tissue under or overheating (77). 
While there are no studies on HIFU-mediated vascular occlusion that investigate the presence 
of tissue fusion, several studies indirectly suggest that it occurs. Disruption of vascular and 
perivascular collagen has been observed with vascular occlusion using histology and electron 
microscopy (33-35).  The collagen changes can extend beyond the tunica media to the tunica 
adventitia and adjacent connective tissue, and shrinkage in these outer layers can result in 
lumenal constriction and occlusion (53, 55).  In one study, vascular occlusion was an 
unintended side effect of HIFU, and fusion of the vessel via collagen was described, along with 
disruption of the elastic lamina (55).  Elastin fragmentation has been demonstrated in occluded 
vessels using van Gieson staining, changes which were not seen in non-occluded vessels (34).   
Other studies have investigated the effects of HIFU specifically on the vascular collagen, using  
Masson’s trichrome stain (79). Although occlusion was not achieved, collagen in the vessel 
walls was fragmented and took on a corkscrew appearance, creating spaces within the tunica 
media which corresponded to the vacuolisation seen in the smooth muscle when haematoxylin 
and eosin (H&E) staining was also performed.  Similarly, collagen fibre swelling and vessel wall 
fracture in response to non-occlusive HIFU exposure (80), and the collapse of collagen in 
damaged microvasculature has been reported (59). 
Successful HIFU-mediated vascular occlusion occurs within the temperature ranges discussed 
above. Occlusion has been reported in the range of 64oC – 98oC (33, 34, 37, 54), with non-
occlusive vascular damage occurring 43oC – 69oC (30, 33, 48) and no damage to the tunica 
media or adventitia at <43oC (30, 36, 44).  This agrees with theoretical modelling of temperature 
change in vessels that shows that collagen shrinkage would predominate in vessels before 
tissue necrosis at the temperatures typically achieved by HIFU (66, 71).  The duration these 
temperatures were maintained varies between studies, affecting the overall amount of thermal 
energy supplied to the tissue, which may explain why the temperature ranges are wide and 
overlapping.   
 
1.2.3.2 Thrombogenesis and endothelial damage 
Thrombogenesis may be an appropriate haemostatic response to vascular injury, or a non-
haemostatic disease process.  Virchow’s triad suggests three predisposing factors which may 
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result in non-haemostatic thrombus formation in vivo: endothelial damage, stasis of blood flow 
or hypercoagulability of blood (24).  With reference to HIFU-mediated vascular occlusion, all 
three mechanisms appear to be contributory to thrombus formation within vessels.  The 
potential effect of ultrasound exposure and heating on blood constituents must also be 
considered. 
Endothelial damage is an established pathophysiological mechanism by which vascular 
occlusion occurs.  It leads to occlusive thrombus generation in the vessel lumen and permanent 
stenosis and fibrosis of the vessel in a chronic inflammatory process.  This can be achieved by 
intravascular injection of sclerosing agents, mechanical damage to the tunica intima or can be 
iatrogenic.   Endothelial damage results in exposure of subendothelial collagen, which is an 
activator of the coagulation cascade.  Primary haemostasis is a sequence of activation, 
aggregation then adherence of platelets to areas of damaged endothelium.  This leads to 
secondary haemostasis with deposition of fibrin around the adhered platelets and organisation 
into stable thrombus.  Widening of gaps between endothelial cells occurs allowing extravasation 
of plasma proteins and acute inflammatory response cells and the collection of subendothelial 
oedema.  With more extreme damage the endothelial cells die and cease their synthetic 
function, leading to a failure of vascular relaxation signalling, which may contribute to vascular 
spasm in addition to thrombogenesis.   
Endothelial damage is often observed with vascular occlusion (Table 1.3, Table 1.4), as would 
be expected given that the endothelium is damaged at the lowest of reported exposures.  It is 
usually accompanied by thrombosis, which can produce an occlusive seal even where 
incomplete tissue fusion has occurred (73).  Transmural vascular damage, including endothelial 
damage and thrombosis has been demonstrated in studies using both scanning electron 
microscopy (39) and histology by phosphotungstic acid haematoxylin (PTAH) staining (34). A 
sequence of changes leading to permanent obstruction has been described in rabbit veins, with 
transmural thermal injury occurring at day 0, followed by fibrin thrombus deposition, endothelial 
cell detachment and acute inflammatory response at day 2.  By day 7 there was occlusive 
organised thrombus and chronic inflammatory response (vacuolar degeneration) that persisted 
until day 28, by which time the vessel had been replaced by fibrous scar tissue without residual 
inflammatory reaction (39).  However, the question of whether HIFU can produce stable 
thrombus and vascular occlusion by endothelial damage alone remains unanswered. 
Isolated endothelial damage has been produced in vivo by HIFU exposure without damage to 
the tunica media, adventitia or surrounding tissue (36, 79, 81) although this has not resulted in 
permanent vascular occlusion in the absence of acoustic cavitation or artificially elevated levels 
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of fibrinogen, which makes the blood hypercoagulable and promotes formation of stable 
thrombus.  It appears that HIFU exposures which do not produce inertial acoustic cavitation can 
damage the endothelium, but do not sufficiently expose subendothelial collagen to produce a 
clinically significant primary haemostatic response in vivo.  This is supported by in vitro studies 
which show that though platelet aggregation occurs with HIFU exposure, adherence requires 
collagen substrate (82). Where inertial cavitation is promoted by ultrasound contrast agent, this 
results in a higher proportion of the endothelial surface area being damaged than at the same 
energy level without these microbubbles,  and in the generation of thrombus (81).  However, 
even with increased endothelial damage,  elevated circulating levels of fibrinogen were required 
to produce occlusive thrombus (41).   
Blood hypercoagulability has been described as the primary cause of “acoustic haemostasis” 
and has also been suggested as a method of thrombogenesis (82, 83).  This describes the 
expression of adhesion molecules on the surface of platelets (activation) in response to HIFU 
exposure and clumping (aggregation) in the absence of triggers from endothelial damage, 
occurring up to 50 s after initial HIFU exposure. It is known that platelets can be activated in the 
absence of tissue damage by shear stresses on their surface (84), and in the studies by 
Poliachik, aggregation occurred in response to acoustic cavitation. This is thought to be due to 
microstreaming causing shear stresses on the surface of the platelets which are sufficient to 
cause activation and aggregation but insufficient to cause disruption of the membrane (85).  
However, adherence has not been observed without an artificial collagenous substrate or 
endothelial damage, meaning the resultant thrombus would be non-adherent in vivo.  Given the 
nature of the continuous flow of the circulatory system, such aggregated platelets are more 
likely to result in distant emboli than occlusive thrombus. 
Heating platelets has not been directly studied with reference to HIFU.  It is known that platelets 
are optimally activated at body temperature, 36-38oC, and are functionally impaired at 
temperatures >45oC, showing an inability to activate or aggregate (86).  Hence it is unlikely that 
platelets heated by HIFU have any role in vascular occlusion, other than as cellular debris in 
organised thrombus.  Similarly, red blood cells haemolyse at >45oC (87). 
Slowing of blood flow has been observed to contribute to HIFU-mediated vascular occlusion as 
unintended occlusion occurred more commonly at points of vessel compression  in one study 
where the aim was to seal lacerated vessels (55).   Stasis of red blood cells is a known effect of 
low intensity unfocused ultrasound (intensities ≤12 W.cm-2), with separation of blood into bands 
of cellular aggregates and plasma due to the ultrasound standing waves (88), with normal 
circulation restored after exposure (89).  To form a standing wave, strong reflection of the plane 
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of the wave is required, which is unlikely to occur in vivo.  To date this effect has not been 
observed in vessels exposed to HIFU.    This remains an area for further investigation in HIFU. 
This evidence suggests that endothelial damage and physiological primary haemostasis are the 
key features in thrombus generation resulting from HIFU exposure of blood vessels.  However, 
there is minimal evidence that this mechanism alone can produce permanent vascular 
occlusion.  It is more likely that thrombosis has contributory role in maintaining and organising 
HIFU mediated vascular occlusion.   
 
1.2.3.3 Blood flow 
Vascular spasm is a recognised response of vessels to injury.  The smooth muscle of the vessel 
contracts, as a physiological method of reducing blood flow, improving the success of primary 
haemostasis and ultimately reducing blood loss (90).    It is seen in vessels exposed to HIFU, 
both in the presence and absence of vascular damage, and can be monitored non-invasively by 
Colour Doppler measurements of peak systolic velocity (PSV). Induction of vascular spasm by 
HIFU to produce temporary cessation of blood flow has been shown (37) although the 
intensities used were above the threshold for acoustic cavitation causing vascular rupture.  
Regardless, this represents a means by which lumenal narrowing can occur. 
Vascular spasm has been seen in vivo at HIFU intensities which produce transmural vascular 
damage (37, 38, 40, 46) but also in exposures which do not produce vascular damage (34, 70) 
and is not reliant on the occurrence of tissue heating (44).  Although the effect is described as 
transient, it persists for sufficient time post HIFU exposure to allow repeat PSV measurements 
taken by Doppler ultrasonography even in absence of evidence of vascular damage on 
histology (44). 
Vascular spasm is likely augmented by the loss of vascular relaxation in response to endothelial 
damage and cessation of endothelial cell synthetic function.  In a series of ex vivo experiments 
in canine coronary arteries, vascular relaxation was lost as a result of endothelial damage and 
disruption of the nitric oxide signalling pathways, but mechanisms of relaxation remain intact in 
the vascular smooth muscle and can be activated by the administration of exogenous  nitric 
oxide donors, isolating the cause as endothelial damage (91).    
The radiation force of high intensity sound waves can create localised streaming of liquids away 
from the focal point (92), even overcoming the physiological pressure gradient normally 
controlling blood flow in vessels.  This has been observed in practice, where reversal of the 
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arterial jet and pulsatile flow was observed in lacerated femoral, axillary and carotid arteries in 
pigs independent of mechanical compression exerted by the transducer being pressed against 
the vessel, which alone was insufficient to obstruct flow even temporarily (51).  The lumens of 
arteries are maintained patent by the pressure gradient of blood flow through them, with a 
typical mean arterial pressure (MAP) in the range of 85-125 mmHg in humans.  Arteries such as 
the femoral, axillary and carotid artery will lose lumenal patency when the MAP ≤50 mmHg (93).  
This suggests the possibility that acoustic streaming could disrupt the local pressure gradient in 
the artery sufficiently to cause it to collapse.  Veins and the microvasculature are much more 
easily collapsible and so would also be expected to collapse by this mechanism. 
A final hypothesised mechanical effect by which HIFU could occlude blood flow is by temporary 
compression of the vessel due to its acoustic radiation force.  When exposed to HIFU, tissue 
cannot respond fast enough to the changes between positive and negative pressures, meaning 
its motion becomes out of phase with the acoustic wave and energy is transferred to the tissue.  
This transfer of momentum to the tissue, in the direction of the wave propagation, results in 
tissue displacement.  The amount of pressure delivered will vary with both the intensity of the 
HIFU source and the attenuation of the overlying tissue, but will be magnified by the small area 
over which it is delivered.     
Although much speculated upon, acoustic radiation force has not been observed to collapse 
blood vessels in vivo, however soft tissue deformation and displacement of 1 – 3 mm has been 
observed in vivo (94).  Given the recognised difficulties in making non-invasive in situ pressure 
measurements (70), it is not unreasonable that in vivo effects of acoustic radiation force have 
not been fully demonstrated.  Synchronised systems to enable use of diagnostic Doppler 
ultrasound during HIFU exposure have been proposed (95, 96), but these would only 
demonstrate “no flow” in a vessel, not a definitive cause, and B-mode ultrasound imaging would 
likely lack the spatial resolution to determine reliable changes in diameter of vessels.  In an 
experimental system to study isolated blood vessels in vitro, acoustic radiation force was 
sufficient to displace vessels out of the field of view of the microscope intended to monitor 
changes in vessel diameter (70).   
Greater deformation and displacement of the proximal wall of the blood vessel compared to the 
distal wall would probably be expected, promoting collapse, as the blood within the vessel is 
much less stiff than surrounding soft tissues.  Even without this difference, unidirectional 
pressure can occlude arterial blood flow at normal pulse pressures (e.g. pressing on a pulse 
point) and can be likened to the effect of momentum in the direction of HIFU wave propagation.  
Blood vessels are also maintained patent by the pulse pressure of blood flow, as previously 
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discussed, and if this pressure has been reduced by acoustic streaming as observed 
experimentally (51) then lower pressures would be needed to produce such collapse or 
deformation.  This is an area which would benefit from further experimental evaluation as 
whether compression and deformation of blood vessels by acoustic radiation force occurs is of 
relevance to the design of HIFU systems. 
 
1.2.3.4 Inflammation and tissue repair 
There has been minimal work specifically on the contribution of inflammatory responses to 
vascular occlusion.  The harmonic scalpel, an invasive system for producing vascular occlusion 
which uses ultrasound to create vibrational forces in the tissue, creates a more pronounced 
acute inflammatory response than electro-cautery, despite resulting in a smaller area of injured 
tissue (77).  HIFU produces extensive oedema, disruption to tissue, inflammatory cell infiltration 
and activation of the cytokine cascade.  Inertial cavitation induced damage produces a 
comparable activation of the acute inflammatory response, though this response does not 
convert into a chronic inflammatory response in the absence of tissue damage (20).  
Extracellular oedema is known to reduce blood flow, especially in smaller vessels, and 
perivascular oedema resulting from HIFU exposure has been cited as contributing to lumenal 
constriction (69).   
The role of the inflammatory response in controlling and organising the physiological response 
to vascular damage cannot be discounted. Collateral circulation was seen to arise quickly 
following vascular occlusion (31), so while a distributing artery may be blocked the area is not 
automatically devascularised. Ultimately, the nature of the chronic inflammatory response will 
determine whether the vessel becomes patent again or remains permanently occluded and 
fibrosed (36, 39). 
 
1.2.3.5 Strategies to produce HIFU mediated vascular occlusion 
Consideration of the theoretical and experimental evidence of the responses of vessels 
exposed to HIFU demonstrates that there are many potential mechanisms through which the 
physical properties of HIFU may interact with a living system that contribute to vascular 
occlusion.  Vascular occlusion cannot be considered simply as a side effect of vessel cellular 
destruction, and protocols for HIFU-mediated vascular occlusion should be designed to 
maximise this plethora of effects (Figure 1.3). 
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Figure 1.3: A suggested multi-stage integrated mechanism for HIFU-mediated vascular occlusion. 
The schema presents the suggested integrated mechanism for HIFU vascular occlusion as a progression through 
the tissue changes produced by time and temperature changes (1) 
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There are various ways in which the effects described above could be combined but as time 
and temperature appears to be important factors in distinguishing acute and more delayed 
vascular occlusion, a multi-stage process can be envisioned taking place along a typical 
heating-time curve of HIFU. 
In the initial stage, we consider the effects taking place before temperatures reach the 64oC – 
98oC range where tissue fusion occurs, which for HIFU could mean from <1 second up to 
approximately 20 seconds.   These effects are temporary, reversible or repairable, and alone 
have not been shown to produce permanent vascular occlusion.  This stage relies on lumenal 
narrowing achieved through combination of the mechanical effects of ultrasound (tissue 
displacement and acoustic streaming), with tissue response such as vascular spasm, cell 
shrinkage, endothelial damage, and accumulation of subendothelial oedema. This stage does 
not necessarily represent lumenal collapse but features processes through which vessel wall 
apposition could be produced. 
 
In the next stage, temperatures will reach a range in which tissue fusion can occur, and the 
energy deposition will be sufficient to produce irreversible damage, with denaturation and 
shrinkage of collagen and fracturing of elastic laminae.  There is also the persistent effect of 
vascular spasm, obstructed blood flow and the increasing endothelial destruction leads to a loss 
of vascular relaxation responses and activates platelets. 
 
The final stage is dominated by tissue response that persists beyond the end of the HIFU 
heating.  The mechanical effects of HIFU are removed and so perivascular oedema is the only 
potential method of weak external compression.  In this stage, the strength of tissue fusion 
and/or thrombotic occlusion is tested by the return of physiological blood pressure.  The vessel 
may be fused in a fully or partially occluded position, or not at all.  Activation of secondary 
haemostatic mechanisms form occlusive, stable thrombus that can withstand the physiological 
flow pressures involved.  Progression from acute to chronic inflammatory responses remodel 
the damaged vessel, which ultimately determines if permanent occlusion of the vessel occurs 
over the following period, up to 28 days. 
 
1.2.4 Bioengineering requirements 
HIFU treatment is comprised of a number of components – targeting, energy delivery and 
monitoring of its effects. Targeting is most usually achieved by either ultrasound or magnetic 
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resonance imaging (MRI).   Therapy ultrasound beams are usually generated from a transducer 
that is focused using either a bowl configuration, a plane transducer/lens combination or a multi-
element array with which focussing is achieved by appropriate application of phase and 
amplitude to each element.  Where ultrasound is used to monitor HIFU ablation of soft tissue, a 
successful treatment is assessed in terms of the appearance of a hyperechoic region, whereas 
with MRI thermometry sequences are used to estimate thermal dose (97).    If the spatial 
precision of HIFU damage is to be harnessed to its fullest extent, it is important to account for 
tissue motion when placing the lesions.  This presents a major challenge to successful targeting 
and treatment delivery and may be achieved, for example, by synchronising the HIFU exposure 
with cardiac or respiratory motion, and specifically for fetal medicine, accounting for movement 
of the fetus and umbilical cord within the amniotic sac. 
In obstetrics, ultrasound image guidance is likely to be the method of choice for reasons of 
safety, clinical and patient familiarity, targeting efficacy and real-time responsiveness to fetal 
movement.  To successfully occlude a selected blood vessel, it needs to be identified clearly for 
targeting, currently best done using Doppler ultrasound techniques.  Vessels of >1 mm diameter 
can be identified in the fetus in clinical practise by Doppler ultrasound (98).    The main 
disadvantage of diagnostic ultrasound is that, unlike MRI, it does not permit the measurement of 
absolute temperature rise during exposure, both due to interference of the therapy beam with 
the diagnostic information, and a lack of consistent sound speed dependence on temperature.  
Should accurate thermal dosimetry become a key factor, then MRI guidance for HIFU would be 
more suitable. 
The choice of appropriate HIFU transducer geometry and exposure frequency depends on the 
clinical application and, more specifically, the depth of vessel to be occluded.  In choosing the 
frequency to be used, a trade-off is necessary between the amount of energy absorbed within 
the target volume (which increases with frequency) and the ability to get sufficient energy to the 
target depth (which decreases with increasing frequency due to attenuation by the overlying 
tissues).  It is also important to recognise that vascular specific HIFU applications typically 
require a higher in situ intensity and a smaller focal zone than for soft tissue applications, which 
would add additional complexity to transducer design.  It  has been shown that a “rule of thumb” 
for determining the optimum frequency is to allow the total attenuation in the overlying tissue to 
be around 10 dB (99). For typical soft tissues with an attenuation of 0.7 dB.cm-1.MHz-1 this 
would imply an optimum frequency of around 2.6 MHz for a target depth of 5 cm and 1.4 MHz 
for 10 cm. It should also be remembered that the focal region is smaller at higher frequencies, if 
all other source geometries remain the same.    The inclusion of a central aperture in the HIFU 
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transducer design allows an US imaging probe to be inserted into the treatment head, thus 
ensuring a fixed geometry between targeting and treatment components, most efficiently with 
coincident acoustic axes.  This also facilitates the monitoring of a treatment immediately after 
cessation of the HIFU exposure.  Therefore, design of a HIFU transducer to meet the specific 
requirements of the vascular application in question is ideal. 
 
1.2.5 Potential complications 
The main specific complication of vessel exposure to HIFU are rupture and haemorrhage.  
Exposure to higher intensities in the experimental range has been associated with rupture of 
vessels, potentially due to acoustic cavitation (31, 32, 37, 47, 100) as has multiple exposures of 
the vessel wall which cause overheating and tissue stiffening by a cumulative effect (38, 45, 
55).  This effectively represents an upper exposure limit above which the application of HIFU 
becomes counterproductive.  Therefore, HIFU appears to differ from several other occlusive 
techniques, particularly laser and electrocautery, which rely on multiple exposures of blood 
vessels to ensure permanent and stable occlusion. It is possible that it would be unsafe to use 
HIFU in this manner, although varying the exposure site in larger vessels may mitigate this 
effect. 
Paradoxically, the non-invasive nature of HIFU also represents a risk of complications.  Invasive 
methods have greater control over where the energy (thermal and mechanical) they supply is 
delivered as they are visually targeted and controlled.  Excessive soft tissue destruction, 
thermal spread to adjacent structures, or heating in front of and behind the focal zone can 
cause pre- and post-focal damage to structures adjacent to the focus, and therefore 
complications.  This is of particular significance where the targets are small, or hard to locate, 
and the margin of error is limited.  Injuries to bowel (37, 61), nerves (31) or adjacent vessels 
(36) have been reported in fetal and vascular HIFU experiments, with or without associated 
vascular occlusion.  Mistargeting is also an issue as not only does it fail to occlude the target 
vessels, but repeat exposure may also be precluded until such time as tissue healing has been 
allowed to occur.  However, accuracy of vascular targeting has been shown to be improved with 
the use of colour flow Doppler ultrasound over even surgical exposure and visual targeting in 
the application of HIFU (52).  
There are also general complications related to HIFU usage.  If an inappropriate acoustic 
window is used, or there are elements in the acoustic window which scatter or reflect, rather 
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than transmitting, the ultrasonic energy, heating to unpredictable locations may occur, causing 
burns, typically on the skin because this has a higher absorption coefficient compared to most 
other soft tissues, although any tissue in the path of the ultrasound energy may be affected.  
The abdominal skin is particularly vulnerable as thermal energy has a tendency to accumulate 
in the subcutaneous tissue due to its greater ability to absorb heat (101) that surrounding tissue, 
its insulator properties (101-103) and the relatively poorer blood supply compared to 
surrounding tissue that prevents it from dissipating heat (104, 105).  The air-skin interface is 
also the most likely area at which acoustic reflection can occur. 
While the use of HIFU in pregnancy has only reached the stage on anecdotal evidence, there is 
safety data regarding the use of HIFU to ablate solid tissue structures in the non-pregnant 
uterus.  Such adverse events are classified by according to the Society of Interventional 
Radiology guidelines, in which type A-B events are reported as minor complications, and type 
C-F events are significant complications (106). 
A recent retrospective review of approximately 9,988 patients treated with HIFU for conditions 
such as uterine fibroids, adenomyosis, placenta accreta, abdominal wall endometriosis and 
caesarean scar pregnancy reported an 10.6% rate of adverse events, 2.4% which were 
significant complications (class C-D).  The most common complication was excessive vaginal 
discharge or bleeding (8.9%), followed by abdominal or buttock pain (3.5%); 2/9988 patients 
experience pain lasting more than 2 months secondary to sciatic nerve injury.  The rate of 
abdominal skin burns was 0.3% (26/9988); 4/26 patients with skin burns required surgical 
removal of necrotic tissue as a result of skin burns.  There were 16 cases of urinary retention, 3 
cases of acute renal failure, which required dialysis, but recovered, and 1 case of bowel 
perforation, which required surgery (107).   
These rates of complications reflect the use of a commercially available HIFU therapy system 
and an established treatment protocol: they also rely on patient reporting of adverse events.  
The rates quoted in the above study are lower than reported in smaller scale prospective 
studies, focused on developing treatment protocols, with planned follow-up of patient outcomes.  
Skin burn rates are between 4% (108-110) and 10% (111).  Burns could be any severity from 
skin reddening (111) to full thickness third degree burns (107, 112).  Cooling of the maternal 
skin to around 20oC during HIFU exposures is a method currently under investigation to reduce 
the risk of maternal skin damage (113).  
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Similarly, many of the published studies report a patient with chronic leg pain secondary to 
sciatic nerve injury (107, 109-111, 114), which is now a recognised significant complication of 
applying HIFU in the pelvic region.  
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1.3 Fetal sheep model  
The chronically instrumented fetal sheep model is a well-recognised method of studying non-
stressed, non-anaesthetised fetal physiology, endocrine and metabolic responses in utero.  It 
allows assessment of fetal responses to challenges such acute and chronic hypoxia, reduction 
or occlusion of umbilical and uterine artery blood flows.  As such, there is a broad range of 
reference data available regarding normal ovine fetal physiology, which has contributed to the 
knowledge base available to obstetric medicine (115).  Current methods of fetal sheep 
instrumentation allow surgical insertion of indwelling catheters and flow probes using aseptic 
techniques.  Indwelling catheters in the fetal circulation allow continuous monitoring of fetal 
heart rate and blood pressure as well as intermittent sampling of fetal blood for arterial blood 
gas, acid-base status, metabolic and endocrine measurements.  Indwelling flow probes allow 
continuous monitoring of fetal heart rate, heart rate variability and blood flow in a vessel, which 
combined with blood sampling from that vessel allows calculation of substrate (notably oxygen 
and glucose) delivery to different vascular beds.  These methods of monitoring allow detection 
of recognised parameters of fetal distress, namely changes in fetal heart rate patterns, acid-
base and metabolic status and redistribution of fetal blood flow from peripheral to central 
vascular beds, the so called “brain sparing effect”.  The fetal sheep model can also be used as 
an acute model to capture physiological, endocrine and metabolic responses in utero to 
anaesthesia, surgery or surgical experimentation, but this has the disadvantage that the effect 
of anaesthesia must be considered in the results obtained. Fetal sheep models have also been 
used to test HIFU techniques for ablation of solid tissue and for ablation of maternal uterine 
arteries (46, 60, 61).   
 
1.3.1 Relevance to human pregnancy 
No animal model can ever truly represent human pregnancy, but the pregnant sheep and fetus 
form a good model for human pregnancy, both in terms of suitability for experimentation and 
comparative anatomy and physiology.   
In terms of experimental suitability, unlike other experimental animals, sheep tend to have only 
singleton or twin pregnancies and the birth weight of the lambs are similar to those of human 
babies, although the lamb is comparatively more developed at birth than the human.  The 
gestational length of the ewe is also 145-150 days, around 50% of the human gestational 
period, longer than many other experimental animals, meaning that techniques, timing and 
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duration of experimentation are more easily translated between a research and clinical context, 
and vice versa.   
The sheep also tolerates uterine surgery well.  Unlike humans and primates, the ovine uterine 
musculature is thinner and does not contract as vigorously when incised.  Some local 
contraction does occur, but the lack of generalised contraction results in an easier surgical 
procedure, requiring less manipulation and stimulation of the fetus, less interruption of uterine 
and umbilical blood flows secondary to uterine contraction, and lower rates of post procedure 
miscarriage and placental abruption or separation (116). 
Both factors allow the successful placement and maintenance of flow probes and catheters on 
both the maternal and fetal sides of the feto-placental unit. 
The sheep conforms to the general pattern of mammalian circulation, and fetal sheep have a 
similar cardiovascular system to human fetuses, including present ductus venosus and 
arteriosus and foramen ovale (117).  These three shunts make the human and sheep fetal 
circulations adaptive to intra-uterine challenges by allowing redistribution of blood from the 
peripheral to central circulation (118).  The mean arterial pressure and oxygen saturation at 
defined points in blood vessels, acid-base endocrine and metabolic status in sheep are 
comparable to human values. Both the sympathetic and parasympathetic nervous systems 
mature during the last third of fetal life (119-121), producing characteristic reduction in fetal 
heart rate and increase in mean fetal arterial blood pressure approaching term (122).  
Accordingly, the late gestation fetal sheep has functional chemo- and baroreceptors as well as 
adrenergic and cholinergic receptors to mediate homeostatic and regulatory responses.  This 
allows fetal sheep to make responses to fetal stress by redistribution of blood flow in a 
comparable manner to human pregnancy.  Adult sheep have similar cardiovascular parameters 
to man if allowances are made for smaller weight of the average sheep (123). 
 
1.3.2 Heart rate variability analysis 
The fetal heart rate (FHR) fluctuates under the influence of centrally mediated sympathetic and 
parasympathetic tone, producing variability, which alters with increasing gestational age as 
these systems mature, and between different fetal behaviour states, the prevalence of which 
also changes with gestational age (124).  Diurnal variation in fetal heart rate  variability (FHRV) 
is also seen (125), as well as intrinsic variability (126).  The variability in fetal heart rate can be 
assessed in a number of ways.   
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The most familiar method from human pregnancy is via the cardiotocograph (CTG) or 
computerised cardiotocograph (cCTG, Figure 1.4).  Unlike clinical assessment of FHRV on a 
traditional cardiotocograph (CTG), which has well acknowledged intra-observer variability (127), 
and does not alter perinatal mortality (128), computerised cardiotocography (cCTG) produces 
objective measures of FHRV based on the Dawes-Redman criteria previously published (129).  
One such measure, short term variation (STV), is a statistical summary measure of the variation 
interbeat intervals of 3.75 s epoch of averaged fetal heart rate recordings, excluding 
pronounced accelerations and decelerations.  A persistent reduction of STV to below 3 ms 
within 24 hours of delivery has been shown to be predictive of an increased risk of metabolic 
acidosis and early neonatal death (130).  As such, interpretation of cCTG based on STV is 
recommended for prenatal surveillance of fetuses with suspected fetal growth restriction to 
detect acute fetal distress requiring delivery (131).  Increases in normal values for STV are seen 
with advancing gestational age (132), likely representing a gradual increase in sympathetic 
rather than parasympathetic tone in the pre-term fetus (133, 134), with lower variability in FGR 
fetuses resulting from sympathetic suppression (133, 135-138).   
 
Figure 1.4: Computerised Cardiotocograph (cCTG). 
The image shows a section of a cCTG from a human patient at 36 weeks’ gestation.  The upper part of the image 
shows the fetal heart rate varying between 130 – 180 bpm, in a normal pattern of active sleep.  The STV was 6.8 
ms.  The lower part of the image shows the fetal movements (an active fetus) and the uterine activity (no 
coordinated activity). 
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Overall heart rate variability, as well as the contribution of the sympathetic and parasympathetic 
nervous system to the variability can also be estimated by time domain and frequency spectrum 
analysis of heart rate recordings.  Time domain analyses are statistical summary measures of 
the inter-beat intervals in milliseconds of successive waveforms of the heart rate (the R-R or N-
N interval, Figure 1.5).  The standard deviation of the NN intervals (SDNN) reflects all the cyclic 
components responsible for heart rate variability in the period of recording, and estimates the 
overall variability of the heart rate.  It is affected by length of recording, so comparison of short 
term variability over standardised 5 minute samples is recommended (139).  The root mean 
square of the successive differences (RMSSD) is a further time domain measure, which reflects 
the parasympathetic control of heart rate and is strongly correlated with high-frequency variation 
of the heart rate (139).   
 
Figure 1.5: Poincaré plot of successive R-R intervals. 
The graph shows each R-R interval plotted against the successive R-R interval in a 5 min sample of heart rate in a 
chronically instrumented fetal sheep in the active sleep state (126 d GA).  The clustering of the points gives a 
qualitative indication of the variability of the fetal heart rate. 
Power spectral analysis of the heart rate variability determines the energy in specific frequency 
components of heart rate variability and allows a more precise evaluation of the sympathovagal 
balance than time domain measures (Figure 1.6).  The low frequency component (LF; 0.04-
0.15Hz) reflects predominantly sympathetic control of heart rate variability but a proportion of 
the variation results from parasympathetic activity (126).  The high frequency component (HF; 
0.15 – 0.4 Hz) reflects parasympathetic control of heart rate variability (140).  The physiological 
explanation of the very low frequency component (VLF; 0-0.04Hz) is less well defined, but is 
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thought to relate to thermoregulation, peripheral chemoreceptor activity and fluctuations in the 
renin-angiotensin system (141).  VLF, LF and HF contribute to total power, which is affected by 
the absolute heart rate (142).  Therefore, in longitudinal studies where fetal heart rate changes 
with gestation (132) normalised LF and HF (LF or HF as a proportion of total power) should also 
be presented to detect changes in relative LF and HF power which can otherwise be masked by 
changes in total power (143). 
 
Figure 1.6: Spectrum plot of specific frequency components of heart rate variability. 
The graph shows the total power of the heart rate variability divided into VLF, LF and HF components.  This is the 
same 5 min sample of heart rate in a chronically instrumented fetal sheep in the active sleep state (126 d GA) 
shown in Figure 1.5.  Comparison of the area under the curve in the LF and HF bands indicates the relative activity 
of the sympathetic and parasympathetic nervous systems. 
Spectral analysis of FHR variability requires the FHR to be acquired on a beat-to-beat basis for 
reliable results (144).  Non-invasive Doppler ultrasound monitoring, as used in computerised 
and traditional CTG, cannot measure beat-to-beat variation because FHR is implicitly averaged 
by correlation based techniques that are used to calculate it (129).  Auto regression techniques 
can be used to obtain FHR on a beat-to-beat basis from Doppler ultrasound derived FHR (135) 
(125), however they can only be considered reliable for frequencies less than half the frequency 
at which the averaging takes place (143).  As the sampling frequency of average heart rate 
produced by CTG machines which typically report every 2.5 s is 0.4Hz  (145) this limits analysis 
to VLF and LF domains (i.e. <0.2 Hz).  Fetal MRI has also been used to measure R-R intervals 
in human fetuses (146, 147), however studies of FGR fetuses in the antenatal period are few in 
number, and this technique is not widely accessible.  
Data on normal values and changes with gestation in fetal HRV measured by time domain and 
power spectra are relatively sparse and the relative contributions of the sympathetic and 
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parasympathetic nervous system remain under debate.   While there is broad agreement that 
SDNN, total power, LF and HF power increase with gestational age and fetal maturity, 
alterations in the LF/HF ratio relative to gestational age, fetal activity/sleep state or fetal 
compromise follow an unclear pattern (126, 143, 145-153).   
 
1.3.3 Sheep placentation 
Unique to this project is the requirement for a model of placental vascular anastomoses, ideally 
in a singleton pregnancy.  The ovine placenta is a specific type of chorioallantoic placenta 
classified as a synepitheliochorial placenta, which is unique to ruminant species.  It is organised 
into discrete regions of maternal and fetal tissue called placentomes: the maternal portion is the 
uterine caruncle and the fetal portion which develops is the cotyledon. Uterine caruncles are 
specialised projections of non-glandular areas of the uterine epithelium (154) to which the fetal 
trophectoderm can first attach, then interdigitate and allow binucleated cells (BNCs) derived 
from the fetal trophectoderm to migrate into the uterine epithelium.  The feto-maternal syncytium 
is formed by fusion of fetal trophectoderm binucleated cells (BNCs) with maternal uterine 
epithelial cells, and the fetal BNCs have the ability to deliver hormones and effectors into the 
maternal circulation.  The placentomes are therefore formed of enmeshed maternal and fetal 
villi, where feto-maternal haemotrophic exchange takes place (155), and fetal allantoic vessels 
arise from this area of the placentome to emerge into the amniotic sac.  These vessels are 
small in diameter (1-3 mm), and run between placentomes before joining together into larger 
vessels, which ultimately form the two umbilical arteries and vein and umbilical cord (Figure 
1.7).  In the human placenta, fetal cotyledons are recognised, with discrete villous trees of fetal 
blood flow, despite the externally continuous nature of the placental surface.  The villous tree of 
both placentae is similar in that they contain stem, intermediate and terminal villi of comparable 
structure and size (156).  Vascular anastomoses between allantoic circulations in multiple 
pregnancy in sheep are rare (157).  Hence while the presentation of the human and sheep 
placental initially appear very different they are functionally comparable and their vasculature is 
anatomically similar: the key difference being the exposed vessels which mimic vascular 
anastomoses in monochorionic placentae. 
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Figure 1.7: Diagram of sheep placentation. 
The image shows the relative arrangement of placentomes, allantoic vessels (which will be targeted as they 
emerge from placentomes in this study) and the formed umbilical cord.  Reproduced from Hafez 2000 (157). 
In sheep, 4 different classes of placentomes (type A-D) are recognised based on their 
morphology, although they are histologically not different, and although type D have been 
suggested to be more efficient than type A (158) they are also larger, and size rather than 
morphology influences vascularity and nutrient transfer (159).  Type A are concave, type D are 
convex, and types B and C are intermediate stages between concave and convex (160) (Figure 
1.8).   
 
Figure 1.8: Placentome types. 
A diagrammatic representation of cross-sectional appearance of sheep placentomes morphology by type, 
reproduced from Vatnick et al. 1991 (160). 
Regardless of type, the organisation of the sheep placenta into placentomes increases the 
surface area of feto-maternal exchange surfaces by 5-10 fold per gram of fetus compared to 
human placentae (161). Placental mass increases until around 70-90 days post conception in 
sheep (term ~150 days post conception) and the surface area of the villi continue to increase 
until around 120-125 days post conception to meet the increasing demand of the growing fetus.  
This increase in surface area is achieved by ongoing branching of the maternal and fetal villi 
and reduction of the intervening connective tissue until the two blood vessel systems are very 
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closely placed with little separation.  Typically, placentomes are type A and B until around 100 
days post conception, and a variable proportion become type C and D after this time (155).  If 
there is a restricted placentome number, such as where uterine caruncles have been removed 
pre-pregnancy, there is a shift towards larger, convex placentomes (162). 
There are a limited number of caruncles per uterus, not all of which are formed into 
placentomes during pregnancy.  The Welsh Mountain breed normally have 70-80 placentomes 
in pregnancy.  Multiple pregnancies have more placentomes than singletons, but the overall 
amount of placentomes per fetus remains reduced compared to singletons.  There is a close 
correlation in sheep between total placentome mass and birthweight (163), majority of maternal 
caruncles need to be removed pre-pregnancy to produce an placental insufficiency or a model 
of growth restriction in pregnancy (164).  The effect of reduction in placental mass in the third 
trimester has not been reported. 
This makes the sheep placenta a suitable for a model of placental vascular anastomoses.  Even 
in singleton pregnancy there are placental blood vessels connecting areas of placental tissue 
which can be identified with Doppler ultrasound and targeted for HIFU mediated vascular 
ablation.  The organisation of the placenta, particularly the large reserve in surface area of feto-
maternal haemotrophic exchange and the capacity to increase the efficiency of remaining 
placentomes in cases of placental insufficiency mean that a clinically relevant number of 
vascular ablations can be performed without the expectation of causing fetal compromise.  
 
1.3.4 Effect of anaesthesia in ewes and fetuses 
In pregnant women, regional anaesthesia is usually preferred for surgical procedures where 
possible due to the lower associated maternal risks of hypoxia, aspiration pneumonia and 
mortality when compared to general anaesthesia (165, 166).  However it is recognised that 
general anaesthesia produces less hypotension, less cardiovascular instability and better 
control over ventilation than regional anaesthesia (167).  Inhalational anaesthetics of the 
halogenated ether class, including isoflurane, sevoflurane and desflurane, are typically used for 
maintenance of anaesthesia, with or without supplemental IV anaesthesia (SIVA). The 
concentration of anaesthetic vapour in oxygen required to produce a given level of sedation 
varies between drugs used, but can be standardised as the minimum alveolar concentration 
(MAC).  A MAC of 1.0 represents the concentration of an anaesthetic vapour in the lungs which 
prevents motor responses to noxious stimuli in 50% of subjects.  SIVA reduces the required 
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concentrations of inhalational anaesthetics in humans (168) and sheep (169), but in sheep any 
potential benefit from this is negated by the increased recovery times from SIVA.  Ruminants 
are at significant risk of regurgitation and bloat when recumbent (170) and that the highest risk 
period of this is during recovery (171) hence prolonging recovery increases morbidity in 
ruminants.  For isoflurane, the blood:gas, blood: brain and fat: blood coefficients are 1.4, 1.6 
and 48 respectively.  Despite these values being on paper inferior to newer agents such as 
sevoflurane and desflurane (172), in practise anaesthetic maintenance and recovery from 
anaesthesia in pregnant sheep is unaltered between the three anaesthetic agents (170). 
The 1.0 MAC value of isoflurane in pregnant sheep has been determined as between 0.86-
1.14% inhaled isoflurane (167, 173, 174).  Isoflurane appears in the fetal circulation within 2 
minutes of maternal administration, but remains lower (50-80%) than maternal levels throughout 
the duration of anaesthesia, with the uptake curve of mother and fetus following the same 
pattern (175).  Fetal 1.0 MAC has estimated in sheep as 0.34% inhaled content (174) and 
measured as 0.5% inhaled content in newborn lambs (176) so it is reasonable to consider that 
the fetus achieves an equivalent or greater depth of anaesthesia as the mother. 
In humans, for maternal procedures low to moderate concentrations of halogenated ether 
inhalational anaesthetics can be used (0.5-1.0 of MAC) can be used to maintain anaesthesia.  
For procedures which require uterine relaxation, such as non-obstetric abdominal surgery (for 
avoidance of intra-operative uterine contraction) or hysterotomy for open fetal surgery, higher 
concentrations are required (2.0-3.0 MAC) (177-180).  Isoflurane is recognised as a potent 
vasodilator which has a dose and duration dependant effect on maternal and fetal physiology 
during the period of anaesthesia, which have been well described in the fetal sheep model.  
Some studies date from the 1980s when isoflurane emerged as a novel anaesthetic agent; 
however there has been renewed interest in the past decade as the increasing success rates of 
fetal ex utero intrapartum treatment (EXIT) procedures has led to pregnant women being 
exposed to general anaesthesia for longer periods at higher concentrations, with the added 
complication of a compromised fetus undergoing a surgical procedure.  There are currently 6 
published works which report ovine maternal and fetal cardiovascular and metabolic responses 
to isoflurane anaesthesia at 0.8 gestational age (summary tables of results provided for 
reference in Appendix I).  
Regardless of stage of gestation, pregnant ewes show and initial bradycardia and arterial 
hypotension combined with decreased uterine blood flow (173-175, 181-184).  This response is 
both dose and time-dependant as these effects are only observed at 1.5-2.0 MAC and above 
(167, 173) and all parameters recover to baseline within 120 minutes of start of anaesthesia 
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(181, 182), or within 6 minutes of extubation (167, 170).  Maternal hypotension can be corrected 
with intravenous fluids or inotropic drugs; however this does not alter the degree of 
cardiovascular compromise observed in the fetus (168).   At MAC 1.5-2.0 there is also a trend to 
increasing arterial carbon dioxide content (paCO2) in the maternal blood, despite tight control of 
end tidal carbon dioxide (EtCO2) and a corresponding decrease in arterial pH (pHa)(167, 173, 
175, 181, 182).  Maternal ventilation responses are supressed at ≥1.0 MAC but automated 
ventilation with an high fraction of inspired oxygen (FiO2) ensure that maternal oxygenation 
remains high (167). 
The fetus shows a dose dependant reduction in fetal heart rate and mean arterial blood 
pressure with left ventricular systolic dysfunction at 1.5-2.0 MAC, which unlike maternal 
responses persisted for the duration of the anaesthetic administration and rapidly recovered on 
extubation.  This was accompanied by increase in fetal paCO2 and decrease in pHa, although 
the acidosis was fully reversible within 24 hours (167, 173, 175, 181, 182).  A marked elevation 
of fetal arterial oxygen content (paO2) is consistently observed due to maternal ventilation with a 
high FiO2, so cerebral oxygenation is either maintained at baseline levels (182) at (ca. 0.6 of 
gestation) or increased in late gestation (ca. 0.8 gestation) (181).  This gestational difference is 
likely due to the development of cerebral blood flow autoregulatory pathways, which mature at 
different gestational ages (185, 186).  The effect of hypercapnia on increasing cerebral blood 
flow may also contribute to maintained or increased oxygenation.  Isoflurane sedation does not 
alter the capacity of fetal sheep to redistribute cerebral – systemic blood flow in response to 
reduced uteroplacental flow or development of acidosis (184), and fetal sheep maintained their 
cerebral blood flow when fetal MAP varied 20-48 mmHg (187). 
 
1.3.5 Effect of uterine manipulation 
The effect of uterine manipulation on fetal wellbeing and physiology has not been well 
documented.  There is currently no little available in humans regarding the physiology of the 
mother and fetus in response to uterine manipulation while under anaesthesia, although what 
there is suggests the fetus initiates cardiovascular defence mechanisms and redistributes blood 
to the brain, despite normal oxygenation (188).  Fetal cardiovascular defence responses have 
been described in sheep fetuses to reduced uterine blood flow (189) primarily mediated by the 
sympathetic nervous response to fetal acidosis (190) and perpetuated by endocrine mediated 
fetal stress responses (191). Elevation of intra-abdominal pressure secondary to gas insufflation 
in laparoscopy has been demonstrated in animal models to decrease uterine blood flow and 
Chapter 1: Introduction 
 
67 
 
cause marked respiratory acidosis in the fetus (192).   The impact of these insults in terms of 
fetal brain oxygenation depends on the developmental maturity of fetal compensatory 
mechanisms from the early third trimester onwards, which are not impaired by general 
anaesthesia (184). Severe functional brain hypoxia is observed in second trimester sheep 
fetuses (193), but there is preserved brain oxygenation in the third trimester (192).  In humans, 
epidemiological data suggests there is a negative impact of undergoing laparoscopy or 
laparotomy between 4-20 weeks gestational age, reported as a statistically increased relative 
risk of growth restriction, low birth weight and premature delivery, although there was no control 
in the data to account for the impact of maternal disease on obstetric outcomes.  Cumulative 
survival to one year of age was unaffected; however there was insufficient data to analyse 
outcomes for operations in the second and third trimester (194).   
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1.4 Doppler Ultrasound 
1.4.1 Principles of action 
Doppler ultrasound is a non-invasive technique which allows assessment of moving structures, 
notably the flow of blood through a vessel or heart valve.  It exploits the fact that movement will 
scatter ultrasound energy more than still tissue, and produce a frequency shift in the reflected 
ultrasound energy that is detected by the ultrasound transducer.  This frequency shift, or 
Doppler effect, can be used to calculate the speed and direction (though not absolute volume) 
of blood flow in a vessel relative to the ultrasound transducer.  Unlike time-transit ultrasonic flow 
probes, Doppler ultrasound results are altered by angle of insonation, with the error increasing 
as the angle between direction of flow and path of the ultrasound beam increases.  Speed and 
direction information can be visually represented to the operator as (among others) colour 
Doppler, where information is presented as a colour-coded overlay on top of 2D B-mode 
imaging.  Pulsed wave Doppler displays velocity information from a subsection of the B-mode 
image (defined by the “Doppler gate”) mapped against time to create a waveform of blood flow 
through a vessel.  From this, values such as peak systolic velocity (PSV), mean velocity and 
end diastolic velocity (EDV) can be measured (Figure 1.9).  Pulsatility index (PI) may then be 
calculated as (PSV-EDV)/MV. 
 
Figure 1.9: Pulsed Doppler representation of a monophasic arterial waveform. 
The diagram shows an illustration of blood flow over three cardiac cycles, measured with pulsed wave Doppler.  
Common metrics (PSV, MV, EDF) which can be derived from these waveforms are shown. Pulsatility index (PI) is 
then calculated as (PSV-EDV)/MV. 
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1.4.2 Mapping of placental anastomoses 
Arterio-arterial and arterio-venous anastomoses in human monochorionic placentae have been 
successfully identified on ultrasound.  Both are located within the placenta using colour Doppler 
waveform interrogated with pulsed wave Doppler to identify the type of vascular anastomoses.  
Arterio-arterial anastomoses appear easier to locate with a sensitivity of 85% and specificity of 
97.3% when compared to placental injection studies (195).  Arterio-venous anastomoses are 
more challenging, with sensitivity of between 25-50% when compared to placental injection 
studies (196-198).  In all cases, identification was easier with larger vessels and anterior 
placental positioning. 
 
 
  
Chapter 1: Introduction 
 
70 
 
1.4.3 Placental mapping in sheep 
There has been limited work characterising placental vessels in sheep although vessels are 
readily apparent on colour Doppler as they emerge from the fetal aspect of the placentomes 
(Figure 1.10).  3D quantification of utero-placental flow has been validated in vivo using the 
pregnant sheep model (199) demonstrating a high degree of accuracy can be obtained in 
imaging and quantification of ovine placental vessels. 
 
Figure 1.10: Doppler ultrasound of a placental vessel emerging from a placentome.   
This is a representative ultrasound image obtained during the study of placental vasculature, using a 3.75 MHz 
convex abdominal probe (PVK-357AT, PowerVision 7000, Toshiba Medical Systems).  Sheep: OR585, 116 d 
gestational age. 
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1.5 Ultrasound assessment of fetal wellbeing in humans 
The following section considers the evidence for assessment of fetal wellbeing in the antenatal 
period and excludes consideration of intrapartum evidence. 
 
1.5.1 Fetal growth rate 
Fetal weight cannot be measured directly, only estimated, from ultrasound derived fetal 
biometry.  The most commonly used fetal measurements for this purpose are the biparietal 
diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length 
(FL).  Typically, the Hadlock formula is used to estimate fetal weight, with a mean error of 10-
15% (200), and serial measurements of fetal biometry and estimated fetal weight can be used 
to calculate the change in size or weight of the fetus over time.   
The human growth rate is rapid during fetal life, and deviation from a consistent pattern of 
growth can be associated with placental insufficiency, metabolic and genetic/chromosomal 
abnormalities or infection.  Fetal growth restriction (FGR) is defined as the failure of a fetus to 
achieve a genetically pre-programmed size while in utero. FGR is an important predictor of 
perinatal morbidity and mortality, but increasingly failure to maintain a consistent fetal growth 
rate growth rate, rather than estimated fetal weight has been recognised as the more important 
predictor of poor outcomes in this group of small fetuses (201). 
As in human pregnancy, ultrasound derived measurement of fetal biometry can be performed in 
utero, except for HC, due to the altered shape of the sheep skull compared to humans.  BPD, 
AC and FL have all been reported to increase in a linear fashion with increasing gestational age 
in sheep until term (202), and to correlate to size at birth (203), although the estimation of fetal 
weight based on these parameters is less accurate than in humans when using the Hadlock 
formulae (203). 
Fetal growth restriction in sheep is defined as a birth weight or size more than 2 standard 
deviation (SD) below the mean of the breeding flock for that season (204).  FGR can be induced 
in fetal sheep by simulation of utero-placental dysfunction (carunclectomy, placental 
embolization, single umbilical artery ligation), maternal hyperthermia, hypoxia or nutritional 
manipulation (205) and is associate with adult cardiac and metabolic dysfunction (206).   
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1.5.2 Umbilical artery Doppler 
Currently, based on a systematic review and meta-analysis of published studies, including more 
than 10,000 pregnancies, Doppler studies of the umbilical artery (UA) are recommended to be 
incorporated into the assessment of fetuses at risk of placental insufficiency (207).  
The waveform of the fetal umbilical artery, as measured by pulsed wave Doppler, reflects the 
fetal cardiac contraction, vessel wall elasticity, afterload in fetal vessels and impedance of blood 
flow from the fetal to the placental vessels (a marker of placental resistance).  The maximum 
velocity (PSV) is related to blood flow from fetus to placenta during ventricular contraction and 
peak systolic arterial pressure; the minimum velocity (EDV) represents blood flow during 
ventricular relaxation and the nadir of diastolic arterial blood pressure.  Forward blood flow is 
expected for the entire duration of the cardiac cycle in a low-resistance system with normal 
placental function (208).  The umbilical artery pulsatility index (UA-PI) shows a progressive 
decline with advancing gestation, as a result of increases in fetal diastolic arterial blood 
pressure, from a mean of 1.07 (95% confidence interval (CI) 0.79 – 1.45) at 28 weeks’ gestation 
to 0.74 (95% CI 0.55 – 1.00) at full term (40 weeks), adjusted for estimated fetal weight (209).   
UA-PI is estimated to show elevation when 60-70% of placental vasculature has become high 
resistance (210).  Waveform changes may include absent or reversed end diastolic flow (211, 
212) which indicate forward blood flow is no longer possible for the entire cardiac cycle, 
denoting an even more pronounced degree of placental failure.  Abnormal waveform patterns 
predict fetal compromise and precede acute fetal deterioration by up to 12 days (213).  The UA-
PI can be altered by the position of the cord from which the measurement is taken (214), fetal 
activity (215), but does not show diurnal variation (216).   
Despite the differences in sheep and human placentation, once in the coiled umbilical cord, 
umbilical artery blood flow in the sheep has a similar waveform to that of humans, with continual 
forward flow throughout the cardiac cycle.   However, there are no longitudinal studies of UA-PI 
throughout gestation.  Additionally, due to the nature of the experimental work being performed, 
many values of UA-PI are taken in anaesthetised animals.  While the trends of UA-PI changes 
correlate well with changes measured by invasive measures of blood flow in the umbilical 
artery, quantitative values for blood flow cannot be predicted base on Doppler studies alone  
(199, 217). 
In un-anaesthetised animals UA-PI is reported as 0.70 – 0.90 at ca. 115-120 d gestation (205, 
218, 219), falling to around 0.50 at 135 days gestation (220).  Just as in humans, hypoxia, 
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hypertension and impaired placental function result in elevation or UA-PI (205, 218, 220).  
Under anaesthesia, the umbilical PI can increase by 1.5 - 2-fold (221). 
 
1.5.3 Middle cerebral artery Doppler 
Doppler assessment of the fetal middle cerebral artery (MCA) can be used to assess fetuses at 
risk developing anaemia, or for evidence of cerebral vasodilation, which may indicate 
preferential redistribution of blood to the fetal brain as part of a fetal cardiovascular stress 
response. 
The peak systolic velocity of the middle cerebral artery (MCA-PSV) waveform as measured by 
pulsed wave Doppler increases with gestational age from a median of 40.5 cm.s-1 (± 1.5 
multiples of median (MoM), 20.3 – 60.7) at 30 weeks’ gestation to 64.4 cm.s-1 (± 1.5 MoM, 32.2 
– 96.6) at 40 weeks’ gestation in normal pregnancy (222) as a result of increasing systolic blood 
pressures.  Elevation of MCA-PSV above 1.5 MoM is known to result from fetal anaemia (223) 
but can also result from severe acute or chronic hypoxia (224, 225). 
The pulsatility index of the middle cerebral artery (MCA-PI) Doppler also decreases with 
gestation from a mean of 1.94 (90% CI 1.45 – 2.47) at 28 weeks’ gestation to a mean of 1.35 
(90% CI 0.83 – 1.93) at 40 weeks’ gestation in normal pregnancy (226) as a result of increasing 
diastolic blood flow.  A reduction in PI below the normal range for that gestational age is a 
marker of cerebral vasodilation, and may therefore represent an early sign of hypoxia in fetuses 
(227-229), although its predicative power for adverse outcomes is low (230, 231). An elevation 
in MCA-PSV has been suggested show cerebral redistribution more consistently and to predict 
perinatal morbidity better than a low MCA-PI in IUGR fetuses (225). 
There are no reported measurements of the middle cerebral artery Doppler in fetal sheep, 
although the anatomy of the circle of Willis in the human and sheep brains is comparable.   
 
1.5.4 Cerebro-placental ratio 
The cerebro-placental ratio (CPR) relates the PI of the UA Doppler to that of the MCA Doppler 
(UA-PI/MCA-PI).  In normal pregnancy, the value of CPR rises to a maximum around 34 weeks’ 
gestation, mean 2.35 (95% CI 1.63 – 3.29), before falling towards term, mean 1.97 (95% CI 
1.29 – 2.88).  A ratio of <1 has long been recognised to fetal brain sparing (232), conferring an 
11-fold increased risk of adverse perinatal outcomes in growth restricted fetuses (233). 
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There are no reported measurements of the cerebro-placental ratio in fetal sheep. 
 
1.5.5 Ductus venosus 
The ductus venosus (DV) is fetal venous shunt which in normal pregnancy allows between 30-
55% oxygenated blood in the umbilical vein (UV) to bypass the hepatic circulation and pass 
directly in to the inferior vena cava (IVC), thereafter to the right atrium (234).  Flow through the 
DV increases with gestation to increase until 31 weeks’ gestation, after which time is remains 
stable despite increases in umbilical blood flow and liver size (235, 236).   
The diameter of the DV is around one third of the UV and it connects to the IVC at a steep 
upward angle: both of these features increase the velocity of blood flow within the DV and 
cause it take on a triphasic waveform pattern.  The ductus venosus pulsatility index for veins 
(DV-PIV) decreases with gestation from a mean of 0.56 (95% CI 0.31 – 0.81) at 28 weeks’ 
gestation to a mean of 0.45 (95% CI 0.21 – 0.71) at 39 weeks’ gestation in normal pregnancies 
(235), reflecting changes in fetal pre- and after-load with increasing maturity. 
In growth restricted fetuses, up to 60% of UV blood flow bypasses the hepatic circulation (234).  
As such, changes in the DV-PIV and characteristics of the waveform, notably absent or reverse 
‘a’ wave, reflect atrial pressure-volume changes during the cardiac cycle.  Elevations of DV-PIV 
have been shown to be associated with the presence of markers of biochemical dysfunction 
(237). A reversed ‘a’ wave results from increased afterload and/or preload (238), and denotes 
the onset of pre-terminal fetal compromise (239).  As such, DV is recommended for timing of 
delivery in early onset fetal growth restriction (131). 
Just as in the human, in the fetal sheep DV shunting of oxygenated blood accounts for 45 – 
60% of umbilical vein blood flow, which is increased during hypoxia or reduced umbilical vein 
flow (234).  In the event of cardiac decompensation, reversal of the ‘a’ wave has been reported 
(240).  There is a single longitudinal study in un-anaesthetised ewes of changes in DV-PIV with 
gestation: akin to humans, there is no significant change between a mean of 0.52 (± 0.02 
standard error of mean (SEM)) at 115 d gestational age to a mean of 0.58 (± 0.03 SEM) at     
136 d gestational age (240). 
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1.5.6 Uterine artery Doppler 
In the non-pregnant state, uterine arterial (UtA) blood flow is low, with high resistance in arteries 
characterised by low end diastolic flow velocities and an early diastolic notch reflecting the 
elasticity of the vessel.  In normal early pregnancy, maternal uterine arteries are remodelled by 
the action of extra-villous trophoblastic tissue to allow high flow, low resistance maternal arterial 
blood flow to the placental bed.  These changes are characterised by pulsed wave Doppler by 
an increase in end diastolic velocities, which reduces the pulsatility index (UtA-PI) and a loss of 
the early diastolic notch.  Persistent notching or elevation of UtA-PI beyond 24 weeks’ gestation 
is an indicator of high pressure blood flow in the arterial lumen and poor arterial relaxation, 
which are markers of inadequate spiral artery remodelling (241, 242), although vasoconstriction 
alone can increase the PI of blood flow through that vessel so long as flow is maintained (243, 
244). 
The UtA-PI falls markedly from early pregnancy until the end of the second trimester, thereafter 
it falls more slowly with a mean of 0.81 (95% CI 0.56 – 1.17) at 28 weeks’ gestation and a mean 
of 0.65 (95% CI 0.47 – 0.89) at 40 weeks’ gestation (245).  An elevation in the UtA-PI, even in 
the third trimester, can be used to predict adverse perinatal outcome in the presence of growth 
restriction (246). 
In sheep, the presence or absence of notching in ovine uterine arteries has not previously been 
reported.  There is a single longitudinal study which reports the decline of the UtA-PI in sheep 
from a mean of 1.0 (± 0.3 SEM) at 112 d gestation to a mean of 0.66 (± 0.1 SEM) at 140 d 
gestation, although this does not reach significance due to the small numbers in the study (247). 
 
1.5.7 Cardiac function 
Fetal echocardiography can be used to assess of the fetal heart function in addition to structure.  
In the fetus, due to the presence of the ductus arteriosus which passes the pulmonary 
circulation, both the left and right ventricle pump blood into the systemic circulation and work in 
parallel to produce the combined cardiac output (CCO).  Maintenance of adequate cardiac 
output depends on the adequate venous return, fetal heart rate and stroke volume, myocardial 
contractility and the afterload of the systemic circulation.  In utero, fetal cardiac function may be 
measured by direct measurements of cardiac dimensions to calculate fractional shortening (FS) 
or ejection fraction (EF) (2D B- or M-mode ultrasound) or ventricular volume (4D ultrasound). 
Function can also be assessed indirectly by qualitative measurements of blood flow (cardiac 
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output), tissue excursion (myocardial contraction force) or time intervals during the cardiac cycle 
(myocardial performance index) (248). 
The left ventricular myocardial performance index (LV-MPI) in normal pregnancy is stable 
through gestation with a mean of 0.36 (95% CI 0.28 – 0.44) (249-252).  Elevation is recognised 
as an early marker of cardiac dysfunction in complicated pregnancy (253, 254). 
Similarly, left ventricular fractional shortening is reported to be constant throughout gestation 
with a mean of 0.33 (95% CI 0.26 – 0.41) (255), with a reduction indicating fetal cardiac 
compromise (256).  Ejection fraction is also gestational age independent, with a mean of 0.74 
(95% CI 0.61 – 0.87); again, reduction indicates fetal cardiac compromise (251). 
While right heart dominance is usual in fetal life, with the right ventricle pumping 55-60% of the 
CCO to the peripheral circulation (257, 258), the balance is changed in hypoxia with the left 
ventricle pumping comparatively more blood to the central rather than the systemic circulation 
(259).  During acidaemia the fetal left ventricle can increase contractility in response to an 
inotropic stimulus – angiotensin II – even in the presence of increased peripheral resistance 
(260), maintaining its systolic function longer than its diastolic function (261).  The left ventricle 
is also more sensitive to progressive acidaemia than the right ventricle (261). 
Again, there are no longitudinal studies of fetal cardiac indices at different gestational ages in 
fetal sheep, and no relevant values are reported in un-anaesthetised sheep. 
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2.1 The unmet clinical need 
Twin to Twin Transfusion Syndrome is a condition where there remains scope for improving the 
treatments available.  SVFL has been used over the last two decades to treat TTTS by ablating 
the abnormal placental anastomoses which cause the disease.  While this can be successful in 
preventing the worsening of TTTS, based on meta-analysis of SVFL used to treat TTTS, there 
is no overall increase in perinatal survival (15).  Recent developments in technology and 
technique, while showing a trend to improvement, have yet to show the anticipated 
improvement in survival rates (19).  Meta-analysis of different invasive methods of treating fetal 
vascular disease in utero suggest that while survival relates to the efficacy of the method of 
vascular occlusion, complication rates (preterm labour or rupture of membranes) increase with 
increasing calibre of the instrument introduced into the uterus (14).  Even with improving 
technology, fetoscopes of 2-3 mm in diameter in use, and fetal demise rates of 5-25% are still 
quoted (262).   
It could be argued that the invasive nature of fetoscopic laser has prevented it from becoming a 
treatment available to all pregnancies with TTTS, such as those identified at an early stage (<III) 
or early gestation (<16-18 weeks’ gestation).  These are both areas of unmet clinical need in the 
management of TTTS. 
Any new treatment to ablate placental vasculature would need to address two key areas: firstly, 
it would be non-invasive and secondly it would include a method of confirmation of anastomotic 
occlusion or complete placental equatorial division. 
 HIFU may be an alternative to invasive fetoscopic laser in TTTS.  The energy levels needed to 
ablate placental vasculature (263) and the focal depths required are within the HIFU range of 
operation, and the reduction in complication rate may allow treatment of less severe disease.  
Either selective vascular occlusion or equatorial division of the placenta could be performed, as 
points or confluent planes of ablation can be achieved with HIFU  (31).  HIFU may be able  to 
reduce rates of recurrent TTTS and TAPS, as residual anastomoses would be identified by 
Doppler ultrasound (196) integrated into the HIFU system for targeting.  This could potentially 
allow HIFU to be used to treat TTTS more widely and at an earlier stage which may confer an 
additional survival benefit beyond that achieved from the non-invasive nature of the technique. 
However, while HIFU has previously been used in pregnancy to successfully treat TRAP, this 
was a soft tissue application, and the area of specifically occluding placental vasculature non-
invasively with HIFU remains unexplored.  Given that there currently exists a treatment modality 
for TTTS that improves the prognosis for affected fetuses, any novel therapy would need to be 
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thoroughly tested for efficacy and safety in a pre-clinical development phase before the 
technology could be considered for a clinical trial.   
 
2.2 Hypotheses 
1. (a) It is possible to occlude placental vasculature in the pregnant sheep using non-
invasive, ultrasound guided HIFU. 
(b) The resulting vascular occlusion is a permanent effect. 
 
2. (a) HIFU mediated placental vascular occlusion can be achieved without significant 
direct iatrogenic harm to mother or fetus in the pregnant sheep model. 
 (b) HIFU mediated placental vascular occlusion can be achieved without significant short 
or long term materno-fetal cardiovascular, metabolic, endocrine compromise or evidence 
of abnormal fetal growth or physiological maturation (indirect iatrogenic harm). 
 
2.3 Experimental design & aims 
This project had two main aims: first, to perform an ultrasound energy delivery study which 
would establish the efficacy, and potential for direct iatrogenic harm, of using ultrasound guided 
HIFU to occlude placental vasculature.  This would enable us to develop an ultrasound guided 
HIFU treatment protocol for selective occlusion of placental vasculature in the pregnant sheep, 
to inform either further animal or human studies.  It was not expected that this treatment 
protocol would be optimised, but would, if successful, serve as a proof of concept for this 
application of HIFU. 
Second, we aimed to investigate the obstetric, cardiovascular, metabolic and endocrine 
responses of the mother and fetus to HIFU mediated placental vascular occlusion, both short 
and long term, providing evidence regarding the maternal and fetal tolerance of, and recovery 
from HIFU treatments.  It would also identify the risk of indirect harm, if any, associated with the 
technique. 
The design of a series of experiments to meet these two, seemingly simple, aims was instead 
complicated by a number of difficulties.  The study design deviated significantly from the one 
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originally planned, and for this reason, the logic behind the experimental design is explained 
below. 
 
2.3.1 Efficacy and safety of placental vascular occlusion 
To meet the first aim, from an experimental point of view, it was not necessary to perform any 
monitoring of mother or fetus beyond confirmation of maternal and fetal survival to the end of 
the planned HIFU exposure and a careful post-mortem examination.  The development of an 
HIFU treatment protocol from the minimal foundations of knowledge described in section 1.2.2, 
however, would require an iterative approach, where successive HIFU treatment protocols were 
experimentally evaluated and refined over time and multiple animal groups. 
This approach clashed with directly with the second aim, to evaluate maternal and fetal 
responses to the “challenge” of HIFU mediated placental vascular occlusion.   Typically, in any 
experimental protocol to assess the response to a particular “challenge”, the challenge itself is 
standardised, an event with fixed characteristics, repeated in multiple subjects.  However, the 
nature of the HIFU treatment protocol development part of this study was that the HIFU 
treatment protocol could change from one experimental subject to the next, based on the 
information gained.  Therefore, the HIFU treatment protocol could not be tested against 
maternal and fetal responses and altered in the same animal. 
This necessitated an experimental design where the HIFU treatment protocol was refined to a 
certain level, then tested (unchanged) in multiple subjects (even if flaws were apparent in the 
protocol before the end of testing), then further refined, then tested (unchanged), through as 
many cycles as needed or possible (Figure 2.1).   
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Figure 2.1: Animal groups.   
This schema shows the progression of animal groups used in this thesis with the key priorities of each group 
summarised. 
Given this iterative design, and that the project had finite resources, time and numbers of 
animals, certain adjustments to the experimental protocols were required.  Essentially, the most 
refined HIFU treatment protocol was not tested in all animals, so the outcome data from each 
animal group is not necessarily directly comparable between groups.   
Additionally, as early treatment protocols were weighted more to efficacy than safety, collating 
data regarding efficacy or safety from all phases of the study may not be valid either.  The 
process of developing the HIFU treatment protocol will be discussed more fully in chapter 4. 
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2.3.2 Maternal and fetal responses to HIFU placental vascular occlusion 
To meet the second aim, the ideal way to structure these experiments would be to place a 
pregnant ewe under general anaesthesia, surgically implant maternal and fetal vascular 
catheters and flow probes, then recover the ewe.  Once both ewe and fetus had recovered from 
the effects of anaesthesia and surgery, and returned to a baseline of normal physiology, 
typically after around 5 days, then HIFU experiments could commence.  This would allow both 
the short-term reaction to, and longer-term recovery from, HIFU placental vascular occlusion to 
be measured.  As the ewe would ideally be un-anaesthetised, this would separate the effects of 
HIFU from those of surgery and anaesthesia.  Maternal and fetal recovery could then be 
monitored until term, when a post-mortem examination could be conducted. 
However, it was not possible to organise the experiments in such a way because of practical 
considerations. These are summarised in Table 2.1.  Overall, it was not possible to separate the 
timing of the application of HIFU from general anaesthesia and materno-fetal surgery.  For this 
reason, the maternal and fetal responses to, and recovery from HIFU were tested in 3 separate 
animal groups (A, S and R: Figure 2.1, and described further in the next section).  Each group 
contributed to the overall analysis of the short and long term materno-fetal cardiovascular, 
metabolic, endocrine and obstetric responses to HIFU mediated placental vascular occlusion.  
 
2.3.3 Animal groups 
These requirements on the experimental design necessitated a stepwise progression through 
six animal groups (Figure 2.1).  Two developed the HIFU treatment protocol: the pilot study and 
transdermal bridging study.  Three tested progressive iterations of the HIFU treatment protocol 
for efficacy and safety: Groups A, S and R.  The final group addressed specific safety concerns 
for which insufficient data had been collected in the preceding 5 groups.  These names for the 
animal groups will be used consistently throughout the thesis to denote to which animal group 
results refer, and a summary of the animal groups is shown in. 
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Requirement Original plan Problem Solution 
The abdomen of the ewe must be 
still during HIFU exposures 
HIFU exposures to be applied 
to un-anaesthetised ewes 
restrained in dorsal 
recumbency 
(i) It was not possible to restrain an un-
anaesthetised animal to a sufficient 
degree; 
(ii) Maternal respiratory movement 
sufficient to cause mistargeting. 
HIFU exposures applied: 
(i) General or regional anaesthesia required to prevent maternal 
movement, 
(ii) General anaesthesia would allow a mechanical ventilation 
pauses to prevent respiratory movement. 
The abdomen of the ewe must be 
exposed and near-horizontal during 
HIFU exposures 
Ewes restrained in dorsal 
recumbency during HIFU 
(sitting at 45o) 
Not possible to restrain an un-
anaesthetised animal in fully recumbent 
position 
HIFU exposures applied in animals under general or regional 
anaesthesia, with ewe fully recumbent. 
Maternal recovery from HIFU 
should not be compromised by 
surgical / anaesthetic procedures 
HIFU to be applied after 
recovery from 
surgery/anaesthesia 
(5 days) 
Fully recumbent pregnant ewe at risk of 
aspiration of gastric contents 
(i) Ewe fasted for 24 h pre-procedure 
(ii) General anaesthesia was preferred to regional anaesthesia 
as it allowed the maternal airway to be protected with cuffed 
endotracheal tube 
Maternal blood pressure should be 
stable 
HIFU to be applied after 
recovery from 
surgery/anaesthesia 
(5 days) 
Fully recumbent pregnant ewe at risk of 
auto-caval compression, and vasodilator 
effect of isoflurane anaesthesia 
(i) A 30o left tilt introduced to theatre table while ewe recumbent 
(ii) Continuous intravenous crystalloid infusion used to support 
maternal blood pressure 
(iii) General anaesthesia was preferred to regional anaesthesia 
as blood pressure control better 
The abdomen of the ewe should be 
unscarred to preserve acoustic 
window 
HIFU to be applied after 
recovery from 
surgery/anaesthesia 
(5 days) 
The healing scar would interrupt the 
acoustic window 
HIFU exposures to be applied: 
 
(i) transuterine (Group A: allows air to be excluded and foreign 
bodies to be moved away, but not non-invasive); 
 
(ii) before surgery on the maternal abdomen (Group R: 
prevents measurement of materno-fetal responses to acute 
application of HIFU, only allows measurement of recovery); 
 
(iii) without surgery on the maternal abdomen (Group S: 
restricts assessment of materno-fetal responses to and 
recovery from HIFU to non-invasive techniques). 
 
The path between the maternal skin 
and anterior surface of the uterus 
should be free of foreign bodies to 
preserve the acoustic window 
HIFU to be applied after 
recovery from 
surgery/anaesthesia 
(5 days) 
Intravascular catheters and flow probe 
cables could migrate to cross the acoustic 
window during recovery. Damage to 
vascular catheters could cause fetal 
haemorrhage. 
The intra-abdominal space of the 
ewe should be free of air to 
preserve acoustic 
HIFU to be applied after 
recovery from 
surgery/anaesthesia 
(5 days) 
Free air will be introduced at the time of 
laparotomy and can take up to 18 d to 
fully clear (264) 
Maternal and fetal physiological 
status before HIFU exposures 
should be representative of 
normality 
HIFU to be applied after 
recovery from 
surgery/anaesthesia (5 days) 
Need for HIFU exposures to be performed 
under general anaesthesia 
(i) Duration of anaesthesia was minimised wherever possible, 
and kept to < 5 h in all cases 
(ii) Control groups were exposed to anaesthesia ± surgery  
 
Table 2.1: Adjustments to original experimental design.   
The table lists the experimental requirements of the study, the original experimental plan to meet these requirements, the practical problems which emerged during and the 
solutions implemented which required adjustment of the experimental protocol. 
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Table 2.2:  Summary of animal groups.   
The table shows a summary of the demographics of animals included in each group, and the surgical procedures, method of invasive and non-invasive follow-up used to 
assess maternal and fetal wellbeing.  The timing and nature of post-mortem examination for each group is also summarised. 
Pilot Transdermal Bridging Specific Safety
NON-RECOVERY NON-RECOVERY NON-RECOVERY
Demonstration of initial 
feasibility
Adaption of transuterine  to 
transdermal application
Collection of data regarding 
outstanding safety concerns
Gestational age 115 ± 2 d 115 ± 0 d 110.5 ± 5.5 d
Treatment applied HIFU HIFU Sham HIFU HIFU Sham HIFU Control HIFU
Number of sheep 5 5 6 2 6 6 10 6 4
Isoflurane anaesthesia Yes Yes Yes
Before HIFU (n = 4 ) Before HIFU (n = 1 )
None (n = 1) None (n = 3)
Hysterotomy None None None
Fetal descending aorta
Maternal descending aorta
Blood samples
None None None
Heart rate variability analysis n/a n/a n/a
Fetal ultrasound biometry None None None
Utero-placental and fetal Doppler studies Intermittent FHR checks Intermittent FHR checks Intermittent FHR checks
Intraoperative maternal pulseoximetery and 
end tidal CO2
Yes Yes Yes
Inspection for maternal distress, injury or 
obstetric complications
n/a n/a n/a
Baseline for comparison established n/a n/a n/a 
Follow-up post HIFU / sham treatment 
completion
< 15 min < 15 min < 15 min
Number of sheep which completed followup 5 5 6 2 6 6 6 6 4
Placental tissue Placental tissue Placental tissue
Iatrogenic damage Iatrogenic damage Iatrogenic damage
None
None
None
None
None
None
Chronic responses to HIFU 
(invasive monitoring)
Group S(urvival)
RECOVERY
Chronic responses to HIFU
(non-invasive monitoring)
Laparotomy Before HIFU After HIFUNone
Placental tissue Placental tissue
Fetal femoral artery Fetal femoral artery
Fetal carotid artery
Fetal descending aorta
Fetal ascending aorta
Yes
None None
n/a Daily after HIFU
Fetal biometry
Iatrogenic damage
Iatrogenic damage
30 min 21 d
Arterial Catheters
- arterial blood pressure
- heart rate
- blood sampling (metabolic / endocrine)
Before HIFU
Maternal descending aorta
After HIFU
IN
V
A
S
IV
E
 M
O
N
IT
O
IN
G
Immediately before, during 
and after HIFU / sham
Daily after HIFU
S
U
R
G
IC
A
L
 
P
R
O
C
E
D
U
R
E
S
 &
 
A
N
A
E
S
T
H
E
S
IA
Yes Yes
Group A(cute) Group R(ecovery)
NON-RECOVERY RECOVERY
Acute responses to HIFU
Placental tissue
Fetal biometry
Organ weights
Iatrogenic damage
Flow probes
- volume of blood flow
- heart rate
Maternal uterine artey
No Yes
Yes
N
O
N
-I
N
V
A
S
IV
E
 
M
O
N
IT
O
R
IN
G
Yes
F
O
L
L
O
W
-U
P
Post mortem examination
30 min before HIFU 
commenced
116 ± 1 d 115 ± 10 d 116.5 ± 1.5 d
None
Cord blood sampled at 
post-mortem
Yes
Day 5 post surgery
None
n/a
Every 5th day after HIFU
Daily for 5 days after HIFU, 
then every 5th day
Daily after HIFU
24-48 h before GA / HIFU
21d 
None
None
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3.1 Sheep Husbandry 
All experiments were conducted on Welsh Mountain ewes, with singleton pregnancies of known 
gestational age. All procedures were licensed by the Home Office (Scientific Procedures) Act 
1986 and were approved by the University of Cambridge Ethical Review Board.  All animal 
experiments were conducted at the large animal facility at the University of Cambridge. 
 
3.1.1 Breeding cycles 
The Welsh Mountain sheep is a highland domesticated breed.  An average mature ewe weighs 
35-45 kg (265). In temperate zones such as England, sheep are seasonally polyoestrous, and 
their sexual and ovarian characteristics follow a pattern determined by day length, breed and 
nutrition.  During the breeding season ewes have an oestrous cycle of between 14-19 days and 
ovulate 1-3 eggs per cycle (157). Welsh mountain ewes have a high singleton pregnancy rate 
with a gestational period of 145-150 days (265, 266), however the photoperiodicity of the 
breeding season effectively limits the reproductive rate of the ewe to one delivery per year.  The 
length of the breeding season can be extended into the typical period of anoestrous (April – 
July) using hormonal control methods of ovine reproduction. Regardless of season, timing of 
ovulation can be synchronised between ewes by vaginal insertion of progesterone-impregnated 
sponges (20 mg Flugestone acetate, controlled release, PV, Chronogest® CR, Intervet UK Ltd., 
Walton, UK) for 14 days which mimics the luteal phase.  Removal of these sponges leads to a 
rapid fall in progesterone levels analogous to corpus luteum regression, and in the natural 
breading season ovulation will occur 48-72 hours later.  In the anoestrous season, ovulation 
rates can be increased by injection of exogenous gonadotrophins at time of sponge removal 
(500 IU, IM, PMSG-Intervet®; Intervet UK Ltd., Walton, UK) although there is a highly variable 
tendency to multiple ovulation in response to dose administration, which increases the rate of 
multiple pregnancy in our population of sheep (unpublished data).  In this study, both natural 
breeding and anoestrous season pregnancies were used. 
 
3.1.2 Tupping and dating of pregnancy 
The Welsh Mountain ewes were mated on site by one of the seven rams kept for the breeding 
programme.  Ewes were placed with these rams immediately following removal of sponges (± 
exogenous gonadotrophins) and insemination was noted to have occurred on the day when 
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fresh raddle-ink marks were present on the rumps of ewes.  If pregnancy was confirmed by 
trans-abdominal ultrasound approximately 60 days later, then the pregnancy was dated from 
the date of insemination.  Fetal number was also determined at this ultrasound examination, 
and confirmed by ultrasound scan at 80 days gestational age. 
 
3.1.3 Management and maintenance of pregnant ewes 
Prior to inclusion in the study, when weather conditions permitted, pregnant ewes could graze 
on open pasture. At other times were housed in stock-holding pens with ad libitum access to 
hay, sheep nuts, mineral lick and water.  Standard veterinary practise was used for treatment of 
any routine conditions.   
 
3.2 Surgical procedures  
3.2.1 Pre-operative preparation 
To reduce the risk of intraoperative regurgitation of intestinal contents or bloat developing, 
which can occur in up to 6% of general anaesthetics in sheep (123),  pregnant ewes had food 
but not water withdrawn for 24 hours prior to induction of anaesthesia (171).  During this time, 
the ewe was held in an individual holding pen in the experimental facility in the sight of other 
sheep.  Immediately prior to operation the ewe was weighed and transferred to the anaesthetic 
room, where a trans-abdominal ultrasound scan was performed to confirm fetal number and 
viability. 
 
3.2.2 Induction and maintenance of anaesthesia  
Induction of anaesthesia was by maternal intra-jugular injection of alfaxalone 3mg.kg-1 
(Alfaxan®, Jurox, UK).  The ewe was intubated with a size 7.0 – 9.0 cuffed endotracheal (ET) 
tube dependent on maternal weight (Portex® Tracheal tube, Smiths Medical International Ltd., 
Luton, UK) in the dorsal recumbent position with neck extended under the guidance of an 
illuminated laryngoscope.  Successful placement of the ET tube was confirmed by auscultation 
of breath sounds through the chest wall and end tidal CO2 (EtCO2) monitoring.  Anaesthesia 
was maintained with isoflurane (1.5-2.5% in 4:1 O2:N2O) administered by positive pressure 
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ventilation (Flomasta ventilator, M & I.E. Dentsply, Exeter, UK.) throughout the operation.  
Depth of anaesthesia was monitored by observing the jaw tension and eye blink reflexes.  The 
ewe was ventilated in a slight head down position to reduce the chance of aspiration of 
regurgitated stomach contents.  A left lateral tilt on the operating table was maintained for 
reduction of autocaval compression by the gravid uterus. 
Carprofen (1mg.kg-1, RimadylTM, Pfizer, Sandwich, UK) a veterinary non-steroid anti-
inflammatory drug, was given at 50% total anaesthetic time to aid maintenance of anaesthesia.   
Maternal hydration was maintained to counteract the cardiovascular depressant effects of 
isoflurane (173) with a 0.9% Sodium Chloride (NaCl) infusion (5ml.kg-1.hr-1 IV, Aquapharm®, 
Animalcare Ltd., York, UK).  This was commenced once the maternal femoral vein catheter was 
inserted, or via an intravenous (IV) cannula (16G Intraflon 2®, Vygon, Swindon, UK) placed in 
the maternal jugular vein if no catheterisation for experimental purposes was performed.  
Non-invasive maternal monitoring and recording of heart rate, oxygen saturation and EtCO2 was 
performed throughout the period of anaesthesia (total time taken for surgery and experimental 
protocol to be completed) with a veterinary anaesthetic monitor (VM-2500, Viamed, Keighley, 
UK).  Values for each parameter were recorded every 8 s and exported to VM-2500 PC 
software, converted into CSV files and were available for offline data analysis postoperatively.  
 
3.2.3 Preparation of maternal skin 
In all animals, wool was shaved from the maternal abdomen and three iodine washes 
(Vetasept: 7.5% povidone iodine, Animalcare Ltd., York, UK) were performed to remove dirt and 
excess lanolin following induction of anaesthesia.  Prior to incision, the abdominal skin was 
washed with a chlorhexidine solution (4% chlorhexidine gluconate, 96% ethanol) which was 
allowed to evaporate before skin incisions were made.  Additional measures were taken to 
prepare maternal skin in animals exposed to transdermal HIFU, and these will be discussed 
where indicated in the HIFU-specific methods sections (chapter 4). 
   
3.2.4 Maternal surgery  
Surgery was performed under aseptic conditions using routine techniques in our laboratory 
(267-269). Drapes, instruments, ligatures and equipment were sterilised by autoclave.  Heat 
sensitive items (catheters, flow probes, plastic protective covers) were gas sterilised (ethylene 
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oxide, H. W. Andersen Products Ltd., Clacton-on-Sea, UK) with a minimum 24 hours between 
completion of sterilisation and use. Unprepared areas of the ewe were covered with sterile 
drapes, the abdomen was covered with a sterile plastic sheet cut where incisions were required 
(Buster Op Cover, Kruuse, Langeskov, Denmark).   
 
3.2.4.1 Maternal descending aorta and IVC catheters 
The skin of the medial aspect of the upper hind limb was incised to expose the Sartorius and 
Adductor muscles.  Blunt dissection of the plane between these muscles allowed visualisation 
of the maternal femoral artery and vein, which  were then cannulated with 
Polytetrafluoroethylene (PTFE) and Polyvinyl chloride (PVC) catheters (described in more detail 
in section 3.2.6) using the technique described by Hecker (123). In short, the vessel was 
occluded distally by a thick linen ligature to prevent backflow, and forward flow temporarily 
occluded by elevation of the vessel by a second proximal ligature.  The vessel was incised 
between these two points and a suitable catheter advanced via the femoral artery or vein into 
the descending aorta or inferior vena cava, respectively.  The proximal ligature was used to seal 
the vessel around the catheter to prevent blood leakage and the suture tails of the distal ligature 
was then used to anchor the catheter in place against the vessel.  The catheter was tested by 
withdrawing blood and flushing it with sterile saline immediately following insertion.   
 
3.2.4.2 Maternal laparotomy 
A 15-20 cm ventral midline incision was made in the skin of the maternal abdomen, avoiding 
mammary veins.  Blended monopolar diathermy was used to divide subcutaneous fat and 
expose the rectus sheath.  The abdominal cavity was opened along the linea alba to expose the 
pregnant uterus. A main branch of the maternal uterine artery was identified and followed back 
to as close to the common origin of the uterine artery as possible, which was isolated carefully 
at this point.  A transit time probe (4mm aperture, S-series, Transonic Systems Inc., Ithaca NY, 
USA) was placed around the uterine artery and secured in place by closure of the visceral 
peritoneum around the body of the flow probe.  An acoustic coupling agent was used to fill the 
resultant pocket and exclude air from the acoustic window of the flow probe to allow immediate 
use (270). 
 
Chapter 3: Experimental animal methods 
90 
 
3.2.5 Fetal surgery  
The exposed pregnant uterus was exteriorised.  Fetal number and position was confirmed by 
palpation.  For insertion of fetal femoral catheters and flow probes, an hysterotomy was 
performed adjacent to the rear fetal hooves, with the incision made in an area of uterine wall 
relatively free of placentomes of vessels.   The edges of the incision and fetal membranes were 
grasped with Babcock forceps and the fetal hind limbs were exteriorised. The Babcock forceps 
were then also used to also grasp the fetal skin to conserve amniotic fluid during 
instrumentation of the fetus, as described elsewhere (123).  Incisions made bilaterally with 
blended monopolar diathermy in the fetal skin to expose the Sartorius and Adductor muscles.  
Blunt dissection between these muscles allowed access to the femoral artery which was 
isolated on both sides along the exposed length.  On one side, the femoral artery was 
cannulated with a PVC fetal arterial catheter.  On the contralateral side a 2mm aperture time 
transit time flow probe (R series, Transonic Systems Inc., Ithaca, USA) was placed around the 
femoral artery and secured to the surrounding tissue with silk sutures (5-0 Mersilk, Ethicon Ltd., 
Livingston, UK) inserted through the plastic flange.  An acoustic coupling agent was used to 
eliminate air from the acoustic window.  The fetal skin was closed with thin linen suture and the 
catheter and flow probes cable were exteriorised through the skin incision and secured with 
ligatures to the fetal skin to prevent accidental removal.  A third catheter was secured to the 
fetal hind limb for monitoring of the amniotic cavity pressure.  The fetus was then returned to the 
uterine cavity and the fetal amnion and chorion were secured around the trailing catheters and 
cables with thin linen ligatures.  The uterine incision was closed with a non-locking continuous 
suture (2/0 Surgicryl® PGA, SMI AG, St. Vith, Belgium) with additional figure-of-eight sutures 
inserted as required to ensure adequate haemostasis. 
If required for insertion of fetal carotid arterial catheters and flow probes, a second hysterotomy 
was then performed and the fetal head and neck were exteriorised using Babcock forceps to 
secure the fetal membranes and wall to the fetal skin to preserve amniotic fluid.  A ventral 
midline incision was made in the skin of the fetal neck and blunt dissection performed between 
the sternocleidomastoid and scalene muscles to expose the carotid artery bilaterally.  The artery 
was isolated along its exposed length, and a fetal arterial catheter was advanced via the carotid 
artery into the ascending aorta using the technique described for the fetal femoral artery.  On 
the contralateral side a 2mm aperture transit time flow probe (R-series, Transonic Systems Inc., 
Ithaca NY, USA) was placed around the carotid artery and secured with silk sutures inserted 
through the plastic flange of the probe and surrounding tissue.  Acoustic coupling agent was 
again used to exclude air.  The fetal skin was closed with thin linen ligature and the catheter and 
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cable exteriorised through the skin incision.  The fetal head was then returned to the uterine 
cavity and the fetal amnion and chorion and uterine incision closed as previously. If there was 
intraoperative loss of amniotic fluid an approximate equivalent volume of warmed sterile saline 
was transfused via the fetal amniotic catheter prior to the commencement of the experimental 
protocol and all vascular catheters were heparinised at this time. 
In Group A animals, the operative procedures were complete at this point and the fetal and 
maternal catheters and flow probes were connected to data acquisition and recording software 
in preparation for the start of the acute HIFU experimental protocol.   
In Group R animals, the fetus was given antibiotics following uterine closure (600mg 
benzylpenicillin IA, Crystapen, Genus Pharmaceuticals, Newbury, UK). The rectus sheath was 
repaired with polyglycan sutures (2 Vicryl, Ethicon Ltd., Livingston, UK).  The maternal skin was 
closed with non-absorbable sutures (2/0 Ethilon, Ethicon Ltd., Livingston, UK.).  Vascular 
catheters were exteriorised via a keyhole incision on the maternal flank; flow probe cables were 
exteriorised through the contralateral flank.  Inhalational anaesthesia was withdrawn and the 
animal was extubated when spontaneous respiratory effort was re-established. 
 
3.2.6 Catheter specifications 
To make maternal arterial catheters a 1.5 m lengths of PTFE clear thin wall sleeving was used 
(bore 1.00 mm, external diameter 1.60 mm, product number 01-96-1725, Altec, Bode, UK).  A 
cuff of wider bore PTFE was adhered to the catheter at 15 cm from the tip to gauge of distance 
of insertion at surgery and allow anchoring at the insertion point to the vessel (Figure 3.1).  Stiff 
materials such as PTFE provide higher fidelity pressure recordings than softer catheter 
materials, but have a higher rate of vessel perforation and are vulnerable to mechanical 
occlusion when kinked. PTFE catheters are more suitable for catheterising larger arterial 
vessels (116). 
Maternal vein and amniotic catheters were made from 1.5 m length of PVC clear laboratory 
tubing (bore 1.00mm, external diameter 2.00m, product number 01-94-1561, Altec, Bode, UK).  
Maternal vein catheters were marked at 8 cm intervals to assess the distance of insertion during 
surgery and for ease of identification when exteriorised.  Fetal amniotic catheters had round 
windows cut into the tip to ensure patency in the amniotic space and allow anchoring (Figure 
3.1). 
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Fetal arterial catheters were made by joining a 7 cm tip of PVC clear single lumen tubing (bore 
0.86 mm, external diameter 1.52mm, Critchley Electrical, NSW, Australia) to a 1.5 m length of 
coloured PVC laboratory tubing (bore 1.00 mm, external diameter 1.60mm, Altec, Bode, UK) 
using cyclohexanone.  During surgery catheter tips were shortened to an appropriate length and 
a 30-400 bevel angle cut to the end to facilitate entry into a smaller vessel (Figure 3.1).  Colour 
coded outer tubing was used for ease of identification of fetal vessels.  PVC is softer and so 
less likely to perforate vessels, but retains adequate stiffness to advance into vessels and 
produce phasic pressure recordings of acceptable accuracy and is not overly susceptible to 
mechanical obstruction.  Additionally, blood does not clot readily in PVC, although fibrin will 
adhere to it, more so in fetal than adult preparations.    The benefit of joining a small tip to a 
wide bore is that sampling of blood is easier and better quality phasic pressure recordings.  
PVC catheters are more suitable for catheterising smaller vessels and veins (116).  
 
Figure 3.1: Surgical catheter tips. 
The diagram shows the different types of maternal and fetal catheter tips used in the instrumented pregnant sheep. 
3.2.7 Post operative care 
Following invasive surgery, if animals were to be recovered, ewes were housed in individual 
floor pens with a 12 hour light and dark cycle with ad libitum access to hay, nuts and water.  
Maternal antibiotics (Procaine Benzylpenicillin 15 mg kg-1 I.M., Depocillin®, Intervet UK Ltd., 
Milton Keynes, UK) were administered for 5 days following surgery and fetal antibiotics (600mg 
benzylpenicillin I.A., Crystapen, Genus Pharmaceuticals, Newbury, UK) were administered daily 
until the end of the experiment. Maternal analgesia (Carprofen 1.4 mg kg-1 S.C., RimadylTM, 
Pfizer Ltd., Sandwich, UK) was administered for 3 days postoperative, and as required if signs 
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of maternal pain were evident based on behaviour, facial expressions, stance and feeding 
patterns.  Animals were checked daily for signs of maternal pain and distress, problems with 
mobility, bladder or bowel function, preterm labour or rupture of membranes or vaginal bleeding. 
 
3.3 Invasive assessment of materno-fetal cardiovascular status 
3.3.1 Invasive blood pressure monitoring 
Intra-arterial catheters were used for the acute and chronic measurement of arterial blood 
pressure in maternal and fetal sheep.  A blunt 18 G needle was inserted into the end of each 
catheter, connected to a 3-way tap and the catheter was filled with a volume in excess of the 
catheter dead space for transmission of phasic pressure changes.  A solution of 0.08 IU 
Heparin (Wockhardt, Wrexham, UK) per ml 0.9 % NaCl (Aquapharm®, Animalcare Ltd., York, 
UK) was used. 
The catheters were connected to pressure transducers (ArgoTransTM Transducer, Argon 
Medical Devices Inc., Plano TX, USA) positioned at the level of the maternal heart.   The 
pressure transducers convert the arterial pressure waveform into an electrical signal which is 
sampled by the CamDAS system at a rate of 500 kHz (private communication).  Phasic arterial 
pressure recordings were corrected for atmospheric pressure (maternal) or amniotic cavity 
pressure (fetal).  For maternal pressure transducer recordings, atmospheric pressure at the 
level of the heart was regarded as zero. 
 
3.3.2 Invasive blood flow monitoring 
Transit time flow probes were used for the acute and chronic measurement of arterial flow rates 
in maternal and fetal sheep.  They are non-constrictive flow probes which can be placed around 
an isolated vessel and secured to adjacent tissues to prevent mechanical irritation or occlusion 
of the vessel by shifting of the flow probe (Figure 3.2).  They are able to measure absolute 
blood flow rates in the vessel they surround, and this is independent of the diameter, shape and 
angulation of the vessel, as well as the flow profile of the blood within (271).  Further details of 
how this is achieved are given in Appendix II.  The transit time flow probes convert the rates of 
arterial blood flow into an electrical signal which is sampled by the CamDAS system at a rate of 
500 kHz (private communication). 
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Figure 3.2 Transonic flow probes. 
The diagram shows a cross sectional representation of a blood vessel positioned within the time-transit flow probe. 
3.3.3 Data Recording System 
Physiological values were obtained and recorded using a customised data acquisition system, 
the Cambridge Data Acquisition System (CamDAS) (268, 269).  This is an ambulatory system, 
housed in a protective jacket worn by the pregnant ewe (Figure 3.3). It makes use of a battery-
powered pressure and PASAQ boxes to continuously transmit digitised pressure and flow 
information to a laptop running IDEEQ (Maastricht Instruments, Maastricht, Netherlands).  
Recorded data were available thereafter for offline analysis (Figure 3.4). 
 
Figure 3.3: Cambridge Data Acquisition System (CamDAS).   
The photograph shows one of the pregnant ewes (‘Spot’) in Group R wearing the CamDAS jacket.  (a) Box for flow 
probe attachment and Bluetooth transmission; (b) box containing pressure transducers; (c) data cables connecting 
pressure box to flow box; (d) battery packs.  Illustration adapted with permission from Allison et al.  (269). 
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Figure 3.4: Schema of CamDAS data transmission.   
The diagram shows the collection and transfer of maternal and fetal cardiovascular data through CamDAS system 
to recording software, where digitised data was stored for further analysis offline. 
3.3.4 Data processing  
Cardiovascular data for arterial blood pressure and blood flows were consolidated into files 
containing either 90 minutes (Group A) or 24 hours of data (Group B, 00:00:00 to 23:25:59) and 
were uploaded into a data analysis program (Labchart 7 Pro, AD Instruments Ltd., NZ).  Using 
this software, mean values for sequential one minute epochs (“minute means”) were generated 
for the systolic peak, diastolic nadir, and amplitude of maternal and fetal arterial blood 
pressures.  Minute means for mean arterial flow rate and mean amniotic cavity pressure were 
also generated by this method.  A maximum of 1440 numerical values for each cardiovascular 
parameter per 24 hours, or 90 per 90 minutes, were exported to a customised spreadsheet 
(Excel ®, Microsoft Corporation, Redmond WA, USA).  Values were first logic checked by the 
customised spreadsheet for data which was non-physiological and produced due to catheter 
blockage or equipment error (“artefact data”, logical arguments detailed further in Appendix III).  
Following the exclusion of “artefact data”, calculations for mean arterial pressure and vascular 
resistance were applied to the remaining minute means.  For Group A, minute means are 
reported directly.  For Group R, minute mean values within any given hour were then averaged 
to give hourly means, and hourly means were further averaged to give the daily means reported 
in this chapter.  This method of using time epochs and sequential averaging is recognised to 
prevent time periods with greater periods of excluded “artefact data” being under-represented in 
the overall average (272). 
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3.4 Heart rate variability  
Continuous values of fetal heart rate were recorded using a customised data acquisition system 
(CamDAS) described in section 3.3.3.  In animals in Group R, fetal heart rate was recorded 
from the immediately post-operative period until post-mortem, and converted into files 
containing 24 hours of data (00:00:00 to 23:25:59) in Labchart (Labchart 7 Pro, AD Instruments 
Ltd., Dunedin, NZ).  The electrical signals produced by the pressure transducers and flow 
probes were sampled at 500 kHz (500,000 readings per second) which is more than sufficient to 
acquire fetal heart rate on a beat-to-beat basis, and measure inter-beat variability in the fetal 
heart rate.   
The fetal heart rate was sampled daily in six, five-minute blocks spaced evenly between 00:00 
and 06:00 using the waveform derived from fetal descending aorta catheter signals.  Mean 
values for fetal heart rate during sequential 2.5 second epochs throughout each block were 
generated for cardiovascular data using Labchart and these values were plotted chronologically 
to create a CTG-like representation of fetal heart rate (Figure 3.5).  Blocks were visually 
identified as FHR patterns A-D, and quiet sleep was defined as FHR pattern A and active sleep 
as FHR pattern B.  If no suitable FHR pattern was acquired, resampling was performed within 
the same time period for that day, offset by 15 minutes. 
 
Figure 3.5 Fetal Heart Rate Variability Patterns.  
A representative example of active sleep (left) and quiet sleep (right), which can be categorised by visual 
identification. 
In blocks defined as active or quiet sleep, the R-R intervals were identified using an automated 
program in Labchart 7 Pro; each block was manually checked for accuracy of R wave 
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identification and missed R waves were manually marked.  Time domain and power spectral 
analysis was then performed; based on previous published literature the frequency boundaries 
used were: VLF 0-0.04 Hz, LF 0.04-0.15 Hz, HF 0.15-0.4 Hz (151, 273, 274). Mean daily values 
for average heart rate, SDNN, RMSSD, absolute and normalised LF and HF, LF/HF ratio and 
total power were calculated daily from the five-minute samples.  Baseline values represent the 
average of the mean values obtained on days three to five following exposure to HIFU or sham 
occlusion of placental vasculature. 
STV was calculated using R-R intervals in a customised excel spreadsheet, as previously 
published (153): first average heart rate was used to calculate the baseline R-R value; second 
the baseline R-R value was used to exclude values representing accelerations or decelerations 
as these are excluded by STV calculation software (129). The remaining values were averaged 
in 3.75 s (1/16th minute) epochs and the mean difference between 16 sequential periods (1 
minute mean difference) was calculated as per published STV calculation algorithms (272). 
Final STV values are the mean of the 5-minute mean difference values.  
 
3.5 Invasive assessment of metabolic and endocrine status 
3.5.1 Blood sampling 
A closed system for management of maternal and fetal catheters was connected under aseptic 
operative conditions using sterile components to reduce the risks of fetal and intrauterine 
infection during regular catheter use.  The ends of maternal and fetal catheters were disinfected 
with immersion in a chlorhexidine solution (4% chlorhexidine gluconate, 96% ethanol) 
immediately following exteriorisation and connected to three-way taps.  One connection of the 
three-way tap was to the pressure transducer described in section 3.3.1; the other connection 
was to a polyethylene extension catheter (Lectro-cath®, Vygon, Swindon, UK) capped with a 
push-fit adaptor containing an one-way bacteriostatic membrane (Bionector 2®, Vygon, 
Swindon, UK), from which blood samples could be drawn using aseptic non-touch techniques 
without opening the closed circuit to the atmosphere.  Bionectors were changed at least every 
seven days as per manufacturer recommendations. Catheters were maintained patent with daily 
flushing with heparinised saline (100 IU.ml-1 heparin sodium in 0.9% NaCl solution, 5 mL flush 
daily). 
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In Groups A and R, blood samples were taken from the maternal and fetal descending aortic 
catheters, and in Group A also from the fetal ascending aorta catheter (0.3 mL each) were 
drawn into sterile syringes at pre-defined time points.  These were used to determine pH, 
arterial base excess, concentration of bicarbonate, partial pressures of oxygen and carbon 
dioxide (ABL5 Blood Gas Analyser, Radiometer, Copenhagen, Denmark).  Blood glucose and 
lactate concentrations were obtained from an automated analyser (YSI 2300 Stat Plus, Yellow 
Springs Instruments, Ohio, USA).  In Group A the haemoglobin, haematocrit and oxygen 
saturation of the blood were determined using an ABL80 Flex analyser (Radiometer, 
Copenhagen, Denmark). In the HIFU exposed animals of Group R haemoglobin and oxygen 
saturation of the blood were determined using the ABL80 Flex analyser.  In the control group R 
animals, the haemoglobin and oxygen saturation of blood were determined using an OSM3 
analyser (Radiometer, Copenhagen, Denmark).  Results obtained by these two methods have 
been previously been compared internally at time of machine replacement and are highly 
comparable (private communication).   
The maternal arterial blood oxygen content (CaO2; in ml O2.ml blood-1), oxygen (ml O2.min-1) 
and glucose (µmol.min-1) delivery to the uterus were calculated using the following equations:  
 
CaO2 = (([Hb] x SaO2)/100)(k/100) + (d x PaO2) 
 
Oxygen delivery = CaO2 x blood flow 
 
Glucose delivery = [glucose] x blood flow 
where [Hb] (g.dl-1) is the concentration of haemoglobin in arterial blood, SaO2 (%) is the 
saturation of haemoglobin with oxygen. Assuming that one molecule of adult haemoglobin binds 
four molecules of oxygen, k is the capacity of haemoglobin to carry oxygen (mlO2.gHb-1), 
usually quoted as 1.34-1.36 at sea level. The coefficient d is the solubility of oxygen in blood, 
usually quoted as 0.003 at body temperature, and PaO2 is the partial pressure of arterial oxygen 
(mmHg), and this section of the equation accounts for the contribution of dissolved oxygen.  The 
concentration of arterial glucose is given in mmol.L-1. Oxygen delivery is therefore given in ml 
O2.min-2, and glucose delivery in µmol.min-1 where uterine blood flow is measured in ml.min-1. 
The fetal arterial blood oxygen content (f CaO2; in mmol.L-1) was calculated using and adaption 
of the standard equation above which accounts for the changes in oxygen carriage by fetal 
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haemoglobin, converts the quantity of oxygen dissolved into the molar form, but treats dissolved 
oxygen as negligible (267): 
f CaO2 = (([Hb] x SaO2)/100) x 0.62 
Oxygen and glucose deliveries were calculated by multiplying the arterial concentration of each 
in by the flow in the corresponding vessel at the same time, as previously.  The flow value used 
was the mean flow during the period in which the sample was taken, which varied in duration 
(Figure 3.6). 
 
Figure 3.6: Arterial pressure artefact (denoting the duration of sampling). 
The screen capture of Labchart software shows the non-pulsatile artefact that occurs when the three-way tap is 
closed to the pressure transducer during blood sampling, which indicates the time during which mean flow should 
be calculated for the substrate delivery equation. 
 
3.5.2 Plasma cortisol assay 
For Group R animals, maternal and fetal blood was collected under basal conditions, with the 
ewe unrestrained in her usual enclosure, by the method described above.  On the fifth day post 
HIFU (baseline) and the day of post-mortem (day 20), in addition to the 0.3 ml required for daily 
analysis, a further 5 ml of maternal and fetal blood was collected into EDTA and centrifuged 
(5000 rpm, 40C, 5 min) for plasma extraction.  All samples were then frozen at -80oC for later 
analysis.  Samples for the HIFU and control animals of Group R were analysed at the same 
time, by the method below. 
The concentration of fetal cortisol in plasma was quantified using a commercially available 
cortisol indirect enzyme-linked immunosorbent assay (ELISA) kit according to the product 
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instructions (RE52061, IBL International, Hamburg, Germany).  This assay has previously been 
validated for use in fetal ovine plasma (275). 
Duplicate 20 µl plasma aliquots (undiluted) were taken from previously unthawed EDTA-treated 
samples for use in the cortisol assay.  Each microtiter plate was also populated with 
manufacturer-provided standard concentrations of cortisol in duplicate (0, 20, 50, 100, 200, 400, 
800 ng.ml-1), manufacturer-provided control solutions, and stripped plasma.  Standard and 
control solutions were placed at opposite ends of the plate to minimise the effect of intra-assay 
variation on the extrapolation of cortisol concentrations.  To make stripped plasma activated 
charcoal was added to fetal plasma at a ratio of 1 g:50 ml, mixed and centrifuged (2996 rpm, 
40C, 10 mins).  This process was repeated and the resulting supernatant was filtered, and used 
in the assay without further dilution.  The samples were incubated with enzyme conjugate at 
room temperature for 1 hour and then washed with buffer, before substrate and stop solutions 
were applied to complete the immunofluorescence reaction.   The optical density of the wells 
was then read at a wavelength of 450 nm (ELx800 Absorbance Reader, Biotek, Winooski VT, 
USA) within ten minutes of the end of the assay. 
A standard curve for interpretation of the results of each plate was produced by plotting the 
mean optical density of manufacturer-provided standard concentrations of cortisol against their 
known concentrations, expressed as a natural logarithm.  The equation of the resulting line of 
best fit was used to extrapolate cortisol concentrations from measured optical densities.  Using 
this method, all control solution values fell within the manufacturer specified ranges; the stripped 
plasma values concentrations of cortisol were 3.2 – 3.6 ng.ml-1, which was the lower limit of 
detection for the assay.  The inter-assay coefficient of variation (CV) for the 2 control samples 
(mean concentrations 68 ± 27 and 206 ± 61 ng.ml-1) was 6.3% and 4.2% respectively, giving 
and overall inter-assay CV of 5.2%.  The intra-assay coefficient of variation for the fetal samples 
reported (n=60) is 5.0% and for the maternal samples reported (n=48) is 8.3%; the overall intra-
assay CV is 6.0%.  The stated cross-reactivity of the cortisol assay with other cortisol related 
compounds is cortisone 4.2%, corticosterone 1.4%, 17α-OH-progesterone 0.4%, 
desoxycorticosterone 0.9%, 11-desoxy-cortisol 7.0%. 
 
3.6 Non-invasive assessment of fetal growth and wellbeing 
All ultrasound scans were carried out by a single operator (CJS) using a 3.75 MHz convex 
abdominal probe (PVK-357AT, PowerVision 7000, Toshiba Medical Systems, Crawley, UK). 
Animals were held in a dorsal recumbent position by an experienced handler and restrained 
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with the minimum force required in order to expose their abdomen, which was shaved and 
depilated at the time of HIFU or sham application and did not require further hair removal 
following this.  All ultrasound examinations were limited to a maximum length of 30 minutes in 
un-anaesthetised sheep.  In all cases, confirmation of fetal heart pulsations was sought before 
proceeding with the rest of the examination. 
Ultrasound measurements were repeated until a minimum of three representative values were 
obtained.  B-mode images were optimised for depth, focus and gain and Doppler assessments 
were performed with appropriate adjustment of pulse repetition frequency and wall motion filter 
for the vessel under examination.  Images could not be saved for offline examination due to the 
basic nature of the ultrasound machine available, therefore assessment for inter-observer 
variability was not possible. 
 
3.6.1 Ultrasound measurement of fetal biometry 
Based on descriptions in published literature, biparietal diameter (BPD) was estimated as the 
widest linear distance between parietal bones behind the proximal end of the supra-orbital 
processes with the fetal head in axial view (202)(Figure 3.7a).  The abdominal circumference 
(AC) was measured using in a transverse circular view of the fetal abdomen at the level of the 
12th thoracic rib, just above the insertion of the umbilical cord, using an ellipse (203)(Figure 
3.7b).  The femur length (FL) was measured as the calcified length of the bone with the angle of 
insonation perpendicular to the shaft of the bone (202)(Figure 3.7c). Amniotic fluid was 
measured as the deepest vertical pool (DVP) within the pregnant horn which did not contain 
fetal parts. 
 
Figure 3.7: Ultrasound assessment of fetal biometry.   
The ultrasound images show (A) axial section of fetal head; (B) transverse circular view of fetal abdomen; (C) fetal 
femur.  These are representative ultrasound images of the type collected in group S animals, using a 1.9 – 6.0 MHz 
convex sector array, (PVT-375BT, i700, Toshiba Medical Systems UK).  Sheep: BL11, 109 d gestational age. 
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Estimated fetal weight was calculated using a sheep specific formula suggested by Carr et al. 
(203) and the Hadlock (BPD-AC-FL) formula optimised for use in human pregnancy (276).  The 
formula used to calculate fetal growth rates was:  
Fetal growth rate = (Day 21 value – baseline value) / 21 
 
3.6.2 Fetal Doppler studies 
The methods used for Doppler evaluation of maternal and fetal vessels are based on good 
practice guidelines published for use in human pregnancy (277). 
The umbilical cord was identified with colour flow Doppler and the arterial pulsatility index (PI) 
was measured with pulsed-wave Doppler, with the PI based on auto-tracing of the best three 
consecutive waveforms.  Umbilical artery Doppler was performed in all cases in a free loop of 
umbilical cord near the cord insertion (Figure 3.8a).   This was done to ensure the sampling was 
performed in the full umbilical cord after all the allantoic vessels had joined.  Although in 
humans there is variation of values for PI within the umbilical cord, with higher values found 
nearer the cord insertion, this technique was the only way to ensure reproducibility between 
animals and samples. 
Middle cerebral artery Doppler was performed in an axial section of the fetal head at the level of 
the sphenoid wings with colour flow mapping used to identify the circle of Willis (Figure 3.8b). 
Sampling was undertaken by pulsed-wave Doppler within the proximal third of the vessel; no 
angle correction was applied and the angle of insonation was kept as close to 00 as possible.  A 
restriction of ± 200 angle of insonation was imposed and values were not recorded when this 
section was not achieved.  PI was measured by auto-tracing of the best three consecutive 
waveforms; peak systolic velocity (PSV) was measured with manual calliper application of the 
same three waveforms. 
Ductus venosus Doppler was performed in either an oblique transverse section through the 
upper abdomen or in the mid-sagittal longitudinal section, depending on fetal positioning.  The 
vessel was first identified with B-mode imaging between the umbilical vein and the inferior vena 
cava, confirmed as having characteristic aliasing on colour flow Doppler (Figure 3.8c), and 
sampled with pulsed-wave Doppler.  PI was measured by auto-tracing of the best three 
consecutive waveforms without contamination from other vessels. 
The maternal uterine artery was identified with colour flow Doppler where it crossed the external 
iliac artery, and the pulsed-wave Doppler gate was placed within 1 cm of this crossover point 
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(Figure 3.8d).  Measurements were taken bilaterally and PI was measured by auto-tracing of the 
best three consecutive waveforms.  Values quoted are an average of both sides. 
 
Figure 3.8: Fetal Doppler studies in sheep.   
The colour flow Doppler images show (A) the insertion of the umbilical cord, (B) the middle cerebral arteries and 
the pulsed wave Doppler images show in (C) the waveform of the ductus venosus and (D) the maternal uterine 
artery.  These are representative ultrasound images of the type collected in group S animals, using a 1.9 – 6.0 MHz 
convex sector array, (PVT-375BT, i700, Toshiba Medical Systems UK).  Sheep: BL11, 109 d gestational age. 
3.6.3 Fetal cardiac function 
The methods used for evaluation of fetal cardiac function are based on good practice guidelines 
published for use in human pregnancy (248). 
In the four-chamber view of the heart, the M-mode axis line was placed perpendicular to the 
intraventricular septum at the tip of the mitral valve leaflets.  One dimensional measurements 
were taken of the ventricular maximum diameter in systole (ESD) and minimum diameter at the 
end of diastole (EDD) over three consecutive beats.  These values were used to calculate 
fractional shortening (FS), ventricular volumes using the Teichholz formula (the end diastolic 
volume (EDV) and end systolic volume (ESV)), and the ejection fraction (EF): 
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FS = (EDD-ESD)/EDD 
EF = (EDV-ESV)/EDV 
In the apical four chamber view, the sample gate of the pulsed-wave Doppler function was 
placed just beneath the atrio-ventricular valves, with the angle of insonation maintained to ± 200 
to the direction of blood flow through the valve.  The isovolumetric contraction time (ICT), 
ejection time (EjT) and isovolumetric relaxation time (IRT) were measured over three 
consecutive beats and used to calculate the myocardial performance index (MPI): 
MPI = (IRT + ICT)/EjT 
 
3.7 Group-specific experimental protocols 
3.7.1 Group A(cute) 
Eleven singleton Welsh Mountain sheep fetuses at 116 ± 1 d gestational age (term ~148d) were 
used (HIFU n=5; Sham n=6).  Under general anaesthesia, maternal laparotomy was performed 
and arterial catheters were placed in the maternal descending aorta and the fetal ascending and 
descending aorta; arterial flow probes were placed around the maternal uterine artery and the 
fetal femoral and carotid arteries (section 3.2.4, 3.2.5).  The uterine incisions were closed and 
the anterior uterine surface was left exposed; the maternal and fetal arterial catheters and flow 
probes were connected to the CamDAS system and calibrated (sections 3.3.1, 3.3.2, 3.3.3).  
Once completed and ready to record, this time point was taken to be the start of the 
experimental protocol (“-30 min”).  The median duration of anaesthesia at the start of the 
experimental protocol ("-30 min”) was 145 min (range 128-180 min) in the sham group and 138 
min (range 125-157 min) in the HIFU group (ns, p=0.14). 
The experimental protocol took place over 90 minutes.  Cardiovascular variables were recorded 
though-out and divided into three, 30 minute periods for analysis (baseline, HIFU/sham 
exposures, recovery, Figure 3.9).  HIFU was applied trans-uterine to occlude between five and 
seven placental vessels using the protocol for group A described later (section 4.3.1.3). At the 
end of the recovery protocol (“60 min”) cardiovascular monitoring was stopped, but in some 
animals further HIFU exposures were delivered as part of the dose-delivery study to maximise 
animal usage.  All animals were euthanised (section 4.3.1.2) for post-mortem examination 
within one hour of the end of the recovery protocol (sections 4.3.1.4, 4.3.1.7).   
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Figure 3.9: Group A experimental timeline.   
Schema of experimental timeline divided into the baseline, HIFU/sham exposures, and recovery periods. 
 
3.7.2 Group S(urvival) 
Twelve singleton Welsh Mountain sheep fetuses at 115 ± 10 d gestational age were used (HIFU 
n=6; sham n=6). Prior to HIFU or sham exposure of placental vasculature, materno-fetal 
ultrasound was performed in un-anaesthetised animals to establish a physiological baseline 
(section 3.6). Between 24-48 h later, animals were placed under general anaesthesia to allow 
prone positioning and control maternal movement, however no invasive surgical procedures 
were performed. Materno-fetal ultrasound was performed shortly after induction of anaesthesia, 
during the HIFU planning period, then at the midpoint and end of HIFU or sham exposures of 
placental vasculature (Figure 3.10).  The median duration of anaesthesia was 147 min (range 
142 – 161 min) in the control group and 144 min (range 128 – 165 min) in the HIFU groups (not 
significant, p = 0.45). 
 
Figure 3.10: Group S experimental timeline.   
Schema of anaesthesia and acute experimental timeline for group c animals, divided into periods of experimental 
preparation (“prep”), planning of vascular exposures, exposure to HIFU, materno-fetal ultrasounds and length of 
anaesthesia. 
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HIFU was applied through intact maternal abdominal skin to occlude four to six placental 
vessels using the Group S HIFU protocol (section 4.5.1.3).  Animals were recovered from 
anaesthesia and monitored for 21 days by ultrasound until approaching term (Figure 3.11), 
when they were euthanised for post-mortem examination (section 4.5.1.2, 4.5.1.4, 4.5.1.7).  In 
addition, fetal weight and biometry was measured; fetal brain, heart, lungs, kidneys, livers, 
adrenal glands, pancreases were weighed. 
 
Figure 3.11: Group S post exposure monitoring timeline.   
The schema shows the relative frequency and timing of daily inspections, materno-fetal ultrasound and post 
mortem examination. 
 
3.7.3 Group R(ecovery) 
3.7.3.1 Control animals 
All experimental procedures and raw data collection in the animals forming the Group R control 
animals had been completed prior to the onset of this study.  This work was performed by 
Professor Giussani, Dr B Allison, Dr N Yiu and Dr K Brain at the large animal facility, University 
of Cambridge.  Professor Giussani provided the raw data (IDEEQ files of cardiovascular data, 
Home Office records of animals, laboratory records of surgical procedures, timings and 
recovery, unprocessed tables of daily blood results, records of post mortem biometry and organ 
weights, and frozen fetal plasma for cortisol assays) for comparison to the HIFU exposed 
animals as part of the collaboration between Imperial College London and the University of 
Cambridge to conduct this study.  All subsequent analysis presented in chapters 5-7 of this raw 
data is my own work, and performed as described in the relevant methods sections. 
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Six singleton Welsh Mountain sheep fetuses at 116 ± 2 d gestational age were used. Under 
general anaesthesia, a maternal laparotomy and uterine hysterotomy were performed.  Arterial 
catheters were placed in the maternal descending aorta and the fetal ascending and 
descending aorta; arterial flow probes were placed around the maternal uterine artery and the 
fetal femoral and carotid arteries (section 3.2.4, 3.2.5).  The uterine and abdominal incisions 
were closed, catheters and flow probe cables were exteriorised through the maternal flank, the 
CamDAS jacket was fitted to the sheep, and catheters and flow probes were connected to the 
CamDAS system (section 3.3) (Figure 3.12).  The median duration of anaesthesia was 145 min 
(range 133 – 170 min).  Animals were recovered from anaesthesia (section 3.2.7), and 24-hour 
cardiovascular recording was commenced and continued for 21 days until approaching term, 
with daily blood sampling at a consistent time of day (Figure 3.13), after which animals were 
euthanised for post-mortem examination.  Records of fetal biometry, organ weights, placentome 
number, type and weights were available for these animals.  
 
3.7.3.2 HIFU exposed animals 
Ten singleton Welsh Mountain sheep fetuses at 116 ± 1 d gestational age were used. Under 
general anaesthesia, HIFU was applied through intact maternal abdominal skin to occlude six 
placental vessels in each animal using the Group R HIFU protocol (section 4.6.1.3).  Following 
this, maternal and fetal surgery was started.  A maternal laparotomy and uterine hysterotomy 
were performed.  Arterial catheters were placed in the maternal and fetal descending aortas and 
an arterial flow probes was placed around fetal femoral artery (section 3.2.4, 3.2.5). A reduced 
amount of fetal and maternal surgical instrumentation was performed compared to the Group A 
and the control Group R animals to keep the anaesthetic time below 5 hours.  The uterine and 
abdominal incisions were closed, catheters and flow probe cables were exteriorised through the 
maternal flank, the CamDAS jacket was fitted to the sheep, and catheters and flow probes were 
connected to the CamDAS system (section 3.3) (Figure 3.12).   The median duration of 
anaesthesia was 238 min (range 211 – 293 min) in these animals.  This was significantly longer 
than the control animals (student’s t test, p < 0.001).  Animals were recovered from anaesthesia 
(section 3.2.7), and 24-hour cardiovascular recording was commenced and continued for 21 
days until approaching term, with daily blood sampling at a consistent time of day (Figure 3.13), 
after which animals were euthanised for post-mortem examination (section 4.6.1.2, 4.6.1.4, 
4.6.1.7).   
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Figure 3.12: Group R surgical and experimental timeline.   
Schema of surgical and acute experimental timeline for group R animals, divided into periods of surgical 
preparation (“prep”), planning of vascular exposures, exposure to HIFU, maternal and fetal surgical procedures and 
fitting and connection of CamDAS system. 
 
 
Figure 3.13: Group R postoperative monitoring timeline.   
The schema shows the relative frequency and timing of cardiovascular monitoring, blood sampling for metabolic 
and endocrine analysis, sampling of the fetal heart rate for analysis of variability, and post mortem examination. 
 
3.8 Statistical analysis 
All statistical analysis was performed in SPSS (version 22, IBM, NY, USA).  Graphs were drawn 
in GraphPad Prism (version 6, GraphPad Software, Inc., San Diego CA, USA).  Statistical 
significance was accepted when p < 0.05 for all tests, although where applicable individual p 
values are presented in graphs and tables. 
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3.8.1 Descriptive and comparative statistics 
3.8.1.1 Continuous data 
Data were assessed for normality using the Shapiro-Wilkes test.  Descriptive analysis was 
performed using mean ± standard error of the mean (SEM) for normally distributed physiological 
and metabolic data; mean ± standard deviation (SD) was used for normally distributed 
ultrasound data.  Median ± 95% confidence intervals (95% CI) were used for non-parametric 
continuous data, unless otherwise stated.  A two-tailed Student’s t-test was used to compare 
means (normally distributed) or a Mann-Whitney U-test was used to compare medians (non-
parametric data).  
To assess the effect of HIFU treatment on a continuous dependent variable when additional 
independent variables needed to be considered, two-way ANOVA testing was used.  A 
repeated measures two-way ANOVA was used to investigate the change in the dependent 
categorical variable due to the interaction of time with HIFU treatment; a standard two-way 
ANOVA was used if the second independent categorical variable was not time.  If a significant 
effect or interaction was identified post hoc testing as applicable was performed to identify the 
source of variation. 
 
3.8.1.2 Area under the curve analysis of cardiovascular data 
In Group A, the experimental protocol was divided into three, 30 minute periods, baseline, HIFU 
or sham exposures, and recovery.  Absolute cardiovascular values in the exposure and 
recovery periods were first compared to the mean of the baseline period, and then the 
magnitude of change from the baseline (in absolute and percentage terms) was calculated.  To 
investigate these comparisons further, a summary measure of analysis, area under the curve, 
was applied to the absolute values, and the values for absolute and percentage change from 
baseline for cardiovascular indices in each of these time periods.  This is a recognised method 
of generating values suited to statistical analysis from detailed short-term physiological data 
(278).  
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3.8.1.3 Categorical data 
Proportions of categorical data are described as numerator over denominator, with a 
percentage value given.  A chi-squared test was used for univariate analysis of categorical data, 
with additional calculation of odds ratios and relative risks and their associated 95% confidence 
intervals.  
 
3.8.1.4 Gestational age 
Gestational age is expressed as the mid-range value of the data set ± half the range.  
 
3.8.2 Modelling statistics   
3.8.2.1 Correlation 
To compare ultrasound to necroscopy measurement of fetal biometry, Pearson correlations 
were performed normally distributed data and Spearman rank correlations were performed for 
non-parametric data. Bland-Altman correlations were performed to examine the limits of 
agreement between the techniques: percentage differences quoted were calculated as 
(100*(USS-PM)/average of USS and PM). 
 
3.8.2.2 Linear regression 
Linear regression was performed to model the relationship between scalar dependent and 
independent continuous variables.  Analysis of covariance (ANCOVA) testing was used to test 
the effect of exposure to HIFU on the relationship of the dependant variable to the independent 
variable where a significant relationship was found by linear regression. 
 
3.8.3   Establishment of a baseline in Group R 
Following the experimental protocol recovery from surgery was monitored for 21 days. Daily 
values for maternal and fetal cardiovascular indices and metabolic status were generated.  As it 
was not possible to establish a pre-operative baseline, the baseline was taken to be on day five 
postoperative.  This is when postoperative recovery is traditionally understood to be complete in 
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the fetal sheep model and has recently been supported by work published from our laboratory 
(269).  Absolute daily cardiovascular and metabolic values were first compared to the day five 
baseline, and then the magnitude of change from the baseline (in absolute and percentage 
terms) was calculated.   
3.8.4 Power calculations 
Testing for indirect iatrogenic harm (Groups A, S and R): 
These phases of the study were powered to detect a difference in means of quantitative data as 
follows: 
Difference in means ≥ 2.5 
Alpha = 0.05 
Power = 80% 
Minimum sample size required = 5  
The expected difference in means was based on published cardiovascular, metabolic and 
endocrine data of chronically instrumented fetal sheep responses to intrauterine challenges 
causing chronic hypoxia, growth restriction or stress (269, 270, 279, 280). 
 
Testing for direct iatrogenic harm (pilot, bridging and specific safety studies): 
These phases of the study were not powered for sample size as there were no quantitative 
outcomes. 
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4.1 Introduction 
The purpose of this study was to test the feasibility, efficacy and safety of HIFU mediated 
selective placental vascular occlusion in a large animal model (as described in Chapter 2).  It 
was a preclinical phase of developing a non-invasive method of placental vascular occlusion, 
with the ultimate intent of providing an alternative method of treatment for conditions arising 
from abnormal placental vasculature, such as TTTS. 
As described in section 1.2.2, at the inception of this study, there was little consensus based on 
published literature relating to the amount of ultrasound energy (in situ intensity), or the number, 
timing, duration or placement of HIFU exposures, required to achieve specific vascular 
occlusion.  Neither was there any conclusive evidence regarding the likely mechanism of 
vascular occlusion, the persistence of that occlusion, if achieved.  The potential rates and types 
of iatrogenic harm for any given set of HIFU exposure variables selected remained unknown. 
As a result, the experimental HIFU treatment protocol used in this study was based on HIFU 
femoral arterial occlusion experiments performed previously in a rodent model by co-
investigators at the Institute of Cancer Research (ICR)(31, 32). This protocol had not previously 
been tested in large animal models, humans or pregnancy in any species. To date, there remain 
no reported cases of selective occlusion of placental blood vessels by HIFU with which to 
modify or further inform our experimental design.  Additionally, the ultrasound guided HIFU 
laboratory system used was originally designed and built by researchers at the ICR for soft 
tissue ablation, not vascular occlusion. As described in section 1.2.2, the theory, methods and 
bioengineering requirements of producing HIFU soft tissue ablation can differ greatly from those 
of specific vascular occlusion.  Therefore, as testing in humans was not ethically justifiable, or 
practically possible given the early stage of development, the pregnant sheep model was 
selected to use in preclinical testing.  This model met both the anatomical requirements of the 
study (a consistent model of placental anastomoses, section 1.3.3), and also provided a 
recognised model of maternal and fetal physiology (section 1.3.1) in which to study potential 
direct and indirect side effect of the technique.   
Due to the constraints on the experimental design discussed in chapter 2, refinement of the 
HIFU treatment protocol occurred in an iterative fashion, towards a treatment protocol which 
combined acceptable levels of efficacy and safety in sheep pregnancy. In this chapter, 
successive iterations (Figure 2.1) of the methods and to develop and test treatment protocols 
for ultrasound-guided HIFU occlusion of placental vasculature will be described.  This chapter 
will describe and discuss how our techniques for applying HIFU evolved based on the results of 
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each previous phase of the study.  Where relevant, it will also explain how the methods were 
influenced by other features of experimental design which aimed to assess the impact of HIFU 
placental vascular occlusion on maternal and fetal physiology.  However, the results of this 
assessment of maternal and fetal physiology will be presented in chapters 5-7 and discussed in 
chapter 8. 
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4.2 Pilot study 
In this first phase of the HIFU study, we sought to: 
(i) establish if it was feasible to use ultrasound guided HIFU to occlude placental vessels 
in the pregnant sheep model; 
(ii) establish if this was an immediately survivable insult for mother and fetus while under 
general anaesthesia.   
 
To achieve this, it was necessary to demonstrate that: 
(i) placental vessels could be identified by ultrasound in sheep pregnancy using colour 
flow Doppler, when also integrated with a HIFU transducer, suspended in a waterbag; 
(ii) integrated colour flow Doppler could be used to target the HIFU focal zone relative to 
placental vessels with sufficient accuracy to achieve occlusion;  
(iii) integrated colour flow Doppler could be used to confirm vascular occlusion; 
(iv) sufficient HIFU energy could be delivered to the placental vessels to produce 
occlusion; 
(v) confirm survival of mother and fetus to the planned end of HIFU exposures (up to 4 h 
from the first occlusions).   
 
At this stage, while there was no deliberate attempt to cause harm, there was also no attempt to 
compromise potential efficacy to avoid harm to mother or fetus.  No safety protocols were 
imposed on the treatment protocols beyond what was required for safe operation of the HIFU 
equipment by the researchers. 
 
4.2.1 Methods  
4.2.1.1 HIFU therapy system 
The equipment for the HIFU therapy system was provided by the Therapeutic Ultrasound team 
at the ICR. The equipment was brought to the large animal facility at the University of 
Cambridge, set up and used in collaboration with 1 - 3 members of the ICR for experiments 
when HIFU (rather than sham HIFU) was used.  The equipment was calibrated (Appendix IV), 
maintained, adapted and repaired by staff at the ICR.   
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The HIFU therapy system was a collection of separate pieces of equipment, some of which was 
custom designed and built at the ICR, not a commercially available, integrated system.  The 
components are shown in outline in Figure 4.1, and as labelled photographs in Figure 4.2. HIFU 
was applied to animal tissue through a degassed water filled plastic polythene bag (the 
‘waterbag’), in contact with the anterior surface of the maternal uterus (transuterine) or 
abdominal skin surface (transdermal), suspended from an arm on the mechanical gantry arm.  
The tap water in the waterbag was degassed before the start of the HIFU exposures using a 
custom built portable degassing system from the ICR.  The degassing system was comprised of 
a ceramic filter (2.5x8 Extra flow Liqui-Cel®, 3M Industrial Group, Bracknell, UK) and a vacuum 
pump (FB65540, Thermoscientific UK, Rugby, UK) to allow degassing, a water filter (RS Pro 
DWFK 10, RS Components Ltd., Northampton, UK) to filter the water, and a water pump (SB30 
secondary circulating pump, Wilo UK, Stafford, UK) to circulate water between the waterbag 
and the degassing system.  Water temperature and oxygen content were monitored ad hoc.  
The waterbag was only degassed before the end of the experiment if cavitation was evident in 
waterbag on ultrasound imaging during exposures 
The HIFU transducer (H148MR, Sonic concepts, Inc., WA, USA) had a frequency of 1.66 MHz; 
its diameter was 64 mm, with a 19 mm circular central aperture to allow diagnostic ultrasound 
imaging parallel to the direction of the path of HIFU energy.  The focal length of the HIFU 
transducer was 63 mm, and the dimensions of the focal zone are diameter 1.2 mm (x axis), 
diameter 1.2 mm (y axis) and length 8.9 mm (z axis) (private communication).  The diagnostic 
ultrasound probe was a 4-10 MHz phased sector array transducer (P10-4, Z.one Zonare 
ultrasound system, Mindray, Shenzen, China), which supported B mode, colour flow, power and 
pulsed wave Doppler, tissue harmonic and compound B-mode imaging.  This probe was 
designed for paediatric echocardiography and neonatal applications, but was used here 
because its small size allowed it to image through the 19 mm central aperture in the HIFU 
transducer. 
The diagnostic ultrasound probe was aligned to the HIFU transducer by means of a customised 
plastic housing which fitted around the diagnostic ultrasound probe and interlocked with the 
upper surface of the HIFU transducer.  This alignment ensured that the HIFU focal zone was 
along the of the ultrasound image at all times.  The centre of the HIFU focal zone was fixed at 
70 mm from the top of the ultrasound image due to the slight offset of the leading edge of the 
diagnostic transducer behind the leading edge of the HIFU transducer. 
Both transducers were held in position within the water bag by the movable arm of a 
mechanised 3D positioning gantry.  This gantry arm prevented accidental rotation or angulation 
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of the diagnostic/therapeutic transducers.  The only planned movements allowed were up and 
down in the path of sound travel/along the midline of the ultrasound image (z axis), or 
orthogonal to the direction of sound (x and y axes, also at right angles to each other).  The 
precision of the position system was reported by the ICR team to be better than 1 mm (private 
communication).  A laptop computer was used to run a custom coded graphical user interface 
(GUI) in MATLAB (MATLAB R2013a, Mathworks, MA, USA) to control and record the 3D 
position of the mechanised gantry arm for each exposure. 
This GUI also controlled the signal generator settings and the firing (switching on/off) of the 
HIFU transducer.  The HIFU exposure conditions which could be varied using the GUI were: (i) 
the drive voltage (a nominal setting, see Appendix IV), (ii) the duration of a HIFU exposure, (iii) 
the time interval between one HIFU exposure and the next in a series of exposures, (iv) the 
distance between one HIFU exposure and the next in a line of exposures, and (v) the number of 
HIFU exposures in a series or line. In addition, the GUI logged the signal generator voltage 
setting, and the start time and duration of each HIFU exposure, which were exported as a text 
file, available for review after experiments.   
 
Figure 4.1: HIFU therapy system components.   
The schema shows the connections of the HIFU transducer in relation to the laptop based control interface, 
mechanical gantry arm, diagnostic ultrasound transducer and other equipment.  The arrows x, y and z denote the 
three directions in which the mechanical gantry arm was able to move (orthogonal to each other).  The z axis is 
also the direction of sound, or the path along which HIFU energy travels, away from the transducer. 
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Figure 4.2: HIFU therapy system setup.   
Top left: the picture shows the mechanical gantry arm and associated support structures in relationship to the 
waterbag, HIFU and diagnostic ultrasound transducers.  Top right: the picture shows an enlargement of the HIFU 
therapy transducer and the housing of the diagnostic transducer which allow integration of the two transducers, and 
their attachment to the mechanical gantry arm.  Bottom: the diagram shows the arrangement of diagnostic and 
HIFU transducers in relationship to the gantry arm, the water bag, degassed water, and the maternal uterine or skin 
surface (not to scale). 
Chapter 4: HIFU treatment protocol 
119 
 
4.2.1.2 Animals and surgical preparation 
Five ewes pregnant with singleton Welsh mountain fetuses at 115 ± 2 days of gestation (term ~ 
145 d) were used.  Under general anaesthesia, a maternal midline laparotomy was performed 
to expose the uterine surface in four animals, and the maternal skin was left intact in a fifth 
animal (sections 3.2.1-3.2.4).   
If the uterus was exposed, the surface of the uterus was first wet with degassed water, then the 
waterbag was placed in direct contact with that area.  Any pockets of trapped air between the 
plastic of the waterbag and the surface of the uterus were smoothed out.   
In the animal where the skin remained intact, the maternal abdominal skin was prepared first by 
shaving with clippers to remove wool, then washed with iodine scrub solution (Vetasept: 7.5% 
povidone iodine, Animalcare Ltd., York, UK) to remove dirt and lanolin, and washed again with 
tap water.  The remaining hair was chemically depilated (Nair ® hair removal cream, Church & 
Dwight Co., Kent, UK) and the skin was washed for a final time with tap water, then wet with 
degassed water.  The waterbag was placed in contact with the maternal skin and trapped air 
between the plastic and the skin was smoothed out.   
Mechanical ventilation of the ewe was paused during HIFU exposures to reduce respiratory 
movement which would lead to mis-targeting, referred to in this thesis as a “breath hold”.  Non-
invasive monitoring of maternal of cardiac and respiratory function was performed to ensure 
correct maintenance of anaesthesia (section 3.2.2).  During breath holds, ventilation was 
recommenced either when the HIFU exposure series was completed, or if maternal oxygen 
saturation (measured by non-invasive pulse oximetry) fell to below 94%, or if maternal end tidal 
CO2 rose to >8%, whichever occurred sooner. 
All fetuses were assessed with ultrasound at the planned end of the HIFU exposures to 
determine presence or absence of fetal heart pulsations, and confirm fetal survival or death.  
Non-invasive maternal recording of maternal heart rate was used to confirm maternal survival to 
the planned end of the experimental procedure.  
On completion of all planned HIFU exposures the ewe and fetus were euthanised without 
recovery from general anaesthesia under schedule one of the UK Animals (Scientific 
Procedures) Act 1986.  A slow IV injection into the maternal jugular vein of 120 mg.kg-1 
pentobarbitone sodium (Pentoject®, Animalcare Ltd., York, UK) was used for this purpose.  Air 
embolus into the jugular vein was used as a secondary confirmation of death.  Maternal cardiac 
activity was auscultated with a stethoscope and death was confirmed on cessation of cardiac 
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and respiratory activity.  Cessation of fetal cardiac activity was confirmed with diagnostic 
ultrasound. 
 
4.2.1.3 Vascular targets and HIFU treatment protocol parameters 
Between 1 and 5 placental vessels (1 vessel per animal, n=1; 3 vessels per animal, n=3; 5 
vessels per animal, n=1) were targeted with colour flow Doppler in each animal, using the HIFU 
transducer, diagnostic ultrasound, control and positioning system described above.  
The initial drive voltage used was the maximum power that was not anticipated to cause 
damage to the HIFU system electrics (-4 dBm), based on advice from the ICR team.  After three 
sheep, this did have to be reduced to -5 dBm to protect the transducer impedance matching box 
from electrical damage.  No further alterations were made to drive voltage in this pilot study, nor 
was there any attempt to correct for depth of the target beneath the surface to maintain a 
constant in situ intensity (Appendix IV).   
The exposure conditions investigated in this study were the time interval (5, 10 or 20 s) and 
distance (1 or 2 mm) between HIFU exposures in a series.  The duration of each exposure was 
kept constant at 5 s, based on previous experience that this was the shortest duration allowable 
to achieve occlusion (31, 32).  Extrapolating from these studies of occluding femoral arteries in 
rats, the initial intention was to place a linear track of HIFU exposures orthogonal to the 
direction of sound, from one edge of a placentome to the opposite one.  This linear track was 
designed to pass through the targeted vessel.  The group of HIFU exposures which comprised 
the planned linear track are called an “exposure series” from here onwards.  A gap of 1 – 2 mm 
between exposures was suggested as the width of the HIFU focus was known to be 1.2 mm; a 
1 mm spacing should therefore produce overlap, a 2 mm spacing should leave a small gap 
between exposures.    
This meant the width (orthogonal to the direction of sound) of each individual placentome and 
spacing of exposures should have determined the number of HIFU exposures in an exposure 
series.  However, the number of exposures required in an exposure series was also 
investigated in these pilot studies, comparing “maximal” with “limited” exposure series (Figure 
4.3).  It is apparent from these images that a maximal exposure series (Figure 4.3d,e,f) may 
need to be placed higher within the placentome to take advantage of the greatest width of 
tissue.  The limited exposure series were more directly localised to the vascular target and 
tended to sit closer to the point at which the vessels emerged from the placentome tissue.  Even  
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Figure 4.3: Types and planning of HIFU exposure series.   
(A) Ultrasound image with colour flow Doppler showing (i) the outline of a placentome, and (ii) the colour flow signal 
indicating the origin of vessels from the fetal portion of the placentome. (B) The photograph shows corresponding 
landmarks in a bisected placentome at post mortem examination.  (C) Shows an enlargement of the same 
placentome annotated in image A.  This enlargement is used in panels D-H to illustrate planning of different types 
of HIFU exposure series.  (D) The yellow arrow denotes the maximum width of placental tissue within this 
placentome, the red arrow measures the minimum width of HIFU exposures that could cross the echolucent area 
from which the target vessel arises, and still start and finish in soft tissue.  (E) The yellow ovals (drawn to scale) 
represent the overlapping placement of 1 mm spaced HIFU exposure series, covering the full width of the 
placentome, the “maximal pattern” (total of 20 ovals).  (F) The yellow ovals represent the non-overlapping, 2 mm 
spaced, placement of HIFU exposures across the full width of the placentome (total of 10 ovals).  (G) The blue 
ovals represent the overlapping placement of 1 mm spaced HIFU exposures from the one soft tissue border of the 
echolucent area to the other, the “limited pattern” (12 ovals), (H) the blue ovals represent the non-overlapping 
placement of 2 mm spaced HIFU exposures from the one soft tissue border of the echolucent area to the other (6 
ovals).  Ultrasound image obtained using a 1.9 – 6.0 MHz convex sector array, (PVT-375BT, i700, Toshiba Medical 
Systems UK).  Sheep: BL11, 109 d gestational age. 
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so, in a limited exposure series, an arbitrary decision was made that the minimum of the first 
and last HIFU exposure series were placed entirely in placental soft tissue (Figure 4.3d,g,h). 
 
4.2.1.4 Assessment of treatment success 
Treatment success was planned to be assessed using two measures, which could be correlated 
to each other.   
The primary measure was the comparison of pre- and post-HIFU exposure colour Doppler 
imaging of the target vessel, because this is the non-invasive measure available clinically to 
judge success and guide therapy.  If there was no colour flow Doppler signal detectable after 
HIFU exposures in the target vessel, this was determined to be “no flow”, indicative of a 
successful vascular occlusion.   If there was preserved colour flow Doppler signal detectable 
after HIFU exposures in the target vessel, this was determined to be “residual flow”, indicative of 
a failed vascular occlusion.  Pre- and post-exposure colour Doppler images were taken from the 
same 3D location, as controlled by the mechanised gantry arm, with precision of at least 1 mm 
as previously described.  During post-HIFU exposure imaging the colour flow velocity scale was 
increased to its maximum (-6.3 – 6.3 cm.s-1) to aid detection of residual blood flow.   
“No flow” was first recorded, real time, in the experimental record; pre- and post-HIFU exposure 
saved imaging was examined after the end of the experiment to verify these findings (“offline 
analysis”).  If there was a discrepancy between the finding of “no flow” in real-time and offline 
analysis of saved imaging, the finding from the saved imaging was used in preference. 
The secondary measure was identification and histological examination of damaged 
placentome vessels and at post-mortem examination (same day).  Exposed placentomes were 
tagged with green dye under ultrasound guidance after completion of each exposure series, for 
ease of identification at post mortem (Figure 4.4).   A map of relative placentome positions was 
retained for differentiation of specific dye-tagged placentomes. 
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Figure 4.4: Dye tagging of targeted placental vessels.   
The picture shows intact placentomes on the inner surface of the maternal uterus inverted at post mortem 
examination.  Areas of green dye mark the placentomes in which vessels have been exposed to HIFU energy. 
After euthanasia, a post-mortem examination of mother and fetus was conducted to recover 
tagged (exposed) placentomes.  All placentomes, tagged with dye or not, were excised from the 
uterus and allantoic membranes, bisected and inspected for damage at this time.  All tagged 
and/or damaged placentomes and two apparently un-tagged and undamaged placentomes 
were retained for histological examination.  Damaged and tagged placentomes were 
photographed.  The visual appearance and location of damage was recorded in the post-
mortem examination record. 
Collected tissues were immersion fixed in 10% neutral buffered formalin for five days before 
being washed and stored in phosphate buffered saline for up to six months at 4-6oC.  
Placentomes were re-photographed after 24 h of immersion in formalin, as tissue damage 
appeared accentuated at this time.  
Tissues were dehydrated through four solutions of increasing concentrations of ethanol before 
being cleared in three immersions of a histological clearing agent (Histo-clear II, National 
Diagnostics, Atlanta, USA) and infiltrated with paraffin wax.  A minimum of four, 8 µm sections 
were taken from areas of interest within placentomes (not serial sections) and were mounted on 
glass microscope slides (Superfrost® Plus, Thermoscientific, MA, USA) ready for histological 
staining. 
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Sections were cleared of paraffin using Histo-clear II and rehydrated through four solutions of 
decreasing concentrations of ethanol before being stained with Harris haematoxylin solution 
(Sigma-Aldrich, MI, USA).  Washing was performed with running tap water, differentiation with 
1% acid-alcohol and bluing with Scott’s tap water at room temperature, before counterstaining 
with an eosin Y 1% stock solution (Eosin Y, Sigma-Aldrich, MI, USA).  Tissues were washed in 
running tap water, then dehydrated through four solutions of increasing concentrations of 
ethanol, cleared in two changes of Histo-clear II, before being cleared in xylene.  Coverslips 
were mounted with synthetic resin mounting media (DPX, Sigma-Aldrich, MI, USA).  Sections 
were examined histologically for evidence of tissue change or damage, and evidence of 
vascular occlusion or rupture.  Findings of individual placentomes were correlated to colour flow 
Doppler findings for that placentome. 
 
4.2.1.5 Treatment monitoring 
Real-time tissue responses during HIFU exposures were planned to be monitored either by 
colour flow Doppler ultrasound, aiming to identify cessation of colour flow signal if it occurred 
before the end of the planned exposure series, or by tissue B-mode imaging, aiming to identify 
areas of hyperecho.   Initially, single freeze-frame images were saved during exposures, but by 
the end of the third sheep experiment it was apparent that this would not provide sufficient 
material for offline analysis of HIFU exposures.     
After this, 3 s video clips (8-10 Hz, ~30 frames) of each HIFU exposure in a series were 
recorded for offline analysis.  Clips were limited to a maximum of 3 s by the ultrasound machine 
settings, and exported as compressed DICOM files.  Each DICOM file was converted into a 
series of still images (one for each frame) using Image J (version 1.49m, public domain licence) 
and a customised script created by the ICR using MATLAB (MATLAB R2013a, Mathworks, MA, 
USA). 
All the still images / frames from a video clip were examined offline.  The linear depth of the 
HIFU focal plane (marked by the ultrasound machine cursor when set at a depth of 7.0 cm) and 
the target vessel beneath the skin or surface of the uterus (parallel to the direction of sound, or 
the central line of the ultrasound image) was measured using onscreen measuring software 
(Screen Calipers v4.0, Iconico, NY, USA).  The linear depth of any overlying amniotic fluid was 
also measured.  These values were used in the calculation of in situ intensity as described in 
Appendix IV.  The position of the ultrasound cursor was checked to be over the intended target 
vessel (when compared to the pre-HIFU colour flow Doppler image) and the on-screen reading 
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of the depth was checked to determine it fell between 6.95 – 7.05 cm (expected 7.0 cm).  If the 
cursor was away from the midline, too shallow or too deep compared to the intended target, or 
there was any other discrepancy in positioning of the focal zone relative to the target vessel, this 
was determined a potential “targeting error”. 
The drive voltage, transducer frequency, duration, start time and position of the transducer (x, y, 
z coordinates, reflecting position of the mechanical gantry arm) was recorded by the GUI 
software and exported to a text file.  The report of gantry positions at each exposure in a series 
was compared to each other to confirm the planned spacing of exposures had occurred.  The 
settings for each exposure were also checked to ensure an exposure of the planned drive 
voltage and duration had been delivered.  Times of the start of each HIFU exposure in a series 
were checked and compared to ensure the planned interval had elapsed between HIFU 
exposures in a series.  If the HIFU control or movement system had failed to deliver the planned 
exposure this was determined a potential “technical error”. 
To calculate the time taken to deliver a HIFU treatment, the onscreen time of the start of the first 
HIFU exposure was read off the saved image of the ultrasound screen (shown to the nearest 
second).  The time of the first adequate image that demonstrated no flow or residual flow was 
also read from the ultrasound screen and recorded as the end of the treatment.  The difference 
between these times was calculated as the treatment duration. 
Maternal respiratory rate was recorded by the veterinary anaesthetic monitor and the data was 
exported as described in section 3.2.2.  The number and duration of breath holds – where 
respiratory rate fell to zero – was read from the capnography data for each HIFU exposure 
series.  The capnograph reports averaged data every 8 s, so breath hold duration is given to the 
nearest multiple of 8 s. 
 
4.2.1.6 Management of treatment failure 
If real-time colour flow Doppler imaging demonstrated residual flow, no retreatment was 
attempted in the pilot study.  This was to preserve tissues unaltered after a failed occlusion 
attempts for further visual and histological examination to help identify why occlusion had failed.  
If a targeting or technical error, as defined above, was identified, this was recorded as a 
potential cause of treatment failure.  All other failed occlusions were otherwise initially 
categorised as having an unknown cause. 
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4.2.1.7 Assessment of iatrogenic harm 
The HIFU transducer was lifted after each completed exposure series to examine the surface of 
the skin or uterus for evidence of burns through the waterbag.  If found, the area was 
photographed at the time of discovery, through the waterbag. 
A systematic inspection of tissues was performed at post mortem examination and a 
photographic record was compiled of damage to: (i) maternal skin (if exposed), (ii) maternal 
rectus sheath (if exposed), (iii) anterior and posterior surface of the uterus, (iv) fetal skin (dorsal, 
ventral, left and right lateral views), and (iv) maternal bladder and bowel.  Areas of maternal and 
fetal skin, rectus and uterus with visual changes suggestive of iatrogenic damage were also 
collected for histological examination, fixed in formalin, sectioned and stained with H&E as 
described in section 4.2.1.4. 
 
4.2.2 Results 
4.2.2.1 Feasibility of using colour flow Doppler to target placental vessels 
In this phase of the study we were able to demonstrate the feasibility of using colour flow 
Doppler to identify placental blood vessels in the sheep.  Figure 4.3a shows an example of the 
high quality of imaging of placental vessels possible in the sheep using a typical probe used for 
obstetric ultrasound (1.9 – 6.0 MHz convex sector array, PVT-375BT) applied intraoperatively 
directly to the maternal abdominal surface, using a loaned modern ultrasound machine (i700, 
Toshiba Medical Systems UK, Sussex, UK). 
The clarity of this imaging was reduced by the requirement to use a paediatric echo probe small 
enough to image through the central (19 mm) aperture of the HIFU transducer, as described in 
section 4.2.1.1.  However, there was still sufficient image quality to identify and target placental 
blood vessels as they emerged from the fetal side of placentomes, and demonstrate presence 
or absence of blood flow post HIFU exposures.  Figure 4.5 shows an example of good 
transuterine colour Doppler imaging of placental blood vessels before and after HIFU treatment, 
with no residual colour flow in the target vessel evident on the post-exposure imaging, indicative 
of a successful occlusion. 
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Figure 4.5: Colour flow Doppler ultrasound imaging of placental vascular occlusion (good quality).  
(A) Pre-exposure colour flow Doppler imaging of a placentome. (B) Post-HIFU exposures colour flow Doppler 
imaging of the same placentome demonstrating no colour flow Doppler signal within the targeted vessel, 
reproduced from Shaw et al. (281).  The HIFU exposure series was comprised of 9 transuterine exposures, 2 mm 
spaced, duration 5 s, interval 20 s, in situ intensity 6.3 kW.cm-2.  Obtained using a 4-10 MHz phased sector array 
transducer (P10-4, Z.one Zonare ultrasound system) in sheep OR616, 110 d gestational age. 
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Even with less clear imaging, it was still possible to identify and target placental blood vessels, 
and demonstrate post-HIFU “no flow” denoting successful occlusion, as shown in Figure 4.6. 
 
 
Figure 4.6: Colour flow Doppler ultrasound imaging of placental vascular occlusion (satisfactory quality). 
(A) Pre-exposure colour flow Doppler imaging of a placentome. The intended vascular target is beneath the 
ultrasound cursor (blue cross).  (B) Post-HIFU exposure colour flow Doppler imaging of the same placentome 
demonstrating no residual colour flow Doppler signal within the targeted vessel.  The HIFU exposure series was 
comprised of 6 transuterine exposures, 2 mm spaced, duration 5 s, interval 20 s, in situ intensity 7.0 kW.cm-2.  
Obtained using a 4-10 MHz phased sector array transducer (P10-4, Z.one Zonare ultrasound system) in sheep 
OR616, 110 d gestational age. 
 
It was also possible to demonstrate failure to occlude a placental vessel by comparison of 
colour Doppler imaging, with preserved colour flow Doppler signal at the target vessel, as 
shown in Figure 4.7.  
 
Figure 4.7: Colour flow Doppler imaging of unsuccessful placental vascular occlusion.  
(A) Pre-exposure colour flow Doppler imaging of a placentome through intact maternal skin.  (B) Post-HIFU 
exposure colour flow Doppler imaging of the same placentome demonstrating residual flow within the targeted 
vessel.  The HIFU exposure series was comprised of 13 transdermal exposures, 2 mm spaced, duration 5 s, 
interval 20 s, in situ intensity 5.8 kW.cm-2.  Obtained using a 4-10 MHz phased sector array transducer (P10-4, 
Z.one Zonare ultrasound system) in sheep OR610, 110 d gestational age. 
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Treatment monitoring of tissue responses during HIFU exposures with colour flow Doppler, 
however, was not possible with our equipment.  There was interference between the HIFU and 
diagnostic ultrasound systems to a sufficient degree that the artefact rendered imaging 
uninterpretable during HIFU exposures.  This meant that the only time in which colour flow 
Doppler could be used was before, between or after HIFU exposures.  However, there was 
artefact for around 3-4 diagnostic ultrasound frames (~0.5 s at a typical frame rate of 8 Hz) 
following the end of a HIFU exposure, before the presence or absence of colour flow signal in 
the targeted vessel could be interpreted.  An example of this is shown in Figure 4.8.  In these 
images the white arrow is aligned to the same 2D position within the ultrasound image for ease 
of comparison: in Figure 4.8a the vascular target is clearly visible before HIFU exposures; in 
Figure 4.8b interference from the active HIFU transducer causes uninterpretable artefact; Figure 
4.8c-f shows persistence of this artefact after the HIFU exposure ends, before in Figure 4.8g it 
is possible to see that there is still colour flow signal in the vascular target despite the single 
HIFU exposure.  The quality of colour flow Doppler imaging was also reduced while the 
motorised gantry arm was moving the transducers to their next position, due to disturbance of 
water in the water-bag.  This effectively meant that when the interval between exposures was 
10 or 20 s there was around 7-17 s to interpret the image on the screen; when the interval 
between HIFU exposures was reduced to 5 s, this time was at most 2.5 s, which increased the 
possibility of human error in interpreting findings.  Additionally, due to the planned movement of 
the gantry arm, imaging was not being collected from the same 3D position as pre-exposure 
imaging, making the findings less reliable.   
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Figure 4.8: Colour flow Doppler artefact during and after HIFU exposures (8Hz frame rate).   
(A) Pre-exposure colour flow Doppler ultrasound imaging of a placentome, the white arrow marks the colour flow 
signal of the targeted vessel.  (B) Colour flow Doppler imaging of the same placentome during a transuterine HIFU 
exposure (5 s duration, in situ intensity 5.6 kW.cm-2) demonstrating artefact in the colour Doppler signal.  Colour 
flow Doppler imaging of the same placentome after HIFU energy source turned off in (C) first frame, (D) second 
frame, (E) third frame, (F) fourth frame, and (G) fifth frame.  Artefact is present until the fifth frame (0.5 s post 
exposure, G), at which time it is evident that there is residual flow within the target vessel.  Obtained using a 4-10 
MHz phased sector array transducer (P10-4, Z.one Zonare ultrasound system) in sheep OR624, 117 d gestational 
age. 
 
By comparison, it was possible to interpret B-mode imaging during HIFU exposures, even in the 
presence of artefact.  Before, during and after HIFU exposures it was possible (although 
difficult) to visually identify the outline of the placentome (Figure 4.9, white arrows) containing 
the targeted vessel and the echolucent area in which the vessel ran (Figure 4.9, blue arrow); 
hyperechoic events could also be identified with B-mode imaging (Figure 4.9, yellow arrows). 
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Figure 4.9:  Hyperecho development during HIFU exposures.   
Top panel: B-mode ultrasound imaging of placentome before HIFU exposures.  The white arrow denotes the 
border of the placentome and the blue arrow points to the echolucent area in the centre of the placentome in which 
the targeted vessels are typically found.  The white cross is the ultrasound cursor marking the position in the tissue 
where the centre of the HIFU focal zone will be positioned – the HIFU exposure series is a maximal one, which will 
progress from the right-hand border of the placentome to the left.  Central panel:  The B-mode ultrasound image 
now shows the artefact produced by HIFU energy; the white cross again shows the centre of the HIFU focal zone 
during this exposure (the 5th in a series of 13 transuterine HIFU exposures, 5 s duration, 20 s interval, 2mm 
spaced, 6.4 kW.cm-2 in situ intensity, target depth 15 mm).  The yellow arrow shows an area of hyperecho involving 
the tissue currently being exposed to HIFU and spreading to the previous exposed locations (to the right of the 
focus).  Bottom panel:  The B-mode ultrasound imaging again shows the artefact due to the HIFU energy, the white 
arrow shows the border of the placentome, and the yellow arrow shows the hyperecho, which has expanded after 
the 8th of 13 exposures, following the track along which the HIFU exposure series has travelled.  Obtained using a 
4-10 MHz phased sector array transducer (P10-4, Z.one Zonare ultrasound system) in sheep OR616, 110 d 
gestational age. 
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4.2.2.2 Feasibility of placental vascular occlusion 
Overall, in the pilot study, 15 placental vessels were targeted with colour flow Doppler.  Based 
on a comparison of pre- and post-HIFU colour Doppler imaging of targeted vessels, 12 out of 15 
(80%) were successfully occluded.   
Secondary confirmation of successful or failed occlusion was obtained in 11 of the 15 vessels 
based on histological examination of exposed vessels (Figure 4.10).  In 9 of the 11 vessels 
which it was possible to examine histologically, there was evidence of trapped erythrocytes 
within vessel lumen, suggestive of occlusive clot.  These 9 vessels were all predicted by colour 
flow Doppler to be occluded.  In the other 2/11 vessels, there was no evidence of trapped 
erythrocytes; failed occlusion had been predicted in these vessels by colour flow Doppler.  
There was no evidence of trapped erythrocytes in the vessel lumen of control placentomes 
which had not been exposed to HIFU. Therefore, at this stage, there was complete correlation 
between colour flow Doppler and histological findings, where histological examination was 
possible.   
In 4 of 15 exposed placentomes, it was not possible to perform histological examination of the 
vessels due to difficulties in preparing tissues for examination.  This was likely a direct result of 
the degree of tissue damage produced by HIFU exposures making the tissue difficult to 
dehydrate and impregnate with paraffin wax, rendering sectioning not possible. 
There was visual evidence of soft tissue damage in all the tagged placentomes, regardless of 
whether occlusion had failed or succeeded.  This served as confirmation that the soft tissue, 
although not necessarily the vessels, had been exposed to HIFU energy.  As a method of 
detecting vascular occlusion, based on these 15 vessels, the specificity of this method was only 
50%. 
Chapter 4: HIFU treatment protocol 
133 
 
 
Figure 4.10: Histological outcomes (acute) in vessels following exposure to HIFU.   
(A) H&E stain of fetal vessels in a control placentome.  The lumen of the vessels are open and unobstructed, 
suggesting they remain patent. There is no extravasion of blood in the other tissues.  (B)  H&E stain of fetal vessels 
in an exposed placentome where colour Doppler imaging suggested occlusion.  While the vessel lumen is not 
collapsed, there are trapped erythrocytes within the lumen suggestive of occlusive clot.  (C) H&E stain of fetal 
vessels in an exposed placentome where colour Doppler imaging suggested failed occlusion.  As in the control 
placentome, these vessel lumen are open and unobstucted, without trapped erythrocytes, however, there is 
extravasation of blood suggestive of some degree of tissue damage which did not result in vessel occlusion. 
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Table 4.1 shows a comparison of which exposure conditions produced successful vascular 
occlusion based on colour flow Doppler findings. 
 
Table 4.1: Pilot study vessel and exposure characteristics.   
The table shows the characteristics of vessels and HIFU exposure series in the pilot study, divided by those which 
resulted in successful of failed occlusion.  The depth of the vascular target is given as the mean ± SD; other 
characteristics are given as ranges or absolute numbers with percentages in brackets where indicated. NR = not 
recorded. 
Based on this comparison, delivering exposure series transuterine, rather than transdermal, 
was the most effective characteristic in improving rates of successful occlusion: 92% of 
exposures delivered transuterine were successful in producing occlusion, compared to only 
33% delivered transdermal. 
Successful 
occlusions
Failed 
occlusions
Vessel characteristics
Number 12 3
Depth of vascular target (mm) 13 ± 5 16 ± 6
Diameter (mm) 0.5 - 2.4 0.6 - 0.9
Exposure characteristics
Drive voltage (dBm) -4 or -5 -4 or -5
In situ intensity (kW.cm
-2
) 4.3 - 7.0 4.5 - 4.6
Spacing (mm) 1 or 2 2
Interval between exposures (s) 5, 10, 20 20
Number of exposures in series 6 - 20 6 - 20
Planning of exposure series
Maximal (n=10) 8 (80%) 2 (20%)
Number of breatholds (maximal) 3 - 13 4 - 5
Treatment time (maximal, s) 380 - 1300 NR
Limited (n=5) 4 (80%) 1 (20%)
Number of breatholds (limited) 1 - 2 2
Treatment time (limited, s) 130 - 290 410
Delivery of exposure series
Transuterine (n=12) 11 (92%) 1 (8%)
Transdermal (n=3) 1 (33%) 2 (67%)
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This did not appear to be a result of the ability to deliver sufficient acoustic energy through the 
maternal skin and rectus sheath.  The reduction of the drive voltage from -4 to -5 dBm made no 
appreciable difference to the success rates of occlusion, and the range of estimated in situ 
intensities for successful and failed occlusions overlapped.  The depths of the vascular targets 
beneath the skin or uterus similarly overlapped 
Successful occlusion could be achieved with intervals of 5, 10 or 20 s between exposures, but 
in the 3 occlusions which failed there was an interval of 20 s between exposures, despite in situ 
intensities and exposure numbers comparable to other exposure series. 
Exposure series were formed of between 6 and 20 exposures; it was possible to achieve 
occlusion with as few as 6 HIFU exposures in a series (a 2mm spaced, limited exposure series, 
example in Figure 4.3h), or fail to occlude a vessel with 20 HIFU exposures in a series (2mm 
spaced, maximal exposure series, example in Figure 4.3e).   
There was no obvious benefit of using 1 mm spaced exposure series compared to 2 mm 
spaced exposure series, however 1 mm spacing increased the number of exposures required in 
a series, the number of breath holds, and the total duration of time and total acoustic energy 
delivery required to occlude a vessel which were all potentially harmful to the ewe and fetus 
(data not shown). 
There was no obvious benefit of using “maximal” or “limited” exposure series, and using a 
“maximal” exposure series also increased the number of exposures required in a series the 
number of breath holds, and the total duration of time (Table 4.1), and energy delivery required 
to occlude a vessel (data not shown). 
 
4.2.2.3 Survival and iatrogenic harm 
All mothers and fetuses survived to the planned end of the experimental procedures.   
While visual identification of tissue damage was not specific as a method of confirming vascular 
occlusion, some appearances were suggestive of over-exposure of tissues with HIFU energy.  
There was visual evidence of extensive extravasation of blood into the soft tissues and tissue 
heating when placentomes were bisected (Figure 4.11) in all 15 of the exposed placentomes, 
regardless of whether occlusion had succeeded or failed.  When visual appearances were 
compared with histological damage, evidence of heat fixation of tissue, extravasation of blood 
into extracellular spaces, tissue boiling and discrete tissue haemorrhage were evident (Figure 
4.12).   
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At this stage, evidence of tissue boiling or discrete tissue haemorrhage were classified as 
excessive, unwanted, tissue damage; whether a degree of heat fixation and extravasation was 
unavoidable was unclear.  Histological evidence of excessive tissue damage was found in 7 of 
the 11 placentomes it was possible to examine, and none of the control placentomes.  In 4 of 11 
placentomes, however, while there was heat fixation of tissues and extravasation into 
extracellular spaces, this was the extent of the damage (Figure 4.13).  Visually, there appeared 
to a lesser degree of tissue damage in these placentomes (Figure 4.14).  Both discrete tissue 
haemorrhage and extravasation of blood into intracellular spaces were different to vascular 
haemorrhage, which is presented below. 
 
 
Figure 4.11: Excessive placental soft tissue damage (visual).  
The photographs show a placentome bisected after exposure to HIFU (16 exposures, in situ intensity 5.3 kW.cm-2, 
2 mm spaced, 10 s interval between exposures, target depth 12 mm) and fixed in formalin for 24 h. The photograph 
in (A) shows the inner surface of the placentome where it has been bisected, and in (B) the outer surface of the 
placentome with allantoic membranes removed. In the line diagrams, there are (i) areas of severely damaged 
tissue and areas of both (ii) tissue pallor, suggestive of heating, and (iii) darkening, suggestive of extravasation, 
adjacent to the (iv) fetal vessels, (v) region of materno-fetal exchange, involving much of the (vi) placental soft 
tissue; (vii) show soft tissue discolouration extending to, but contained within, the outer capsule of the placentome, 
suggestive to tissue boiling. 
 
Chapter 4: HIFU treatment protocol 
137 
 
 
Figure 4.12: Excessive placental soft tissue damage (histology).   
The photograph on the upper left is a close-up of the placentome shown in Figure 4.11.  The image on the upper 
right is a H&E stained section of tissue from the same placentome.  The black arrow points to normal tissue, the 
red arrow shows the region where there is extravasation of blood into the intracellular spaces, the green arrow 
denotes a region of homogenised tissue suggestive of heat fixed tissue, and the blue arrow points to the area 
where tissue boiling damage has occurred, with loss of tissue architecture and large, regular intracellular spaces.  
The yellow area is a section of extracellular erythrocytes within a cavity, suggestive of discrete tissue haemorrhage 
resulting in an area of clot within the tissue.  Magnified sections are displayed in beneath, in colour-coded boxes, to 
match the arrows. 
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Figure 4.13: Non-excessive placental soft tissue damage (histology).   
The image on the left is a H&E stained section of a control placentome.  The blue arrow points to areas of 
extravasation around the materno-fetal interface, despite not being exposed to HIFU.  These are potentially an 
artefact of the process of bisecting the placentome at post-mortem. The un-occluded lumen of the target vessels 
can be seen.  The image on the right is of an placentome exposed to HIFU (6 exposures, in situ intensity 5.0 
kW.cm-2, 2 mm spaced, 5 s interval between exposures, target depth 14 mm, visual appearances shown in Figure 
4.14).  The black arrow points to normal tissue, the red arrow shows the region where there is extravasation of 
blood into the intracellular spaces, the green arrow denotes a region of homogenised tissue suggestive of heat 
fixed tissue.  The blue arrow shows extravasation at the materno-fetal interface, such as seen in the control 
placentome. There are no regions of clot in the tissue, or evidence of boiling. 
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Figure 4.14: Non-excessive placental soft tissue damage (visual).  
The photographs show a placentome bisected immediately after exposure to HIFU (6 exposures, in situ intensity 
5.0 kW.cm-2, 2 mm spaced, 5 s interval between exposures, target depth 14 mm) and fixed in formalin for 24 h. The 
photograph in (A) shows the inner surface of the placentome where it has been bisected, and in (B) the outer 
surface of the placentome with allantoic membranes removed. In the line diagrams, there are areas of (i) tissue 
pallor, suggestive of heating, and (ii) darkening, suggestive of extravasation, adjacent to the (iii) region of materno-
fetal exchange, involving a portion of the (iv) placental soft tissue and crossing the (v) origin of targeted vessels. On 
the outside of the placentome there is no evidence of capsule damage, the regions marked (vi) are green dye 
adherent to the surface, discoloured by formalin. 
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A comparison of targets and exposure characteristics which resulted, or not, in excessive tissue 
damage is given in Table 4.2. 
 
Table 4.2: Excessive tissue damage (pilot study).   
The table shows the exposure and vessel characteristics in the 11/15 placentomes which were examined 
histologically, divided into those with and without excessive tissue damage.  The depth of the vascular target is 
given as the mean ± SD; other characteristics are given as ranges or absolute numbers with percentages in 
brackets where indicated. 
Based on this comparison, excessive tissue damage appeared more likely to occur in 
placentomes exposed to higher in situ intensities, as there was no overlap in these ranges, 
although numbers were too small to draw a definitive conclusion.  While drive voltage had no 
effect of the degree of tissue damage, the shallower targets, particularly if exposed transuterine, 
were more prone to excessive tissue damage.  Both of these factors contributed to higher in situ 
intensities.  Neither the time interval between, nor the spacing between, HIFU exposures in a 
series appeared to affect the likelihood of excessive tissue damage.  Number of exposures in a 
series similarly did not discriminate between groups; maximal and limited exposure series both 
produced excess tissue damage if the in situ intensities were high enough.   
There were 2 placentomes in which blood was coagulated in the allantoic membranes (Figure 
4.15a-c), initially thought to be possible instances of vascular haemorrhage from the target 
Excessive tissue 
damage
No excessive 
tissue damage
Vessel characteristics
Number 7 4
Depth of vascular target (mm) 12 ± 4 19 ± 3
Successfully occluded 7 2
Exposure characteristics
Drive voltage (dBm) -4 or -5 -4 or -5
In situ intensity (kW.cm
-2
) 5.3 - 7.0 4.3 - 5.0
Spacing (mm) 1 or 2 2
Interval between exposures (s) 5, 10, 20 5, 20
Number of exposures in series 6 - 20 6 - 20
Planning of exposure series
Maximal (n=7) 4 (57%) 3 (43%)
Limited (n=4) 3 (75%) 1 (25%)
Delivery of exposure series
Transuterine (n=8) 7 (87%) 1 (13%)
Transdermal (n=3) 0 (0%) 3 (100%)
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vessels.  In situ intensities of 6.4 and 7.0 kW.cm-2 were delivered to these placentomes, and 
tissue boiling and discrete tissue haemorrhage reaching the edge of the placentome tissue was 
seen histologically.  It was not, however, possible to identify the vascular haemorrhage 
histologically, and in both these placentomes there was also evidence of occluded vessels.  It is 
possible that the blood seen was an extension of the discrete tissue haemorrhage seen, and not 
a haemorrhage as a result of wall damage in the targeted vessel. 
There were two uterine burns (Figure 4.15d); both were related to placentomes in which boiling 
and discrete haemorrhage occurred and reached the edge of the placentome tissue.  In situ 
intensities of 6.4 kW.cm-2 (13 exposures, 2mm spacing and 20 s interval) and 5.6 kW.cm-2 (7 
exposures, 2mm spacing and 5 s interval) were delivered to the vascular targets at 8 and 9 mm 
depth respectively beneath the uterine surface.  As such, these burns may be the result of pre-
focal damage, but other high intensity exposures were delivered at similar depths without 
resulting in a burn. 
There were two fetal burns.  In one, the fetal back was 12 mm beneath the vascular target, 
which was exposed to a series of 20 exposures of 4.5 kW.cm-2 in situ intensity, 2 mm spacing 
and 20 s interval between exposures (Figure 4.15e).  In the second, the fetus was 19 mm 
beneath a vessel exposed to 20 exposures at 5.5 kW.cm-2 in situ intensity, 2 mm spacing and 
20 s interval between exposures (Figure 4.15f).  As such, these burns may have been the result 
of post-focal damage.  The fetus was not visible in saved ultrasound images during the 
treatment of any other placentomes, meaning it was at least 40 mm away from the HIFU focus, 
dependant on the depth of the target vessel and the ultrasound screen settings. 
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Figure 4.15: Iatrogenic damage (pilot study).   
The photographs show (A) a placentome from which a string of clots (white arrow) is visible in the allantoic 
membranes, and (B) a diffuse blood trapped in the allantoic membranes (white arrow) surrounding a placentome.  
(C) shows the placentome in (B), once it was excised from the allantoic membranes; the clotted blood is adherent 
to the surface of the placentome and the target vessels can still be seen emerging from the placentome (blue 
arrows) although they have a shrunken appearance.  (D) shows a uterine burn on the serosal surface of the uterus 
(black arrow).  (E, F) show areas of burn on the fetal skin (yellow arrows). 
 
4.2.3 Pilot study: discussion 
The HIFU exposure series in the pilot study demonstrated it was possible to use HIFU to 
occlude placental blood vessels non-invasively.  This was the first time, based on a review of 
published literature (1), that this had been demonstrated, and validated in principal the basic 
premise of the study.   
At this early stage, the capacity of the mother and fetus to tolerate a period of HIFU placental 
vascular occlusion was unknown, although there were prior reports of fetal sheep surviving 
HIFU ablation of fetal soft tissue targets in the short term (60, 61).  In this series of 5 sheep, all 
mothers and fetuses survived the HIFU exposures, suggesting that at least in the short term, 
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HIFU mediated placental vascular occlusion of 1-5 blood vessels was a survivable procedure in 
sheep.   
Using a drive voltage of -5 dBm, we showed that it was possible to deliver sufficient HIFU 
energy to the target tissues, through the surface of the uterus or skin, to result in vascular 
occlusion.   However, at least 65% of these exposure series also resulted in excessive tissue 
damage, i.e. tissue boiling and discrete tissue haemorrhage (given that there were 4 
histologically unexamined placentomes which also had macroscopic evidence of significant 
tissue damage).  It appeared that the possibility of excessive tissue damage was relative to the 
in situ intensity of HIFU energy delivered to the tissues (Table 4.2).  Based on this small 
sample, there was no evidence that reducing the number of exposures, spacing exposures 
further apart, or allowing a longer cooling time did not protect the tissues from the high in situ 
intensities, if used.  The threshold above which excessive tissue damage occurred following 
HIFU exposures appeared to be between 5.0 – 5.3 kW.cm-2. 
It appeared that more widespread tissue and/or vessel haemorrhage, and uterine burns could 
also result from in situ intensities resulting in excessive tissue damage, although the composite 
rate of this was lower than for excessive tissue damage (3/15, 20%).  There was limited data 
available, but the estimated in situ intensity threshold above which fetal and uterine burns or 
vessel haemorrhage into allantoic membranes should be anticipated appeared to be 5.6 – 7.0 
kW.cm-2.  Exposures at these high in situ intensities have previously been associated with 
vessel rupture (37, 45).  It was, however, possible to achieve vascular occlusion without 
excessive tissue damage or iatrogenic harm, using an in situ intensity of 4.3 kW.cm-2.  This is 
consistent with other published studies which have achieved vascular occlusion with in situ 
intensities of 2.0 – 4.0 kW.cm-2 (Table 1.3). 
There were a total of 3 HIFU exposure series which resulted in failed occlusion.  In one 
(transuterine, drive voltage -5 dBm, in situ intensity 5.8 kW.cm-2, 6 exposures, “limited” pattern, 
20 s intervals between exposures, 2 mm spaced) there was a failure of the mechanical arm of 
the gantry to move along the 10 mm track and only 2 mm movement was recorded.  As such, 
this was defined as a technical failure, and was the first indication that the linear track was an 
important feature of successful occlusion, although gave no suggestion as to what the 
mechanism of this could be.  It was possible that the length of the linear track corrected for any 
small (<5-10 mm) targeting errors; it is also possible that the cumulative effect of tissue heating 
surrounding vessels in addition to within the vessel walls and lumen was of benefit, potentially 
by producing tissue oedema (section 1.2.3.4) or shrinkage of connective tissue surrounding the 
vessels (section 1.2.3.3). 
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The other 2 exposure series which failed were applied through intact maternal skin.  There were 
no obvious targeting or technical errors to account for the failure and as shown in Table 4.3, the 
only difference in exposure conditions from successful occlusions was the interval between 
exposures of 20 s.   However, given that other exposure series with 20 s intervals between 
exposures also produced occlusion, the significance of this was uncertain.   
The pilot study results also showed it was possible to use integrated colour flow Doppler 
ultrasound to identify and target placental vessel in the pregnant sheep model with sufficient 
accuracy to occlude them non-invasively.  Colour Doppler was suggested to be a sensitive and 
specific method to determine if occlusion had occurred or not following a HIFU exposure series, 
as these results correlated well with histological findings of occlusion in target vessels.  While 
the use of Doppler ultrasound has previously been reported to target blood vessels and 
demonstrate occlusion in other animals and human fetuses (section 1.2.2) this was the first time 
this had been demonstrated in sheep placental vessels.  This validated using colour flow 
Doppler as the primary outcome measure of treatment success for subsequent animal groups in 
our study. 
However, interference between the HIFU ultrasound energy and the diagnostic ultrasound 
meant that there was artefact on both the B-mode and colour Doppler imaging while the HIFU 
source was in use.  The degree of artefact and distortion of the image for this system when 
colour Doppler was selected as the monitoring method meant it could not be used during a 
HIFU exposure to monitor the progress of the treatment, and was not easy to use in the 
intervals between exposures.  Artefact was also present during B-mode imaging during HIFU 
exposures, but with adjustment to the gain it was still possible to interpret the images acquired. 
Although the imaging cycle of diagnostic transducer (~30 Hz) can be synchronised to on/off 
pulses of the HIFU transducer to negate this interference, so that the HIFU transducer is off 
when the diagnostic ultrasound is acquiring an imaging frame, (282) this is a significant software 
engineering project which was not planned for this study. It also required pulsing of the HIFU 
energy when we had planned for continuous exposures.  Therefore, during HIFU treatments, a 
decision was made that tissue responses were monitored by B-mode ultrasound imaging (real-
time).  An additional finding, which had not initially been part of the plan to monitor treatment 
responses or assess success was the development of hyperecho during HIFU exposures.  The 
significance of hyperecho during exposures was identified as an area requiring further study in 
subsequent animal groups. 
Given that the principle of using Doppler ultrasound guided HIFU to occlude placental vessels in 
sheep had been shown feasible, the next stage based was to attempt to quantify the acute 
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impact of ultrasound guided HIFU placental vascular occlusion on maternal and fetal 
physiology.   
It was important that the magnitude of the potential intrauterine insult – namely the number of 
placental blood vessels occluded, and the length of time this was carried out over – was both a 
fixed magnitude of insult and comparable to any potential human treatment to make results 
more directly translatable.  
A relatively wide range for the number of anastomoses ablated by fetoscopic laser (per patient) 
is quoted in published literature: Ierullo et al. (283) report a mean of 4 (range 1-11); Lopriore et 
al. (284) report a mean of 6-7 (range 3-12) and Slaghekke et al. (19) report a mean of 8 (range 
5-11).  Typical total treatment times are in the range of 5 - 25 minutes (19, 283).   
We also need to limit the total exposure time of the fetus to general anaesthesia, so that 
physiological responses to HIFU vascular occlusion, and not pathological responses due to 
prolonged anaesthesia would be assessed.  For these two reasons, it was decided to: (i) limit 
the HIFU treatment time to 30 min, and (ii) aim to target 6-7 placental vessels during the 30 
minutes.  Therefore, the target time to identify, plan, deliver HIFU and confirm successful or 
failed occlusion was a maximum of 5 minutes.   Based on the findings of the pilot study, “limited” 
series of HIFU exposures with a 5 s interval, 2 mm spaced were the only type of exposure 
series which could be reliably delivered, and occlusion success assessed, in less than 5 
minutes.  This was predominantly due to the fact, they could be completed in a single breath 
hold.  This was also hypothesised to be of benefit in stabilising maternal anaesthesia and 
oxygenation intraoperatively and so improving fetal condition.  
Three “limited” exposure series with the characteristics suggested for Group A animals were 
delivered in the pilot study: drive voltage -5 dBm, in situ intensities 5.0 – 5.7 kW.cm-2, 6-9 
exposures in a series, target depth 8 – 14 mm.  All 3 produced successful vascular occlusion, 
and were delivered and assessed in < 5 minutes. 
From an experimental design perspective, there was a necessity to apply HIFU directly to the 
uterine surface in order to record acute fetal physiological responses to HIFU mediated 
placental vascular ablation (section 0).  Given the lower rate of successful occlusion in 
transdermal application of HIFU compared to transuterine application at the stage, a decision 
was made to refine the HIFU treatment protocol for transuterine application, where targeting 
was quicker and easier (as the uterus could be manipulated) and energy losses were lower, 
before attempting a transdermal approach.   
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4.3 Transuterine efficacy and safety study: Group A(cute) 
In this second phase of the study, we sought to: 
(i) establish if HIFU could be used as a method to consistently occlude placental blood 
vessels (transuterine); 
(ii) assess the rates and types of iatrogenic harm to mother and fetus (transuterine); 
(iii) assess acute changes in materno-fetal physiology in response to HIFU mediated 
placental vascular occlusion (methods, results and discussion in chapter 3, 5, 6 and 
8).   
Establishing HIFU as a consistent method of occluding placental vessels without imposing an 
excessive burden of iatrogenic harm on the mother and fetus were prerequisites to moving to 
the phase of the study in which animals were recovered from anaesthesia and longer term 
follow-up was planned, due to ethical and financial constraints. 
The results of the pilot study had enabled the development of a transuterine HIFU treatment 
protocol in which exposure conditions did not vary, and in the pilot study had a 100% successful 
occlusion rate, although only based on 3 vessels.  The characteristics of this standard 
transuterine protocol should also enable the planned HIFU exposure series to meet the 
requirements of the experimental protocol for quick vascular occlusions.  By standardising the 
exposure conditions, we anticipated that we would be able to deliver a consistent challenge to 
ewes and fetuses, and also better compare the characteristics of exposure series which 
resulted in successful and failed occlusions.  
 
4.3.1 Methods 
4.3.1.1 HIFU therapy system 
No changes were made to the system described in section 4.2.1.1. 
 
4.3.1.2 Animals and surgical methods 
In brief, 5 pregnant ewes carrying singleton fetuses at 116 ± 1 d gestational age were placed 
under general anaesthesia (section 3.2.1, 3.2.2); maternal and fetal surgical instrumentation 
(sections 3.2.4, 3.2.5) was performed for the purpose of monitoring acute maternal and fetal 
cardiovascular, acid-base and metabolic responses to HIFU mediated placental vascular 
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occlusion.  The uterus was left exposed through a midline laparotomy following the completion 
of surgery.   
This animal group was the first in which maternal and fetal cardiovascular, acid-base and 
metabolic responses to HIFU mediated placental vascular occlusion were to be monitored in the 
acute setting.  The results of the acute changes in materno-fetal physiological responses to 
HIFU or sham mediated placental vascular occlusion will be presented and discussed in 
chapters 5-8, where groups A, S and R can be compared. 
Following the completion of surgery, the experimental protocol was divided into three 30 minute 
periods.  The first 30 minutes (-30 to 0 min) was the time allowed to identify vascular targets 
and plan HIFU exposure series, followed by a 30 minute treatment phase (0-30 min) during 
which HIFU or sham exposures were performed, then a 30 minute recovery phase (30-60 min, 
Figure 3.9).  During the planning time, the uterus was scanned with B-mode and colour flow 
Doppler imaging, but not manipulated. At the end of the planning time, the surface of the uterus 
was wet with degassed water, then the waterbag was placed in direct contact with that area.  
Pockets of trapped air between the plastic of the waterbag and the surface of the uterus were 
smoothed out.   
During the HIFU treatment time, if required, the uterus was manipulated gently to facilitate good 
access to placental vessels in areas of the uterus away from the fetus, and the waterbag 
repositioned and smoothed accordingly.  HIFU exposures were delivered according to the 
protocol described in the next section.  Breath holds were used to pause respiratory movement 
as described in section 4.2.1.2. 
Once the experimental protocol was completed, additional HIFU exposure series were 
performed as part of a dose de-escalation protocol, also described during the next section.  This 
was to examine the effect of reducing drive voltage and to maximise the use to which each 
experimental animal was put, during which time no monitoring of fetal physiology was 
performed. 
On completion of all the planned HIFU exposures the ewe and fetus were euthanised without 
recovery from general anaesthesia under schedule one of the UK Animals (Scientific 
Procedures) Act 1986.  A slow intravenous injection into the maternal femoral vein catheter of 
120 mg.kg-1 pentobarbitone sodium (Pentoject®, Animalcare Ltd., York, UK) was used for this 
purpose.  Air embolus into the femoral vein was used as a secondary confirmation of death.  
Maternal cardiac activity was auscultated with a stethoscope and death was confirmed on 
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cessation of cardiac and respiratory activity.  Cessation of fetal cardiac activity was confirmed 
with diagnostic ultrasound. 
 
4.3.1.3 Vascular targets and HIFU treatment protocol parameters  
HIFU was applied transuterine to between 4 and 7 placental vessels per animal in the time-
limited experimental protocol (7 per animal, n=2; 6 per animal, n=2; 4 per animal, n=1).   HIFU 
exposure conditions were: drive voltage -5 dBm, 5 s exposure duration, 5 s intervals between 
exposures, 2 mm spacing between exposures.   
HIFU was applied transuterine to between 1 and 4 placental vessels per animal in the dose de-
escalation protocol (4 per animal, n=2; 3 per animal, n=1; 1 per animal, n=1).  HIFU exposure 
conditions were: drive voltage -5 to -8 dBm, 5 s exposure duration, 5 s intervals between 
exposures, 2 mm spacing between exposures.   
In both cases, the “limited” model was used to plan exposure series and determine exposure 
number (Figure 4.3h).  However, unlike in the pilot study, there was no requirement to place at 
least the first and last exposure in a series in the soft tissue of the placentome adjacent to the 
echo-lucent area.  This was a non-evidence based limit imposed in the pilot study and its 
necessity was unknown, so it was not included in this phase of the study.  
The planning of a HIFU exposure series was limited to information available from B-mode and 
colour Doppler ultrasound imaging: the size of the placentome (height, width, cross sectional 
area); the size of the echo lucent area from which vessels arise (height, width, cross sectional 
area); and the depth of the colour signal beneath the surface of the uterus (linear target depth, 
Figure 4.16).  The diameter of the targeted vessel or the rate/volume of blood flow within it could 
not be reliably assessed with colour flow or pulsed wave Doppler. 
The cross-sectional area of the echo lucent region (in 2D) was used as a simple marker of the 
area of the size of the region containing target vessel(s), in lieu of being able to measure the 
vessels themselves.  The height and width of the echo-lucent area were converted into a 
simplified cross-sectional area using the standard formula for the surface area of a regular 
ellipse:  
Cross sectional echolucent area = (height/2)(width/2) 
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Figure 4.16: Ultrasound information for planning of HIFU exposure series.   
The panel on the left shows the same colour flow Doppler image of placentomes and vascular targets as in Figure 
4.3.  In the left panel, the green arrow shows the direction of sound, along the midline of the image.  The black 
arrow shows the width of the placentome, and the white arrow shows the linear distance between the surface of the 
uterus to the centre of the targeted vessel, parallel to the direction of sound (the linear target depth).  The central 
panel shows the maximum height and width of the colour flow Doppler signal of the targeted vessels.  The right 
hand panel shows the equivalent maximum height and width of the echolucent area of the placentome in B-mode 
imaging (where the colour flow Doppler signal had previously been seen). Images obtained using a 1.9 – 6.0 MHz 
convex sector array, (PVT-375BT, i700, Toshiba Medical Systems UK).  Sheep: BL11, 109 d gestational age. 
The cross-sectional area of tissue exposed to HIFU energy in an exposure series was also hard 
to assess accurately.  As a crude measure, the known length of movement of the gantry arm 
orthogonal to the direction of sound, and the size of the HIFU focus were used to estimate the 
cross-sectional area of the blue outline, using the formula below (Figure 4.17): 
Cross sectional HIFU treatment area = (length of HIFU focal zone x orthogonal gantry 
movement) + (length of HIFU focal zone/2)(width of HIFU focal zone/2) 
 
As the length of the HIFU focus in the direction of sound is known to be 8.9 mm, and the width 
of the focus is 1.2 mm, this can be simplified as: 
HIFU treatment area (mm2) = (8.9 x orthogonal gantry movement) + 8.4 
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Figure 4.17: Estimation of HIFU treatment area.   
The diagram shows the basis of the formula used to estimate the area of tissue exposed to HIFU.  The ovals (each 
scaled to 1.2 x 8.9 mm) represent the position of the HIFU focus in an exposure series of 5 HIFU exposures, 2 mm 
spaced. The area calculated by the formula 8.9 x orthogonal gantry movement + 8.4 is outlined in blue. 
These approximations of the cross-sectional area of (i) the region to be treated and (ii) the area 
exposed to HIFU were created for this project.   
When the HIFU treatment area is divided by the echolucent area: 
• a ratio = 1 would indicate they were of the same 2D size; 
• a ratio > 1 would indicate the HIFU treatment area was bigger than the target area, a 
potential spatial over treatment; 
• a ratio < 1 would suggest the treatment area was smaller than the target area, a potential 
spatial under-treatment.   
This ratio of echolucent cross sectional area to HIFU treatment cross sectional area is 
henceforth referred to as the “cross-sectional treatment area ratio” or C-STAR for brevity. 
In these animals, the suggested morphology of the placentome was also considered (Figure 
4.18).  Type A/B placentomes were selected in preference to type C/D placentomes based on 
ultrasound appearances, as the inverted shape of type A/B placentomes provided a discrete 
target based on colour Doppler. It was also hypothesised that the position of vessels running 
through a narrow tissue passage before emerging into the allantoic membranes would assist to 
hold vessels in a fixed position and provide a better mimic of vascular anastomoses in human 
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placentae, which are predominantly fixed in tissue, not free to move in the chorio-amniotic 
membranes. 
 
Figure 4.18: Placentome morphology (ultrasound appearances).   
The colour flow Doppler ultrasound image shows a placentome and target vessels, which on the upper left panel 
appears to be type A or B, and on the upper right panel appears to be type C or D.  The corresponding line 
diagrams beneath indicates the position of (i) the border of the placentome, (ii) the border of the echo lucent area 
and (iii) the colour flow Doppler signal indicating the position of target vessels (only seen in the type A/B 
placentome).  Images obtained using a 1.9 – 6.0 MHz convex sector array, (PVT-375BT, i700, Toshiba Medical 
Systems UK).  Sheep: BL11, 109 d gestational age. 
4.3.1.4 Assessment of treatment success 
Primary confirmation: comparison of pre- and post-HIFU exposure colour flow Doppler imaging 
for evidence of “no flow” or “residual flow” as described in section 4.2.1.4. 
Secondary confirmation: histological examination of exposed placentomes for evidence of 
occlusion within vessel lumen as described in section 4.2.1.4.  In addition, 6 placentomes per 
animal (n=6) were collected at the post mortem examination of sham exposed control animals 
and examined histologically for comparison.  Vessel diameters were not corrected for shrinkage 
as heat fixed tissue is known to shrink by a lesser degree than undamaged vessels. 
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4.3.1.5 Treatment monitoring 
Real-time tissue responses during HIFU exposures monitored with B-mode imaging, aiming to 
identify areas of hyperecho.  These were logged in the experimental record. 
A new safety feature was introduced to the treatment monitoring protocol in this phase of the 
study.  Ultrasound imaging was checked before the start of each HIFU exposure series for the 
presence of the fetus in the post-focal region.  The depth of the ultrasound image was increased 
to maximum to perform this check, before being decreased again to improve the quality of the 
imaging of the vascular target. 
Three second video clips (8-10 Hz, ~30 frames) of each HIFU exposure in a series were 
recorded for offline analysis.  Analysis of images, the records of exposures generated by the 
GUI and maternal respiratory rate from the capnography were as described in section 4.2.1.5.  
In addition, video clips were assessed for the appearance of hyperecho during HIFU exposures. 
 
4.3.1.6 Management of treatment failure 
If colour flow Doppler imaging demonstrated preserved blood flow after a HIFU exposure series 
then this was termed a failed occlusion.  At the outset of this phase of the study, it was unclear if 
retreatment would be safe and/or beneficial, so a decision was made to place limits on 
retreatments.   
After a HIFU exposure series resulting in a failed occlusion, a single retreatment could be 
attempted, unless as a result of the previous exposure series: (i) there was evidence of a 
uterine burn; (ii) there was suspicion of fetal or other maternal injury; (iii) there was an identified 
targeting and/or technical error which could not be corrected. 
If retreatment was not contraindicated, one further HIFU exposure series was re-planned and 
delivered to attempt to achieve successful vascular occlusion.  If successful vascular occlusion 
was not achieved after a maximum of two HIFU exposure series, no further attempts to achieve 
vascular occlusion were made. 
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4.3.1.7 Assessment of iatrogenic harm 
The HIFU transducer was lifted after each completed exposure series to examine the surface of 
the uterus for evidence of burns through the waterbag.  If found, the area was photographed at 
the time of discovery, through the waterbag. 
A systematic inspection of tissues was performed at post mortem examination and a 
photographic record was compiled of damage to: (i) anterior and posterior surface of the uterus, 
(ii) fetal skin (dorsal, ventral, left and right lateral views), and (iii) maternal bladder and bowel.  
Tissue listed with visual changes suggestive of iatrogenic damage were also collected for 
histological examination, fixed in formalin and stained with H&E as described above. 
 
4.3.2 Results 
4.3.2.1 Efficacy of vascular occlusion: time-limited protocol 
HIFU mediated vascular occlusion was attempted in 30 placental vessels during the time-limited 
experimental protocol.  The mean depth of the vascular target beneath the uterine surface was 
13.4 mm (SD ± 3.9 mm).  The range of estimated in situ intensities delivered to the target tissue 
was 4.0 – 5.7 kW.cm-2.  The median number of exposures to complete a series was 5.5 (range 
4 – 10); the median duration of the mechanical ventilation pause was 52 s (range 40 – 96 s) and 
the median time require to perform an exposure series and confirm occlusion or failure was 
102.5 s (range 70 – 483 s).  
Using the standardised transuterine protocol in which exposure conditions did not vary 
(although vessel characteristics did), 28/30 vessels were successfully occluded (93%) based on 
comparison of pre- and post-exposure colour flow Doppler imaging, with 27/30 occluded in a 
single exposure series.  There were two retreatments attempted in the three un-occluded 
vessels, one of which resulted in successful occlusion, giving a total of 32 exposure series.  
Hyperecho following two or more successive exposures was associated with successful 
occlusion in 28/28 exposure series and was only seen in 1/4 unsuccessful exposure series.   
Histological evidence of erythrocytes trapped within the vessel lumen, suggestive of clot was 
found in 24/28 placentomes where occlusion was indicated by “no flow” on post exposure colour 
flow Doppler imaging.  In 4/28 where occlusion was indicated by “no flow” post HIFU exposures, 
the tissue was either too friable to allow sectioning or there were no vessels visible in the only 
sections which could be obtained.  Again, this difficulty in obtaining adequate sections for 
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histological examination was likely related to the degree of damage and tissue destruction 
within the placental tissues.  In the two placentomes where colour flow Doppler predicted 
occlusion had failed, there was no histological evidence of trapped erythrocytes.  There was 
again complete correlation between the colour flow Doppler and histological findings of vascular 
occlusion. 
There was no evidence of trapped erythrocytes in the vessels of sham exposed placentomes (n 
= 36/36). 
The mean vessel diameter measured histologically in vessels where occlusion had occurred 
(not corrected for shrinkage) was 1.2 mm (range 0.4 – 2.4 mm). 
A comparison of vessel characteristics and in situ intensities of successful and failed occlusions 
– based on first HIFU exposure series of a vascular target only, using colour flow Doppler 
comparisons as the measure of successful occlusion – is made in Table 4.3: 
 
Table 4.3: Group A vessel and exposure characteristics (time-limited transuterine protocol).   
The table shows the characteristics of vessels and HIFU exposure series, divided by those which resulted in 
successful or failed occlusion based on comparison of pre- and post-HIFU colour flow Doppler imaging.  The depth 
of the vascular target, the echolucent and HIFU treatment areas, the C-STAR, and the diameter of vessels are 
given as the mean ± SD; estimated in situ intensity is quoted as the median, with the full range given in brackets. 
 
There was no difference in the depth, diameter or echolucent area of the vascular targets in 
which HIFU exposures resulted in a successful or failed occlusion.  Similarly, there was overlap 
in the range of in situ intensities or numbers of exposure delivered to target vessels which 
Successful 
occlusions
Failed 
occlusions
Vessel characteristics
Number 27 3
Depth of vascular target (mm) 13 ± 4 16 ± 3
Echolucent area (mm
2
) 30 ± 20 40 ± 10
Diameter (mm) 1.2 ± 0.5 1.9 ± 0.6
Exposure characteristics
In situ intensity (kW.cm
-2
) 5.2 (4.0 - 5.4) 5.0 (4.5 - 5.3)
Number of exposures in series 4 - 7 5 - 6
HIFU treatment area (mm
2
) 90 ± 30 20 ± 10
C-STAR 5.3 ± 3.8 0.5 ± 0.2
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resulted in successful or failed occlusion.  However, when the HIFU treatment areas were 
compared there was a potential difference.  In two of these failed occlusions, the gantry arm did 
not perform the planned movement due to a technical error; in the third target, the only direction 
of movement planned was in the z axis.  Both these circumstances greatly increased the 
overlap of the HIFU exposures in a series and decreased the area of the placentome that was 
exposed to HIFU energy.  This appeared to contribute to failure of the exposure series to 
produce occlusion.  In agreement with this, the C-STAR in failed occlusions was lower than in 
successful occlusions (t-test, p <0.001). 
 
4.3.2.2 Efficacy of vascular occlusion: dose de-escalation protocol. 
In the dose de-escalation study, a further 12 vascular targets were exposed to HIFU, and 9/12 
(75%) were occluded.  Eight vessels were occluded in a single exposure series; the ninth was 
occluded after a retreatment.  In 2/3 un-occluded vessels, a retreatment was attempted, but this 
also failed to produce occlusion.  
In these placentomes, histological examination was possible in all 12 exposed placentomes.  
Secondary confirmation of occlusion was obtained histologically (trapped erythrocytes seen 
within vessels) in all 9 vessels where occlusion was identified by colour flow Doppler.  There 
were no trapped erythrocytes seen within vessel lumen in the 3/12 vessels where colour flow 
Doppler had shown residual flow post-HIFU exposures. 
When vessel characteristics and estimated in situ intensities of successful and failed occlusions 
– based again on first HIFU exposure series only – are compared for these placentomes, there 
are no clear differences between groups (Table 4.4).   
There was, again, no differences in depth, diameter or echolucent area of the vascular targets 
between successful and failed occlusions.  The range of estimated in situ intensities was 
overlapping between successful and failed occlusion.  It was possible to achieve occlusion with 
estimated in situ intensities as low as 2.4 kW.cm-2, although occlusions at higher intensities also 
failed.  One exposure series which failed to produce occlusion delivered 5.2 kW.cm-2 estimated 
in situ intensity to the target tissue, but only 3 exposures were used: The C-STAR was 1.0 in 
this placentome.  Otherwise there were no targeting or technical errors identified in these HIFU 
exposure series. 
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Table 4.4: Group A vessel and exposure characteristics (dose de-escalation transuterine protocol).   
The table shows the characteristics of vessels and HIFU exposure series in the pilot study, divided by those which 
resulted in successful or failed occlusion.  The depth of the vascular target, echolucent and HIFU treatment areas, 
C-STAR, and diameter of vessels are given as the mean ± SD; estimated in situ intensity is quoted as the median, 
with the full range given in brackets. 
4.3.2.3 Iatrogenic harm: time limited and dose de-escalation transuterine protocols 
There was a single instance of vessel haemorrhage in the 42 vascular targets exposed to HIFU 
in the time-limited and dose de-escalation protocols used in these animals (1/42, 2%).  This 
occurred in a placentome in which there was a technical error with the movement of the gantry 
arm and 4 of 5 HIFU exposures in the series were delivered into the same 3D position.  There 
was evidence of extensive bleeding into the allantoic membranes surrounding this placentome 
at the time of post mortem examination and fetal anaemia preceding post-mortem examination.   
Excessive placental soft tissue damage was noted in 23/38 placentomes which could be 
examined histologically (26 from the time-limited group, 12 from the dose de-escalation group).  
Again, estimated in situ intensity appeared to be the main determinant of the amount of tissue 
damage that occurred (Table 4.5).  This comparison indicates the upper threshold for this type 
of damage to occur is an estimated in situ intensity of 5.1 – 5.2 kW.cm-2 delivered to the 
placental tissue.  
Successful 
occlusions
Failed 
occlusions
Vessel characteristics
Number 8 4
Depth of vascular target (mm) 11 ± 2 8 ± 3
Echolucent area (mm2) 0.2 ± 0.1 0.3 ± 0.1
Diameter (mm) 0.9 ± 0.3 1.6 ± 0.7
Exposure characteristics
In situ intensity (kW.cm-2) 4.1 (2.4 - 5.5) 3.0 (2.2 - 5.2)
Number of exposures in series 5 - 6 3 - 6
HIFU treatment area (mm2) 0.8 ± 0.2 0.7 ± 0.2
HIFU : echolucent areas ratio 4.6 ± 1.8 3.7 ± 2.2
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Table 4.5: Excessive tissue damage (Group A).   
The table shows the characteristics of vessels and HIFU exposure series, divided by those with and without 
excessive tissue damage to the placentome soft tissue.  The depth of the vascular target is given as the mean ± 
SD; estimated in situ intensity is given as median and full range.  The exposure characteristics of the 4/42 
placentomes which could not be examined histologically are excluded from this table. 
There was a single maternal uterine burn associated with an exposure series which resulted in 
excessive tissue damage (drive voltage -5 dBm, in situ intensity 5.5 kW.cm-2, 5 exposures, 10 
mm target depth).  There were no fetal burns. 
 
 
4.3.3 Transuterine efficacy and safety study: discussion 
In these animals, by using a standardised protocol, we were able to demonstrate that it was 
possible to achieve a consistently high rate (93%) of transuterine HIFU placental vascular 
occlusion in sheep, in vessels with clinically relevant diameters.  This suggested that the 
treatment protocol which had been selected due to the fact it was able to deliver treatment 
quickly was also an effective method of achieving vascular occlusion.  This spacing and timing 
of HIFU exposures within a series was therefore adopted for subsequent animal groups, 
although some modification to energy levels and the spatial pattern of exposures was required. 
Estimation of the in situ intensities delivered to the target vessels suggested that high amounts 
of acoustic energy were being delivered to the tissues, even compared to published studies of 
vascular applications of HIFU (Table 1.3).  The presence of hyperecho linked to successful 
occlusions suggests that tissue heating was occurring, and that accumulation of thermal energy 
is an important feature of achieving occlusion.    
Histologically, while there was evidence of occlusive clot within vessel lumen, there was no 
evidence of vessel wall fusion seen.  Similarly, there was no evidence of vessel wall oedema, 
Excessive 
tissue damage
No excessive 
tissue damage
Vessel characteristics
Number 23 15
Depth of vascular target (mm) 12 ± 3 11 ± 5
Successfully occluded 22 14
Exposure characteristics
In situ intensity (kW.cm-2) 5.4 (5.2 - 5.7) 4.1 (2.2 - 5.1)
Number of exposures in series 3 - 7 4 - 7
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collagen shrinkage (although no specific collagen stains were performed), and the endothelium 
of vessels was not examined.  Therefore, while it appeared that vascular occlusion had been 
achieved, this had not occurred via the integrated mechanism suggested in Figure 1.3.  
Therefore, there remained the possibility that the vascular occlusion produced by occlusive clot 
would be a transient effect, and that the vessels could recanalise over time if the lumen was not 
fused closed.  As animals were euthanised within 4 hours of HIFU exposures, no further 
comment regarding this can be made based on the current evidence. 
This possibility needs to be balanced against the findings of excessive tissue damage to 
placental tissue (which has an important synthetic function) which occurred at the same time as 
HIFU exposures of placental vasculature.  However, when the highest and lowest in situ 
intensities at which occlusion was achieved in this group are compared, there is just over a two-
fold difference (Table 4.4).  While this underlines the potential overexposures of tissue which 
may have occurred, and that this may have been the reason for the high efficacy of occlusion, it 
also indicates that a lower, safer estimated in situ intensity can also produce vascular occlusion 
in this animal model.  These findings from the dose-delivery study, however, justify further 
investigation.  These results also suggest that even with the additional attenuation of overlying 
maternal skin, fat and rectus sheath, adequate HIFU energy can be delivered into the 
intrauterine space.  This has been demonstrated using different HIFU systems in humans and 
baboons, without maternal or fetal iatrogenic damage (43, 285, 286).  The next phase of the 
study is planned to be transdermal, and the additional attenuation provided by the maternal skin 
and rectus sheath should reduce the estimated in situ intensity below the 5.0 kW.cm-2 threshold 
suggested to prevent excessive tissue damage, even when using the maximum drive voltage.    
Despite its efficacy, the standard transuterine protocol used did not achieve occlusion in every 
target, the integration of colour flow Doppler imaging with the therapeutic ultrasound source 
meant it was possible to identify failed occlusion in real-time and plan for immediate 
retreatment.  In Group A animals, retreatment was attempted in 4 vascular targets, 2 of which 
were successfully occluded as a result.  Retreatment was not associated with evidence of 
uterine or fetal burns, or risk of haemorrhage.  Given the rate of excessive tissue damage, it 
was not possible here to assess the impact of retreatment on excessive tissue damage.  
Residual anastomoses are identified in 15-30% of cases following fetoscopic laser (16) and may 
lead to recurrent disease with a worse overall prognosis (16) or a threefold greater incidence of 
TAPS (17).  Hence, a method to identify residual anastomoses and provide a retreatment is an 
important feature of any HIFU treatment protocol developed.  Currently, residual anastomoses 
are only identified after completion of fetoscopic laser procedures, and further treatment to 
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coagulate them may be contraindicated.  Technique changes in fetoscopic laser designed to 
overcome this limitation, namely a move from selective coagulation of visualised placental 
anastomoses to the Solomon technique in which the entire “vascular equator” is coagulated, 
have reduced recurrent TTTS and TAPS rates without improving perinatal survival or 
decreasing procedure-related complications (19).   
A low C-STAR was also possibly associated with a risk of vascular haemorrhage.  Based on 
previously published studies, vascular occlusion typically requires higher levels of HIFU energy 
compared to ablation of soft tissues (1) and this carries with it potential complications of vessel 
rupture and haemorrhage, attributed to rapid changes in tissue pressure (31, 32, 37) or 
accumulation of excessive thermal energy in the vessel wall (38, 45, 55).  Haemorrhage had 
occurred in the pilot study in association with gross over-exposure (both in terms of estimated in 
situ intensity and C-STAR) of the tissues and vessels.  However, in Group A, both estimated in 
situ intensity and the number of HIFU exposures had been reduced by the use of -5 dBm drive 
voltage and moving to the “limited” exposure pattern, 2 mm spaced.  Despite this, there was still 
an instance of vessel haemorrhage in the group A animals.   
This haemorrhage was associated with unintentional non-movement of the mechanical gantry 
arm due to a software error.  In the pilot study, “limited” exposure series were designed to have 
1-2 HIFU exposures in the soft tissue surrounding the echo-lucent area containing vessels.  
This was not done in Group A animals, resulting in a number of exposure series where the C-
STAR < 1, a spatial undertreatment, despite the estimated in situ intensity remaining high.  This 
was the only feature which was found to contribute to failed occlusions in this animal group.  
Based on this fining, the restriction of placing the first and last HIFU exposure in placental tissue 
was reintroduced for subsequent animal groups.  This may be of benefit by inducing heating in 
the soft tissues surrounding the target vessel.  This could reduce the diameter of the vessel 
lumen be either inducing collagen shrinkage in connective tissues, or external compression of 
the vessel as a result of tissue oedema, however no histological evidence of either was seen. 
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4.4 Transdermal bridging study 
In this third phase of the study, we sought to investigate if HIFU could be used non-invasively to 
occlude placental vasculature, by applying it through intact maternal skin, incorporating and 
extending the treatment protocols used in Group A animals.   
In the pilot study, 3 HIFU exposure series had been attempted in one animal through intact 
maternal skin: difficulties were encountered in targeting and occluding placental blood vessels, 
with only a 33% successful occlusion rate and a fetal burn.  Additionally, the time required to 
plan and deliver each HIFU exposure series was over an hour.  However, the transuterine study 
had provided experience in targeting and occluding placental blood vessels, and the HIFU 
treatment protocol used had been streamlined since the pilot study, suggesting the possibility 
that quicker planning and delivery of transdermal occlusions would now be possible. 
Therefore, once again it was necessary to assess: 
(i) If it was feasible to use colour flow Doppler integrated with the therapeutic transducer 
and suspended in a waterbag to identify, target and confirm post-exposure outcome 
through intact maternal skin. 
(ii) If sufficient HIFU energy could be delivered into the intrauterine space to result in 
vascular occlusion. 
(iii) The rates and types of iatrogenic harm to mother and fetus.  
 
4.4.1 Methods 
 
4.4.1.1 HIFU therapy system 
No changes were made to the system described in section 4.2.1.1. 
 
4.4.1.2 Animals and surgical methods 
Two pregnant ewes carrying singleton fetuses at 115 d gestational age were placed under 
general anaesthesia (sections 3.2.1, 3.2.2).  No invasive surgical procedures were performed, 
and maternal abdominal skin remained intact.   
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The maternal abdominal skin was prepared first by shaving with clippers to remove wool, then 
washed with iodine scrub solution (Vetasept: 7.5% povidone iodine, Animalcare Ltd., York, UK) 
to remove dirt and lanolin, and washed again with plain water.  The remaining hair was 
chemically depilated (Nair ® hair removal cream, Church & Dwight Co., Kent, UK) and the skin 
was washed for a final time with plain water, then wet with degassed water.  The waterbag was 
placed in contact with the maternal skin and trapped air between the plastic and the skin was 
smoothed out.   If the waterbag was repositioned, the layer of degassed water on the skin was 
replaced, and air pockets were smoothed out again.   
Breath holds were performed during each HIFU exposure series (section 4.2.1.2). 
All fetuses were assessed with ultrasound at the planned end of the HIFU exposures to 
determine presence or absence of fetal heart pulsations.  Non-invasive maternal recording of 
maternal heart rate was used to confirm maternal survival to the planned end of the 
experimental procedure.  
On completion of the HIFU exposures the ewe and fetus were euthanised without recovery from 
general anaesthesia under schedule one of the UK Animals (Scientific Procedures) Act 1986, 
as per section 4.2.1.2. 
 
4.4.1.3 Vascular targets and HIFU treatment protocol 
HIFU was applied trans-dermally to occlude 4-5 vessels per animal (5 per animal, n=1; 4 per 
animal, n=1).   
HIFU exposure series were based on the transuterine time-limited protocol from Group A, but 
allowed for a reduction in drive voltage in order to avoid delivering in situ intensities > 5.0 
kW.cm-2: drive voltage -5 to -6 dBm, 5 s exposure duration, 5 s intervals between exposures, 2 
mm spacing between exposures, placement of exposure following the “limited” pattern.   
The C-STAR was planned to be > 1 in all cases, based on the results shown in Table 4.3, and 
the possible associated risk of haemorrhage.  This required that all exposure series were 
planned to start and finish in placental soft tissue bordering the echo lucent area from which 
vessels arise.  The movement of the mechanical gantry arms was restricted to axes orthogonal 
to the direction of sound (i.e. x or y only) as the GUI software could not reliably support 
movement in 2 or more axes, and this restriction would reduce the risk of technical error.  As in 
the Group A study, HIFU exposure series were not planned in vascular targets where the fetus 
was seen in the post focal region.   
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4.4.1.4  Assessment of treatment success 
Primary confirmation: comparison of pre- and post-HIFU exposure colour flow Doppler imaging 
for evidence of “no flow” or “residual flow” as described in section 4.2.1.4. 
Secondary confirmation: histological examination of exposed placentomes for evidence of 
occlusion within vessel lumen as described in section 4.2.1.4.  No control tissues were 
obtained. 
 
4.4.1.5  Treatment monitoring 
Tissue responses (real-time): as described in section 4.3.1.5. 
Offline analysis of saved imaging: as described in section 4.3.1.5. 
Identification of fetal position relative to HIFU focus: as described in section 4.3.1.5. 
 
4.4.1.6 Management of treatment failure 
There were no failed occlusions in this phase of the study. 
 
4.4.1.7 Assessment of iatrogenic harm 
To monitor for maternal skin burns the maternal abdominal skin was photographed before the 
start of HIFU exposure series and at the end of all HIFU exposure series without the waterbag 
in situ.  These images were compared offline to examine for the appearance of additional skin 
trauma between the beginning and the end of the HIFU exposure series, as in some cases 
clipping and chemical depilation had caused prior superficial skin trauma.  Between HIFU 
exposure series the maternal skin was examined and photographed through the waterbag.  
Changes in maternal skin colouration suggestive of erythema or burns and their location were 
recorded real time in the experimental record and photographed.  These areas were examined 
again at the end of all HIFU exposure series to determine if they had faded (erythema) or were 
still present (burns) 
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A systematic inspection of tissues was performed at post mortem examination and a 
photographic record was compiled of damage to: (i) maternal skin, (ii) maternal rectus sheath, 
(iii) anterior and posterior surface of the uterus, (iv) fetal skin (dorsal, ventral, left and right 
lateral views), and (iv) maternal bladder and bowel.  Areas of maternal and fetal skin, rectus and 
uterus with visual changes suggestive of iatrogenic damage were also collected for histological 
examination, fixed in formalin, sectioned and stained with H&E as described previously. 
 
4.4.2 Results 
4.4.2.1 Feasibility of placental vascular occlusion 
Overall, in this transdermal bridging study, 9 placental vessels were targeted with colour 
Doppler.  Based on a comparison of pre- and post-HIFU exposure colour flow Doppler imaging, 
all 9 of 9 targeted vessels were successfully occluded.  Hyperecho was seen in the placental 
tissue surrounding of all 9 of the targeted vessels.  Both mothers and fetuses survived to the 
end of the planned HIFU exposure series. 
Estimated in situ intensities of 3.0 – 3.9 kW.cm-2 were delivered to the target tissue, using 
between 5 and 7 exposures in a series.  The reduction in drive voltage from -5 to -6 dBm made 
no difference to the success rates of occlusion, although numbers are too small to draw a 
definitive conclusion.  The mean distance of the target vessel beneath the surface of the 
maternal skin was 17.5 mm (SD ± 6.6 mm).   All planned exposure series were successfully 
completed moving in the y axis alone, without the need to correct for angulation of tissue by 
moving in the z axis. 
The median time to complete a treatment was 101 s (range 71 – 141 s) which was comparable 
to the median time in the transuterine study, with a median breath-hold duration of 56 s (range 
48 – 64 s).  However, treatment planning time was extended, such that for the first animal it took 
3 hours to plan and occlude 5 vessels; in the second animal it took 1 hour 10 minutes to plan 
and occlude 4 vessels. 
Retained erythrocytes within vessel lumen, suggestive of occlusive clot, were identified 
histologically on H&E stain in all 9 placentomes examined. Once again, the occluded vessels 
were of clinically relevant dimensions: 0.8 – 2.9 mm.  As in previous phases of the study, the 
colour flow Doppler finding of “no flow” correlated completely with the histological findings of 
occluded vessels.  There was no evidence of tissue boiling or discrete clots within any of these 
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9 placentomes histologically (markers of excessive placental soft tissue damage) although heat 
fixation and extravasation were still noted.   
There were no instances of vascular haemorrhage, nor were there any uterine of fetal burns 
noted.  There were 4 maternal skin burns recorded, all in the second animal exposed to HIFU; 
in the first animal there were no maternal skin burns.  There was also skin irritation in both 
animals evident following shaving and chemical depilation of the skin (Figure 4.19).  This was a 
new finding, as previous animals had only been shaved, except for the one animal in the pilot 
study, which had also been shaved and chemically depilated, but this skin reaction had not 
been noted. 
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Figure 4.19: Maternal skin burns (transdermal bridging study).   
(A) The image shows the condition of the maternal skin following shaving and chemical depilation before any HIFU 
exposures were made.  The skin appears to show irritation.  The black dotted rectangle is the region enlarged in 
(B) showing the condition of maternal skin following HIFU exposures.  The areas of burns are indicated with black 
arrows, and skin irritation can still be seen additional to these areas of burns.  The black arrow marked with an 
asterisk shows the burn presented in (C) as a H&E stained section of a full thickness maternal skin burn.  The blue 
arrow shows normal epidermis, the grey arrow shows burned epidermal cells.  The red arrow shows a clot within 
the subdermal tissue and the green arrow shows the border with the connective tissue, which is not disordered. 
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4.4.3 Transdermal bridging study: discussion 
This transdermal bridging study showed that it was still possible to maintain a consistently high 
occlusion rate for placental vasculature when HIFU was applied through intact maternal skin.  
This agrees with the findings of other studies (43, 285, 286) which demonstrate that it is 
possible to deliver sufficient transdermal energy into the intrauterine space to perform soft 
tissue ablation.  However, these experiments were the first to indicate that sufficient energy for 
selective vascular occlusion could also be delivered into the intrauterine space.  This was 
possible even with the additional attenuation of the maternal skin and rectus sheath. 
The lower range of estimated in situ intensities delivered to the tissues in these animals 
compared to Group A shows that the high rate of vascular occlusion in Group A was unlikely to 
be due to overexposure.  These experiments showed that lower levels of in situ intensity could 
be consistently successful in occluding placental vasculature, confirming the findings from the 
additional exposures in the dose de-escalation transuterine study (Table 4.4). 
The HIFU treatment protocol had been modified in this study to include additional safety 
features.  These did not appear to reduce efficacy, but avoided the incidence of vessel or tissue 
haemorrhage or excessive tissue damage, although number of exposure series on which to 
base this comment remained small.  Given that all the estimated in situ intensities fell beneath 
the 5.0 kW.cm-2 upper threshold instituted following the Group A transuterine study, this was an 
expected, but also a useful confirmation.   
These animals also showed that it was still possible to use colour flow Doppler to identify, target 
and confirm successful occlusion of placental blood vessels through skin, although the process 
was slower than in the transuterine studies.  It was also possible to identify hyperecho during 
HIFU exposures through intact maternal skin, at greater treatment depths. 
These two animals also demonstrated the possibility of maternal skin burns, although from the 
data it was difficult to draw any supported conclusions.  In one of the animals there were 
maternal abdominal skin burns as a result of each HIFU exposure series; in the other animal 
there were none.  With such a small sample, the significance of this was hard to interpret.   
The animal without burns had a lower maternal weight – 32 kg – compared to the animal with 
burns – 54 kg – suggesting the could be an influence of subcutaneous maternal fat, potentially 
in propagating thermal spread from the target vessel to the skin.  However, in the case or either 
pre-focal heating or thermal spread, there would have been damage to the uterus, fat and 
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rectus sheath in the path between the burn and the vascular target, none of which was 
observed.   
Both animals were shaved and washed with iodine scrub 5-10 min before being chemically 
depilated with the same agent (Nair).  In the second animal, the depilatory cream was washed 
off with water and liquid soap before being washed again with water; in the first animal only 
water was used.  In the second animal, we had not recorded whether there was degassed water 
and/or removal or pockets of air between the abdominal skin and the waterbag, suggesting the 
protocol had not been followed.  This non-adherence to protocol was a potential cause of skin 
burns.  Interestingly, each of the burns was also associated with a successful vascular 
occlusion.  Had the burn been the result of poor acoustic coupling between the skin and the 
waterbag and the resultant deposition of acoustic energy onto the skin, the transmission of 
sufficient acoustic energy to occlude the vascular target would have been unlikely.  This 
reduced the likelihood that the presence of liquid soap, air pockets or the absence of degassed 
water was a major contributory factor to the burns, as their main action would have been to 
reduce the quality of the acoustic coupling between skin and waterbag.  The temperature of the 
water in the waterbag and the oxygen content of the degassed water were not measured during 
the HIFU exposures, so cannot be commented on.  For these reasons, the rate of maternal 
burns could only be quoted as 0 – 100%, with unclear evidence as to what the contributory 
factors were at this stage.   
However, as there were no fetal or uterine burns, no evidence of haemorrhage or excess tissue 
damage, a decision was made to proceed into recovery studies.  Maternal skin burns are a 
known side effect of HIFU treatments, and as such were described as a potential adverse effect 
in the study plan approved under the UK Animals (Scientific Procedures) Act 1986 and the 
Ethical Review Committee of the University of Cambridge.  Hence, the occurrence of maternal 
skin burns was unlikely to present a sufficient welfare issue that animals would need to be 
culled for humane reasons before the end of the planned follow-up.  Additionally, further 
investigation of the exposure conditions and contributory factors which promoted the occurrence 
of maternal skin burns would be useful information should the technique ultimately be translated 
into human use. 
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4.5 Transdermal survival study: Group S(urvival) 
Based on the transdermal bridging study, we had an indication that it was possible use HIFU 
through intact maternal skin to occlude placental vasculature, and that the protocol adapted 
from the transuterine study appeared effective.   
However, while fetal survival under general anaesthesia, with and without surgical procedures, 
to the end of planned HIFU exposures was established, fetal survival and rates of obstetric 
complications beyond reversal of anaesthesia remained unknown.  It remained unknown what 
the effect of an unrecognised uterine burn or placental vascular haemorrhage (as the maternal 
skin would remain intact during the treatments) could be on the progress of the pregnancy.  At 
this stage our lack of familiarity with the transdermal protocol, particularly targeting, rendered it 
too slow to be integrated with the planned recovery studies in chronically instrumented maternal 
and fetal sheep preparations designed to assess this (Figure 3.12).   
In addition, while maternal recovery following reversal of anaesthesia was anticipated, and post-
mortem examination in previous non-recovery animals suggested no significant maternal injury 
had occurred to bladder, bowel, major blood vessels in the maternal abdomen or pelvis, there 
had been no opportunity to make a functional assessment of this, as all previous ewes had 
been euthanised while under general anaesthesia.   Maternal skin burns were anticipated, but 
the rate and the severity of these was also uncertain, as were ways to prevent them. 
Therefore, this phase of the study sought to:  
(i) demonstrate longer term fetal survival following HIFU exposures of placental 
vasculature without any additional surgical procedures; 
(ii) establish if HIFU could be used as a method to consistently occlude placental blood 
vessels (transdermal) 
(iii) assess the rates and types of maternal and fetal iatrogenic harm, and identify 
procedural modifications or safety limits that could prevent harm; 
(iv) reduce the total HIFU treatment time sufficiently to allow the planned recovery studies 
in chronically instrumented sheep to proceed. 
 
4.5.1 Methods 
These animals (n=6) were the first in which were recovered from anaesthesia following HIFU 
exposures of placental vasculature.  To assess the quality of fetal recovery, they were paired 
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with sham-exposed animals (n=6) who underwent general anaesthesia, but were not exposed 
to HIFU.  Utero-placental function, fetal survival and growth, cardiovascular function and 
initiation of cardiovascular defence mechanisms were measured with non-invasive ultrasound 
and materno-fetal Doppler studies before, during and after HIFU exposures (section 3.6).  
These results will be reported and discussed separately in chapters 5-8.  These 12 animals will 
be referred to as ‘Group S’. 
 
4.5.1.1 HIFU therapy system 
The system described in section 4.2.1.1 was used.  However, after 3 animals, the protocol for 
degassing the water in the water bag was changed and a new provision to cool the water was 
introduced.   
In the first 3 of 6 animals in this group, the water in the water bag was taken cold from the tap 
and not cooled further; it was degassed before the start of HIFU exposures and only again if 
cavitation was seen in the water on ultrasound during exposures.  In the last 3 of 6 animals in 
this group the water in the water bag was cooled with ice sealed in plastic (so the melting ice 
water did not mix with degassed water in the bag) and was degassed before each HIFU 
exposure series.  The water was cooled to between 19.7 – 26.3oC and degassed to contain 
dissolved oxygen between 0.8 – 2.8 mg.l-1 in these exposure series. 
 
4.5.1.2 Animals and surgical methods 
Six pregnant ewes carrying singleton fetuses at 115 ± 10 d gestational age were placed under 
general anaesthesia (sections 3.2.1, 3.2.2).  No invasive surgical procedures were performed, 
and maternal abdominal skin remained intact.   
The maternal abdominal skin was shaved, washed and chemically depilated as described in 
section 4.4.1.2, with the exception that a different chemical depilatory was used (Veet ® hair 
removal cream, Reckitt Benckiser, Slough, UK) in an attempt to reduce skin irritation.  When 
this did not work in the first animal, the interval between shaving and chemical depilation was 
changed from 5 – 10 min in the first of the 6 animals, to 24 – 48 h in the remaining 5 of 6 ewes.  
Following depilation, the skin was washed for a final time with plain water and wet with 
degassed water.  The waterbag was placed in contact with the maternal skin and trapped air 
between the plastic and the skin was smoothed out.  If the waterbag was repositioned, the layer 
of degassed water on the skin was replaced, and air pockets were smoothed out again.   
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Breath holds were performed during each HIFU exposure series (section 4.2.1.2). 
Following completion of planned HIFU exposure series, animals were recovered from 
anaesthesia and monitored for 21 days.  Animals were checked daily for signs of maternal pain 
or distress, infection or poor healing of skin burns, problems with mobility, bladder or bowel 
function, preterm labour, rupture of membranes or vaginal bleeding. Maternal analgesia 
(Carprofen 1.4 mg.kg-1 S.C., RimadylTM, Pfizer Ltd., UK) was administered if signs of maternal 
pain or distress were evident based on behaviour, facial expressions, stance or feeding 
patterns.   
Following recovery, animals were housed in individual pens in an outdoor barn (light and dark 
cycle dependent on seasonal variation) with ad libitum access to hay, nuts, mineral lick and 
water.  After five days, animals were transferred to communal pens in an outdoor barn with 
access ad libitum to hay, mineral lick and water; nuts were provided daily.     
After the completion of 21 days follow-up, the ewe and fetus were euthanised under schedule 
one of the UK Animals (Scientific Procedures) Act 1986.  A slow intravenous injection into the 
maternal jugular vein of 120 mg.kg-1 pentobarbitone sodium (Pentoject®, Animalcare Ltd., UK) 
was used for this purpose.  Air embolus into the jugular vein was used as a secondary 
confirmation of death.  Maternal cardiac activity was auscultated with a stethoscope and death 
was confirmed on cessation of cardiac and respiratory activity.  Cessation of fetal cardiac 
activity was confirmed with diagnostic ultrasound. 
 
4.5.1.3 Vascular targets and HIFU treatment protocol 
HIFU was applied trans-dermally to occlude 4-6 vessels per animal (6 per animal, n=5; 4 per 
animal, n=1).   
HIFU exposure series were based on the protocol used in the transdermal bridging study, but 
allowed for greater reductions in drive voltage.  This was an attempt to reduce the rate of skin 
burns: drive voltage -5 to -9 dBm, free field intensity 2.5 – 6.7 kW.cm-2, 5 s exposure duration, 5 
s intervals between exposures, 2 mm spacing between exposures, placement of exposure 
following the “limited” pattern.   
The following safety limits were adopted from the bridging study: (i) all exposure series were 
planned to start and finish in placental soft tissue bordering the echo lucent area from which 
vessels arise; (ii) the C-STAR was planned to be >1; (iii) movement of the mechanical gantry 
arms was restricted to one direction on an axis orthogonal to the direction of sound; and (iv) 
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predicted in situ intensities above 5.0 kW.cm-2 were not planned.  As in Group A, vascular 
targets were not selected if there were fetal parts in the post-focal region, at any distance.   
No safety limits on exposure conditions specifically to reduce the rate of maternal skin burns 
were planned at the outset of this animal group as none had been identified.  
 
4.5.1.4 Assessment of treatment success 
Primary confirmation: comparison of pre- and post-HIFU exposure colour flow Doppler imaging 
for evidence of “no flow” or “residual flow” as described in section 4.2.1.4. 
Secondary confirmation: as these were survival studies, with 21 days between HIFU exposures 
and collection of tissue at post-mortem examination, direct secondary confirmation of occlusion 
for each placentome could not be sought from visual identification and histological examination 
of damaged tissue.   The dye that had previously been used to tag placentomes was not 
permanent and there was no known safety data regarding intra-uterine use of permanent tissue 
dyes.  Therefore, while it was possible to identify and retrieve placentomes with evidence of 
HIFU damage at the time of post-mortem, these could not be directly correlated to any specific 
exposure series performed in that animal.  However, given the strong correlation between 
Doppler and histological findings in previous phases of the study, a finding of the same number 
of damaged placentomes with histologically occluded vessels as predicted by colour flow 
Doppler would serve as secondary confirmation of persistent vascular occlusion. 
Following euthanasia of ewe and fetus, at post mortem examination, all placentomes were 
bisected and examined for evidence of tissue damage, weighed and classified by morphological 
type.  In HIFU exposed animals, all placentomes with evidence of tissue damage were retained 
for histological examination.  In addition, 2 placentomes per animal without any evidence of 
HIFU damage in HIFU exposed animals were retained for histological examination.  One 
placentome was taken from the same region in which the exposed placentomes were found, 
and the second placentome was taken from a distant region.  An additional 6 placentomes, 
randomly selected, were retained from each sham-exposed animal.  Retained placental tissues 
were fixed, sectioned and stained with H&E as described in section 4.2.1.4, with the exception 
that histological findings could not be correlated to specific colour Doppler findings. 
The 21 day interval between HIFU exposure and tissue collection allowed for the first time 
allowed the possibility of examining vessels for evidence of persistent vascular occlusion.  As 
the suggested method of occlusion to this point was occlusive clot, in addition to H&E staining, 
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Phosphotungstic Acid-Haematoxylin (PTAH) staining, which stains organised fibrin, was 
planned.  From each animal in which had been exposed to HIFU the two placentomes which 
showed the clearest evidence of occluded vascular lumen on H&E staining were selected for 
PTAH staining; from sham exposed animals one randomly selected placentome was used.  All 
placentomes could not be stained due to financial restrictions on provision of PTAH staining 
materials.  Sections were cleared of paraffin using Histo-clear II and rehydrated through four 
solutions of decreasing concentrations of ethanol before being washed with distilled water.  
Slides were incubated in a preheated zinc chloride solution (80-90oC, Abcam, Cambridge, UK) 
before being washed in running tap water and rinsed in distilled water.  Slides were then 
immersed in ferric ammonium sulphate aqueous solution (80-90oC, Abcam, Cambridge, UK) 
and heated before being washed in running tap water and rinsed in distilled water.  Finally, 
slides were incubated in preheated PTAH stain solution (80-90oC, Abcam, Cambridge, UK) 
before being differentiated in 95% reagent alcohol and dehydrated in three changes of absolute 
ethanol and cleared in two changes of Histo-clear II and one of xylene.  Coverslips were 
mounted with DPX mountant.  Slides were examined and the findings were correlated to H&E 
findings from the same placentome. 
 
4.5.1.5  Treatment monitoring 
Tissue responses (real-time): as described in section 4.3.1.5. 
Offline analysis of saved imaging: as described in section 4.3.1.5. 
Identification of fetal position relative to HIFU focus: as described in section 4.3.1.5. 
 
4.5.1.6  Management of treatment failure 
If colour flow Doppler imaging demonstrated preserved blood flow after a HIFU exposure series 
(“residual flow”) then this was termed a failed occlusion.  Based on the limited data from the 
transuterine study that retreatment was beneficial and safe, a plan was made to retreat 
unsuccessful occlusions.  After a failed occlusion, retreatment could be planned, unless as a 
result of the initial exposure series: (i) there was evidence of a maternal skin burn; (ii) there was 
suspicion of fetal or other maternal injury; (iii) there were targeting or technical errors which 
could not be overcome at that time. 
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If retreatment was not contraindicated, one further HIFU exposure series was re-planned and 
delivered to attempt to achieve successful vascular occlusion.  If successful vascular occlusion 
was not achieved after a maximum of two HIFU exposure series, no further attempts to achieve 
vascular occlusion were made. 
Failed occlusions were classified as targeting or technical errors as described as in section 
4.2.1.5.  Failed occlusions were also correlated with the presence or absence of maternal skin 
burns or erythema, and the suspicion of uterine or fetal burns (recorded as burns).   
 
4.5.1.7  Assessment of iatrogenic harm 
Maternal skin burns:  These were monitored intraoperatively as described in section 4.4.1.7.  
These areas were examined again at the end of all HIFU exposure series and daily thereafter.  
Any area of skin reddening which resulted from a HIFU exposure series but faded fully within 24 
h of exposure was classified as erythema; other areas of damage resulting from HIFU exposure 
which persisted > 24h were classified as skin burns.  These were photographed daily for the 
first 5 days and then every 5th day to record healing. 
A systematic inspection of tissues was performed at post mortem examination and a 
photographic record was compiled of damage to: (i) maternal skin, (ii) maternal rectus sheath, 
(iii) anterior and posterior surface of the uterus, (iv) fetal skin (dorsal, ventral, left and right 
lateral views), and (iv) maternal bladder and bowel.  Blood samples were drawn into sterile 
syringes from the umbilical artery and vein (0.5 ml each).  The haemoglobin concentration of the 
blood was determined using an ABL80 Flex analyser (Radiometer, Denmark). Areas of 
maternal and fetal skin, rectus and uterus with visual changes suggestive of iatrogenic damage 
were also collected for histological examination, fixed in formalin, sectioned and stained with 
H&E as described previously. 
 
4.5.2 Results 
4.5.2.1  Efficacy of vascular occlusion 
HIFU mediated vascular occlusion was attempted in 34 placental vessels.  The mean depth of 
the target vessels was 26 mm (SD ± 9 mm), which was deeper than in either the transuterine or 
transdermal bridging studies. Drive voltage ranged from -5 to -9 dBm, and estimated in situ 
intensities from 1.3 – 4.4 kW.cm-2.  The median number of exposures required to complete a 
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series was 6 (range 4 – 7); the median duration of the mechanical ventilation pause was 56 s 
(range 24 – 64 s) and the median time to complete an HIFU exposure series and determine if 
occlusion had occurred was 103 s (range 49 – 1087 s). The median maternal weight was 36.5 
kg (range 33 – 53 kg). 
Based on comparison of pre- and post-HIFU exposure colour flow Doppler imaging 31/34 
vessels were successfully occluded (91%).  Of these, 29/31 vessels were occluded in a single 
exposure series; 2/31 vessels were occluded following retreatment with a further exposure 
series, giving a total of 36 exposure series, 5 of which resulted in failed occlusion.  Hyperecho 
during B-mode ultrasound treatment monitoring was seen in 26/31 (84%) HIFU exposure series 
resulting in successful vascular occlusion and 2/5 HIFU exposure series resulting in failed 
vascular occlusion.  
In 2/5 HIFU exposure series which resulted in failed occlusion, the planned exposure series 
were curtailed by problems with control of movement of the mechanised gantry arm (1 software 
crash, 1 trapped cable preventing movement).  In both cases this was recognised and the HIFU 
exposure series was manually stopped before multiple HIFU exposures could be delivered to 
the same location, to reduce the risk of vessel haemorrhage.  These were the only 2 exposure 
series where the C-STAR was below 1 (a spatial undertreatment).  However, in both, 
retreatment was contraindicated by maternal skin damage.  
In a further 2/5 HIFU exposure series which resulted in a failed occlusion there was a 
mistargeting of 10-14 mm which resulted in failure of occlusion.  In 1 of these a maternal skin 
burn prevented retreatment; in the other correction of the targeting error resulted in successful 
occlusion. 
In the final 1/5 HIFU exposure series which resulted in a failed occlusion there was no 
immediate cause of failure which could be identified.  The planned exposures were delivered 
correctly by the system (5 exposures, drive voltage -6 dBm, 3.0 kW.cm-2 estimated in situ 
intensity, 17 mm target depth, 8 mm gantry movement).  The subsequent retreatment, which 
was successful in producing occlusion, had only a 2 mm difference in depth of the HIFU focal 
plane (5 exposures, drive voltage -6 dBm, 3.1 kW.cm-2, 15 mm target depth). The C-STAR was 
>1 in both the original exposure series and subsequent retreatment.  There was no skin 
damage or evidence of cavitation in the waterbag during the exposure series; the appearance of 
hyperecho during the first HIFU exposure series at the site of the intended target suggested that 
acoustic energy was reaching the intended target initially.    
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As such, there was only one HIFU exposure series in which the exposure conditions, rather 
than operator or equipment error, could have resulted in failure of occlusion, making a 
comparison of successful and failed exposure conditions trivial.  However, the larger number of 
exposure series, including more exposures at lower drive voltages, provided further information 
about where the minimum threshold of in situ intensity to achieve placental vascular occlusion 
may lie.  Figure 4.20 shows the distribution of estimated in situ intensities which produced 
successful occlusions in Group S animals.  There were no estimated in situ intensities > 4.4 
kW.cm-2, nor were there any successful occlusions <2.3 kW.cm-2.  The majority of successful 
occlusions were produced with estimated in situ intensities 2.5 – 3.5 kW.cm-2, suggesting that 
this is could be the therapeutic window in which HIFU exposure series should be planned.  
However, the exposure series discussed above, which failed for unknown reasons delivered 3.0 
kW.cm-2 estimated in situ intensity to the target tissues, so this is not an absolute guarantee of 
successful occlusion. 
 
Figure 4.20: Estimated in situ intensity resulting in successful occlusion (Group S).    
The histogram shows the relative frequency of estimated in situ intensities which produced successful vascular 
occlusion using the standard protocol for group S. 
After 21 days of follow-up, a total of 34 placentomes with evidence of tissue damage were 
retrieved at post-mortem examination in animals exposed to HIFU: both the total number and 
the number per animal matched the number of exposed vascular targets.  No damage was seen 
in the sham exposed placentomes.   
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Examples of tissue damage in placentomes retrieved on the day of HIFU exposures and after 
21 days recovery are compared in Figure 4.21 and Figure 4.22.  It is not possible to show the 
same placentome, excised and bisected immediately after HIFU, and then again after 21 days 
of healing.  However, placentomes treated by HIFU exposure series with similar characteristics 
in non-recovery animals (Group A or bridging study) and Group S animals are shown in these 
figures for the purposes of visual comparison only.   
While the tissue damage is clearer immediately post HIFU exposures, the presence of damage 
is still evident after 21 days of healing.  However, beyond this, there was little obvious 
correlation between the visual appearance of the placentome and the exposure conditions; 
while tissue damage was a sensitive and specific marker for placentomes containing vessels 
exposed to HIFU, it was not a sensitive or specific marker of vascular occlusion. 
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Figure 4.21: Macroscopic tissue changes following HIFU (pallor).   
(A) The photograph shows a placentome bisected on the same day as exposure to HIFU, photographed after 
formalin fixation for 24 h, with an area of tissue pallor surrounded by an area of tissue darkening (Group A, OR638, 
115d GA, HIFU exposure series: transuterine, 6 exposures, 2 mm spaced, 5 s duration, estimated in situ intensity 
2.7 kW.cm-2, target depth 9 mm, echolucent area 0.16 mm2).  (B) The photograph shows a placentome bisected 21 
days after exposure to HIFU, photographed after formalin fixation for 24 h, with a less obvious area of tissue pallor 
which has become soft and yellowed with a small rim of persistent tissue darkening. (Group S, BL89, 128 d GA, 
HIFU exposure series: transdermal, 5 exposures, 2 mm spaced, 5 s duration, estimated in situ intensity 2.7 kW.cm-
2, target depth 9 mm, echolucent area 0.21 mm2).  (A,B) The line diagrams represent (i) tissue darkening (ii) tissue 
pallor (iii) area of materno-fetal exchange surrounding origin of fetal vessels (iv) placental tissue.  Scale bars for A 
and B are 1 cm (photographs and line diagrams to same scale). 
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Figure 4.22: Macroscopic tissue changes following HIFU (darkening).   
(A) The upper photograph shows a placentome bisected on the same day as exposure to HIFU, photographed 
after formalin fixation for 24 h, with an area of tissue darkening extending into the origin of the fetal vessels, 
(Bridging study, BL10, 115 d GA, HIFU exposure series: transdermal, 6 exposures, 2 mm spaced, 5 s duration, 
estimated in situ intensity 3.5 kW.cm-2, target depth 8 mm, echolucent area 0.25 mm2). (B) The upper photograph 
shows a placentome bisected 21 days after exposure to HIFU, photographed after formalin fixation for 24 h, with a 
less obvious area of tissue darkening which has partially resolved over time, (Group S, BL53, 116 d GA, HIFU 
exposure series: 5 exposures, 2 mm spaced, 5 s duration, estimated in situ intensity 3.3 kW.cm-2, target depth 24 
mm, echolucent area 0.29 mm2).  (A,B) The line diagrams represent (i) tissue darkening (ii) area of materno-fetal 
exchange surrounding origin of fetal vessels (iii) placental tissue.  Scale bars for A and B are 1 cm (photographs 
and line diagrams to same scale). 
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In total, 82 placentomes from Group S animals were examined histologically using H&E stain: 
34 with evidence of HIFU damage; 12 undamaged placentomes from animals in which HIFU 
exposures had been performed, and 36 placentomes from control, sham-HIFU exposed, 
animals.   
Trapped erythrocytes within vessel lumen suggestive of occlusive clot was found in 30/34 
placentomes which had been exposed to HIFU; in one placentome the tissue could not be 
sectioned adequately to visualise the vessels.   In 3 vessels where there was no histological 
evidence of trapped erythrocytes within vessel lumen.  There was no evidence of excessive 
tissue damage in any of the 34 HIFU exposed placentomes examined.  The mean diameter of 
occluded vessels was 1.4 mm (range 0.3 – 3.3 mm). 
While histological findings could not be correlated directly to specific placentomes, the number 
of occluded and non-occluded target vessels per animal matched the number predicted by 
colour flow Doppler, with the exception of the single animal where once placentome could not 
be sectioned adequately. 
There was no evidence of trapped erythrocytes within vessel lumen or excessive tissue damage 
within any of the 12 undamaged placentomes of 36 control placentomes examined. 
An additional finding, compared to the examination placental vessels within hours of HIFU 
occlusion, was the presence of vacuolar change around occluded vessels, suggestive of 
degeneration of the connective tissue surrounding vessels (Figure 4.23c).  This was found 
surrounding occluded vessels in 24/30 placentomes where there was histological evidence of 
occlusion; there was no evidence of similar vacuolar degeneration surrounding the 3 vessels 
where occlusion failed, nor surrounding vessel lumen taken from either undamaged (n=12) or 
sham-HIFU exposed placentomes (n=36). 
In 12/30 placentomes (n=2 from each animal) where occlusion and vacuolar degeneration of 
vessels was suggested by H&E staining, and 6 sham-HIFU exposed placentomes, PTAH 
staining was performed.  All 12 HIFU exposed vessels demonstrated organised fibrin (clot) 
within the vessel lumen, which was not seen in sham exposed vessels (Figure 4.23d,e).   The 
connective tissue around all 12 occluded vessels stained much more faintly than in control 
samples, again suggestive of vacuolar change and degeneration of the tissue (Figure 4.23e,f). 
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Figure 4.23: Histological confirmation of vascular occlusion after 21 days (Group S).   
(A) H&E stain of fetal vessels in a sham exposed placentome.  The lumen of the vessels are open and unobstructed, suggesting they remain patent, and the tissue around 
the vessels shows regular pink staining of normal connective tissue.  (B)  H&E stain of fetal vessels in an exposed placentome where colour Doppler imaging suggested 
occlusion.  While the vessel lumen is not collapsed, there are trapped erythrocytes within the lumen suggestive of occlusive clot.  (C) H&E stain of fetal vessels in an exposed 
placentome where colour Doppler imaging suggested occlusion; again the lumen are occluded with trapped erythrocytes.  The black arrow marks pale, irregular staining in the 
tissue around the vessels denoting vacuolar degeneration.  (D) PTAH stain of fetal vessels in a control placentome.  The lumen are open and unobstructed and the 
connective tissue around the vessels has regular purple staining of normal collagen.  (E) PTAH stain of a fetal vessel exposed to HIFU and suggested to be occluded by 
colour flow Doppler studies.  The lumen is stained black, indicating that it is occluded by organised fibrin, a definitive appearance of occlusive clot.  (F) PTAH stain of HIFU 
exposed fetal vessels: there is again black staining in the lumen, but also regions of irregular, pale staining in the collagenous regions surrounding the vessels, matching the 
H&E finding of vacuolar degeneration. 
Chapter 4: HIFU treatment protocol 
181 
 
4.5.2.2  Iatrogenic harm 
All ewes and fetuses were alive at the end of the planned HIFU exposure series and 
survived to the end of the 21 d follow-up period.  During this period, there were no 
indicators of maternal pain or distress as a result of the HIFU exposures or maternal skin 
burns.  
There was no evidence of significant maternal injury during the follow-up period as a result 
of exposure to HIFU. Based on daily systematic observation of maternal movements and 
gait, pain scores and analgesia requirements, food and fluid intake and passage of urine 
and faeces there were no complications observed in any animal.  Specifically, there was no 
suggestion in any animal from maternal behaviour or recovery that injury to the spinal cord, 
bladder or bowel had occurred.   
At the time of post mortem examination, there was also no evidence on visual inspection of 
burns to the rectus sheath or uterus, faecal peritonitis, lesions on the bowel, uroperitoneum 
lesions on the bladder, or injury extending into the retroperitoneum, although the spine was 
not formally examined.   
There was no evidence of obstetric complications during the follow-up period as a result of 
exposure to HIFU.  Specifically, there were no instances of preterm delivery, preterm 
rupture of membranes or vaginal bleeding.  Non-invasive fetal monitoring with Doppler 
ultrasound (MCA-PSV, methods described in section 3.6.2) showed no evidence of 
anaemia in the fetuses following HIFU exposures (Figure 4.24).  All fetuses remained in 
utero at the time of post-mortem, and on visual inspection there was no evidence of fetal 
burns or damage.  There was also no post-mortem evidence of haemorrhage from 
placental vessels or the umbilical cord, and the fetal haemoglobin concentration of cord 
blood was not significantly different between sham and HIFU exposed animals at the time 
of post mortem examination (Figure 4.24). 
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Figure 4.24: Monitoring for fetal anaemia (Group S).   
Values represent the mean ± SD of fetal middle cerebral artery peak systolic velocity, a predictor of fetal 
anaemia in human fetuses, before, during and after HIFU (n=6, closed circles) or sham (n=6, open circles) 
exposures under general anaesthesia.  Dotted lines demarcate the 3 values taken under general anaesthesia; 
all other measurements were taken in un-anaesthetised animals.  Statistical significance was assessed using 
a repeated measures two-way ANOVA and no differences were found.  (B) Values represent the mean ± SD 
of fetal haemoglobin sample from the umbilical cord at post mortem examination 21 d after HIFU (n=6) or 
sham (n=6) exposure of placental vasculature.  Statistical significance was assessed using a 2-tailed 
Student’s t-test and no differences were found. 
The additional findings of the materno-fetal ultrasound studies and fetal post-mortem 
examination are reported and discussed in chapters 5-8, where groups A, S and R can be 
compared. 
 
4.5.2.3  Maternal skin burns 
There were 10 instances of skin erythema and 4 maternal skin burns as a result of a total of 
36 HIFU exposure series, giving a rate of 28% for skin erythema (resolution within 24 h) 
and 11% for skin burns in this group of animals.   
There initially appeared to be a tendency for skin burns to occur at higher drive voltages: 3 
of 4 burns resulted from exposure series performed at -5 dBm.  However, a reduction in 
drive voltage produced no obvious improvement in skin damage rates: 10/26 (38%) of 
exposure series at -5 or -6 dBm resulted in some form of skin damage, compared to 4/10 
(40%) of exposure series at -7 to -9 dBm.  Skin burns occurred when in situ intensities of 
2.7 – 4.4 kW.cm-2 were delivered to the target tissue; skin erythema occurred when in situ 
Chapter 4: HIFU treatment protocol 
183 
 
intensities of 1.3 – 3.4 kW.cm-2 were delivered to target tissue, with no obvious pattern to 
which exposures series resulted in a burn based on this alone. 
There was also appeared to be a tendency for skin burns to happen at shallower target 
depths: 3 of 4 burns were in exposure series with a target depth ≤ 15 mm.  In fact, all 4/4 
exposures at ≤ 15 mm target depth resulted in a burn; however 10/32 (31%) of skin 
damage occurred when the target depth was > 15 mm.   
Skin damage showed clustering in individual animals, however this no longer appeared 
related to maternal weight, as the highest rate of skin damage occurred in both the heaviest 
(50 kg) and lightest (33 kg) ewes.  It is possible that differences in skin condition between 
individual animals played a role that has not be quantified in this study. 
A step-wise series of safety measures were introduced to try and reduce the rate of 
maternal skin burns.  The first measure was designed to reduce the skin irritation and 
erythema which was evident after shaving and depilation.  Separation of clipping and 
chemical depilation by 24-48 h appeared to reduce the degree of, if not totally prevent, skin 
irritation in all 5 animals in this group where it was performed (Figure 4.25).  Reduction of 
skin irritation by separation of clipping and chemical depilation also appeared to be 
beneficial in reducing the rate of HIFU skin damage:  7/13 exposure series (54% - including 
data from the transdermal bridging study) performed after clipping and chemical depilation 
on the same day resulted in skin damage, compared to 11/32 (34%) when there was a 
separation of at least 24 hours between the two procedures.  However, this was a non-
significant reduction (Chi-square test, p=0.23) 
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Figure 4.25: Maternal skin irritation from shaving (Group S).   
(A) This photograph shows the abdominal skin of an ewe that was shaved and had chemical depilation 
performed on the same day immediately before any HIFU exposures, with skin irritation evident from the red 
marks.  (B) This photograph shows the abdominal skin of an ewe shaved 48 h before chemical depilation.  
There is minimal skin irritation in evidence. 
 
The next measure to be introduced was cooling and degassing of the water in the waterbag 
as described in section 4.5.1.1.  Before this was begun 7/12 (58%) of exposure series 
resulted in skin damage (even when clipping and depilation separated by 24-48 h), 
compared to 4/18 (22%) of exposure series after it routinely performed.  This was a 
borderline significant reduction (Chi-square test, p=0.04). 
When these two interventions are compared together, however they have a clearer value, 
with a 0.33 relative risk reduction (95% CI 0.12 – 0.94) in the rate of maternal skin burns 
(Table 4.6). 
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Table 4.6: Effect of interventions to reduce maternal skin burns (Group S).   
The table shows the burns resulting from the 13 HIFU exposures series before clipping and depilation were 
separated and before repeated cooling and degassing of the waterbag was introduced, compared to the 22 
HIFU exposure series after both these interventions became part of the safety protocols of Group S.  The 
interventions produced a reduction in risk (Chi-squared test, p = 0.03). 
 
The 4 maternal skin burns showed evidence of healing without infection during the 21 d 
period.  The 10 regions of maternal skin erythema (by definition) were not visible by day 1 
following HIFU exposures.  An example of skin burns and erythema is shown in Figure 
4.26.  Despite the separation of shaving from chemical depilation by 24 – 48 h in this 
animal, there is still evidence of some skin damage prior to the start of HIFU exposures, 
shown with black arrows, numbered 1-8, in the pre-HIFU image.   
By the end of the HIFU exposures (post-HIFU image), shaving marks 7-8 have faded, 1-3, 
5 and 6 remain unchanged.  The original skin mark labelled 4 appears to have become 
more pronounced, and this was called a region of erythema overlying pre-existing skin 
damage (causative HIFU exposure series: 6 exposures, estimated in situ intensity 2.4 
kW.cm-2, 5 s, 2 mm spaced, target depth 20 mm).  There is a new raised area demarcated 
by a black circle – this is the burn which resulted from a HIFU exposure series of 7 
exposures, estimated in situ intensity 4.3 kW.cm-2, 5 s duration, 2 mm spaced.  Due to the 
targeting error in this placentome, the HIFU energy was delivered only 10 mm beneath the 
surface of the skin, instead of the intended 24 mm.  An enlargement of the burned area, the 
area of erythema and one of the shaving marks is shown in panel A.   
By day 1 post HIFU exposures, the burn (black circle) is still evident and healing has begun, 
as the area is starting to show fibrinous exudate.  Although the angle of the maternal 
Maternal 
skin 
damage
No maternal 
skin 
damage
Clipping on same day as depilation &
Waterbag cooled and degassed before each 
HIFU exposure series
7 6
Clipping 24-48 h before depilation &
Waterbag cooled and degassed at start of HIFU 
exposures only
4 18
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abdomen is different in the semi-recumbent position to the previous prone positions shown, 
there does not appear to be any clear evidence of a burn at location 4, supporting its 
classification as erythema.  The shaving mark at location 3 is also starting to scab. 
By day 15 post HIFU, the burned area has scabbed over, as has a small area of the 
shaving mark at location 3.  There is no evidence of infection or purulent discharge.  While 
there is still no evidence of skin damage at the site marked 4, the wool is showing an 
altered pattern of regrowth in this region.   
At the time of post-mortem (day 21) the abdomen is again shown with the animal in a prone 
position.  The scab from the burn has detached showing a raised white area where the burn 
had been, marked by arrow 9; histological examination showed dense scar tissue in this 
region consistent with the maturational phase of healing of a full thickness burn. 
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Figure 4.26: Maternal skin burn healing (Group S).   
Pre-HIFU: this panel shows the maternal abdomen after shaving and depilation (24 h apart) before exposure to HIFU.  Arrows 1-8 mark areas of skin irritation or damage as a 
result of shaving or chemical depilation.  Post HIFU:  the maternal abdominal skin is shown after completion of 6 HIFU exposure series.  The circled area is a skin burn which 
was not present before HIFU; the arrow marked 4 shows an area of skin irritation which has enlarged, and appears to be erythema.  Areas of skin irritation 1-3 and 5-6 remain 
unchanged, 7-8 are no longer visible.  An enlargement of the new areas of skin damage is shown in panel A.  Day 1: the burn has darkened and has a small yellow area of 
fibrinous exudate.    There is now no clear evidence of skin damage at location 4, supporting the classification of erythema; there appears to be an area of persistent skin 
irritation at location 3, which is starting to develop a fibrinous scab.  Day 15:    The burned area has formed a fibrinous scab with no sign of infection.  A small area of fibrinous 
scab remains at the area of skin irritation (3); and while there is no skin damage at site 4, the regrowth of hair is altered.  Post-mortem: by day 21, the area of skin irritation 
has healed and the burn is a raised while area of tissue (shown enlarged in the inset, marked by arrow 9). 
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4.5.3 Transdermal survival study: discussion 
In these animals, we were able to once again demonstrate that it was possible to achieve a high 
rate of placental vascular occlusion (91%) in sheep, using HIFU, this time through intact 
maternal skin.  As previously, identification, targeting and confirmation of occlusion was 
performed with colour flow Doppler integrated with the HIFU transducer, in vessels of clinical 
relevant diameters, the importance of which has previously been discussed.  While HIFU 
ablation of placental tissue through intact maternal skin has previously been demonstrated (285, 
286), it appears that this was the first demonstration that selective placental vascular ablation 
during pregnancy could be achieved. 
Additionally, for the first time, we were also able to demonstrate survival of mothers and fetus 
beyond the immediate end of HIFU exposures.  All six mothers and fetus who underwent 
anaesthesia and exposure to HIFU survived without evidence of significant maternal or obstetric 
complications for a period of three weeks following this.  Such survival has not been 
demonstrated in any other pregnant animal model following HIFU exposure of the placenta (60, 
61, 281, 286), although there are 2 case reports in humans of fetal survival and delivery 
following HIFU energy delivery into the intrauterine space (although not used on placental 
vessels) (43, 57).  This is an advance in demonstrating the potential of HIFU mediated placental 
vascular occlusion as a therapy suitable for use in human pregnancy. 
Overall, the increased safety features in the treatment protocol - the restrictions on maintaining 
the C-STAR >1, moving the HIFU transducer in only one plane, orthogonal to the direction of 
sound, starting and ending HIFU exposure series in soft tissue and avoiding in situ intensities > 
5.0 kW.cm-2 - together meant that there were no further instances of vessel haemorrhage in this 
animal group.  This is despite two technical malfunctions which could have replicated the 
conditions which resulted in a vascular haemorrhage in the Group A animals (non-movement of 
the gantry arm and repeated HIFU exposure of the same tissue location).  Based on this 
experience, both these situations were recognised by visually monitoring the gantry arm and 
ultrasound screen for movement between each HIFU exposure in a series, and were manually 
stopped before harm occurred.  While this system was effective in this circumstance, it was 
vulnerable to failure through inattention or distraction, and is an area which would require closer 
regulation in any future, improved HIFU system to be used in this field.  An automated 
confirmation of completed movement and correct positioning of the gantry arm before any HIFU 
exposure could be delivered would be ideal. 
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In the pilot, transuterine and transdermal bridging studies, high drive voltages were used to 
deliver high levels of HIFU energy to the tissue, based on previous studies which had shown 
that vascular occlusion typically requires such energy levels, with the attendant risk of 
complications (37, 45).  Prior to this phase of the study, there had been only minimal attempts to 
de-escalate the amount of HIFU energy delivered to the tissues, leading to probable ongoing 
over-exposure vascular targets, and resulting in unnecessary soft tissue damage.  In the Group 
S animals, driven mainly by a desire to avoid maternal skin burns, there was a reduction in the 
amount of HIFU energy delivered to tissues, which did not reduce the efficacy of vascular 
occlusion.  In the Group A animals, the median in situ intensity was 5.4 kW.cm-2 (IQR 5.1-5.5 
kW.cm-2); in these Group S animals, the corresponding values were 2.9 kW.cm-2 (IQR 2.5 – 3.1 
kW.cm-2).  Accordingly, there was no histological evidence of excessive tissue damage in the 
exposed placentomes of the Group S animals, although this does not exclude the possibility of 
healed damage.  As such, this is an indicator that the therapeutic window for estimated in situ 
intensity is lower than had previously been selected, and in the region of 2.5 – 3.5 kW.cm-2, 
although at present there is insufficient evidence to refine this further. 
A further consequence of either this reduction in energy delivery to the tissue or imaging 
through skin (or a combination of both) is that both the presence or absence of hyperecho and 
structural change within the placentome structure now appear to be less sensitive and specific 
markers of successful vascular occlusion.  This supports the finding that localised, rather than 
generalised, tissue heating and ablation is compatible with placental vascular occlusion, 
although the study was not designed in such a way as to allow mechanisms of occlusion to be 
fully investigated. 
This phase of the study was also the first to demonstrate the persistence of vascular occlusion 
following exposure to HIFU to 21 days.  Rather than simply showing trapped erythrocytes within 
the lumen of exposed vessels and inferring the presence of organised clot (H&E staining), we 
were also able to show the presence of organised thrombus within exposed vessels at 21 days 
after HIFU exposures (PTAH staining).  This combined with the vacuolar degeneration seen 
surrounding the vessels matches the previously described sequence of histological changes of 
occluded vessels following HIFU exposure (35).   
One of the outstanding question from the transuterine study was whether using occlusive 
clotting as the mechanism of vascular occlusion would have a transient or persistent effect.  
Occlusive clot can lead to permanent vascular occlusion by a process of fibrosis obliterans, or 
the clot itself can be reabsorbed over time as the vessel recanalises.  While there is no fixed 
time limit over which either process can occur, the presence of organised thrombus in the 
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presence of vacuolar degeneration is suggestive of the former, rather than the later, process.  
However, to fully demonstrate the potential of occlusive clot to be useful in human pregnancy, 
where the interval between HIFU exposures and delivery could be up to 6 months, an animal 
model with a longer gestational period than the sheep would be required.   
A second conclusion drawn from the presence of persistent vascular occlusion to 21 days was 
that not only were mothers and fetus recovering from anaesthesia and HIFU exposures, they 
were doing so in the presence of ongoing placental vascular occlusion.  This indicates the 
results presented from Group S in chapters 5-7 are representative of this. 
While, as discussed above, there were no significant maternal or fetal injuries or obstetric 
complications identified, the rate of maternal skin burns continued to be a problem.  The 
incremental protocol changes – reduction in drive voltage, reduction in skin irritation, cooling 
and degassing of the water in the water bag – did produce a progressive reduction in the rate of 
skin burns, but were not able to fully prevent skin burns.  These are a relatively common 
complication of HIFU therapies, and had been predicted as the most likely source of iatrogenic 
harm in these experiments.   
As in the transdermal bridging study, the actual rate of maternal skin burns was difficult to 
properly determine due to the fact that progressive changes to the HIFU treatment protocol 
were being made to reduce the number of skin burns occurring.  For this reason, the overall rate 
of skin burns does not necessarily reflect the likelihood of skin burns occurring when the final 
protocol – rather than the initial one – is used, and this will need to be evaluated further in the 
next group of animals where HIFU was again planned to be applied transdermal. 
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4.6 Transdermal chronically instrumented recovery study: Group 
R(ecovery) 
Based on the transdermal survival study, we now had an indication that it was feasible to use 
HIFU through intact maternal abdominal skin with a similarly high degree of efficacy as 
demonstrated in the prior transuterine studies.  These animals also demonstrated that maternal 
and fetal survival without serious adverse events could be anticipated, although the rate of 
maternal skin damage remained undesirably high.   
We had gained familiarity with the identification of placental vascular targets and planning of 
HIFU exposure series gained during the Group S animals.  The reduction in time required to 
plan and deliver HIFU exposure series meant that it should now be possible to complete HIFU 
occlusion of at least 6 placental vessels with the Group R protocol, which allowed 60 minutes to 
complete this part of the experimental protocol.  This protocol also allocated time under 
anaesthesia to surgical implantation of a limited number (compared to Group A and the Group 
R control animals) of maternal and fetal vascular catheters and flow probes.  This would allow 
more detailed examination of the maternal and fetal cardiovascular, metabolic and endocrine 
function to be performed during the recovery phase of these animals, in keeping with the type of 
information gained from the Group A and Group R control animals. 
This animal group also represented the final opportunity to test the efficacy and safety of the 
most developed version of the HIFU treatment protocol in this study.  The previous HIFU 
treatment protocols had prioritised efficacy over safety, whereas this treatment protocol 
attempted to balance the two.  All the limits on HIFU exposure series previously developed to 
improve safety were now implemented into this protocol, and no further changes were allowed.  
The suggested therapeutic window of 2.5 – 3.5 kW.cm-2 derived from the experiments in Group 
S animals (Figure 4.20) was now adopted, and drive voltage was adjusted in real-time to 
achieve this target.  This animal group was also planned to be the largest of any of the animal 
groups, to provide the greatest amount of data about the efficacy and safety of the most 
developed HIFU treatment protocol in this study. 
Therefore, this phase of the study sought to assess the final transdermal HIFU treatment 
protocol developed by this study.  The key areas to evaluate were: 
(i) the efficacy of ultrasound-guided HIFU placental vascular occlusion in the pregnant 
sheep model; 
(ii) the rates and types of maternal and fetal direct iatrogenic harm; 
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(iii) the rates and types of maternal and fetal indirect iatrogenic harm; 
(iv) the time required to plan, perform and complete the planned vascular occlusions. 
 
4.6.1 Methods 
In addition to HIFU exposures in these animals (n=6) fetal cardiovascular, metabolic and 
endocrine wellbeing was assessed by surgically implanted arterial catheters and flow probes 
following reversal of anaesthesia for 21 days (Figure 3.13).  To assess the degree of fetal 
recovery, they were compared to a control group of pregnant ewes (n=6) who underwent 
surgical implantation of catheters and flow probes under anaesthesia, before being recovered 
and monitored for 21 days, but were not exposed to HIFU.  These results will be reported and 
discussed separately in chapters 5-8.  These 12 animals will be referred to as ‘Group R’ in 
chapters 5-8. 
 
4.6.1.1  HIFU therapy system 
The system described in section 4.2.1.1 was used.   
In all experiments, the water in the water bag was taken cold from the tap and cooled with ice 
sealed in plastic (so the melting ice water did not mix with degassed water in the bag) and was 
degassed before each HIFU exposure series.   
 
4.6.1.2  Animals and surgical methods 
Ten pregnant ewes carrying singleton fetuses at 116.5 ± 1.5 d gestational age were placed 
under general anaesthesia (sections 3.2.1, 3.2.2).  The maternal abdominal skin had been 
shaved with clippers 24 – 48 hours previously to remove wool.   
Following induction of anaesthesia, the skin was washed with iodine scrub solution to remove 
dirt and lanolin, and washed again with tap water.  The remaining hair was chemically depilated 
(Nair ® hair removal cream, Church & Dwight Co., Kent, UK), the skin was washed for a final 
time with tap water and coated with degassed water.  The waterbag was placed in contact with 
the maternal skin and trapped air between the plastic and the skin was smoothed out.  If the 
waterbag was repositioned, the layer of degassed water on the skin was replaced, and air 
pockets were smoothed out again.  HIFU exposure series were carried out through intact 
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maternal skin (see next heading) before any invasive surgical procedures were performed, 
following the experimental timeline shown in Figure 3.12. 
Breath holds were performed during each HIFU exposure series (section 4.2.1.2). 
Following completion of all planned HIFU exposures, the maternal skin was cleaned with a 
chlorhexidine solution (4% chlorhexidine gluconate, 96% ethanol) which was allowed to 
evaporate before skin incisions were made.  Under sterile conditions, a midline laparotomy and 
hysterotomy was performed to surgically implant fetal arterial catheters and flow probes and an 
incision in the maternal hindlimb was performed to insert maternal femoral arterial catheters.  
The underside of the visible rectus sheath and visible surface of the uterus were examined at 
this time for burns, and were photographed if found.  Incisions were closed and the ewes were 
recovered from anaesthesia (section 3.2.4, 3.2.5).  The post-operative care is described in 
section 3.2.7.  Methods for invasive monitoring of materno-fetal wellbeing are described in 
sections 3.3 - 3.5. 
For the next 20 days, ewes were checked daily for signs of maternal pain or distress, infection 
or poor healing of skin damage, problems with mobility, bladder or bowel function, preterm 
labour, rupture of membranes or vaginal bleeding.  During follow-up, two ewes were removed 
from the study before the completion of 20 d due to catheter blockage or flow probe failure.  
One ewe was euthanised for welfare concerns on day 4 post-operative due to colonisation of a 
fetal arterial catheter with pseudomonas which caused intrauterine infection.   A fourth ewe was 
euthanised for welfare concerns on day 5 post-operative and was found at post-mortem to have 
a dehiscence of the hysterotomy incision and intra-abdominal amniotic fluid leak.  These 4 
animals were excluded from Group R follow-up as the complications were recognised post-
operative complications, not a result of HIFU exposures.  While their cardiovascular, metabolic, 
endocrine or post mortem data will not be discussed, there was no reason, however, to exclude 
their data regarding immediate outcomes of HIFU application from this study group, as this did 
not deviate from planned HIFU delivery experimental protocol. 
After the completion of 20 days post-exposure follow-up, the remaining 6 ewes and fetuses 
were euthanised under schedule one of the UK Animals (Scientific Procedures) Act 1986 for 
post mortem examination and collection of tissues.  A slow intravenous injection into the 
maternal femoral vein catheter of 120 mg.kg-1 pentobarbitone sodium (Pentoject®, Animalcare 
Ltd., UK) was used for this purpose.  Air embolus into the femoral vein was used as a 
secondary confirmation of death.  Maternal and fetal cardiac activity was monitored via the 
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arterial catheters and cession of cardiac activity was confirmed when asystole was seen on the 
IDEEQ software. 
 
4.6.1.3  Vascular targets and HIFU treatment protocol 
HIFU was applied trans-dermally to occlude 6 vessels per animal (n=10).   
HIFU exposure series were based on the protocol used in the transdermal survival study: drive 
voltage -5 to -8 dBm, free field intensity 3.2 – 6.7 kW.cm-2, 5 s exposure duration, 5 s intervals 
between exposures, 2 mm spacing between exposures, placement and number of exposure 
following the “limited” pattern.   
The following safety limits were adopted from the previous treatment protocols: (i) all exposure 
series were planned to start and finish in placental soft tissue bordering the echo lucent area 
from which vessels arise; (ii) the ratio of HIFU treatment area to echolucent area of the 
placentome was planned to be >1; (iii) movement of the mechanical gantry arms was restricted 
to one direction on an axis orthogonal to the direction of sound; (iv) predicted in situ intensities 
above 5 kW.cm-2 were not planned; (v) vascular targets were not selected if there were fetal 
parts in the post-focal region, at any distance; (vi) the water in the water bag was cooled and 
degassed between each HIFU exposure series; and (vii) the depth of the target vessel beneath 
the skin was used to select the drive voltage, aiming to deliver an in situ intensity 2.5 – 3.5 
kW.cm-2 (Figure 4.20). 
 
4.6.1.4  Assessment of treatment success 
Primary confirmation: comparison of pre- and post-HIFU exposure colour flow Doppler imaging 
for evidence of “no flow” as described in section 4.2.1.4. 
Secondary confirmation: identification of occlusive clot within vessel lumen after 20 days in 
exposed placentomes as described in section 4.5.1.4.  No placentomes were taken from the 
control group, as the completion of this group predated the start of the HIFU study.  Retained 
placental tissues were fixed, sectioned and stained with H&E or PTAH as described in section 
4.5.1.4. 
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4.6.1.5  Treatment monitoring 
Tissue responses (real-time): as described in section 4.3.1.5. 
Offline analysis of saved imaging: as described in section 4.3.1.5. 
Identification of fetal position relative to HIFU focus: as described in section 4.3.1.5. 
 
4.6.1.6  Management of treatment failure 
No changes were made to the methods described in section 4.5.1.6. 
 
4.6.1.7  Assessment of iatrogenic harm 
Maternal skin burns:  These were monitored intraoperatively as described in section 4.4.1.7.  
These areas were examined again at the end of all HIFU exposure series.  It was not possible 
to monitor the burns thereafter as the maternal abdomen was wrapped in TubigripTM (Mölnlycke 
Health Care Ltd., Oldham, UK) to reduce the risk of midline hernia and the design of the 
CamDAS jacket did not facilitate access to the maternal abdomen without removal of all 
monitoring equipment. Any area of skin reddening which resulted from a HIFU exposure series 
but faded fully by the time the CamDAS jacket was fitted (ca. 2-3 h post-exposures) was 
classified as erythema; other areas of damage resulting from HIFU exposure which persisted 
beyond that were classified as skin burns. 
A systematic inspection of tissues was performed at post mortem examination and a 
photographic record was compiled of damage to: (i) maternal skin, (ii) maternal rectus sheath, 
(iii) anterior and posterior surface of the uterus, (iv) fetal skin (dorsal, ventral, left and right 
lateral views), and (iv) maternal bladder and bowel.  Areas of maternal and fetal skin, rectus and 
uterus with visual changes suggestive of iatrogenic damage were also collected for histological 
examination, fixed in formalin, sectioned and stained with H&E as described previously. 
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4.6.2 Results 
4.6.2.1  Efficacy of vascular occlusion 
Overall, in Group R animals, HIFU mediated vascular occlusion was attempted in 60 placental 
vessels.  The mean depth of the target vessels was 24 mm (SD ± 6 mm), comparable to the 
animals in the transdermal survival study.  Drive voltage ranged from -5 to -8 dBm, and 
estimated in situ intensities which from 1.8 – 3.9 kW.cm-2, and the distribution of estimated in 
situ intensities which resulted in successful occlusion is shown in Figure 4.27.   The median 
number of exposures required to complete a series was 6 (range 3-7).  The median time to 
complete an HIFU exposure series and determine if occlusion had occurred was 96 s (range 60 
– 714 s); the median duration of each breath hold was 56 s (range 24 – 64 s).  The median total 
time to plan, treat and assess if occlusion had occurred of 6 vascular targets, with retreatments 
if required, in this animal group was 62 min (range 50 – 75 min). 
 
Figure 4.27: Estimated in situ intensity resulting in successful occlusion (Group R).    
The histogram shows the relative frequency of estimated in situ intensities which produced successful vascular 
occlusion using the standard protocol for Group R. 
Based on a comparison of pre- and post-HIFU exposure colour flow Doppler imaging, 58/60 
vessels were successfully occluded (97%).  Of these, 55/60 (92%) vessels were occluded in a 
single exposure series; a total of 4 retreatments were attempted, of which 3 produced 
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successful occlusions, giving a total of 64 exposure series.  Hyperecho was seen on B-mode 
ultrasound imaging of HIFU exposures in 56/58 HIFU exposure series resulting in successful 
vascular occlusion, however it was also seen in 4/6 HIFU exposure series resulting in failed 
vascular occlusion. 
In 3/6 HIFU exposure series which resulted in failed occlusion, there was mistargeting of 
between 5-10 mm.  In all 3 of these vascular targets, a retreatment which corrected this original 
mistargeting produced successful vascular occlusion. 
In 3/6 HIFU exposure series which resulted in failed occlusion (2 in the same vascular target, 
the original HIFU exposure series and the retreatment) there was no immediate cause for failure 
identified.  One of the three failed occlusions was only recognised by offline analysis of pre- and 
post-HIFU exposure colour flow Doppler images, so the opportunity to attempt retreatment was 
missed, as it would not have been contraindicated had it been recognised at the time.  All 3 
exposure series had an estimated in situ intensity 2.7 – 3.8 kW.cm-2, target depth 22 – 27 mm, 
with exposure series formed of 6-7 exposures.  All the C-STARs were >1.  However, both 
vascular targets were in the same animal, and when were retrieved at post mortem were arising 
near the formed umbilical cord.  The vessel diameters measured histologically were 2.4 and 2.8 
mm. 
A total of 60 placentomes with evidence of tissue damage were retrieved at post-mortem 
examination, 21 days after HIFU exposures were performed: both the total number and the 
number per animal matched the number of exposed vascular targets.  
In total, 72 placentomes from Group R animals were examined histologically using H&E stain: 
60 with evidence of HIFU damage and 12 undamaged placentomes from animals in which HIFU 
exposures had been performed.  There was no placental tissue available from the Group R 
control animals.  Trapped erythrocytes within vessel lumen suggestive of occlusive clot was 
found in 58/60 placentomes which had been exposed to HIFU.   In 2/60 vessels there was no 
histological evidence of trapped erythrocytes within vessel lumen.  These two vessels were 
found in the animal where colour flow Doppler had identified a failed occlusion in two 
placentomes.  There was no evidence of trapped erythrocytes within vessel lumen taken from 
either undamaged placentomes.  The diameter – measured histologically – of occluded vessels 
was between 0.4 – 2.9 mm (mean 1.4 mm). 
Vacuolar change was found surrounding vessels in 49/58 (85%) placentomes where there was 
histological evidence of occlusion. There was no evidence of similar vacuolar degeneration 
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surrounding the 2 vessels where occlusion failed, or surrounding vessels in undamaged 
placentomes.   
In 20/60 placentomes (n=2 from each animal) where occlusion and vacuolar degeneration of 
vessels was suggested by H&E staining, PTAH staining was performed to identify organised 
fibrin (clot).  All 20 vessels demonstrated organised fibrin (clot) within the vessel lumen, which 
was not seen in vessels within undamaged placentomes.   The connective tissue around all 20 
occluded vessels stained much more faintly than in control samples, again suggestive of 
vacuolar change, loss of collagen and degeneration of the tissue.  This was not seen in 
undamaged placentomes. 
 
4.6.2.2  Iatrogenic harm 
There was again no evidence of significant maternal injury during the follow-up period as a 
result of exposure to HIFU. Based on daily systematic observation of maternal movements and 
gait, pain scores and analgesia requirements, food and fluid intake and passage of urine and 
faeces there were no complications observed in any animal.  Specifically, there was no 
suggestion in any animal from maternal behaviour or recovery that injury to the spinal cord, 
bladder or bowel had occurred.  The single maternal skin burn healed well without evidence of 
infection (discussed further in the next section). 
At the time of post mortem examination, there was also no evidence on visual inspection of 
burns to the rectus sheath or uterus, faecal peritonitis, lesions on the bowel, uroperitoneum 
lesions on the bladder, or injury extending into the retroperitoneum, although the spine was not 
formally examined.   
There was no evidence of obstetric complications during the follow-up period as a result of 
exposure to HIFU.  Specifically, there were no instances of preterm delivery, preterm rupture of 
membranes or vaginal bleeding.  As discussed in the methods (section 4.6.1.2) a full 20 days of 
follow-up could not be completed in 10 animals: 2 were excluded due to catheter blockage 
and/or flow probe failure; 2 more were excluded due to recognised post-surgical complications 
of chronically instrumented fetal sheep preparations.  Of the remaining 6 ewes and fetuses, all 
mothers survived with fetuses alive in utero at the time of post-mortem. 
There was also no post-mortem evidence of haemorrhage from placental vessels or the 
umbilical cord.  There had been one uterine burn noted at laparotomy (day 0, discussed further 
in the next section) which was still evident at day 20 (Figure 4.29b), although its appearance 
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had changed suggesting healing had taken place.  There was no evidence of an open defect in 
the uterine wall at the site of the burn.  The contributory factors to the uterine burn, if any, are 
unknown. 
There was one fetal burn in this group of animals (Figure 4.28).  The fetal burn was a result of 
inadvertent non-adherence to the safety protocols, i.e. not recognising in real-time that 
ultrasound showed a fetal limb was near the intended vascular target.  A series of 5 HIFU 
exposures with an in situ intensity of 2.4 kW.cm-2 was delivered at a depth of 20 mm beneath 
the surface of the skin and 9 mm (measured parallel to the direction of sound) above the fetal 
limb which was injured.  The burn was full thickness, and there was mild swelling and deformity 
of the joint evident in comparison to the other hindlimb, with no evidence of infection.  This 
suggests there would have been functional impairment of the joint of uncertain prognosis due to 
this injury to the fetus.  However, as the fetus was euthanised before birth, it was not possible to 
test this hypothesis, or perform further functional assessment. 
The additional findings of the materno-fetal cardiovascular, metabolic, endocrine and fetal post-
mortem examination are presented and discussed in chapters 5-8 as part of an integrated 
consideration (using information from Groups A, S and R) of the effect of HIFU, surgery and 
anaesthesia on utero-placental function, initiation of fetal defence mechanisms, growth and 
development. 
 
Figure 4.28: Fetal limb injury (Group R).   
(A) The photograph shows the fetal hind limbs in comparison, with the one on the left side of the image uninjured 
and the skin burn evident on the other. (B) The photo graph shows the same burn from the anterior aspect, 
enlarged.  This resulted from 5 HIFU exposures of 2.4 kW.cm-2 estimated in situ intensity, 5 s duration, 2 mm 
spaced, target depth 20 mm.  In both cases, the scale bar represents 1 cm.  
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4.6.2.3  Maternal burns 
As previously noted, there was one maternal skin burn (rate 2%) and 6 instances of maternal 
skin erythema, all of which had faded by the end of surgery, (rate 10%) as a result of HIFU 
exposing 60 vascular targets.  These occurred in the first 2 animals in the group; no further 
protocol changes were made between these animals and the subsequent 8 animals, but there 
were no further instances of skin damage.   
The maternal skin burn resulted from a series of 6 HIFU exposures of 2.6 kW.cm-2 at a target 
depth of 22 mm, comparable to many other exposure series which did not produce a burn.  The 
exposure series which resulted in erythema were all in a single animal, and resulted from each 
exposure series, 2.4 – 2.6 kW.cm-2, 6-7 exposures, target depth 17-32 mm, again comparable 
to many other exposure series which did not produce this reaction. 
There was one uterine burn (rate 2%) noted at the time of laparotomy (Figure 4.29a).  This was 
not repaired at the time of surgery, and there was no evidence of uterine rupture or leak of 
amniotic fluid.  The uterine burn was not attributable to a specific exposure series, as 
laparotomy was only performed after all HIFU exposures had been completed.  The range of in 
situ intensities of HIFU exposures in this animal was 2.6 – 3.1 kW.cm-2, target depths 23 – 40 
mm.  There was one successful retreatment performed in this animal. 
 
 
Figure 4.29: Uterine burn (Group R).   
(A) The photograph shows a uterine burn immediately following HIFU exposures (noted at subsequent laparotomy 
– specific HIFU exposure series unknown).  The inset shows a close-up of the affected area.  (B) The photograph 
shows the same uterine burn after 21 days, demonstrating healing without rupture; the inset shows a close-up of 
the damage.  The scale bars represent 1 cm. 
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4.6.3 Transdermal chronically instrumented recovery study: discussion 
This group of animals once again provided evidence regarding the efficacy of using HIFU to 
occlude placental blood vessels in sheep placentae.  The occlusion rate remained high (97%) 
over 60 vascular targets despite a further de-escalation of drive voltage in an attempt to reduce 
side effects.  The median estimated in situ intensity or HIFU exposure series was 2.6 (IQR 2.5 – 
2.9) kW.cm-2 in this animal group compared to Group S: 2.9 (IQR 2.5 – 3.1) kW.cm-2.  This not 
only represents a reduction in the amount of energy delivered to the tissues, but the narrowing 
of the interquartile range suggests an increased consistency in the amount of energy delivered 
to tissues, also notable when the relative frequencies of estimated in situ intensities resulting in 
successful occlusion in Group S (Figure 4.20) and Group R (Figure 4.27) are compared.  In fact, 
in Group R, some successful vascular occlusions were produced with estimated in situ 
intensities of 1.8 kW.cm-2. This suggested the previously therapeutic window of 2.5 – 3.5 
kW.cm-2 may still represent overtreatment. 
The rate of initial HIFU exposure series which produced occlusion was also high: 55/60 (92%).  
With the reduction in skin burns, however, there were 4 repeat exposures of target vessels 
following failed occlusion.  As previously discussed, 3 of these were to correct mistargeting – 
effectively exposing a new area of target tissue – and were successful.  The fourth repeat 
exposure was unsuccessful, and it cannot be excluded that this retreatment of the same tissue 
volume resulted in a uterine burn.  Given the cause of the original failure remains unclear, and 
there was nothing to correct in the application of the HIFU, it is perhaps unsurprising that the 
repeated treatment of the same vascular target failed.  This was one of the larger vessels 
treated in this, or any group, of animals, but not larger than what had previously been occluded.  
The C-STAR was 2.9 in this target, and hyperecho was seen, which suggests that with an 
estimated in situ intensity of 3.2 kW.cm-2 delivered, the target should have received sufficient 
energy.  It is possible that a combination of a larger vessel, closer to common umbilical cord 
meant that the vessel had higher flow than others selected for occlusion, increasing the cooling 
effect on the tissue, but this remains speculative at best. 
Hence, the evidence regarding retreatment following failed occlusions remains mixed and 
based on small numbers: where there is a clear error to correct, this is likely to be effective and 
safe, but where there is no apparent cause of failure, delivery of repeated energy to the tissue 
may be at best ineffective and at worse damaging to surrounding tissues.  Given these findings, 
there is insufficient evidence to make a recommendation regarding retreatment and further 
investigation is needed. 
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This animal group provided further evidence regarding survival following HIFU placental 
vascular occlusion.  This group was always going to be high risk: complications with chronically 
instrumented fetal sheep preparations are recognised, although not widely reported.  
Postoperative complications such as non-recovery from anaesthesia, haemorrhage, infection 
and wound dehiscence should be anticipated, akin to any other form of major abdominal 
surgery.  Similarly, invasive monitoring equipment, particularly intravascular lines cannot be 
maintained indefinitely free of infection or clot in the human clinical setting.  However, in the 
animal setting, repeated anaesthesia to change lines was not permitted under the project 
licence, and would represent too great a deviation from the experimental recovery protocol to be 
allowable.  For these reasons, 100% survival of this animal group was never anticipated, and 
was not achieved.  However, as explained in section 4.6.1.2, the reasons animals were 
removed from this group relate to known complications of surgery, post-operative recovery, and 
the difficulties of keeping intravascular catheters patent, rather than complications of HIFU.  
While unsatisfactory to have only 6 of 10 animals complete the 20 days follow-up, the evidence 
from Group S is that, when not subjected to invasive surgical procedures, 100% survival should 
be anticipated following HIFU exposures. 
Another notable feature of the HIIFU exposure series in this group of animals is that there were 
no system errors.  The failed occlusions resulting from mistargeting and the fetal burn were all 
the result of human errors in target selection in planning of HIFU exposure series.  Subjectively, 
these errors were the result of the increased time pressure to occlude six placental vessels 
within the allotted 1.5 hours allowed in the experimental timeline.  Equally, the lack of system 
errors was likely the result of increased familiarity with the capabilities and restrictions of the 
HIFU system, as no software or hardware alterations were made between this and other 
groups.  This meant that the rates of iatrogenic harm are more likely to accurately reflect the risk 
of complications.  
Reassuringly, in this group of animals compared to the previous transdermal bridging and 
survival groups, the rate of maternal skin burns was reduced.  The rate of skin burns was 2% in 
this group, compared to 11% in Group S. The overall rate of burns and erythema in Group R 
was 11%. For a common HIFU complication such as superficial skin burns a rate of at least 2%, 
would not be unreasonable, although 11% would be higher than expected (section 1.2.5).  All of 
the instances of erythema occurred in a single animal in Group R, there was erythema as a 
result of each exposure, and the reaction was short lived (< 2 h).  This raises the possibility that 
there are unknown conditions which will render individual subjects vulnerable to skin damage 
regardless of safety limits placed on the application of HIFU.   
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It remains clear, that despite the safety protocols introduced and the increased experience of 
application of HIFU to occlude placental vessels, the process of applying HIFU to placental 
vessels will not be risk free.  The risk of uterine and fetal burns cannot be excluded, and skin 
burns will likely be regarded as the most common complication.  In these animals, while there 
was a uterine burn, it was in one of the animals which completed 20 days follow-up, and it is 
reassuring that this did not lead to either uterine rupture (although not tested during 
contractions) or any other obstetric complications. Similarly, the single instance of fetal injury 
occurred in an ewe which completed 20 days follow-up and the fetus survived for the duration of 
follow-up, with no indication of the injury from the measures taken until the time of post-mortem 
examination.   
The risk of fetal and maternal injury are not confined to HIFU: both maternal and fetal harm 
have resulted from fetoscopic laser ablation of placental anastomoses.  Combined rates of 
injury to maternal bowel, uterine blood vessels, trans-placental entry and intra-amniotic 
haemorrhage of up to 8% are reported (287, 288), although most authors report no significant 
perioperative complications.  As in our study, while these complications were recorded, they did 
not increase rates of pregnancy loss or affect fetal survival.  There are also case reports of fetal 
injuries to abdominal wall (289) in which the fetuses survived until delivery and a 1-2% 
incidence of damage to limbs (290).  Again, there is uncertainty regarding which injuries can be 
attributed to ischaemia and which to direct laser damage (291-293), but fetal damage 
subsequent to accidental laser exposure is at least feasible. 
With regards to translation into human studies, this group of animals confirmed the high efficacy 
of HIFU to occlude placental vessels in sheep.  This was achieved at lower estimated in situ 
intensities than in any other study group, and operator error notwithstanding, mitigated many of 
the side effects of excessive energy delivery to tissues.  The addition of a standard set of safety 
protocols which did not alter during the study group also contributed to this reduction in 
iatrogenic harm, though as previously discussed could not remove all risks associated with the 
procedure. However, collection of data regarding the safety and efficacy of retreatment and 
exposure conditions which resulted in vascular haemorrhage or fetal injury had been 
opportunistic in this and all previous study groups.  Therefore, while these remain important 
questions before translation of the technique, the high rates of occlusion and measures 
introduced to prevent fetal damage or vessel haemorrhage had hampered efforts to collect data 
in these areas. 
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4.7 Specific safety study 
At the outset of the project, some key concerns regarding safety of HIFU treatment were raised 
from the review of published literature (section 1.2.5).  These concerns regarded:  
(i) the safety of repeat HIFU treatments to the same tissue volume; 
(ii) the minimum distance required between the HIFU focus and the fetus to prevent post-
focal damage; 
(iii) the risk of haemorrhage from targeted vessels if exposed but not occluded.   
While there had been some opportunistic data collection in these areas in earlier phases of the 
project, there had a no deliberate attempt to cause iatrogenic harm.  These concerns would 
need to be addressed, not least by regulatory bodies or ethics committees, before considering 
translating the technique into humans.  The aim of this final animal group, therefore, was to 
provide additional data, by systematically planning exposure series designed to answer these 
questions, rather than show the efficacy of HIFU as a method of vascular occlusion.   
This phase of the project was a late addition to the overall design of work, as the potential of the 
technique became apparent, and was therefore animal number was particularly limited by both 
time and financial constraints.  As such, the data generated were not exhaustive, but rather to 
give pilot data for any future human translational project, which would likely include a further 
pre-clinical safety testing phase of updated equipment and treatment protocols. 
 
4.7.1 Methods 
4.7.1.1 HIFU therapy system 
The system described in section 4.2.1.1 was used.   
In the first 2 of 4 animals in this group, the water in the water bag was taken cold from the tap 
and cooled with ice sealed in plastic (so the melting ice water did not mix with degassed water 
in the bag) and was degassed before each HIFU exposure series.  In the subsequent 2 of 4 
animals, the water was continually cooled and degassed using a water cooling unit (HC-100A, 
Hailea, Guangdong, China) in conjunction with the previously described degassing system. 
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4.7.1.2 Animals and surgical methods 
Four pregnant ewes carrying singleton fetuses at 110.5 ± 5.5 d gestational age were placed 
under general anaesthesia (sections 3.2.1, 3.2.2).   
In the first 1 of 4 animals the uterus was exposed through a midline laparotomy and the surface 
of the uterus was wet with degassed water, then the waterbag was placed in direct contact with 
that area.  Any pockets of trapped air between the plastic of the waterbag and the surface of the 
uterus were smoothed out.  HIFU exposures were performed through the intact uterine surface; 
no uterine incisions were performed. 
In the remaining 3 of 4 animals the maternal abdominal skin had been shaved with clippers 24 – 
48 hours previously to remove wool.  Following induction of anaesthesia, the skin was washed 
with iodine scrub solution to remove dirt and lanolin, and washed again with tap water.  The 
remaining hair was chemically depilated (Nair ® hair removal cream, Church & Dwight Co., 
Kent, UK), the skin was washed for a final time with tap water and coated with degassed water.  
The waterbag was placed in contact with the maternal skin and trapped air between the plastic 
and the skin was smoothed out.  If the waterbag was repositioned, the layer of degassed water 
on the skin was replaced, and air pockets were smoothed out again.  HIFU exposure series 
were carried out through intact maternal skin.  In all 3 of these animals, once the placental 
vessels which could be targeted transdermal had be occluded, a midline laparotomy was 
performed in order that the uterus could be manipulated.  HIFU exposures were then performed 
transuterine as described in the paragraph above. 
Breath holds were performed during each HIFU exposure series (section 4.2.1.2). 
All fetuses were assessed with ultrasound at the planned end of the HIFU exposures to 
determine presence or absence of fetal heart pulsations.  Non-invasive maternal recording of 
maternal heart rate was used to confirm maternal survival to the planned end of the 
experimental procedure.  
On completion of the HIFU exposures the ewe and fetus were euthanised without recovery from 
general anaesthesia under schedule one of the UK Animals (Scientific Procedures) Act 1986, 
as per section 4.2.1.2. 
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4.7.1.3 Experimental protocol: safety of repeat HIFU treatments of target vessels 
Assessing the safety of repeat HIFU treatments required a two-pronged approach.  Thus far in 
the various study phases, HIFU exposure series had failed to result in vessel occlusion due to 
targeting or technical errors, or for unknown reasons.   
In the event of a targeting or technical error (section 4.2.1.5), it could not be assumed that the 
planned amount of acoustic energy had been delivered to the target vessel.  In some cases, as 
described, it was likely that either no energy or a reduced amount of acoustic energy had been 
delivered to the target vessel, due to targeting or technical errors.  In these cases, correcting the 
targeting or technical error should have resulted in acoustic energy being delivered to a different 
target volume to the first series.  While iatrogenic harm could still result from the first HIFU 
exposure series which had been either planned or delivered incorrectly, there was no logical 
reason to assume a second exposure series delivered to a different (if nearby) target volume 
would compound that harm.  Data about these kinds of retreatments had been collected 
opportunistically in the previous transdermal survival, chronically instrumented and transuterine 
safety and efficacy studies, so it was decided not to simulate this type of failure and retreatment 
further given the limited availability of resources. 
However, in the target vessels where there was no attributable cause for failure, the hypothesis 
was that the planned acoustic energy had been delivered to the target vessel in full, as no 
technical or targeting error to prevent this happening could be identified.  As the initial HIFU 
exposure series had been correctly planned, it was delivered again in the same 3D positions as 
determined by the mechanised gantry arm/positioning system, using 1 dBm higher drive 
voltage, unless -5 dBm (maximum) had already been used in the first instance, when -5 dBm 
was used again.  This doubling (at least) of acoustic energy delivered to the same target volume 
had the theoretical potential to cause iatrogenic harm, and more data was needed.  As it was 
not possible to simulate this kind of failed occlusion (by definition, the causes remained 
unknown) accidental repeat treatment of an already occluded vessel was simulated instead, as 
a worst-case scenario.    
HIFU was applied transuterine to 3 vascular targets in 1 animal and transdermal to 2-3 vascular 
targets in 3 animals (3 per animal, n=2; 2 per animal, n=1).  HIFU exposure series were based 
on the transdermal chronically instrumented protocol.  All the safety limits described in section 
4.6.1.3 were adopted, with the exception that the depth of the target vessel beneath the skin 
was used to select a drive voltage which should deliver exposures of an estimated in situ 
intensity 3.0 – 4.5 kW.cm-2 to the target volume.  This was a higher range than in the previous 
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transdermal studies, but exposures with predicted in situ intensities > 5.0 kW.cm-2 were still not 
planned.  HIFU settings used were: drive voltage -5 to -7 dBm, free field intensity 4.1 – 6.7 
kW.cm-2, 5 s exposure duration, 5 s intervals between exposures, placement of exposures 
following the “limited” pattern.   
A first HIFU exposure series was delivered to the target vessel as per previous studies, and 
success or failure of vascular occlusion was assessed by comparison of pre- and post-HIFU 
colour flow Doppler (section 0).  “No flow” on post-exposure colour flow Doppler in this setting 
signified not only that the vessel was occluded, but also that an adequate amount of acoustic 
energy to occlude a blood vessel had been delivered to the intended target volume.  If residual 
flow was seen following the first HIFU exposure series, that vascular target was retreated, if 
allowable, as per previous protocols (section 4.5.1.6) and its results were added to the 
targeting/technical or unknown cause of failed occlusion subgroup as described above. 
Following confirmation of “no flow” a second HIFU exposure series was delivered to the target 
vessel, to simulate accidental repeat treatment of an already occluded vessel.  The drive 
voltage used in the second series was the same as selected for the first.  The mechanised 
gantry arm was used to deliver HIFU exposures to the same 3D position; the gantry arm 
precision of positioning was better than 1 mm.  Colour flow Doppler was then used to assess 
the vascular target again for any new signals when compared to the previous post-exposure 
imaging, which could represent haemorrhage.  Treatment monitoring was otherwise as 
described in section 4.3.1.5. 
Outcomes of these repeated exposure series were assessed by comparison of pre- and post-
first and second HIFU exposure series as described above.  A post mortem examination was 
performed following the end of all planned exposure series in these animals (0.5 – 4 h after the 
exposure series described) and placentomes which received repeated exposures were 
examined for any evidence of haemorrhage into surrounding allantoic membranes, excised, 
bisected and retained for histological examination with H&E stain. 
 
4.7.1.4 Experimental protocol: safety of HIFU exposures near fetal parts 
Following the demonstration in the pilot study and Group R of the vulnerability of the fetus to 
post focal HIFU damage, planning HIFU treatments away from fetal parts had been an 
important safety feature of all subsequent protocols.  In our study design this was possible, as 
the high number of placentomes provided a choice of vascular targets, such that typically 6 
could be selected away from the fetus, any placental blood vessel being as suitable a target as 
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any other.  However, the reality of the clinical situation is that the AVAs crossing the placental 
equator would need to be occluded, not simply the placental blood vessels easiest to target.  It 
was therefore important to understand how close to the fetus the HIFU focus could be targeted 
before there was evidence of fetal injury.  Such information would dictate the exclusion criteria 
with regard to fetal positioning relative to the target vessels in any future human study. 
HIFU was applied transuterine to 15 vascular targets in 3 animals (5 per animal, n=3) and 
transdermal to 6 vascular targets in 2 animals (3 per animal, n=2).  HIFU exposure series were 
based on the transdermal chronically instrumented protocol.  All the safety limits described in 
section 4.6.1.3 were adopted, with the exception that vascular targets above fetal parts were 
selected rather than excluded.  HIFU settings were: drive voltage -5 to -8 dBm, free field 
intensity 3.2 – 6.7 kW.cm-2, 5 s exposure duration, 5 s intervals between exposures, placement 
of exposures following the “limited” pattern. 
Vascular targets above identifiable fetal parts were selected and HIFU exposure series were 
planned as per the chronically instrumented protocol.  Only one exposure series was performed 
near the identified fetal part.  Success or failure of vascular occlusion was assessed by 
comparison of pre- and post-HIFU colour flow Doppler (section 4.2.1.4).  “No flow” on post-
exposure colour flow Doppler signified that an adequate amount of acoustic energy had been 
delivered to the intended vascular target, and as such implied that any resultant fetal damage 
was post-focal and not the result of mistargeting. 
Offline analysis of saved imaging was performed as described in section 4.3.1.5.   The linear 
distance (parallel to the direction of sound) was measured between the intended target (marked 
by the ultrasound cursor) and the uppermost surface of the nearest fetal part (section 4.2.1.5); 
this is reported as the distance to fetus. 
Fetuses were examined at post mortem for evidence of burns; sites of potential injuries which 
had previously been identified on ultrasound and were examined with care.  Burns were linked 
to specific HIFU exposure series in this way.  If damage to the fetal skin was found, the skin 
was excised to examine if there was injury to the underlying tissues.  Fetal injuries were then 
categorised into fetal skin burns – where the injury was confined to the skin – or fetal damage, 
where underlying tissue was also injured (Figure 4.30). It was not possible to report skin 
erythema as the experiments were non-recovery and the uterus was not opened until post-
mortem, so resolution of erythema had either already occurred by the time of post-mortem 
examination (and was therefore missed), or was seen as a permanent change without time for 
healing. 
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Figure 4.30: Classification of fetal injury.   
(A) Photograph showing burns which resulted in injury classified as fetal damage; the inset shows extension of the 
damage into the subcutaneous tissues and muscles. HIFU exposure series: 6 exposures, estimated in situ intensity 
3.6 kW.cm-2, 5 s duration, target depth 7 mm, linear distance from fetus 13 mm.  (B) Photograph shows areas of 
reddening on the skin classified as skin burns, with no damage to underlying tissues.  HIFU exposures: 6 
exposures, estimated in situ intensity 3.8 kW.cm-2, 5 s duration, target depth 31 mm, linear distance from fetus 22 
mm.  In all cases the scale bars represent 1 cm. 
4.7.1.5 Experimental protocol to assess risk of vascular haemorrhage 
There were three potential methods by which HIFU exposure of vessels could cause vessel 
haemorrhage to occur.   
The first potential method is the delivery of excessive energy to the vessel, causing vessel wall 
rupture.  Two potential incidences of the had been observed in the pilot study (Figure 4.15a-c) 
associated with very high in situ intensity exposure series (6.4 and 7.0 kW.cm-2).  No further 
instances of this had been observed since the upper limit of 5.0 kW.cm-2 was imposed on 
planned HIFU exposure series.   
The second potential method is repeat exposures of the vessel wall to HIFU causing rupture.  
This had not been observed in any of the retreatments in the previous animal groups.  The risk 
of retreatment causing haemorrhage will also be further addressed by the experimental protocol 
described in section 4.7.1.3.   
The third potential method is by under-treatment of the targeted vessel, delivering sufficient 
energy to damage the vessel wall but not enough to result in vascular occlusion.  The vascular 
haemorrhage reported in the Group A animal group was thought to be due to the non-
movement of the gantry arm.  While the in situ intensity delivered to the tissue in this case (4.9 
kW.cm-2) was higher than eventual therapeutic window established in Group R, the C-STAR < 1 
due to the technical error, suggesting a spatial under-treatment, which could have caused 
vessel wall damage without resulting in occlusion.  This raised the possibility that the way in 
which the HIFU energy was applied to the vessel was at least as important as the amount of 
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energy delivered to the tissue.  However, there were other HIFU exposure series with C-STAR 
< 1 which had not resulted in haemorrhage. 
HIFU exposure series which mimicked these undertreatments were therefore planned, with the 
intention to monitor for signs of haemorrhage by ultrasound imaging. 
HIFU was applied transuterine to 9 vascular targets in 3 animals (3 per animal, n=3) and 
transdermal to 2 vascular targets in 1 animal.  HIFU settings used were: drive voltage -5 to -7 
dBm, free field intensity 4.1 – 6.7 kW.cm-2, 5 s exposure duration, 5 s intervals between 
exposures, 3 exposures in each series.  The 3 exposures were all delivered to the same 3D 
position in the centre of the echolucent area, resulting in a C-STAR <1.  In situ intensities were 
planned to be in the range 2.5 – 5.0 kW.cm-2.  Exposures with predicted in situ intensities > 5.0 
kW.cm-2 were not planned and vascular targets above fetal parts were not selected; no other 
safety features from previous protocols were adopted. 
Pre- and post-HIFU exposure colour Doppler imaging was compared for evidence of persistent, 
absent or altered colour flow signal following these exposures.  A post mortem examination was 
performed following the end of all planned exposure series in these animals (0.5 – 4 h after the 
exposure series described) and placentomes which received these “under-treatment” exposures 
were examined for any evidence of haemorrhage into surrounding allantoic membranes, 
excised, bisected and retained for histological examination with H&E stain. 
 
4.7.2 Results 
4.7.2.1  Safety of repeat HIFU treatments to the same target volume 
A total of 11 vascular targets were selected.  The drive voltages were between -5 to -7 dBm, 
estimated in situ intensity 3.0 – 4.0 kW.cm-2.  Exposure series were composed of 6-7 HIFU 
exposures, 2 mm spaced.  The mean depth of the target vessel was 19 mm (SD ± 6 mm).  Both 
in situ intensity and exposure number were at the higher end of previously quoted ranges in the 
transdermal studies. There were no skin, uterine or fetal burns, or vessel haemorrhages 
resulting from these exposures. 
Of these, 8 repeat HIFU exposure series of the target vessel (3 transuterine, 5 transdermal) – 
after the first exposure series had resulted in successful vascular occlusion based on colour 
flow Doppler comparisons – were performed.  In 3 targeted vessels (all transdermal), the first 
exposure series resulted in failed vascular occlusion for unknown reasons, and a second 
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exposure series at the same or an increased drive voltage (other parameters unchanged) 
resulted in successful occlusion based on colour flow Doppler comparisons.   
Eleven damaged placentomes were retrieved and examined histologically.  There was evidence 
of trapped erythrocytes suggestive of occlusive clot within the lumen of vessels in all 11 
placentomes.  Tissue changes associated with heat fixation and extravasation were seen in all 
11 placentomes, and in 1/11 placentomes was there evidence of tissue boiling and discrete clot 
formation, despite an estimated in situ intensity of 3.5 kW.cm-2. (Figure 4.31).  There was no 
evidence of excessive placental soft tissue damage in the other 10/11 placentomes. 
 
 
Figure 4.31: Macroscopic and histological consequences of vessel retreatment.   
(A) Placentome bisected on the same day as exposure to 2 HIFU exposure series, and photographed after 24 h to 
improve visual contrast.  There is an area of tissue darkening extending into the origin of the placental vessels, with 
a central area of paling and extensive tissue damage.  (B) H&E stained section of tissue from the same 
placentome.  The area in the green box is enlarged in panel (C) and shows trapped erythrocytes within target 
vessels suggestive of occlusion.  The area in the blue box is enlarged in panel (D) and shows an area of tissue 
boiling (white arrow) and discrete tissue haemorrhage (black arrow) corresponding with the areas showing the 
greatest visual damage in panel A. The target vessels and placentome were exposed to 2 HIFU exposure series of 
6 exposures, estimated in situ intensity 3.5 kW.cm-2, 5 s duration, target depth 21 mm. 
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Table 4.7: Summary of failed occlusion and retreatments.   
The table shows the characteristics of the first and, if attempted, second HIFU exposure series in target vessels 
from Groups A, S, R and the specific safety group where there was initially a failed occlusion.  The reason, if 
known, for this failed occlusion is given, and whether the retreatment resulted in successful occlusion. Key: ‘c’ 
denotes that the histological vessel size could not be linked to a specific HIFU exposure series. 
1st -5.0 5.0 15 5 0.3 1.1 targeting, 10 mm, z axis, 9 mm y axis
2nd -5.0 4.8 17 5 2.5 1.1 - Yes
1st -5.0 5.4 14 5 0.6 2.4 technical: gantry non movement
2nd -5.0 5.4 13 5 1.9 2.4 unable to control haemorrhage No
1st -5.0 4.5 20 6 0.6 2.2 unknown
2nd - No
1st -5.0 5.2 12 3 1.0 1.0 unknown
2nd -5.0 5.5 9 2 0.6 1.0 unknown No
1st -8.0 2.9 5 5 2.0 2.9 targeting: 8mm, y axis
2nd -8.0 2.9 5 6 2.4 2.9 unknown No
1st -8.0 3.2 18 6 6.4 2.1 unknown
2nd No
1st -7.0 3.1 14 4 5.1 1.0 technical: cavitation in waterbag
2nd -7.0 3.1 15 5 6.6 1.0 - Yes
1st -6.0 3.0 17 5 3.2 c unknown
2nd -6.0 3.1 15 5 3.2 c - Yes
1st -9.0 1.3 23 4 1.7 0.9
technical: emergency stop activated, 
drive voltage accidentally set too low
2nd - No
1st -7.0 2.4 17 3 1.7 0.7 technical: software crash
2nd - No
1st -5.0 4.3 10 7 9.4 0.8 targeting: 14 mm, z axis
2nd - No
1st -5.0 4.1 30 6 5.0 c targeting: 10 mm, z axis
2nd -5.0 3.9 40 6 5.0 c - Yes
1st -6.0 2.7 27 7 3.0 c unknown
2nd -5.0 3.9 22 6 2.5 c unknown No
1st -5.0 3.8 24 6 2.9 c unknown
2nd c No
1st -6.0 2.5 28 5 3.6 c targeting: 5 mm axis
2nd -5.0 3.3 23 5 4.2 c - Yes
1st -5.0 2.4 40 4 0.9 c targeting: 9 mm, z axis
2nd -5.0 2.7 31 6 1.5 c - Yes
1st -7.0 2.8 18 6 1.5 c targeting: 10 mm, z axis
2nd -6.0 3.3 28 6 1.5 c - Yes
1st -6.0 2.7 21 6 5.6 3.0 unknown
2nd -6.0 2.7 25 6 5.6 3.0 - Yes
1st -6.0 2.5 29 6 5.0 0.6 unknown
2nd -5.0 2.9 29 6 5.0 0.6 - Yes
1st -6.0 2.3 16 6 2.8 2.3 unknown
2nd -5.0 3.0 17 6 2.8 2.3 - Yes
Vessel 
size 
(mm)
Not performed - skin erythema
Not performed - skin burn
Not performed - skin erythema
Not performed - insufficient time in treatment protocol remaining
Not performed - missed in real time
Specific 
Safety
Skin
Skin
Skin
Not performed - missed in real time
Successful 
retreatment
Reason for failure (error type)
A
S
R
Uterus
C-STAR
Applied 
through
Depth of 
target 
(mm)
Number of 
exposures
Study 
Group
Exposures
Power 
(dBm)
Exposure 
series to 
target
In situ 
Intensity 
(W.cm
-2
)
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Although these results have previously been described in the relevant sections, the 17 failed 
occlusions and 11 retreatments in Groups A, S and R animals are tabulated together with the 3 
failed occlusions and retreatments in the specific safety group (Table 4.7).   
There were 7 failed occlusion which were classified targeting errors.  In one a retreatment could 
not be attempted as a skin burn was present.  In the other placentomes 5/6 (83%) of these were 
successfully occluded after correction of the targeting error.   
There were 4 failed occlusions as a result of technical errors, and only 2 were eligible for 
retreatment: 1/2 (50%) were successfully occluded after correction of the technical error. 
Of the remaining 9 failed occlusions, it was not possible to identify a targeting or technical error, 
and 6 were suitable for retreatment.  Of these, 4/6 (67%) were successfully occluded following a 
repeat HIFU exposure series.   
This gives an occlusion rate of 10/14 (71%) following retreatment, and an overall successful 
occlusion rate following an initial failed occlusion of 10/20 (50%).   
There was one fetal burn and one instance of vascular haemorrhage as a result of the exposure 
series in Table 4.7, and possibly one uterine burn.  There was one skin burn and two instances 
of skin erythema. 
 
 
4.7.2.2  Safety of HIFU exposures near fetal parts 
In all groups after the pilot study, exposure series were planned to avoid fetal injury by selecting 
vascular targets more than 40 mm from fetal parts visible on ultrasound imaging, and excluding 
vascular targets where this could not be achieved. This was a highly successful strategy in 
avoiding fetal injury: in 153 HIFU exposure series in 21 animals there was only one recorded 
accidental fetal injury (rate 0.7%), a burn to the fetal hind limb (Figure 4.28).  The fetal hind limb 
was closer than had been recognised at the time: the fetal distance, measured as described in 
the methods, was 9 mm from the vascular target.   
In this animal group, HIFU mediated vascular occlusion was attempted in 21 vascular targets 
that were between 4-48 mm above the nearest fetal part.  Drive voltages ranged from -5 to -8 
dBm; the median estimated in situ intensity was 3.6 kW.cm-2 (IQR 2.8 – 4.1 kW.cm-2).  The 
median number of exposures in a series was 6 (range 5-6) and the mean depth of the target 
vessels was 16 mm (SD ± 8 mm).  The mean linear distance between the vascular target and 
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the nearest fetal part was 21 mm (SD ± 10 mm).  Based on colour Doppler imaging, successful 
occlusion was confirmed in all 21/21 vascular targets. 
Fetal damage (a burn which involved skin and underlying tissues) was found at post mortem 
examination in the area of the fetus nearest to 7/21 target vessels.  A fetal skin burn (without 
involving underlying tissues) was found on the nearest fetal part to a further 5/21 target vessels.  
The relationship of the estimated in situ intensity delivered to the target vessel and the linear 
distance from the fetus is shown in Figure 4.32.  Fetal damage was more likely to occur when 
the vascular targets were located nearer the fetus, or when higher estimated in situ intensities 
were delivered to the target tissues.  No fetal skin burns or damage resulted from occluding 
vascular targets more than 25 mm from the fetus; there were no instances of fetal damage 
resulting when estimated in situ intensities of below 3.0 kW.cm-2 were delivered to the tissues. 
 
Figure 4.32: Fetal damage relative to distance from HIFU focal plane.   
The graph shows type of fetal damage relative to in situ intensity and distance from the fetus (measured parallel to 
the direction of sound). 
 
4.7.2.3 Risk of vascular haemorrhage 
A total of 11 vascular targets were included in this subsection of the study (9 transuterine, 2 
transdermal).  The drive voltages were between -5 to -7 dBm, estimated in situ intensity 2.7 – 
5.0 kW.cm-2.  Exposure series were composed of 3 exposures, all delivered to the same 3D 
location with precision of better than 1 mm.  The median treatment area ratio was 0.4 (range 0.2 
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– 0.7).   The mean depth of the target vessel was 19 mm (SD ± 6 mm).  There were no skin 
burns in the 2 transdermal exposures, and no uterine or fetal burns resulting from any of these 
HIFU exposure series. 
Based on comparison of pre- and post- colour Doppler imaging, 4/11 (36%) of these HIFU 
exposure series resulted in successful occlusion and 7/11 (64%) resulted in failed occlusion.  
There was no evidence of vascular haemorrhage in any of the 4 placentomes where colour 
Doppler had indicated successful occlusion.  There was, however, visual evidence at post 
mortem (blood in the allantoic membranes) of haemorrhage in 4/7 (57%) vessels where 
persistent colour flow Doppler signals suggested a failed occlusion. 
It was not possible to determine, even on retrospective examination of stored imaging, 
differences between the persistent colour flow Doppler signal of failed occlusion and vascular 
haemorrhage in this experimental animal group. 
In addition to these 11 deliberate under-exposures, there were 7 undertreated (C-STAR <1) 
vascular targets in Group A (transuterine).  The undertreatment was either due to an error in the 
movement of the mechanical gantry arm (2/7), or because the planned movement of the gantry 
arm was parallel, not orthogonal, to the direction of sound (5/7).   
The drive voltages of these exposure series were between -5 to -6 dBm, estimated in situ 
intensity 4.5 – 5.7 kW.cm-2.  Exposure series were composed of 5-7 HIFU exposures, the mean 
treatment depth was 14 mm (SD ± 4 mm).  None of the undertreatments resulted in uterine or 
fetal burns.  The median treatment area ratio was of these exposure series 0.5 (range 0.2 – 
0.9).  There was a single instance of vascular haemorrhage (1/7, 14%) in these undertreated 
vessels. 
 
4.7.3 Specific safety study: Discussion 
In Group S and R animals, vascular targets were not selected if there were fetal parts in the 
post-focal region, at any distance.  Based on the ultrasound machine settings for maximum 
depth, and the offset of the diagnostic ultrasound probe above the maternal uterus or skin, this 
distance can be estimated to be a minimum of 40 mm linear separation between the HIFU focal 
zone and the nearest fetal part. 
The additional data generated in this specific safety group suggests that HIFU exposure series 
are likely to result in some form of fetal damage when the separation between the fetus and 
central point of the HIFU focal zone < 25 mm.  Based on Figure 4.32, this threshold was valid 
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for estimated in situ intensities in the proposed therapeutic window of 2.5 – 3.0 kW.cm-2.  While 
it is reasonable to expect that this minimum separation could be reduced at lower estimated in 
situ intensities, data is lacking to support this in our study.  However, Figure 4.32 does suggest 
the severity of fetal injuries increased with reduction in the separation between fetus and HIFU 
focal plane, and at higher estimated in situ intensities.  There is no published literature with 
which to compare this study: in Peak et al.(60), there is no report whether the single ablation of 
placental tissue cause fetal damage, and given that fetal targets were also deliberately ablated, 
this would have been hard to assess.  Caloone et al. (286) report no damage to the fetus in their 
study ablating areas of a primate placenta during pregnancy, but the position of the fetus in 
relationship to the HIFU focal plane is not recorded.  Similarly, in the human in utero 
applications of HIFU (43, 57) the target was the acardiac twin, and the proximity of the live twin 
is not reported, although there was no neonatal injury evident after delivery in either surviving 
twin. 
Regardless of distance or intensity considerations, this subsection of the study serves to clearly 
demonstrate the severity of the fetal damage that can be cause by HIFU exposures.  This study 
was not designed, nor ethically approved, to investigate the long-term impact of such injuries, 
the impact of which would likely depend of the area of the fetus affected.  However, as 
discussed in Group R animals, one fetus had a significant injury to the fetal hind-limb, and did 
not show evidence of fetal distress or compromise as a result.  As with other fetal injuries 
described following fetoscopic laser (289, 290), HIFU injury to the fetus may represent a 
survivable in utero insult. 
These considerations underlie the need for careful case selection, identification of vascular 
targets, planning of HIFU exposure series and rigorous safety checks to minimise the risk of 
fetal damage should the technique be translated in to human use.  However, the concept that a 
minimum separation of around 25 mm between the fetus and the HIFU focal plane would be 
required is not an obvious bar to translating the technique to human pregnancy.  The location of 
the AVAs in relation to the donor twin are likely to be of key importance.  The donor twin has 
limited space in which to move due to oligohydramnios, whereas the polyhydramnios 
surrounding the recipient twin means it is more likely to be able to move > 25 mm away from the 
vascular equator.   
The minimum separation of 25 mm between HIFU focal plane and nearest fetal part is a finding 
that is specific to the HIFU transducer used in this study.  The source geometry of a HIFU 
transducer – and so the intensities delivered to the post focal region - is affected by the radius 
of curvature of the transducer and the presence and size of a central aperture, among other 
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considerations.  This means that in any future study with a different transducer, the minimum 
separation between HIFU focal plane and the fetus would need to be retested.  Human 
applications of this technique may require a transducer with a longer focal length (implying a 
wider radius of curvature), or a larger central aperture to allow a larger diagnostic ultrasound 
probe and better ultrasound imaging of the target. 
Overall, as with the consideration of excessive soft tissue damage in the placenta, maternal and 
uterine burns, it seems that the best strategy to avoid fetal damage is to deliver the minimum 
amount of ultrasound energy to the target vessel that will achieve occlusion, as far as possible 
from the fetus.  While the distance between the fetus and HIFU plane may be difficult to control, 
the HIFU energy delivered to the tissues is under direct control of the HIFU operators. 
Selection of the “correct” drive voltage at which to expose target vessels, in relation to their 
characteristics, was a concept that had evolved with successive iterations of the HIFU protocol.  
Initially, the highest drive voltage that could be generated safely by the HIFU therapy equipment 
(-5 dBm) was used (Pilot study, Group A) before an upper limit of 5.0 kW.cm-2 was introduced to 
prevent against excessive soft tissue damage (Transdermal bridging study, Group S).  To 
reduce the risk of maternal skin damage, the ratio of drive voltage to target depth was altered in 
Group R.  This was permitted as the therapeutic window of estimated in situ intensity which 
would result in successful vascular occlusion in Group S (Figure 4.20) was lower than 
anticipated in the preceding study groups, 2.5 – 3.5 kW.cm-2.  Finally, because of the findings in 
group R animals, that the therapeutic window for vascular occlusion is in the region of 2.5 – 3.0 
kW.cm-2 (Figure 4.27), this ratio of drive voltage to target depth could be further reduced. 
This trend to reduction in HIFU energy delivery to the target vessel raises the possibility that 
some vessels will be incorrectly exposed to sub-therapeutic doses of ultrasound energy, 
resulting in failed occlusions (although not a spatial under-treatment as defined by the C-STAR).  
This was not seen in Group R animals, where 92% of vessels were occluded after a single 
exposure series, compared to 90% in Group A.  However, if further reductions in energy 
delivery are intended, the requirements for retreatments of the same tissue volume may 
theoretically increase.   
As described in section 4.7.1.3, data regarding repeat HIFU exposures of the same target 
volume had not been opportunistically collected in any of the previous study groups.  The 
findings of this specific safety study suggest that repeat exposures of the same target volume, 
even when containing blood vessels, does not increase the risk of vascular haemorrhage, or 
affect an otherwise successful vascular occlusion.  It also does not appear to increase the risk 
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of maternal or fetal injury, although there is a slightly increased risk of excessive tissue damage 
to the surrounding placental tissue. 
This suggests that if there is uncertainty about the correct drive voltage with which to expose 
the target vessel, a feasible alternative is a cautious approach.  This would mean a potentially 
sub-therapeutic dose of ultrasound energy is used, with the knowledge a retreatment may be 
required.  This may be safer than using a higher dose of ultrasound energy, with attendant 
increases in risk of maternal and fetal damage, although it would increase the number of HIFU 
exposures, and the time to complete occlusions.  Conversely, the increase in number of HIFU 
exposures itself may increase the risk of maternal and fetal burns, so the cautious approach 
may be counter-intuitively more dangerous.  We did not have the opportunity to test this 
hypothesis, which we only generated after the end of the specific safety study, in this project, 
but this would be an important avenue of investigation in any future pre-clinical or translational 
study. 
Considering the retreatments performed in the first five study groups, which were required by 
unanticipated failure to produce vascular occlusion, the most amenable to retreatment were 
those that resulted from targeting errors.  Overall, 83% (5/6) of vessels where successfully 
occluded following a correction of targeting error.  While this is based on a small sample, the 
principle seems sound that these should be the easiest errors to correct.  However, these 
retreatments are also associated with a higher risk of iatrogenic harm: 1 uterine burn, 1 fetal 
burn and 1 maternal skin burn.  This harm is likely to be due to the original mistargeting, but 
exacerbation of the injury by a second deposition of HIFU energy near the site of the injury 
cannot be excluded.  Therefore, once again, this finding underlies the need for rigorous, and 
possibly automated, safety checks in the planning and delivery of HIFU exposure series. 
Successful occlusion was also possible following correction of a technical error.  There were a 
total of 7 technical errors recorded in this study: 6 were failure of the gantry arm to complete the 
movements programmed, 1 was a failure to de-gas the water in the water bag adequately, such 
that cavitation in the waterbag was obvious during the exposures, and minimal energy was 
delivered to the tissues.  Of these technical errors, 4 resulted in failed occlusion; 2 of these were 
eligible for retreatment (1 gantry failure resulting in haemorrhage, and the exposure series with 
cavitation in the waterbag).  As a result of these technical errors, there were 2 instances of skin 
damage and 1 instance of vascular haemorrhage (all related to gantry non-movement).  As in 
the discussion of targeting errors, the unplanned delivery of HIFU energy into a single location 
increased the risks of iatrogenic harm above the background risk. 
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It should be noted that in Group R, there were no technical errors in a total of 64 HIFU exposure 
series.  Given that 7 technical errors occurred in the preceding 92 exposure series, this is a 
notable reduction.  While it was not a formal safety protocol, we had developed the practice of 
using a dummy-run of the planned gantry arm movement before the planned HIFU exposure 
series was delivered.  This demonstrates that such a safety check before delivering a HIFU 
exposure series, perhaps introduced as an automated procedure, should be an effective way of 
reducing technical errors, and guarding against the related harm and need for retreatment. 
Finally, only 60% of vessels were successfully occluded following a first HIFU exposure series 
which failed for unknown reasons.  These HIFU exposure series, unlike the failures resulting 
from targeting or technical errors, were not associated with any instances of maternal or fetal 
iatrogenic harm.  This suggests that there remain unknown characteristics of vessels which 
have contributed to the failure of these occlusion, rather than inappropriate delivery of HIFU 
energy to the tissues.  It is possible these vessels may have had higher flow rates, although the 
diameter of the vessels falls within the range of others successfully occluded, or been nearer 
larger vessels with a greater cooling effect, although numbers remain too small for a systematic 
study. 
Overall, retreatment appears to be safe, if somewhat less efficacious at producing occlusion 
than could be expected.  The findings of this specific safety study and the opportunistic 
collection of data regarding retreatments emphasise that the conditions which contributed to the 
failed occlusion, particularly if an error is recognised, need to be careful considered before 
embarking on a retreatment.  Errors are likely to be a function of the difficultly in targeting a 
vessel, whether that be related to fetal position, maternal habitus, equipment functionality or 
time pressures, and these difficulties may contribute to an increased risk of iatrogenic harm and 
decreased rate of successful occlusion. 
The final specific safety concern related to the risk of vascular haemorrhage.  The rate of 
haemorrhage was low in the preceding 5 animal study groups, 3/153 (2%) with only one of 
those being a proven vascular haemorrhage (1/153, 0.7%).  Two haemorrhages occurred in the 
pilot study, and one in Group A.  The risk factors for haemorrhage which were identified were 
estimated in situ intensities > 6.0 kW.cm-2 and undertreatment (as defined by the treatment area 
ratio) of the vascular target.  The eventual therapeutic window of estimated in situ intensity 
required to achieve successful vascular occlusion fell well below the threshold of 6.0 kW.cm-2, 
and so this had negligible impact on development of the HIUF treatment protocol.  The safety 
protocols introduced into the transdermal bridging study and Group S and R animals prevented 
these exposure conditions from recurring, and there were no further haemorrhages observed.  
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These findings are supported by the fact that there was no evidence of anaemia in either the 
Group S animals (Figure 4.23). 
The only circumstance in which vascular haemorrhage appeared to be reproducible was a 
spatial undertreatment of the vascular target, as defined by the C-STAR.  However, even in the 
specific safety protocol, where these conditions were deliberately replicated, the rate of 
haemorrhage was 4/11 (36%), which provides some measure of reassurance that haemorrhage 
is difficult to cause with this application of HIFU.  The proposed safety limit to reduce the risk of 
haemorrhage, that all HIFU exposure series were planned to start and finish in placental soft 
tissue bordering the echo lucent area from which vessels arise, is made possible by the 
mechanical gantry arm.  While freehand application of the HIFU focus to the tissue would likely 
lack the precision to form a confluent line of HIFU exposures with millimetre precision, this is 
well within the capability of the mechanical gantry arm or a robotic arm.   While technical errors 
were encountered in this study, these were issues that could be overcome with improvements 
to the control software used and the introduction of automated checks that planned gantry arm 
movements had been made before the HIFU source was fired, not a fault of the gantry system 
itself. 
Our attempts to further investigate the exposure conditions which resulted in vascular 
haemorrhage, and potentially apply further HIFU treatments to control that haemorrhage, were 
prevented by the fact that we could not identify vascular haemorrhage using colour flow 
Doppler.  As stated in the results, even on retrospective examination, it was not possible to 
determine any indicators of haemorrhage using the ultrasound imaging system available.  This 
could have been due to limitations of the ultrasound technology, and so could be improved by 
use of a different ultrasound system, better attuned to vascular imaging.  Equally, the flow from 
the area of vessel damage may have been sufficiently low flow so as not to show up on colour 
flow Doppler imaging.   
The identification and methods of control of vascular haemorrhage remains a key area for any 
future pre-clinical or translational study to examine.  While, as in previous safety concerns, 
careful planning of HIFU exposure series and rigorous safety checks to ensure the HIFU energy 
is delivered to the tissue as planned are an essential part of avoiding iatrogenic harm, it is 
unreasonable to assume that this alone will prevent vascular haemorrhage. 
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5.1 Comparison of Group A and Group R animals 
The experimental design required that invasive monitoring of cardiovascular (i) responses to, 
and (ii) recovery from HIFU placental vascular occlusion were conducted in different animal 
groups (as discussed in section 2.3).  These were Group A(cute) and Group R(ecovery) 
respectively.   
Table 5.1 shows a comparison of demographics and basic maternal cardiovascular status of 
ewes, subdivided by treatment group, in Group A during the last 30 minutes of the experimental 
protocol, and in Group R during the first 30 minutes following reversal of anaesthesia.  All 
groups were comparable for maternal weight.  The maternal heart rate was not significantly 
different between any of the groups.  The maternal mean arterial pressure was higher in un-
anaesthetised animals (Group R) in both sham/control and HIFU exposed animals when 
compared to the anaesthetised values (Group A). 
 
  Sham/Control HIFU 
p value 
  Group A Group R Group A Group R 
Weight (kg) 47.6 ± 2.1 42.1 ± 2.7 42.3 ± 3.1 48.7 ± 3.1 ns 
Mean arterial pressure 
(mmHg) 
57.6 ± 3.8 90.1 ± 1.4 * 65.3 ± 3.5 82.5 ± 4.9 * 0.002 
Heart rate (beats.min-1) 95 ± 4 114 ± 3 111 ± 7 101 ± 3 ns 
Table 5.1: Maternal cardiovascular comparisons (Group A to R).  
Values represent the mean ± SEM of maternal weight on the day of surgery and the mean arterial blood pressure 
and heart rate during the recovery period (30 min) in group A ewes, and during the first 30 min following the 
reversal of anaesthesia in group R ewes.  Statistical significance was assessed using a one-way ANOVA with post 
hoc Tukey’s test: * denotes a significant difference in HIFU or sham treated animals in group R animals compared 
to their group A counterparts with p values given in the table (ns = not significant, p>0.05). 
Table 5.2 shows a comparison of demographics and the cardiovascular status of fetuses, 
subdivided by treatment group, in Group A during the last 30 minutes of the experimental 
protocol, and in Group R during the first 30 minutes following reversal of anaesthesia.  All 
groups were comparable for gestational age.  The duration of anaesthesia was significantly 
shorter in Group R control fetuses, for the reasons previously described (section 3.7.3).  There 
were no further differences between fetal mean arterial blood pressure, heart rate, femoral 
blood flow or vascular resistance. 
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    Control HIFU 
p value 
  Group A Group R Group A Group R 
Gestational age (d) 116 ± 2 116 ± 2 116 ± 1 116 ± 1 ns 
Total duration of anaesthesia 
(min) 
235 
(218 - 270) 
145 * 
(133 - 170) 
228 
(215 - 247) 
238 
(211 - 293) 
< 0.001 
Mean arterial pressure 
(mmHg) 
35.0 ± 2.0 34.8 ± 2.3 39.0 ± 1.4 34.0 ± 0.8 ns 
Heart rate (beats.min-1) 175 ± 16 192 ± 11 169 ± 10 186 ± 9 ns 
Femoral blood flow (ml.min-1) 23.2 ± 1.4 26.3 ± 5.1 24.1 ± 1.8 26.9 ± 2.5 ns 
Femoral vascular resistance 
(mmHg(ml.min-1)-1) 
1.9 ± 0.2 1.6 ± 0.3 1.9 ± 0.3 1.5 ± 0.3 ns 
Table 5.2: Fetal cardiovascular comparisons (Group A to R).   
Values represent the range of fetal gestational age on the day of surgery, the median and range of the total 
duration of anaesthesia, and the mean ± SEM of fetal mean arterial blood pressure, heart rate, femoral arterial 
blood flow rate and vascular resistance during the recovery period (30 min) in Group A fetuses, and during the first 
30 min following the reversal of anaesthesia in Group R fetuses.  Statistical significance was assessed using a 
one-way ANOVA with post hoc Tukey’s test: * denotes a significant difference in HIFU or sham treated animals in 
group R animals compared to their group A counterparts with p values given in the table (ns = not significant, 
p>0.05). 
 
5.2 Maternal cardiovascular responses 
5.2.1 Heart rate and blood pressure 
Table 5.3 shows that maternal heart rate and mean arterial blood pressure were not affected by 
exposure to HIFU: the mean values were not different between HIFU and control groups, either 
while under anaesthesia (Group A) or after 5 days post procedure recovery (Group R).  
Compared to the un-anaesthetised values in Group R animals, maternal mean arterial blood 
pressure, but not heart rate, was reduced during the period of anaesthesia preceding the HIFU 
or sham exposures of placental vasculature in Group A. This reduction was of approximately 
the same magnitude between treatment groups. 
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HIFU Control 
Baseline 
recording 
(A) 
Day 5 post-
operative 
(R) 
Baseline 
recording 
(A) 
Day 5 post-
operative 
(R) 
Mean arterial blood 
pressure (mmHg) 
64.5 ± 0.2 * 79.0 ± 1.9 68.1 ± 0.3 * 80.6 ± 0.3 
Heart rate (beats.min-1) 92.8 ± 0.2 107.0 ± 5.7 96.3 ± 0.2 98.3 ± 5.9 
Table 5.3: Baseline maternal mean arterial blood pressure and heart rate.   
Values represent the mean ± SEM of maternal mean arterial blood pressure and heart rate during the specified 
recording periods for HIFU (baseline, n=5; day 5, n=6) and sham/control (baseline and day 5, n=6) treatment 
groups.  Significant differences of the effect of time and treatment group were assessed using a repeated 
measures two-way ANOVA.  No significant differences for the effect of treatment were found, but where authorised 
post hoc Tukey’s tests demonstrated a significant effect of time (* p<0.001) during the experimental protocol. 
Maternal mean arterial blood pressure and heart rate remained stable (compared to baseline) 
throughout the application of transuterine HIFU or sham exposures of placental vasculature in 
Group A animals, and was not different between HIFU and sham exposed animals (Figure 
5.1a).  In Group S animals, maternal heart rate remained stable during transdermal HIFU or 
sham exposures, and again was not different between HIFU and sham exposed animals (Figure 
5.1b)   Similarly, in Group R animals, post-procedure 24-hour averages of maternal heart rate 
and blood pressure were stable for the duration of the 21 day follow-up period (Figure 5.2). 
 
Figure 5.1: Maternal cardiovascular acute responses to HIFU placental vascular occlusion.   
(A) Group A animals.  Values represent the mean ± SEM of maternal mean arterial pressure and heart rate 
averaged over sequential 60 s intervals for HIFU (closed circles; n=5) and sham (open circles; n=6) treatment 
groups, measured from pulsatile flow in the maternal descending aorta arterial catheter.  The baseline, HIFU/sham 
and recovery periods each have a duration of 30 mins, demarcated by dotted lines.  (B) Group S animals.  Values 
represent the mean ± SEM of maternal heart rate averaged over sequential 60 s intervals for HIFU (closed circles; 
n=6) and sham (open circles; n=6) treatment groups, measured non-invasively with a pulse-oximeter.  The baseline 
and HIFU/sham periods have a duration of 60 mins; the recovery period is 30 mins and are demarcated by dotted 
lines.  No significant effects of time or treatment were found using a repeated measures two-way ANOVA. 
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Figure 5.2 Maternal cardiovascular recovery from HIFU placental vascular occlusion.   
Group R animals.  Values represent the mean ± SEM of maternal mean arterial pressure and heart rate averaged 
over sequential 24 h intervals for HIFU (closed circles; n=6) and control (open circles; n=6) treatment groups, 
measured from pulsatile flow in the maternal descending aorta arterial catheter, and compared to the baseline 
established on day five postoperative (dotted line).  No significant effects of time or treatment were found using a 
repeated measures two-way ANOVA. 
   
5.2.2 Uterine artery blood flow 
The mean ± SEM rate of uterine arterial blood flow in Group A ewes was the same in both 
treatment groups during the baseline recording period.  In the HIFU exposed animals uterine 
blood flow was 285 ± 2 ml.min-1 and 276 ± 2 ml.min-1 in the sham exposed animals (t-test, 
p=0.42).  During both transuterine HIFU and sham exposures, there was a further reduction in 
uterine artery blood flow to a nadir of up to 40% below baseline flow rates.  The reduction in 
uterine blood flow had a similar time of onset in both HIFU and sham exposures, and 
corresponded with the start of a period of gentle uterine manipulation in both treatment groups.  
The magnitude reduction was not different between treatment groups, and returned to baseline 
during the recovery period, while still under general anaesthesia (Figure 5.3).   
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Figure 5.3: Changes in maternal uterine artery blood flow during HIFU or sham exposures.   
Group A animals.  Values represent the mean ± SEM of percentage change in uterine artery blood flow from 
baseline during the specified recording periods (each lasting 30 min) for HIFU (closed circles; n=5) and sham (open 
circles; n=6) treatment groups.  Statistical significance was assessed using a repeated measures two-way ANOVA 
with post hoc Tukey’s test; * denotes a significant difference of time with respect to baseline, with the exact p value 
given on the graph.  There was no significant effect of treatment. 
The decrease in uterine blood flow corresponded with an increase in uterine artery vascular 
resistance during HIFU or sham exposures in Group A animals (Figure 5.4a).  The impact of 
these changes on substrate delivery will be discussed in chapter 6.  Uterine artery vascular 
resistance was also monitored non-invasively by Doppler ultrasound in Group S animals.  UtA-
PI was measured before, during and after HIFU or sham exposures of placental vasculature, 
while the ewe was under general anaesthesia, and at interval during the following 21 d.  Figure 
5.4b shows the increase in UtA-PI that occurred while under isoflurane anaesthesia, even 
before the application of HIFU or sham exposures, reflecting a near doubling of the PI values.  
Uterine artery notching also developed to a variable degree while the ewes were under general 
anaesthesia (Figure 3.8d), but was not present in un-anaesthetised animals. Uterine artery PI 
returned to baseline levels by the first post-operative day, and showed no evidence of notching.  
There were no further changes in UtA-PI with advancing gestational age, or differences in 
response between treatment groups. 
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Figure 5.4: Changes in maternal uterine artery vascular resistance.   
(A) Group A animals.  Values represent the mean ± SEM of maternal uterine artery vascular resistance during the 
specified recording periods (30 min each) for transuterine HIFU (closed circles; n=5) and sham (open circles; n=6) 
treatment groups. (B) Group S animals.  Values represent the mean ± SD of maternal uterine artery pulsatility index 
before, during (at approximately 10, 60 and 120 mins of anaesthesia) and after transdermal HIFU (closed circles; 
n=6) or sham (open circles; n=6) placental vascular occlusion under general anaesthesia.  Statistical significance 
was assessed using a repeated measures two-way ANOVA with post hoc Tukey’s test; * denotes a significant 
difference of time with respect to baseline/day -1, with exact p values given on the graph.  There was no significant 
effect of treatment. 
 
5.3 Fetal cardiovascular responses 
5.3.1 Heart rate and blood pressure 
Table 5.4 shows that fetal heart rate, mean pre- and post-ductal arterial blood pressure was not 
affected by exposure to HIFU: mean values were not different between HIFU and control 
groups, either while under anaesthesia (Group A) or after 5 days post procedure recovery 
(Group R).  Compared to the un-anaesthetised values in Group R animals, fetal heart rate was 
reduced during the period of anaesthesia preceding the transuterine HIFU or sham exposures 
of placental vasculature in Group A. This reduction was of approximately the same magnitude 
between treatment groups.  There was no difference in the un-anaesthetised values for pre-
ductal mean arterial pressure in Group R and Group A animals.  Post-ductal mean arterial 
pressure in sham exposed Group A animals was increased compared to un-anaesthetised 
Group R controls, but there was no difference in the HIFU exposed animals in Groups A and R. 
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HIFU Control 
Baseline 
recording 
(A) 
Day 5 post-
operative 
(R) 
Baseline 
recording 
(A) 
Day 5 post-
operative 
(R) 
Mean arterial blood pressure: 
Post- ductal (mmHg) 
36.5 ± 0.7 32.5 ± 1.4 45.1 ± 0.5 * 31.0 ± 2.3 
Mean arterial blood pressure: 
Pre- ductal (mmHg) 
31.8 ± 4.2 n/a 30.5 ± 1.9 n/a 
Heart rate (beats.min-1) 167 ± 2 * 187 ± 3 172 ± 2 * 180 ± 3 
Table 5.4 Baseline fetal mean arterial pressure and heart rate.   
Values represent the mean ± SEM of fetal mean arterial pressure and heart rate during the specified recording 
periods for HIFU (baseline, n=5; day 5, n=6) and sham (baseline and day 5, n=6) treatment groups.  Significant 
differences of the effect of time and treatment group were assessed using a repeated measures two-way ANOVA.  
No significant differences for the effect of treatment were found, but where authorised post hoc Tukey’s tests 
demonstrated a significant effect of time (* p<0.001) during the experimental protocol. 
Fetal mean arterial pressure and heart rate (corresponding to anaesthetised baseline values) 
remained stable throughout the application of HIFU or sham exposures of placental vasculature 
in Group A (Figure 5.5a).   In Group S animals, there is a fall in fetal heart rate, which occurs 
during the first 60 minutes of exposure to general anaesthesia.  The fetal heart rate was 
reduced to a similar nadir as seen in Group A animals during the baseline recording period 
(Figure 5.5b).   
After recovery from general anaesthesia, the fetal heart rate in Group R and S animals was not 
different between treatment groups during the 21 day follow-up period (Figure 5.5b, Figure 5.6).   
Mean post-ductal arterial blood pressure (Group R) was also not different between treatment 
groups during follow-up (Figure 5.6).   
There was however an effect of gestational age observed during the follow-up period.  In Group 
R animals, the fetal heart rate decreased and the post-ductal mean arterial pressure increased 
with increasing gestational age.  In Group S animals, the fetal heart rate also decreased with 
increasing gestational age (Figure 5.5b, Figure 5.6). 
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Figure 5.5 Fetal mean arterial pressure and heart rate (intraoperative).   
(A) Group A animals.  Values represent the mean ± SEM of fetal mean arterial blood pressure and heart rate during 
the specified recording periods (30 min each) for transuterine HIFU (closed circles; n=5) and sham (open circles; 
n=6) treatment groups. (B) Group S animals. Values represent the mean ± SD of fetal heart rate before, during (at 
approximately 10, 60 and 120 mins of anaesthesia) and after transdermal HIFU (closed circles; n=6) or sham (open 
circles; n=6) treatment groups.  Statistical significance was assessed using a repeated measures two-way ANOVA 
with post hoc Tukey’s test; * denotes a significant difference of time with respect to baseline/day -1, with exact p 
values given on the graphs.  There was no significant effect of treatment. 
 
Figure 5.6  Fetal mean arterial pressure and heart rate (follow-up period).   
Group R animals.  Values represent the mean ± SEM of fetal mean arterial blood pressure and heart rate averaged 
over sequential 24 h periods following HIFU (closed circles; n=6) or sham (open circles; n=6) placental vascular 
occlusion and fetal instrumentation under isoflurane anaesthesia.  Statistical significance was assessed using a 
repeated measures two-way ANOVA with post hoc Tukey’s test; * denotes a significant difference of time with 
respect to baseline, with exact p values given on the graphs.  There was no significant effect of treatment. 
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5.3.2 Cardiovascular defence mechanisms 
At the start of the “baseline” period preceding HIFU or sham exposures of placental vasculature 
in Group A, fetuses had already undergone a period of general anaesthesia, a period of uterine 
handling and surgical intervention.  Table 5.5 provides a comparison of femoral and carotid 
arterial blood flow values in comparison to the normal range for gestation derived from un-
anaesthetised, chronical instrumented fetal sheep.  Femoral vascular resistance is the only 
measurement which fell outside the normal range. 
  
Normal 
range for 
gestation 
Baseline in 
HIFU group 
Baseline in 
sham group 
(95% CI) 
Femoral artery blood flow 
28 – 40 30.3 ± 0.3 29.4 ± 0.6 
(ml.min-1) 
Femoral vascular resistance 
(mmHg.(min.ml-1)-1) 
0.69 – 1.19 1.2 ± 0.01 1.6 ± 0.01 
Carotid artery blood flow  
58 – 91 85.6 ± 0.3 87.1 ± 0.9 
(ml.min-1) 
Carotid artery vascular 
resistance (mmHg.(min.ml-1)-1) 
0.24 – 0.66 0.37 ± 0.01 0.42 ± 0.01 
Ratio of carotid to femoral 
arterial blood flow 
1.5 – 3.0 3.0 ± 0.01 2.7 ± 0.01 
Table 5.5 Normal fetal blood flow dynamics compared to operative baselines.   
Group A animals.  In the black column, values represent the normal range for gestation, given as a 95% confidence 
interval, of fetal femoral and carotid artery blood flows and vascular resistances, and the ratio of carotid to femoral 
blood flow (Derived from experiments performed in the same laboratory (279)).  These are compared to the mean ± 
SEM values during the baseline recording periods for HIFU (n=5) and sham (n=6) treatment groups for the same 
blood flow measurements.  The effect of treatment was assessed between the HIFU and sham groups during the 
baseline period using a two-tailed student’s t-test and no significant differences were found. 
During the 30-mintue time period in which HIFU or sham exposures of placental vasculature 
were performed, there was a reduction in fetal femoral artery blood flow and an increase in 
femoral artery vascular resistance compared to the baseline, with no difference between 
treatment groups (Figure 5.7a).  These changes occurred in conjunction with the reduction in 
maternal uterine artery blood flow, and persisted beyond the restoration of maternal uterine 
artery blood flow to normal. Carotid artery blood flow and vascular resistance again remained 
stable throughout the duration of the HIFU experimental protocol and no effect of treatment was 
observed (Figure 5.7b).   
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Figure 5.7 Changes in fetal femoral and carotid blood flow and resistance (acute phase).   
Group A animals.  Values represent the mean ± SEM of absolute change from baseline of (A) fetal femoral blood 
flow and vascular resistance and (B) fetal carotid blood flow and vascular resistance during the specified recording 
periods (30 min each) for transuterine HIFU (closed circles; n=5) and sham (open circles; n=6) treatment groups.  
Statistical significance was assessed using a repeated measures two-way ANOVA with post hoc Tukey’s test; * 
denotes a significant difference of time with respect to baseline, with exact p values given on the graphs.  There 
was no significant effect of treatment.   
During the post-exposure follow-up period in Group R animals, there was an increase in mean 
fetal femoral blood flow and pulse pressure with increasing gestation age (Figure 5.8).  There 
was no effect of treatment on these increases.  In the first 24 hours of surgical recovery there 
was an increase in fetal femoral artery vascular resistance.  It was no longer statistically 
increased after this time, but continued to show a trend to decrease for three to four days post 
procedure, until a stable baseline was formed (Figure 5.8).  Carotid artery flow probes were not 
placed in Group R animals due to the necessity to avoid prolonged anaesthesia by restricting 
the time allocated to both HIFU and surgical procedures. 
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Figure 5.8 Fetal femoral artery flow dynamics after transdermal HIFU/sham exposures (follow-up period).   
Group R animals.  Values represent the mean ± SEM of fetal femoral arterial blood flow, pulse pressure and 
vascular resistance during the recovery period from HIFU (closed circles; n=5) or sham (open circles; n=6) 
exposures.  The dashed line represents the day five “baseline” against which other values are compared. Statistical 
significance was assessed using a repeated measures two-way ANOVA with post hoc Tukey’s test; * denotes a 
significant difference of time with respect to baseline, with exact p values given on the graphs.  There was no 
significant effect of treatment.   
In Group S animals, even in the absence of invasive surgical procedures, and, in the sham 
animals, in the absence of HIFU exposures, changes in fetal blood flows were noted.  Figure 
5.9a shows the changes in umbilical artery resistance, reported as PI values.  Pre-procedure 
(24-48 hours), the umbilical artery PI for both groups was < 1.0.  Following induction of 
anaesthesia, there was a progressive rise in the UA-PI with increasing duration of anaesthesia.  
These changes followed the same pattern as maternal UtA-PI with increasing duration of 
anaesthesia (Figure 5.4b).  Like the changes in fetal femoral artery resistance (Figure 5.8), this 
elevation in UA-PI was statistically significant for 24 h after the HIFU or sham exposures, and 
returned to baseline levels over the subsequent 3-4 days, although elevations were not 
statistically significant during this time.  These increases in UA-PI were not different between 
HIFU and sham treated groups. 
Unlike the carotid arterial flow and resistance, which remained stable, (Figure 5.7b), the middle 
cerebral artery PI did decrease during the period of anaesthesia and HIFU or sham exposures 
(Figure 5.9).  This change was slower to achieve statistical significance than the changes in 
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uterine and umbilical artery PI.  However, the decrease in MCA-PI, and consequently cerebro-
placental ratio, persisted for the first 3 days of the follow-up period (Figure 5.9).   Again, the 
timing and magnitude of these changes were not different between HIFU and sham treated 
groups. 
 
Figure 5.9 Fetal Doppler indices before, during and after HIFU/sham exposures.   
Values represent the mean ± SD of fetal umbilical and middle cerebral artery pulsatility index and the ratio of the 
two, the cerebro-placental ratio, before, during and after transdermal HIFU (closed circles; n=6) or sham (open 
circles; n=6) non-invasive placental vascular occlusion under anaesthesia.  Statistical significance was assessed 
using a repeated measures two-way ANOVA with post hoc Tukey’s test; * denotes a significant difference of time 
with respect to day -1, with exact p values given on the graph.  There was no significant difference of the effect of 
treatment. 
                                                                                                                                  
5.4 Fetal cardiac function 
In addition to in vivo invasive assessment of fetal cardiovascular function in Group A and R 
animals, fetal echocardiography was performed in Group S animals.   
During the period of general anaesthesia, changes in fetal cardiac function were observed, 
characterised by significant increases in LV-MPI and DV-PIV, compared to the baseline in un-
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anaesthetised sheep.  Left ventricular EF and FS were unchanged during anaesthesia.  There 
were again no differences between treatment groups in the timing or magnitude of these 
changes (Figure 5.10).   
During the follow-up period, in both treatment groups, LV-MPI remained elevated for the first 24 
h.  The left ventricular EF was increased during the day 1-2 assessments post HIFU or sham 
exposures; left ventricular FS was increased during the day 1-4 assessments post HIFU or 
sham exposures.  DV-PIV was not significantly increased following the reversal of anaesthesia 
(Figure 5.10).   
 
Figure 5.10: Fetal cardiac function (Group S).   
Values represent the mean ± SD of fetal cardiac ejection fraction, fractional shortening, left ventricular myocardial 
performance index and ductus venosus pulsatility index before, during and after transdermal HIFU (closed circles; 
n=6) or sham (open circles; n=6) exposures.  Dotted lines demarcate the measures performed in anaesthetised 
animals; all other values were in un-anaesthetised animals.  Statistical significance was assessed using a repeated 
measures two-way ANOVA with post hoc Tukey’s test; * denotes a significant difference of time with respect to day 
-1, with exact p values given on the graphs.  There was no significant effect of treatment. 
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6.1 Comparison of Group A and Group R animals 
The experimental design required that invasive monitoring of cardiovascular and metabolic 
(i) responses to, and (ii) recovery from, HIFU mediated placental vascular occlusion were 
conducted in different animal groups (as per section 2.3).  These were Group A(cute) and 
Group R(ecovery) respectively.  In the Group R controls, there was no blood sampling of 
the ewe or fetus performed following reversal of anaesthesia due to a difference in 
experimental protocols, so the Group A sham animals cannot be compared to Group R 
controls. 
Table 6.1 shows a comparison of the metabolic characteristics of ewes (exposed to HIFU 
only) in Group A during the last 30 minutes of the experimental protocol, and in Group R 
during the first 30 minutes following reversal of anaesthesia.  With the exception of the 
arterial partial pressure of oxygen, there were no differences between groups. 
 
  HIFU 
p value 
 
Group A Group R 
PaO2 (mmHg) 202 ± 55 109 ± 19 * < 0.001 
Oxyhaemoglobin saturation 
(%) 
102.3 ± 1.4 104.0 ± 0.2 ns 
Haemoglobin (g.dL-1) 8.6 ± 0.3 7.2 ± 0.7 ns 
Glucose (mmol.L-1) 2.2 ± 0.2 2.5 ± 0.3 ns 
pH 7.51 ± 0.02 7.47 ± 0.02 ns 
Arterial base excess  
(mmol.L-1) 
7.7 ± 0.7 4.8 ± 1.4 ns 
PaCO2 (mmHg) 40.5 ± 3.0 37.0 ± 2.6 ns 
Arterial lactate (mmol.L-1) 1.1 ± 0.2 1.1 ± 1.5 ns 
Bicarbonate (mEq.L-1) 31.0 ± 1.0 27.8 ± 1.7 ns 
Table 6.1: Maternal metabolic status comparisons (Group A to R).   
Values represent the mean ± SEM of maternal arterial partial pressure of oxygen (PaO2) and carbon dioxide 
(PaCO2), oxygen saturation of haemoglobin, haemoglobin concentration, concentrations of arterial glucose, 
lactate, bicarbonate and arterial base excess in the descending maternal aorta.  Samples were taken either at 
the end of the recovery period in Group A ewes or within 30 min following the reversal of anaesthesia in 
Group R ewes.  While values for sham treated animals in Group A are available, the corresponding values in 
Group R control ewes are not, so these comparisons cannot be drawn.   Statistical significance was assessed 
using a two-tailed students’ t-test: * denotes a significant difference in HIFU treated animals in Group R 
animals compared to their Group A counterparts with p values given in the table (ns = not significant, p >0.05). 
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Table 6.2 shows a comparison of the metabolic characteristics of fetuses (exposed to 
HIFU) in Group A during the last 30 minutes of the experimental protocol, and in Group R 
during the first 30 minutes following reversal of anaesthesia.  The fetuses of un-
anaesthetised ewes in group R have a higher arterial pH, a lower PaCO2, show a lesser 
degree of haemoconcentration and have a higher delivery rate of femoral oxygen and 
glucose that the fetuses of anaesthetised ewes in Group A.   
  HIFU 
p value 
  Group A Group R 
PaO2 (mmHg) 18.4 ± 0.9 19.0 ± 1.7 ns 
Oxyhaemoglobin saturation 
(%) 
46.8 ± 2.8 45.7 ± 3.8 ns 
Haemoglobin (g.dL-1) 11.1 ± 0.2 10.6 ± 0.2 * 0.02 
Haematocrit (%) 35.2 ± 0.4 32.6 ± 0.6 * 0.01 
Arterial oxygen content 
(mmol.ml-1) 
2.2 ± 0.3 3.1 ± 0.2 ns 
Femoral oxygen delivery 
(mmol.min-1) 
55 ± 8 93 ± 5 * 0.02 
Glucose (mmol.L-1) 0.8 ± 0.1 0.8 ± 0.1 ns 
Femoral glucose delivery 
(µmol.min-1) 
19 ± 4 22 ± 4 0.02 
        
pH 7.18 ± 0.02 7.24 ± 0.01 * 0.03 
Arterial base excess 
(mmol.L-1) 
-4.4 ± 0.7 -3.3 ± 1.4 ns 
PaCO2 (mmHg) 78 ± 7 60 ± 2 * 0.02 
Arterial lactate (mmol.L-1) 3.0 ± 0.4 2.2 ± 0.2 ns 
Bicarbonate (mEq.L-1) 24.6 ± 0.2 23.8 ± 1.4 ns 
Table 6.2: Fetal metabolic status comparisons (Group A to R).   
Values represent the mean ± SEM of fetal arterial partial pressure of oxygen (PaO2) and carbon dioxide 
(PaCO2), oxygen saturation of haemoglobin, arterial oxygen content, haemoglobin concentration, haematocrit, 
concentrations of arterial glucose, lactate, bicarbonate, arterial base excess and femoral arterial oxygen and 
glucose delivery rates in the fetal ascending aorta (Group A) or descending aorta (GroupR).  Samples were 
taken either at the end of the recovery period in Group A animals or within 30 min following the reversal of 
anaesthesia in Group R animals.  While values for sham treated animals in Group A are available, the 
corresponding values in Group R control ewes are not, so these comparisons cannot be drawn.   Statistical 
significance was assessed using a two-tailed Student’s t-test: * denotes a significant difference in HIFU 
treated animals in Group R animals compared to their Group A counterparts with p values given in the table 
(ns = not significant, p >0.05). 
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6.2 Maternal substrate availability and delivery 
In Group A ewes, there were no differences in maternal arterial oxygenation, saturation of 
oxyhaemoglobin or haemoglobin during the acute experimental protocol.  In Group S ewes, 
there were no differences in maternal saturation of oxyhaemoglobin measured non-
invasively in animals exposed to HIFU or sham (Figure 6.1).  In Group R ewes, maternal 
oxygenation and haemoglobin was also stable during the five days of postoperative 
recovery to “baseline” and in the monitoring period to day 21 thereafter, when HIFU 
exposed animals were compared to the control (Table 6.4).   
 
Figure 6.1: Maternal respiratory function under anaesthesia (Group S).   
Values represent the mean ± SEM of maternal EtCO2 and respiratory rate measured by capnography, and 
saturation of maternal haemoglobin with oxygen measured non-invasively with a pulse-oximeter, averaged 
over sequential 60 s intervals for HIFU (closed circles; n=6) and sham (open circles; n=6) treatment groups.  
The baseline and HIFU/sham periods have a duration of 60 mins; the recovery period is 30 mins and are 
demarcated by dotted lines.  No significant differences of the effect of time or treatment were found using a 
repeated measures two-way ANOVA. 
Maternal glucose concentration shows a statistically, but not physiologically, significant 
decrease with increasing duration of the acute experimental protocol, representing a fall 
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from 2.7 to 2.3 mmol.l-1 (Table 6.3).  For comparison, the mean values of maternal glucose 
concentration in the 21 day follow-up period varied between 2.3 and 2.6 mmol-1, showing 
no statistically significant effect of time or treatment (Table 6.4). 
As would be expected, given the reductions in uterine artery blood flow discussed in section 
5.2.2, oxygen and glucose delivery by the uterine artery was decreased during HIFU or 
sham exposures, but was restored to baseline during the recovery phase of the acute 
protocol (Table 6.3).  However, given the maternal super-oxygenation resulting from 
mechanical ventilation with a high fraction of inspired oxygen, this decrease in oxygenation 
does not equate to hypoxaemia.  Uterine artery flow probes were not placed in Group R 
HIFU exposed animas due to the necessity to avoid prolonged anaesthesia by restricting 
the time allocated to both HIFU and surgical procedures, so it is not possible to comment of 
uterine artery delivery of oxygen and glucose beyond the end of the acute experimental 
protocol.  However, from previously chronically instrumented ovine studies, the normal 
range of uterine artery oxygen delivery is 83-200 ml.min-1 and glucose delivery is 396-1188 
µmol.ml-1 at approximately this gestational age (unpublished data) (95% confidence 
intervals), and the values in Table 6.3 fall within this range. 
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Table 6.3: Maternal substrate availability and delivery during placental vascular exposures (Group A).   
Values represent the mean ± SEM of maternal oxygen partial pressure (PaO2), oxyhaemoglobin saturation, oxygen content, haemoglobin, haematocrit, glucose 
concentration in the descending aorta, and uterine artery oxygen and glucose delivery, for animals in the HIFU (n=5) and sham (n=6) treatment groups in each time period 
of the experimental protocol.  Significant differences of the effect of time and treatment group were assessed using a repeated measures two-way ANOVA.  No significant 
differences for the effect of treatment were found (†) but where authorised post hoc Tukey’s tests demonstrated a significant effect of time (*) during the experimental 
protocol, with relevant p numbers given in the table. 
Baseline Recovery
(-30 min) (0 min) (15 min) (30 min) (60 min) (* time) († treatment)
HIFU 216.0 ± 47.5 200.4 ± 67.3 190.4 ± 74.2 186.2 ± 72.4 218.2 ± 64.2 0.60 0.71
Sham 198.8 ± 25.4 169.8 ± 22.8 163.8 ± 23.4 183.3 ± 32.3 180.0 ± 26.2
HIFU 102.3 ± 1.2 100.1 ± 2.2 97.6 ± 3.0 100.5 ± 1.9 101.9 ± 1.6 0.77 0.96
Sham 95.1 ± 7.8 102.3 ± 1.3 102.0 ± 1.5 101.3 ± 1.9 102.4 ± 1.1
HIFU 8.0 ± 0.4 7.8 ± 0.4 8.0 ± 0.5 8.2 ± 0.4 8.5 ± 0.4 0.06 0.14
Sham 8.9 ± 0.6 8.9 ± 0.6 9.1 ± 0.6 9.4 ± 0.4 9.6 ± 0.5
HIFU 0.24 ± 0.01 0.24 ± 0.02 0.25 ± 0.02 0.25 ± 0.01 0.26 ± 0.01 0.00 0.73
Sham 0.24 ± 0.01 0.24 ± 0.01 0.25 ± 0.01 0.28 ± 0.01 * 0.28 ± 0.01*
HIFU 0.76 ± 0.1 0.71 ± 0.2 0.68 ± 0.2 0.67 ± 0.2 0.77 ± 0.2 0.61 0.77
Sham 0.71 ± 0.1 0.63 ± 0.1 0.62 ± 0.1 0.68 ± 0.1 0.67 ± 0.1
HIFU 203 ± 28 182 ± 49 133 ± 43 * 128 ± 41 202 ± 53 0.00 0.77
Sham 210 ± 26 197 ± 33 138 ± 20 * 183 ± 15 181 ± 15
HIFU 2.6 ± 0.2 2.5 ± 0.2 2.5 ± 0.1 2.5 ± 0.2 * 2.3 ± 0.1 * <0.001 0.84
Sham 2.7 ± 0.2 2.5 ± 0.2 2.4 ± 0.2 2.4 ± 0.2 * 2.3 ± 0.2 *
HIFU 730 ± 55 672 ± 44 485 ± 49 * 477 ± 50 * 617 ± 117 <0.001 0.42
Sham 812 ± 111 762 ± 121 595 ± 131 * 704 ± 124 * 648 ± 96
p  value
Uterine glucose 
delivery 
(µmol.min
-1
)
Glucose
(mmol.L
-1
)
Uterine oxygen 
delivery (ml.min
-1
)
Oxygen content 
(ml O2.mL
-1
)
Haematocrit (%)
Haemoglobin 
(g.dL
-1
)
Oxyhaemoglobin 
Saturation (%)
PaO2 (mmHg)
Variable Group
Exposure Series
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Table 6.4: Maternal substrate availability following placental vascular exposures (Group R).   
Values represent the mean ± SEM of maternal oxygen partial pressure (PaO2), oxyhaemoglobin saturation, oxygen content, haemoglobin, haematocrit and glucose 
concentration in the descending aorta for animals in the HIFU (n=6) and sham (n=6) treatment groups.  Values for days one to five following HIFU or sham exposures 
(“post-operative recovery”) are presented as daily means; values for the “monitoring period” are presented as the mean ± SEM of five day values.  Before values given in 
the “monitoring period” were grouped into five-day means they were compared individually to each other and the baseline.  Grouping values into five day means did not 
alter any significant outcomes (or lack thereof), and they are presented grouped for ease of expression.  Significant differences of the effect of time and treatment group 
were assessed using a repeated measures two-way ANOVA.  Where authorised, post hoc Sidak’s tests demonstrated a significant effect of treatment (†) and post hoc 
Tukey’s tests demonstrated a significant effect of time (*) during the experimental protocol, with relevant p numbers given in the table.   
Variable Group Baseline
  1 2 3 4 Day 5 6-10 11-15 16-20 (* time) (
† treatment)
HIFU 96 ± 3 92 ± 6 92 ± 4 89 ± 3 94 ± 3 99 ± 2 93 ± 2 99 ± 1
Control 111 ± 7 105 ± 6 96 ± 3 103 ± 3 100 ± 1 101 ± 3 105 ± 3 97 ± 2
HIFU 103 ± 1 102 ± 2 101 ± 1 102 ± 1 103 ± 1 104 ± 1 103 ± 1 104 ± 1
Control 103 ± 1 102 ± 1 102 ± 1 102 ± 1 103 ± 1 103 ± 1 102 ± 1 103 ± 1
HIFU 10.9 ± 0.3 10.4 ± 0.2 10.2 ± 0.4 10.3 ± 0.5 10.4 ± 0.3 10.5 ± 0.2 10.1 ± 0.2 10.5 ± 0.3
Control 11.2 ± 0.2 10.6 ± 0.2 10.0 ± 0.3 10.0 ± 0.7 9.3 ± 0.4 9.8 ± 0.2 9.7 ± 0.2 9.7 ± 0.1
HIFU 0.44 ± 0.01 0.42 ± 0.02 0.41 ± 0.02 0.41 ± 0.01 0.42 ± 0.01 0.44 ± 0.01 0.42 ± 0.01 0.44 ± 0.01
Control 0.49 ± 0.03 0.46 ± 0.02 0.43 ± 0.01 0.45 ± 0.02 0.43 ± 0.01 0.44 ± 0.01 0.45 ± 0.01 0.42 ± 0.01
HIFU 2.6 ± 0.3 2.3 ± 0.1 2.5 ± 0.2 2.5 ± 0.2 2.4 ± 0.1 2.6 ± 0.1 2.5 ± 0.1 2.3 ± 0.1
Control 2.5 ± 0.2 2.4 ± 0.4 2.5 ± 0.1 2.7 ± 0.1 2.6 ± 0.1 2.7 ± 0.1 2.5 ± 0.1 2.3 ± 0.1
0.10
p valueMonitoring period (day)
0.06 0.78
0.13 0.47
0.12 0.16
0.71 0.61
0.09PaO2 (mmHg)
Oxyhaemoglobin 
Saturation (%)
Haemoglobin 
(g.dL
-1
)
Oxygen content 
(ml O2.mL
-1
)
Glucose
(mmol.L
-1
)
Post-operative recovery (day)
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6.3 Fetal substrate availability and delivery 
Carotid arterial oxygen and glucose delivery to the fetal brain remained unaltered during the 
experimental procedure, despite a reduced partial pressure of oxygen and saturation of 
oxyhaemoglobin in the fetal blood by the end of the recovery period.  Fetuses also showed 
a trend to haemoconcentration by the end of the recovery period.  These changes were 
present in both the HIFU and sham groups with no effect of treatment seen; additionally, 
these changes occurred at the same time points for both treatment groups (Table 6.5).   
By the first postoperative day, these changes in oxygenation had recovered, and notably 
the saturation of oxyhaemoglobin of the fetal blood was increased to above baseline levels.  
This resulted in normalisation of fetal femoral oxygen delivery by the time of the day one 
samples (Table 6.6), even given the persistence of increased fetal femoral vascular 
resistance and reduction in pulse pressure noted (Figure 5.8).  Fetal femoral oxygen 
delivery increases with advancing gestational age, related to the previously mentioned 
increases in femoral arterial blood flow with increasing gestational age (Figure 5.8).   There 
is again no effect of treatment.   
Fetal haemoglobin was stable and within the normal range, with no evidence of fetal 
anaemia or polycythaemia. 
Fetal glucose concentration remained unchanged throughout the acute experimental 
protocol in the Group A animals.  Decreases in femoral oxygen delivery were observed in 
line with the pattern of decreased femoral and maternal blood flows (Figure 5.7).  The fetal 
glucose concentration remained stable throughout the follow-up period, but femoral glucose 
delivery increased with advancing gestational age, similar to the changes noted with 
oxygen delivery.  As previously, there were no statistically significant differences between 
treatment groups. 
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Table 6.5: Fetal substrate availability during placental vascular exposures (Group A).   
Values represent the mean ± SEM of fetal arterial oxygen partial pressure (PaO2), oxyhaemoglobin saturation, haemoglobin, haematocrit and glucose concentration in the 
pre-ductal circulation in animals in the HIFU (n=5) and sham (n=6) treatment groups in each time period of the experimental protocol.  Significant differences of the effect 
of time and treatment group were assessed using a repeated measures two-way ANOVA.  No significant differences for the effect of treatment were found (†) but where 
authorised post hoc Tukey’s tests demonstrated a significant effect of time (*) during the experimental protocol, with relevant p numbers given in the table. 
 
 
 
Baseline Recovery
(-30 min) (0 min) (15 min) (30 min) (60 min) (* time) († treatment)
HIFU 25.2 ± 1.1 25.0 ± 2.8 23.8 ± 3.3 23.0 ± 3.2 18.4 ± 0.9 *
Sham 27.2 ± 1.2 28.3 ± 1.2 27.7 ± 1.2 26.3 ± 1.9 22.3 ± 1.9 *
HIFU 72.8 ± 1.1 72.3 ± 2.9 69.3 ± 8.3 66.3 ± 7.4 46.8 ± 2.8 *
Sham 70.4 ± 7.5 64.8 ± 2.9 64.3 ± 3.9 63.1 ± 4.7 51.2 ± 9.5 *
HIFU 10.0 ± 0.2 10.2 ± 0.2 10.7 ± 0.3 11.0 ± 0.5 11.1 ± 0.2 *
Sham 9.3   ± 0.2 10.5 ± 0.3 9.8   ± 0.2 10.0 ± 0.2 10.7 ± 0.4 *
HIFU 0.32 ± 0.01 0.33 ± 0.01 0.34 ± 0.02 0.35 ± 0.01 * 0.35 ± 0.01*
Sham 0.27 ± 0.02 0.34 ± 0.02 0.32 ± 0.02 0.34 ± 0.02 * 0.33 ± 0.03*
HIFU 0.70 ± 0.12 0.66 ± 0.14 0.70 ± 0.10 0.83 ± 0.11 0.79 ± 0.13
Sham 0.99 ± 0.17 0.89 ± 0.08 0.86 ± 0.09 0.81 ± 0.11 0.87 ± 0.14
0.03 0.55
0.69 0.39
Glucose
(mmol.L
-1
)
p  value
Treatment 
group
Exposure series
< 0.0001 0.21
< 0.0001 0.62
0.0026 0.06
Variable
Haematocrit (%)
PaO2 (mmHg)
Oxyhaemoglobin 
Saturation (%)
Haemoglobin 
(g.dL
-1
)
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Table 6.6 Fetal substrate delivery during placental vascular exposures (Group A).   
Values represent the mean ± SEM of fetal carotid and femoral arterial oxygen and glucose deliveries and the ratio of both pre- and post-ductal oxygen and glucose delivery 
for animals in the HIFU (n=5) and sham (n=6) treatment groups in each time period of the experimental protocol.  Significant differences of the effect of time and treatment 
group were assessed using a repeated measures two-way ANOVA.  No significant differences for the effect of treatment were found (†) but where authorised post hoc 
Tukey’s tests demonstrated a significant effect of time (*) during the experimental protocol, with relevant p numbers given in the table. 
 Baseline Recovery
 (-30 min)  (0 min) (15 min) (30 min) (60 min) (* time) († treatment)
HIFU 383 ± 30 374 ± 39 373 ± 41 352 ± 28 283 ± 19
Sham 359 ± 82 361 ± 40 312 ± 37 334 ± 50 281 ± 33
HIFU 116 ± 9 106 ± 13 73 ± 15 * 67 ± 12 * 55 ± 8 *
Sham 114 ± 14 116 ± 13 82 ± 10 * 99 ± 10 * 91 ± 18 *
HIFU 3.1 ± 0.4 3.2 ± 0.2 4.8 ± 0.6 5.2 ± 1.1 * 4.6 ± 0.3
Sham 3.7 ± 1.0 3.3 ± 0.5 4.0 ± 0.7 3.3 ± 0.7 3.0 ± 0.4
HIFU 61 ± 14 57 ± 16 64  ± 15 77 ± 19 72 ± 13
Sham 78 ± 14 75 ± 12 72  ± 14 67 ± 16 74 ± 19
HIFU 21 ± 3 19 ± 3 15 ± 2 * 16 ± 3 * 19 ± 4
Sham 30 ± 6 26 ± 3 19 ± 3 * 24 ± 4 * 24 ± 3
HIFU 3.0 ± 0.4 2.9 ± 0.3 4.2 ± 0.8 * 4.7 ± 0.7 * 4.0 ± 0.2
Sham  2.6 ± 0.4  2.7 ± 0.3 3.9 ± 0.7 * 2.9 ± 0.5 * 3.0 ± 0.5
0.59 0.74
0.003 0.17
0.0004 0.26
p  value
0.21 0.63
< 0.0001 0.28
0.04 0.33
Variable
Carotid : Femoral 
Oxygen Delivery Ratio
Carotid : Femoral 
Glucose Delivery Ratio
Carotid Arterial Oxygen 
Delivery (mmol.min
-1
)
Femoral Arterial 
Glucose Delivery 
(µmol.min
-1
)
Carotid Arterial Glucose 
Delivery (µmol.min
-1
)
Femoral Arterial Oxygen 
Delivery (mmol.min
-1
)
Exposure SeriesTreatment 
group
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Table 6.7: Fetal substrate availability and delivery following placental vascular exposures (Group R).   
Values represent the mean ± SEM of fetal arterial oxygen partial pressure (PaO2), oxyhaemoglobin saturation, haemoglobin, haematocrit and glucose concentration in the 
post-ductal circulation and femoral arterial oxygen and glucose delivery for animals in the HIFU (n=6) and sham (n=6) treatment groups.  Values for days one to five 
following HIFU or sham exposures (“post-operative recovery”) are presented as daily means; values for the “monitoring period” are presented as the mean ± SEM of five 
day values.  Before values given in the “monitoring period” were grouped into five-day means they were compared individually to each other and the baseline.  Grouping 
them into five day means did not alter any significant outcomes (or lack thereof) they are presented grouped for ease of expression.  Significant differences of the effect of 
time and treatment group were assessed using a repeated measures two-way ANOVA.  No significant differences for the effect of treatment were found (†) but where 
authorised post hoc Tukey’s tests demonstrated a significant effect of time (*) during the experimental protocol, with relevant p numbers given in the table. 
Variable Group Baseline
  1 2 3 4 Day 5 6-10 11-15 16-20 (* time) (
† treatment)
HIFU 21.8 ± 1.3 20.6 ± 1.7 19.6 ± 2.2 19.0 ± 1.7 20.2 ± 1.5 22.2 ± 0.9 21.2 ± 0.6 20.1 ± 0.4
Control 22.0 ± 0.9 21.2 ± 1.6 18.8 ± 0.5 19.6 ± 0.6 19.4 ± 1.0 19.5 ± 0.6 19.3 ± 0.4 19.5 ± 0.5
HIFU 63.7 ± 2.3 55.0 ± 5.3 53.4 ± 6.1 54.5 ± 6.1 57.6 ± 3.5 57.3 ± 1.5 55.8 ± 1.6 55.5 ± 1.0
Control 64.8 ± 2.7 56.9 ± 5.5 49.2 ± 4.1 52.7 ± 4.1 52.9 ± 4.1 54.3 ± 1.7 54.1 ± 1.6 50.5 ± 1.8
HIFU 9.9 ± 0.8 * 10.1 ± 0.7 9.2 ± 0.7 8.7 ± 0.5 8.6 ± 0.8 9.5 ± 0.4 9.9 ± 0.4 10.6 ± 0.3
Control 10.0 ± 0.5 * 9.2 ± 0.6 8.4 ± 0.4 8.5 ± 0.3 8.7 ± 0.3 8.5 ± 0.3 8.8 ± 0.3 9.2 ± 0.4
HIFU 0.95 ± 0.13 0.83 ± 0.09 1.01 ± 0.10 0.93 ± 0.10 0.92 ± 0.10 0.96 ± 0.04 0.90 ± 0.05 0.82 ± 0.03
Control 0.75 ± 0.10 0.83 ± 0.13 0.81 ± 0.10 0.85 ± 0.10 0.97 ± 0.15 0.80 ± 0.04 0.74 ± 0.03 0.70 ± 0.03
HIFU 104.5 ± 8.9 94.7 ± 6.8 90.9 ± 8.6 89.6 ± 9.0 94.0 ± 8.9 124.9 ± 5.5 * 141.1 ± 6.4 * 136.2 ± 7.3 *
Control 105.1 ± 10.7 108.2 ± 13.4 88.4 ± 13.1 101.5 ± 7.8 103.9 ± 3.1 100.6 ± 5.5 121.9 ± 5.5 * 109.5 ± 2.8
HIFU 27.5 ± 4.5 24.8 ± 3.3 31.2 ± 3.2 29.6 ± 3.6 30.2 ± 4.1 37.3 ± 2.6 * 38.9 ± 2.7 * 33.1 ± 2.3
Control 24.0 ± 4.6 28.1 ± 3.2 29.0 ± 5.9 31.8 ± 4.1 33.0 ± 4.1 30.5 ± 1.5 31.2 ± 1.7 28.6 ± 1.3
0.001
0.02
0.34
0.52
0.38
0.26
0.31
0.44
Glucose concentration
(mmol.L
-1
)
Femoral Arterial Oxygen 
Delivery (mmol.min
-1
)
Femoral Arterial Glucose 
Delivery (µmol.min
-1
)
Monitoring period (day) p value
0.18
0.06
0.01
0.07
PaO2 (mmHg)
Oxyhaemoglobin 
Saturation (%)
Haemoglobin (g.dL
-1
)
Post-operative recovery (day)
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6.4 Maternal metabolic by-product clearance 
During the acute experimental protocol in Group A ewes, there were no significant effects 
due to the duration of anaesthesia or time.  There were, however, significant differences in 
maternal pH and arterial partial pressure of carbon dioxide (PaCO2) apparent between the 
treatment groups, which only reached significance by the end of the exposure series (30 
mins) and persisted to the end of the recovery period (60 mins, Table 6.8).  These changes 
in pH are accounted for by the difference in PaCO2 levels between the groups, as 
concentrations of arterial lactate were not different between groups, and did not show 
elevation during the entire protocol.  Conversely, in Group S animals, end tidal expired CO2 
levels remained normal at 5-6% while under anaesthesia (Figure 6.1), only rising during the 
recovery period when ventilation rates were reduced in preparation for reversal of 
anaesthesia to promote spontaneous respiratory effort. 
There were no differences in maternal PaCO2 or pH in Group R ewes on day one post-
operative.  The pH was higher in Group R controls compared to HIFU exposed animals 
between days two and five post-operative (Table 6.9).  Neither PaCO2 nor arterial lactate 
levels are significantly different between groups, nor were there any differences in arterial 
base excess or bicarbonate concentration to show differential buffering.  Measurement of 
maternal respiratory rate was part of the daily assessment for pain or distress, and no 
elevation was noted in either group (data not shown). 
Arterial lactate showed elevation on the first post-operative day; this was not significantly 
different by the second post-operative day and had returned to the normal range for adult 
pregnant sheep by the third day.  Beyond this there were no other differences or trends 
observed in maternal metabolic by-product clearance once the immediate effect of 
anaesthesia and surgery had passed.   
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Table 6.8: Maternal metabolic by-product clearance during placental vascular exposures (Group A).   
Values represent the mean ± SEM of maternal pH, arterial base excess, carbon dioxide partial pressure (PaCO2), concentration of lactate and bicarbonate in the 
descending aorta for animals in the HIFU (n=5) and sham (n=6) treatment groups in each time period of the experimental protocol.  Significant differences of the effect of 
time and treatment group were assessed using a repeated measures two-way ANOVA.  No significant differences for the effect of time were found (*) but where authorised 
post hoc Sidak’s tests demonstrated a significant effect of time (†) during the experimental protocol, with relevant p numbers given in the table. 
 
 Baseline Recovery
 (-30 min)  (0 min) (15 min) (30 min) (60 min) (* time) († treatment)
HIFU 7.51 ± 0.02 7.50 ± 0.03 7.47 ± 0.03 7.49 ± 0.01 7.51 ± 0.02
Sham 7.44 ± 0.01 7.43 ± 0.01 7.42 ± 0.01 7.40 ± 0.02 
†
7.40 ± 0.02 
†
HIFU 8.2 ± 0.9 7.6 ± 0.7 7.4 ± 0.8 7.6 ± 0.8 7.2 ± 0.6
Sham 4.8 ± 1.5 5.7 ± 1.1 5.5 ± 1.0 5.7 ± 1.1 5.3 ± 1.3
HIFU 40.0 ± 1.6 42.0 ± 3.4 43.8 ± 3.7 41.8 ± 1.0 38.6 ± 2.9
Sham 48.7 ± 2.2 49.0 ± 4.0 54.3 ± 2.0 54.3 ± 1.3 
†
52.7 ± 1.8 
†
HIFU 1.2 ± 0.2 1.1 ± 0.2 1.1 ± 0.1 1.0 ± 0.1 1.1 ± 0.2
Sham 0.7 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1
HIFU 32.0 ± 1.0 31.8 ± 1.1 31.8 ± 0.8 31.7 ± 0.8 31.0 ± 1.0
Sham 30.8 ± 1.4 31.8 ± 1.4 31.8 ± 1.3 31.8 ± 1.3 31.8 ± 1.3
0.048
0.16 0.09
0.32 0.84
Treatment 
Group
p value
Variable
0.27 0.007
0.86 0.16
pH
Arterial Base 
Excess (mmol.L
-1
)
PaCO2 (mmHg)
Arterial lactate 
(mmol.L
-1
)
Bicarbonate 
(mEq.L
-1
)
Exposure Series
0.17
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Table 6.9: Maternal metabolic by-product clearance following placental vascular exposures (Group R).   
Values represent the mean ± SEM of maternal pH, arterial base excess, carbon dioxide partial pressure (PaCO2), concentration of lactate and bicarbonate in the 
descending aorta for animals in the HIFU (n=6) and sham (n=6) treatment groups.  Values for days one to five following HIFU or sham exposures (“post-operative 
recovery”) are presented as daily means; values for the “monitoring period” are presented as the mean ± SEM of five day values.  Before values given in the “monitoring 
period” were grouped into five-day means they were compared individually to each other and the baseline. Grouping them into five day means did not alter any significant 
outcomes (or lack thereof), and they are presented grouped for ease of expression.  Significant differences of the effect of time and treatment group were assessed using a 
repeated measures two-way ANOVA.  No significant differences for the effect of time were found (*) but where authorised post hoc Sidak’s tests demonstrated a significant 
effect of time (†) during the experimental protocol, with relevant p numbers given in the table.  
Baseline
1 2 3 4 Day 5 6-10 11-15 16-20 (* time) (
† treatment)
HIFU 7.47 ± 0.02 7.48 ± 0.01 7.45 ± 0.02 7.48 ± 0.01 7.48 ± 0.01 7.46 ± 0.01 7.46 ± 0.01 7.47 ± 0.01
Control 7.52 ± 0.03 7.55 ± 0.01
†
7.53 ± 0.01
†
7.55 ± 0.01
†
7.54 ± 0.02
†
7.49 ± 0.01 7.47 ± 0.01 7.50 ± 0.01
HIFU -2.0 ± 0.9 0.8 ± 0.6 0.8 ± 1.1 1.5 ± 0.6 1.3 ± 1.4 0.9 ± 0.7 1.8 ± 0.3 2.3 ± 0.5
Control 2.8 ± 2.0 4.0 ± 2.2 5.5 ± 1.3 4.0 ± 0.4 4.0 ± 0.4 3.0 ± 0.7 2.8 ± 0.5 3.9 ± 0.5
HIFU 31.0 ± 0.7 32.8 ± 1.1 33.0 ± 1.1 34.0 ± 1.1 34.3 ± 1.8 33.5 ± 0.6 35.8 ± 0.5 36.0 ± 0.6
Control 30.0 ± 0.6 29.5 ± 1.8 32.8 ± 1.1 32.3 ± 0.5 32.0 ± 2.0 32.6 ± 0.8 34.2 ± 0.7 33.4 ± 0.6
HIFU 1.15 ± 0.3* 0.63 ± 0.1 0.67 ± 0.1 0.70 ± 0.3 0.62 ± 0.1 0.56 ± 0.1 0.55 ± 0.1 0.49 ± 0.1
Control 1.11 ± 0.3*  1.00 ± 0.3 0.75 ± 0.1 0.41 ± 0.1 0.31 ± 0.03 0.54 ± 0.1 0.53 ± 0.1 0.56 ± 0.1
HIFU 21.3 ± 0.5 23.3 ± 0.8 23.0 ± 1.3 23.8 ± 0.5 23.8 ± 1.3 23.2 ± 0.6 24.3 ± 0.4 24.9 ± 0.5
Control 24.0 ± 2.2 25.8 ± 1.8 27.0 ± 1.2 25.2 ± 0.5 25.8 ± 0.6 25.5 ± 0.7 25.3 ± 0.6 26.2 ± 0.5
Treatment 
group
0.04
0.2
0.03
0.07
0.09
0.92
0.14
Post-operative recovery (day) Monitoring period (day) p value
0.07
0.2
0.03
Variable
pH
Arterial Base Excess 
(mmol.L
-1
)
PaCO2 (mmHg)
Arterial lactate 
(mmol.L
-1
)
Bicarbonate 
(mEq.L
-1
)
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6.5 Fetal metabolic by-product clearance 
In Group A fetuses, by the end of the recovery period there was a gradual 
deterioration in the fetal clearance of metabolic by-products: both PaCO2 and arterial 
lactate concentrations were elevated, leading to the development of a mixed 
metabolic and respiratory acidosis in the fetuses. There was an elevation in arterial 
base excess, but no alteration in bicarbonate concentrations.  This deterioration 
occurred at the same rate in both groups, and reached significance by the end of the 
exposure series (30 min) and continued to worsen until the end of the recovery 
period (60 min, Table 6.10), after which time the experimental protocol stopped. 
Fetuses in Group A had already developed a respiratory acidosis at the start of the 
baseline (-30 mins), which deteriorated over the subsequent 90 minutes of the 
experimental protocol (Table 6.8).  Fetuses had developed a mixed acidosis by the 
end of the experimental protocol.  The pH values did not fall to levels associated with 
fetal birth asphyxia (pH < 7.0) in either the sham or HIFU group. 
In Group R fetuses, there is evidence of a partial recovery in both groups by day one 
post-operative, as levels have improved between the end of the recovery period (60 
min) and the time of blood sampling the next morning, although there is still a 
statistically significant mixed respiratory and metabolic acidosis.  Fetuses have 
recovered to baseline by day two post-operative, and remained stable throughout the 
rest of the post-operative recovery and monitoring periods.     The arterial base 
excess and bicarbonate levels were unremarkable and stable.  There were no 
effects of treatment seen between HIFU exposed and control fetuses.  
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Table 6.10: Fetal metabolic by-product clearance during placental vascular exposures (Group A).   
Values represent the mean ± SEM of fetal pH, arterial base excess, carbon dioxide partial pressure (PaCO2), concentration of lactate and bicarbonate in the post-
ductal circulation in animals in the HIFU (n=5) and sham (n=6) treatment groups in each time period of the experimental protocol.  Significant differences of the effect 
of time and treatment group were assessed using a repeated measures two-way ANOVA.  No significant differences for the effect of treatment were found (†) but 
where authorised post hoc Tukey’s tests demonstrated a significant effect of time (*) during the experimental protocol, with relevant p numbers given in the table. 
 
Baseline Recovery
(-30 min) (0 min) (15 min) (30 min) (60 min) (* time) († treatment)
HIFU 7.27 ± 0.01 7.28 ± 0.01 7.26 ± 0.02 7.23 ± 0.01 * 7.18 ± 0.02*
Sham 7.21 ± 0.03 7.21 ± 0.02 
†
7.18 ± 0.02 
†
7.17 ± 0.02 * 7.15 ± 0.03*
HIFU -0.4 ± 0.9 -0.2 ± 0.6 -0.6 ± 0.7 -1.8 ± 0.4 -4.4 ± 0.7 *
Sham -1.2 ± 1.6 -0.8 ± 0.8 -2.2 ± 0.7 -2.3 ± 0.8 -2.5 ± 1.2 *
HIFU 62.4 ± 3.7 61.8 ± 5.5 70.4 ± 11.4 69.4 ± 7.4 77.6 ± 6.9 *
Sham 73.0 ± 4.3 76.5 ± 2.8 75.8 ± 3.5 75.3 ± 3.9 80.5 ± 5.5 *
HIFU 2.3 ± 0.4 2.2 ± 0.3 2.2 ± 0.3 2.8 ± 0.4 3.0 ± 0.4 *
Sham 1.7 ± 0.2 1.7 ± 0.2 1.8 ± 0.2 1.8 ± 0.2 2.3 ± 0.3 *
HIFU 25.6 ± 1.3 26.4 ± 0.8 25.2 ± 0.8 25.0 ± 0.6 24.6 ± 0.2
Sham 27.8 ± 1.7 28.7 ± 0.9 27.5 ± 1.3 27.7 ± 1.2 27.8 ± 0.8
0.91
p  value
< 0.0001
0.003
0.003
0.0003
0.22
0.02
0.73
0.31
0.12
PaCO2 (mmHg)
Arterial lactate 
(mmol.L
-1
)
Bicarbonate 
(mEq.L
-1
)
Arterial Base 
Excess (mmol.L
-1
)
Treatment 
group
Exposure series
Variable
pH
  
 
2
5
1
 
 
 
 
 
 
 
Table 6.11: Fetal metabolic by-product clearance following placental vascular exposures (Group R).   
Values represent the mean ± SEM of fetal pH, arterial base excess, carbon dioxide partial pressure (PaCO2), concentration of lactate and bicarbonate in the post-
ductal circulation in animals in the HIFU (n=6) and sham (n=6) treatment groups.  Values for days one to five following HIFU or sham exposures (“post-operative 
recovery”) are presented as daily means; values for the “monitoring period” are presented as the mean ± SEM of five day values.  Before values given in the 
“monitoring period” were grouped into five-day means they were compared individually to each other and the baseline (values shaded grey).  Grouping them into five 
day means did not alter any significant outcomes (or lack thereof), and they are presented grouped for ease of expression.  Significant differences of the effect of time 
and treatment group were assessed using a repeated measures two-way ANOVA.  Where authorised, post hoc Sidak’s tests demonstrated a significant effect of 
treatment (†) and post hoc Tukey’s tests demonstrated a significant effect of time (*) during the experimental protocol, with relevant p numbers given in the table. 
Baseline
1 2 3 4 Day 5 6-10 11-15 16-20 (* time) († treatment)
HIFU 7.36 ± 0.02 * 7.33 ± 0.01 7.33 ± 0.02 7.34 ± 0.02 7.33 ± 0.01 7.33 ± 0.02 7.34 ± 0.02 7.35 ± 0.02
Control 7.39 ± 0.01 * 7.37 ± 0.01 7.36 ± 0.01 7.36 ± 0.01 7.37 ± 0.01 7.33 ± 0.04 7.36 ± 0.01 7.37 ± 0.01
HIFU -1.8 ± 0.8 
†
-1.6 ± 0.7 
†
-3.2 ± 1.5 
†
-1.2 ± 2.2 -2.0 ± 1.9 
†
-1.1 ± 0.6 -0.8 ± 0.6 0.9 ± 0.5 
†
Control 3.4 ± 0.9 
†
1.2 ± 1.0 
†
2.2 ± 1.6 
†
1.6 ± 1.0 4.0 ± 0.7 
†
-0.4 ± 0.7 2.5 ± 0.6 4.4 ± 0.4 
†
HIFU 45.2 ± 1.9 * 47.6 ± 2.2 47.6 ± 1.3 49.2 ± 1.1 48.2 ± 0.6 49.8 ± 0.5 49.3 ± 0.4 50.0 ± 0.6
Control 50.7 ± 1.4 * 46.8 ± 1.7 51.7 ± 1.5 49.5 ± 0.9 52.3 ± 1.3 51.7 ± 0.9 53.8 ± 0.9 54.3 ± 0.8
HIFU 1.3 ± 0.1 * 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.2 0.9 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1
Control 1.6 ± 0.3 * 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.1 1.1 ± 0.1
HIFU 22.8 ± 1.1 
†
23.4 ± 1.0 22.4 ± 1.1 
†
24.4 ± 1.8 23.0 ± 1.4 
†
24.1 ± 0.5 24.3 ± 0.5 25.5 ± 0.6 
†
Control 28.0 ± 0.7 
†
25.8 ± 1.0 27.0 ± 1.7 
†
26.4 ± 1.0 29.0 ± 0.7 
†
24.8 ± 0.7 27.8 ± 0.6 29.6 ± 0.4 
†
0.25
0.04
0.06
0.3
0.03
Bicarbonate 
(mEq.L
-1
)
Treatment 
group
Post-operative recovery (day) Monitoring period (day) p value
<0.001
0.06
0.03
0.008
0.34
Variable
pH
Arterial Base Excess 
(mmol.L
-1
)
PaCO2 (mmHg)
Arterial lactate 
(mmol.L
-1
)
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7.1 Fetal growth  
7.1.1 Ultrasound biometry 
In Group S, fetal growth was measured non-invasively by ultrasound assessment between the 
day of exposure to HIFU or sham placental vascular occlusion and the end of the follow-up 
period, 21 days later. Baseline fetal biometry estimated by ultrasound on the day of HIFU or 
sham exposures was not different between animals in either treatment group (Table 7.1). 
 
 
 
 
 
Table 7.1 Baseline fetal biometry (Group S). 
Values represent the mean ± SD of fetal biparietal diameter, abdominal circumference and femur length measured 
by ultrasound and estimated fetal weight calculated using the Hadlock (BPD-AC-FL) formula for fetuses in the 
HIFU (n=6) and sham (n=6) groups, performed on the day of HIFU or sham exposures (day 0).  Baseline values in 
both groups were assessed using a two-tailed student’s t-test and no significant differences were found (p values 
shown). 
 
While it was not possible to perform a direct comparison between ultrasound measurements 
performed at baseline and actual fetal size, there was a strong correlation between ultrasound 
estimation of fetal biometry on the day of post mortem and the measurements taken within the 
subsequent hour at necroscopy.  The correlations of the data were: BPD, r2 0.96, p < 0.001; AC, 
r2 0.94, p < 0.001; FL, r2 0.89, p < 0.001; EFW, r2 0.77, p < 0.001.  The Bland-Altman Correlation 
plots (Figure 7.1) show that in addition to being strongly correlated, the 95% limits of agreement 
suggest a ± 5% difference between ultrasound and necroscopy measurements for BPD, AC and 
FL.  However, the EFW performed worse, with a tendency to under-estimate weight, in smaller 
fetuses particularly. 
Ultrasound measurement 
Sham 
exposed 
HIFU 
exposed p value 
Biparietal diameter (mm) 47.6 ± 5.1 47.5 ± 4.5 0.98 
Abdominal circumference (mm) 242 ± 14 233 ± 24 0.44 
Femur length (mm) 53.8 ± 9.3 45.8 ± 6.5 0.11 
Estimated fetal weight (g) 1080 ± 320 880 ± 250 0.26 
Chapter 7: Fetal growth and development 
254 
 
 
Figure 7.1 Correlation of ultrasound and necroscopy measurements of fetal biometry (Group S).   
Bland-Altman Correlation plots of the mean measurement at post-mortem of biparietal diameter (top left), 
abdominal circumference (top right), femur length (bottom left) and fetal weight (bottom right) compared to the 
ultrasound percentage difference in measurement. The dashed line represents the bias; the solid lines represent 
the 95% limits of agreement of the technique. 
 
There appeared to be a linear, rather than curvilinear, relationship between the increases in all 
four of the ultrasound measurements, relative to advancing gestational age, demonstrated by 
the scatter plots for these data in Figure 7.2a.  In order to account for the greater variation in 
gestation age at time of HIFU or sham exposure in this group (105-125 days) fetal size is also 
presented relative to time after HIFU or sham exposure and linear regression was performed on 
these values (Figure 7.2b).  Analysis of covariance (ANCOVA) of the slopes of these regression 
lines demonstrates that there is no difference between groups (BPD p=0.90, AC p=0.43, FL 
p=0.77, EFW p=0.34).  This is supported by the calculated daily growth rates over full duration 
of the 21 d follow-up period in presented in Table 7.2, which are not significantly different.  
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Figure 7.2 Ultrasound measurement of fetal growth (Group S).   
(A) Values represent actual ultrasound measurements of fetal BPD, AC, FL and EFW for animals in sham (open 
circles, n=6) and HIFU (closed circles, n=6) groups relative to gestational age on the day of assessment.  (B) 
Values represent the mean ± SD of fetal BPD, AC, FL and EFW measured by ultrasound relative to the day HIFU 
(closed circles, n=6) or sham (open circles, n=6) exposures were performed.  Linear regression lines (HIFU, solid; 
sham, dashed) are applied to these graphs.  Comparison of slopes was performed by ANCOVA analysis and 
demonstrated no significant difference; p values given in text. 
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Daily growth rate 
 Sham 
exposed 
HIFU 
exposed 
p value 
Biparietal diameter (mm.d-1)  0.9 ± 0.3 0.8 ± 0.3 0.37 
Abdominal circumference (mm.d-1)  3.0 ± 0.9 3.7 ± 0.8 0.21 
Femur length (mm.d-1)  1.7 ± 0.6 1.8 ± 0.6 0.57 
Estimated fetal weight (g.d-1)  107 ± 27 90 ± 20 0.26 
Table 7.2 Fetal growth rates (Group S).   
Values represent the mean ± SD of the calculated fetal growth rate of biparietal diameter, abdominal 
circumference, femur length (measured) and estimated fetal weight (calculated) for fetuses in the HIFU (n=6) and 
sham (n=6) groups during the 21 day follow-up period.  Rates for both groups were assessed using a two-tailed 
student’s t-test and no significant differences were found (p values shown in table). 
 
7.1.2 Size at post mortem 
In addition to estimation of fetal growth and size by ultrasound biometry, fetal size was 
measured at post-mortem in both groups where fetuses were recovered.  This confirmed that 
there were no significant differences between groups exposed to HIFU or sham placental 
vascular occlusion in the un-instrumented fetuses (Group S, Table 7.3), as suggested by 
ultrasound estimation of fetal growth (Table 7.2), or the chronically instrumented fetuses (Group 
R, Table 7.4). Notably, fetal BMI and the ratio of abdominal circumference to biparietal diameter 
(an index of asymmetric growth) were not different between groups. 
The seasonal data for the breeding flock from which the Group S and Group R HIFU ewes were 
selected was: mean gestational age at delivery: 148 d (range 145-152 d); mean birth weight: 3.9 
kg (SD 0.6 kg).  Based on this any lamb born with a weight below 2.7 kg at term would be 
classed as growth restricted.  Even given the fact that the lambs in Groups S and R were 
delivered an average of 10 days before term, no individual lamb weighed less than 2.7 kg.  
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Sham 
exposed 
HIFU 
exposed 
p value 
Maternal weight (kg) 46 ± 2.7 46 ± 1.5 0.99 
Gestational age (d) 136.5 ± 2.5 135.3 ± 2.4 0.78 
Male : female (fetus) ratio 1:1 1:2 0.26 
Fetal weight (kg) 3.8 ± 0.3 3.3 ± 0.2 0.28 
Fetal BMI (kg.m-2) 15.6 ± 0.6 16.6 ± 0.8 0.40 
Crown-rump length (cm) 49.1 ± 1.4 44.8 ± 1.5 0.10 
Biparietal diameter (cm) 6.6 ± 0.3 6.4 ± 0.2 0.66 
Abdominal circumference (cm) 30.5 ± 0.8 31.3 ± 1.1 0.58 
BPD : AC ratio 0.22 ± 0.01 0.21 ± 0.01 0.36 
Femur length (cm) 9.2 ± 0.5 8.9 ± 0.5 0.73 
Table 7.3: Fetal biometry at post-mortem (Group S).  
Values represent mean ± SEM of maternal characteristics and fetal biometry measured at post-mortem, 21 days 
after HIFU (n=6) or sham (n=6) exposure of placental vasculature and general anaesthesia.  Differences between 
groups were assessed with a two-tailed student’s t-test and no significant differences were found (p values shown 
in table). 
 
  
Sham 
exposed 
HIFU 
exposed 
p value 
Maternal weight (kg) 42.1 ± 1.5 51.3 ± 2.1 * 0.01 
Gestational age (d) 137 ± 0.2 136 ± 0.4 0.06 
Male : female ratio 2:1 1:2 0.47 
Fetal weight (kg) 3.3 ± 0.2 3.4 ± 0.1 0.58 
Fetal BMI (kg.m-2) 17.3 ± 0.8 16.4 ± 0.7 0.46 
Crown-rump length (cm) 43.2 ± 0.52 45.5 ± 0.84 0.08 
Biparietal diameter (cm) 6.3 ± 0.1 6.7 ± 0.1 0.13 
Abdominal circumference (cm) 34.4 ± 2.0 31.8 ± 0.7 0.27 
BPD : AC ratio 0.18 ± 0.01 0.21 ± 0.01 0.06 
Femur length (cm) 9.8 ± 0.2 9.2 ± 0.3 0.44 
Table 7.4: Fetal biometry at post-mortem (Group R).   
Values represent mean ± SEM of maternal characteristics and fetal biometry measured at post-mortem, 20 days 
after HIFU (n=6) or sham (n=6) exposure of placental vasculature, maternal and fetal surgery and general 
anaesthesia.  Differences between groups were assessed with a two-tailed student’s t-test and significant 
differences (denoted with *) were accepted when p < 0.05 (p values shown in table). 
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7.1.3 Organ weights 
An assessment of fetal organ growth and development was performed in Group S fetuses 
alone, as these were the only animals in which no surgical procedures were performed.  
Absolute organ weights and organ weight in relation to fetal body weight were compared 
between treatment groups, and are presented in Table 7.5. The values show no overall 
difference between groups, regardless of exposure to HIFU or not. 
  
Sham 
exposed 
HIFU 
exposed 
p value 
Brain weight (g) 46.9 ± 2.2 41 ± 2.0 0.10 
Brain : body weight ratio 12.6 ± 0.5 12.6 ± 0.9 0.99 
Brain : liver ratio 0.55 ± 0.02 0.58 ± 0.04 0.54 
Pituitary weight (g) 0.05 ± 0.02 0.07 ± 0.03 0.66 
Total lung weight (g) 76.3 ± 4.9 80.5 ± 7.5 0.67 
Lung : body weight ratio 20.3 ± 0.5 24.2 ± 1.6 0.06 
Heart weigh (g) 23.7 ± 1.7 23.3 ± 1.5 0.85 
Heart : body weight ratio 2.58 ± 0.07 2.68 ± 0.25 0.75 
Liver weight (g) 86.3 ± 4.0 82.7 ± 4.5 0.08 
Liver : body weight ratio 23.5 ± 1.8 22.1 ± 1.4 0.59 
Total adrenal weight (g) 0.66 ± 0.13 0.56 ± 0.1 0.59 
Adrenal : body weight ratio 0.18 ± 0.04 0.17 ± 0.03 0.93 
Pancreas weight 3.06 ± 0.24 2.92 ± 0.27 0.73 
Pancreas : body weight ratio 0.82 ± 0.05 0.88 ± 0.07 0.50 
Total renal weight (g) 17.6 ± 0.9 19.2 ± 1.4 0.35 
Renal : body weight ratio 4.8 ± 0.3 5.7 ± 0.5 0.05 
Total peri-renal fat (g) 11.5 ± 1.4 11.2 ± 0.8 0.87 
Peri-renal fat : body weight ratio 3.0 ± 0.2 3.4 ± 0.2 0.23 
Table 7.5 Fetal organ weights at post-mortem (Group S).  
Values represent mean ± SEM of fetal absolute organ weights and relative to body mass measured at post-
mortem, 21 days after HIFU (n=6) or sham (n=6) exposure of placental vasculature and general anaesthesia.  
Differences between groups were assessed with a two-tailed student’s t-test and no significant differences were 
found (p values shown in table). 
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7.2 Placental size and morphology 
Examination of placental size and development was performed in Group S animals.  Total 
placental weight and placentome number were not different between treatment groups.  Total 
placentome weights and numbers of placentomes within the pregnant horn of the uterus were 
comparable between both HIFU and sham exposed groups.  In both groups, assessed either by 
total placentome weight or number, there were predominantly type A or B placentomes, and the 
ratio of A/B types to C/D types was not different between treatment groups (Table 7.6). 
 
Sham 
 
HIFU  p value 
Placentome weight 
Total (g) 297.3 ± 23.0 
 
285.7 ± 21.9 0.75 
Pregnant Horn (g) 215.0 ± 17.5 
 
245.6 ± 20.2 0.32 
A or B type (g) 250.2 ± 20.1 
 
210.5 ± 25.9 0.30 
Proportion A or B type 
of total weight (%) 
85.5% ± 6.0% 
 
73.2% ± 7.0% 0.25 
C or D Type (g) 47.2 ± 20.0 
 
56.8 ± 10.0 0.70 
Proportion C or D type 
of total weight (%) 
14.5% ± 6.0% 
 
21.8% ± 5.5% 0.44 
A or B type : C or D type  
weight ratio 
15.3 ± 5.7 
 
6.5 ± 2.9 0.21 
Placentome number 
Total (g) 83.8 ± 6.2 
 
64.3 ± 4.5 0.05 
Pregnant Horn (g) 57.2 ± 5.6 
 
53.7 ± 5.5 0.69 
A or B type (g) 73.7 ± 5.9 
 
54.5 ± 5.5 0.06 
Proportion A or B type 
of total number (%) 
89.0% ± 5.4% 
 
83.5% ± 4.2% 0.49 
C or D Type (g) 10.2 ± 5.3 
 
9.0 ± 1.9 0.85 
Proportion C or D type 
of total number (%) 
11.0% ± 5.4% 
 
15.3% ± 4.2% 0.58 
A or B type : C or D type  
number ratio 
27.2 ± 14.6 
 
19.1 ± 11.9 0.71 
Table 7.6: Placentome weight and number at post-mortem (Group S). 
Values represent mean ± SEM of weight and number of all placentomes retrieved at post-mortem examination, 21 
days after HIFU (n=6) or sham (n=6) exposure of placental vasculature and general anaesthesia.  These values 
have been further subdivided by placentome type (A/B or C/D).  The weight and numbers of A/B or C/D subtypes 
are presented as mean ± SEM, and as percentages of the overall total placentome number or weight in each 
animal.  Differences between groups were assessed with a two-tailed student’s t-test and no significant differences 
were found (p values shown in table). 
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7.3 Fetal maturation 
7.3.1 Cortisol  
Fetal plasma cortisol concentrations taken under basal conditions in Group R animals were not 
different between treatment groups at either baseline (day 5) or at the end of the follow-up 
period (day 20).  However, there was a significant increase in plasma cortisol concentrations 
between 121 ± 2 days gestation age and 136 ± 2 days gestational age (Figure 7.3).  
 
Figure 7.3: Fetal plasma cortisol levels (Group R).   
Values represent mean ± SEM of fetal plasma cortisol concentration five and 20 days after surgery in HIFU 
exposed (n=6) or control (n=6) fetuses.  Significant differences: * p < 0.001 effect of gestational age, two-way 
repeated measures ANOVA with Tukey’s and Sidak’s post Hoc tests.  There was no effect of treatment. 
 
7.3.2 Fetal heart rate variability 
Fetal heart rate variability was assessed in Group R fetuses between day 3 and day 15 of the 
follow-up period.  A total of 765 fetal heart rate records were analysed (381 control; 384 HIFU).  
108 (14%) samples were taken during quite sleep and 428 (56%) were taken in active sleep.  
There was no difference between the fetal heart rate or fetal heart rate variability indices at in 
the baseline measurements (the mean of day 3-5) in either HIFU exposed or control fetuses.  
There was, however, a significant effect of sleep state on both FHR and FHRV indices in the 
baseline measurements, which was not dependant on treatment group (Table 7.7).   
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Active sleep Quiet sleep p value 
 
Control HIFU Control HIFU sleep state treatment 
Heart rate (beat.min-1) 177 ± 2 181 ± 2 172 ± 2 179 ± 3 0.02 * 0.11 
SDNN (ms) 13.2 ± 0.4 12.7 ± 0.6 7.0 ± 0.5 6.6 ± 0.3 < 0.001 * 0.38 
STV (ms) 5.6 ± 0.5 6.4 ± 0.9 2.5 ± 0.2 3.1 ± 0.2 < 0.001 * 0.21 
Total power (ms2) 185 ± 15 206 ± 19 50 ± 8 36 ± 3 < 0.001 * 0.81 
LF power (ms2) 75 ± 6 65 ± 9 9 ± 2 8 ± 1 < 0.001 * 0.32 
Normalised LF power (nu) 42 ± 1 43 ± 6 30 ± 9 26 ± 3 0.01 * 0.77 
HF power (ms2) 10.7 ± 0.6 8.3 ± 0.8 6.5 ± 0.7 5.5 ± 0.9 0.04 * 0.12 
Normalised HF power (nu) 8.7 ± 0.7 8.1 ± 1.3 7.0 ± 1.1 8.4 ± 1.5 0.15 0.60 
LF:HF power 6.0 ± 0.5 5.5 ± 0.8 1.3 ± 0.2 1.6 ± 0.3 < 0.001 * 0.91 
Table 7.7: Baseline fetal heart rate variability in quiet and active sleep (Group R).   
Values represent mean ± SEM of baseline fetal heart rate and indices of fetal HRV in quiet and active sleep in 
HIFU exposed (n=6) or control (n=6) fetuses. Significant differences: * p < 0.05 effect of sleep state, two-way 
ANOVA.  There were no effects of treatment group. 
Fetal heart rate was lower in quiet sleep compared to active sleep.  SDNN, STV, total power, LF 
and nLF power, and the LF/HF ratio were higher in active sleep.  Absolute HF power is lower in 
the quiet sleep state compared to active sleep, but there is no difference in the normalised HF 
power between sleep states.   
During the follow-up period during which fetal HRV indices were measured daily, there 
appeared to be an effect of increasing gestational age, but no apparent effect of exposure to 
HIFU on the fetuses.  In both quiet and active sleep, there was a significant decrease in mean 
fetal heart rate with advancing gestational age, and corresponding gestational-age dependent 
increases in the indices of overall variability in the fetal heart rate, SDNN and STV.  Total power 
increased with gestation in active sleep, and showed a trend to increase in quiet sleep (Figure 
7.4).  For this reason, normalised rather than absolute LF and HF power should be used to 
assess the relative contribution of the sympathetic (nLF) and parasympathetic (nHF) nervous 
systems to fetal HRV, as it adjusts for changes in total power with increasing gestational age.  
With advancing gestation, there was a significant increase in nLF power in active sleep; there 
was also an increase in nHF power in quiet sleep.  The ratio between absolute LF and HF 
powers remained unchanged with gestation (Figure 7.5).  
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Figure 7.4: Change in fetal heart rate variability indices with gestational age (Group R).   
Values represent mean ± SEM of indices of total fetal heart rate variability following HIFU (n=6) or sham (n=6) 
exposure of placental vasculature, maternal and fetal surgical instrumentation and general anaesthesia.  Significant 
differences of the effect of time and treatment group were assessed using a repeated measures two-way ANOVA.  
Where authorised, post hoc Tukey’s tests demonstrated a significant effect of time (*), with relevant p numbers given 
on the graphs. 
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Figure 7.5: Autonomic nervous system contribution to fetal heart rate variability (Group R).   
Values represent mean ± SEM of indices of the contribution of the sympathetic and parasympathetic nervous system 
to fetal heart rate variability following HIFU (n=6) or sham (n=6) exposure of placental vasculature, maternal and fetal 
surgical instrumentation and general anaesthesia.  Significant differences of the effect of time and treatment group 
were assessed using a repeated measures two-way ANOVA.  Where authorised, post hoc Tukey’s tests 
demonstrated a significant effect of time (*), with relevant p numbers given on the graphs. 
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CHAPTER 8: MATERNO-FETAL PHYSIOLOGY 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The text in this chapter is substantially based on a previously published paper, Shaw et al. 2016 
(281).  
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8.1 Maternal physiology 
8.1.1 Intraoperative 
Maternal physiology was monitored non-invasively in all animals during the intraoperative period 
to ensure the safe and effective delivery of general anaesthesia and the maintenance of 
adequate maternal cardiovascular function (as described in section 3.2.2).  Additional 
monitoring of maternal physiology was performed during the application of HIFU or sham 
treatments in Group A and S animals, to observe the potential effects of HIFU exposures on the 
ewe in addition to general anaesthesia and/or invasive surgical procedures.   
 
8.1.1.1 Acute maternal responses to HIFU (Group A) 
The maternal mean arterial blood pressure and heart rate were measured during the baseline 
recording period of the Group A animals.  Both the baseline blood pressure and heart rate were 
within the normal ranges for adult Welsh mountain pregnant sheep, although mean arterial 
pressure was lower than in un-anaesthetised sheep.  In contrast, the maternal heart rate was 
not significantly different between anaesthetised and un-anaesthetised animals (Table 5.1, 
Table 5.3).  While the normal range of mean arterial blood pressure for pregnant ewes is 
comparable to values for pregnant women, the normal range of resting heart rate is increased 
by approximately 20 beats per minute in sheep compared to humans (270, 294).  The more 
pronounced depressive effect of isoflurane anaesthesia on mean arterial pressure than heart 
rate has previously been described (167, 173, 182).  The effects of anaesthesia on maternal 
blood pressure were minimised with maternal positioning to avoid auto-caval compression and 
infusion of intravenous fluids to increase venous return, both of which were routinely performed 
in anaesthetised ewes.  Therefore, while there was a statistically significant fall in maternal 
mean arterial pressure, this was not indicative of clinically significant hypotension. 
In Group A animals, relative to the baseline recording period, maternal blood pressure and heart 
rate were stable throughout the acute experimental protocol, whether associated with HIFU or 
sham treatment (Figure 5.1). Intraoperatively, therefore, while a stable reduction in maternal 
blood pressure related to general anaesthesia, not HIFU or sham exposures, was noted, the 
more potentially clinically relevant findings were the changes in maternal uterine artery flow. 
In Group A animals, following the completion of surgery, the mean rate of uterine artery blood 
flow remained within the normal range for pregnant sheep at this gestational age:                  
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230 – 490 ml.min-1 (95% CI).  This was measured in our laboratory, using similar chronically 
implanted Transonic flow probes to measure the flow rate of uterine artery blood as were used 
in the Group A animals in this study (270).  However, in the Group A animals, there was a fall in 
uterine artery blood flow of up to 40% during the treatment phase of the acute experimental 
protocol, in both HIFU and sham exposed animals (Figure 5.3).  This resulted in a 
corresponding reduction in uterine artery oxygen and glucose delivery to the uterus (Table 6.3).   
Maternal super-oxygenation due to mechanical ventilation meant that maternal oxygen 
availability was high and stable, so even the lowest rate of intraoperative delivery of uterine 
oxygen remained within the normal range of uterine arterial oxygen delivery in the un-
anaesthetised animal (270).  Therefore, this change does not represent a hypoxic challenge to 
the fetus.   
The concentration of maternal arterial glucose showed a statistically significant reduction with 
time during the experimental protocol, unrelated to treatment group.  However, both the highest 
and lowest values still fell within the normal range for an un-anaesthetised sheep (Table 6.4), as 
did the uterine arterial rate of glucose delivery to the uterus, even during the period of lowest 
uterine flow (Table 6.3)(270).   Again, this does not represent a period of clinically significant 
glucose inavailability for the fetus. 
Hence, these reductions in uterine delivery of oxygen and glucose to the should be seen as 
secondary to the changes in uterine flow, and not a result of primary substrate inavailability.  
The reductions were also not sufficient to anticipate severe fetal compromise as a result.  There 
were no significant differences between treatment groups for any of these variables, suggesting 
that the effect was due to common feature of the experimental protocol – namely, general 
anaesthesia, maternal surgery, uterine ultrasound imaging or handling – rather than a 
consequence of the application of HIFU to placental vasculature. 
An acute, anaesthetic-related reduction in uterine perfusion, secondary to maternal hypotension 
and/or bradycardia has been previously linked to isoflurane anaesthesia in sheep (173-175, 
181-184). This response was both time- and dose-dependent. All maternal variables recovered 
to baseline in these studies, at a MAC of 1.5-2.0, within 120 minutes of start of anaesthesia 
(181, 182).  In our experiments, the start of the baseline recording period in Group A animals 
was between 125 – 180 minutes after the start of anaesthesia, and isoflurane delivery (1.5-2.5% 
inhaled concentration, equivalent to 1.4 – 2.2 MAC) remained stable throughout the 
experimental protocol.  Accordingly, maternal mean heart rate and uterine arterial blood flow 
were appeared to have recovered from any acute anaesthetic-related reaction and were within 
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normal ranges for un-anaesthetised sheep for the duration of the baseline recording period, and 
were stable during the experimental protocol as previously discussed (Figure 5.1).  Therefore, 
while autoregulatory falls in uterine arterial blood flow are described in response to maternal 
bradycardia or hypotension, this explanation does not appear to account for the fall in uterine 
arterial flow observed in Group A animals.   
As maternal surgery was also completed by the time of the baseline recording period, in which 
maternal heart rate and blood pressure were essentially normal, the preceding maternal surgery 
should not account for the changes seen in uterine artery blood flow.  Neither should exposure 
of the maternal uterus to ultrasound imaging, as this took place during the baseline recording 
period and the treatment phase, and so preceded the onset of the fall in uterine artery blood 
flow. 
In fact, the fall in uterine artery blood flow coincided with the start of the treatment phase in both 
HIFU and sham exposed animals, and recovered following the end of the treatment phase.  
This indicates the most likely cause was the uterine handling needed to alter uterine position 
and optimise the acoustic window during the treatment phase.  This was the only shared feature 
which started and stopped at those time point in both groups.  The effect of direct intraoperative 
uterine contact and handling on uterine blood flow has not been previously reported.  In our 
experiments, the reduced uterine artery blood flow was associated with an increase in uterine 
arterial vascular resistance (Figure 5.4a), which may be suggestive of localised vasospasm in 
response to uterine handling. 
This fall in uterine blood flow during HIFU or sham exposures, and the associated changes in 
oxygen and glucose delivery, therefore appears to be a consequence of the invasive 
experimental procedures required for this phase of the study protocol.  From this point of view, it 
is not clinically relevant, as the uterus would remain untouched in any potential non-invasive 
human treatment.   
While maternal oxygenation and glucose availability remained clinically stable throughout the 
experimental protocol, there was a suggestion of differences in the clearance of bi-products of 
metabolism between treatment groups.  By the end of the treatment period, and during recovery 
period (the last 30 minutes of the 90 minute experimental protocol), there was a significant 
difference in maternal PaCO2 and pH between treatment groups.  This was a subtle effect, as 
compared to baseline, neither animal group developed a statistically significant decrease in pH 
or elevation in PaCO2 (i.e. there was no effect of time).  Arterial lactate, bicarbonate 
concentration and arterial base excess remained unaffected (Table 6.8).   
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In both treatment groups, at the start of baseline maternal PaCO2 levels were elevated above 
the normal levels for un-anaesthetised sheep, and were not different to each other (Table 6.8, 
Table 6.9).  This elevation in PaCO2 would be anticipated for an ewe under prolonged 
anaesthesia, mechanically ventilated in a recumbent position from previously published 
literature, due to the accumulation of CO2 in the dead space of the lungs (182).  However, 
during the treatment period, in HIFU exposed, but not sham exposed ewes, breath holds were 
performed.  In order to maintain oxygenation during the breath holds, ewes in the HIFU exposed 
arm were pre-oxygenated by hyperventilation, between 4 and 7 times (once preceding each 
breath hold).  This did not occur in the sham exposed groups, as breath holds were viewed to 
be a part of the HIFU treatment, not an experimental procedure.  Hyperventilation is a more 
effective method of clearing CO2 from the dead-space in the maternal lungs, compared to 
standard ventilation. Therefore, in HIFU exposed animals, maternal hyperventilation would have 
allowed increased clearance of CO2 from the maternal blood, without accentuating the already 
pronounced effects of maternal super-oxygenation due to the high fraction of inspired oxygen.  
This may explain why maternal arterial pH and PaCO2 were different between treatment groups 
only after the treatment period of the experimental protocol. 
 
8.1.1.2 Acute maternal responses to HIFU (Group S) 
In Group S animals, maternal heart rate and oxygen saturation were monitored with a non-
invasive pulse oximeter. End tidal expired CO2 was monitored by capnography and uterine 
artery vascular resistance was monitored with Doppler ultrasound, which shows a significant 
correlation to absolute uterine arterial blood flow in pregnant sheep (295).  However, unlike 
Group A, in Group S preparations, the baseline monitoring period commenced only 4-7 minutes, 
not 120-180 minutes, after the induction of anaesthesia.   
Therefore, it was anticipated that there would be changes in uterine blood flow during the 
baseline (0-60 mins) and HIFU/sham exposure (60-120 mins) time periods with normalisation 
following induction of anaesthesia beginning during the recovery period (120-150 mins)(173-
175, 181-184).  This reduction in uterine flow was anticipated despite the use of maternal tilting 
to offset auto-caval compression and infusions of crystalloid fluids into the maternal venous 
circulation, but not confirmed as we did not monitor maternal blood pressure non-invasively.   
Maternal heart rate remained stable and within normal limits for an un-anaesthetised ewe 
throughout the baseline, HIFU/sham and recovery time periods (Figure 5.1b).  However, as 
maternal heart rate had remained stable and normal in Group A ewes, despite a reduction in 
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mean arterial pressure, this is not indicative of normal blood pressure in Group S ewes.   
Maternal oxygen saturation, isoflurane usage (1.5 – 2.5% inhaled concentration) and end tidal 
expired CO2 also remained stable during all 3 phases of the experimental protocol, suggesting 
that an appropriate and stable level of general anaesthesia was delivered to the ewes 
throughout the experimental protocol (Figure 6.1).  There was also no direct uterine handling.  
Matched breath holds (number, spacing and duration) and periods of hyperventilation were 
applied to both HIFU and sham exposed animals equally in this group.  
On this background, evidence of changes in uterine arterial blood flow were still seen.  There 
was an elevation in maternal UtA-PI following the induction of anaesthesia compared to values 
established in the un-anaesthetised ewe, 24 h earlier (day -1).  This elevation of PI was coupled 
with the development of mild notching in the uterine artery.  Considered together, this is 
suggestive of an increase in uterine artery vascular resistance.  The onset of these changes 
preceded the application of HIFU or sham exposures, or placement of the waterbag on the 
maternal abdominal skin.  The effects were of the same magnitude in both HIFU and sham 
treated groups (Figure 5.4b), further supporting that this was not a result of exposure to HIFU.   
The UtA-PI had normalised by the first postoperative day, compared to the day -1 value, 
measured again in un-anaesthetised ewes. Both the un-anaesthetised and anaesthetised 
values for uterine artery PI in sheep, although different to each other, agree with those 
published elsewhere, which have only reported anaesthetised or un-anaesthetised values, not 
the change between states (218, 247, 296).  This suggests that the increases in UtA-PI are a 
result of isoflurane anaesthesia, maternal positioning in a recumbent position (head down with a 
left lateral tilt), or a combination of the two.  Regardless of cause, the alterations in uterine 
artery blood were transient, and fully reversible following the removal of anaesthesia and normal 
positioning of the ewe.   
Whether this increase in resistance was sufficient to produce a clinically significant reduction in 
uterine arterial flow cannot be quantified by non-invasive measures, and uterine arterial 
notching is a risk predictor, not a diagnostic feature of utero-placental dysfunction in human 
pregnancy.  As any human HIFU treatment would not be anticipated to be performed under 
general anaesthesia, there is little clinical importance of this finding to future translational 
studies. 
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8.1.2 Post-operative recovery (Groups R and S) 
Maternal physiology was monitored for 20-21 days in Group R and S animals following 
application of HIFU or sham exposures.  In Group R ewes, this was achieved by placement of 
an arterial catheter in the descending maternal aorta.  In Group S ewes, uterine artery vascular 
resistance was monitored with Doppler ultrasound; operative time constraints prevented the 
placement of a uterine arterial flow probe in the Group R animals. Table 5.1 and Table 6.1 
demonstrate that measurements of maternal cardiovascular and metabolic variables at the end 
of the acute experimental protocols in Group A and R were not significantly different, with the 
exception of maternal blood pressure, as expected given the previous discussion.  Hence, 
findings of Group A and R, while not derived from the same animals, can be considered relative 
to each other.   
In Group R, maternal mean arterial blood pressure recovered quickly to a stable level following 
reversal of isoflurane anaesthesia and showed no further changes or effect of treatment over 
the post-operative period in Group R animals.  Maternal mean arterial pressure and heart rate 
were within the normal ranges for adult Welsh mountain pregnant sheep (270, 294) for the 
duration of the post-operative recovery (Figure 5.2).   
There were no differences observed in maternal oxygenation, haemoglobin, glucose or lactate 
arterial concentrations between the treatment groups for the duration of the follow-up period.  
There were also no differences in maternal PaCO2, arterial base excess, arterial bicarbonate or 
lactate concentrations between treatment groups.  The differences in maternal pH between 
treatment groups days 2-5 post-operative, again while statistically significant are not of clinical 
concern.   All maternal pH values remained within the range expected for adult sheep, and do 
not represent respiratory or metabolic disturbances, based on the normality of the other 
variables.  There was a transient increase in arterial lactate noted on day one post-operative in 
keeping with recovery from a period of fasting for surgery, which was not different between 
groups, and not sufficient to produce metabolic acidosis, or require renal buffering. 
In Group S, non-invasive monitoring suggested that the uterine artery vascular resistance was 
normalised within 24 hours of the end of the period of general anaesthesia, both in terms of 
uterine artery PI (Figure 5.4b) and absence of notching in the pattern of flow, and remained 
stable for the remainder of the follow-up period.  There was no significant change with 
advancing gestational age, in keeping with previously published values (247)  
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Together, these observations suggest that HIFU exposures did not compromise maternal 
physiology during the recovery period.  Overall, both sham and HIFU exposed animals 
recovered well from a variable combination of general anaesthesia, surgery and HIFU occlusion 
of placental vasculature. 
 
8.2 Fetal physiology 
8.2.1 Intraoperative 
Fetal physiology was monitored in the intraoperative period and during the application of HIFU 
or sham treatments in Group A (invasive monitoring) and Group S (non-invasive) fetuses.   
 
8.2.1.1 Acute fetal responses to HIFU (Group A) 
The fetal heart rate and mean arterial pressure were within normal ranges during the baseline 
recording period of the acute HIFU experimental protocol (Group A) for fetal Welsh mountain 
sheep at this stage of gestation (279).  While the normal range of mean arterial blood pressure 
for fetal sheep is comparable to preterm and term human values at birth (297, 298), the normal 
range of resting heart rate is increased by approximately 20 beats per minute in sheep 
compared to the human fetus at a comparable gestational age (132, 279).  
In Group A fetuses, unlike the ewes, mean post-ductal arterial blood pressure was not reduced 
by the effect of general anaesthesia, and was increased in the sham exposed fetuses.  
Conversely, the fetal heart rate showed a decrease in rate in both the HIFU and sham treated 
groups compared to un-anaesthetised fetuses (Table 5.2, Table 5.4), suggestive of the known 
effect of isoflurane type anaesthesia to depress fetal left ventricular cardiac output, certainly by 
reducing heart rate, and potentially by reducing fractional shortening of the left ventricle (168, 
299).  Regardless, fetal mean arterial blood pressure and heart rate remained stable throughout 
the acute experimental protocol and the application of sham or HIFU exposures (Figure 5.5). 
Fetal haemodynamic function appeared to be normal during the baseline recording period in 
Group A animals, even after the preceding period of anaesthesia and invasive surgery, apart 
from an increase in femoral vascular resistance, a marker of peripheral vascular resistance 
(Table 5.5).  The elevation of femoral vascular resistance occurred in both groups, and the 
magnitude of increase was greater in the sham exposed group.  This increase in peripheral 
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vascular resistance is the most probable cause of the elevation in fetal mean arterial pressure 
observed in the sham exposed Group A animals.  It is unclear why this response should be 
more pronounced in sham exposed animals compared to HIFU exposed animals.  During this 
period, there was no evidence of central redistribution of the fetal circulation, as carotid arterial 
blood flow and vascular resistance remained within normal range, as did the ratio of carotid to 
femoral blood flow, a suggested index of brain sparing in fetal sheep (269, 300). 
In the period of application of HIFU or sham exposures to the uterus, coinciding temporally with 
the reduction in maternal uterine arterial flow, there was a further increase in fetal femoral 
vascular resistance.  There was a corresponding decrease in femoral arterial blood flow, which 
persisted beyond the recovery of the maternal uterine arterial flow to its baseline flow rates.  
There was no change in fetal carotid artery blood flow or vascular resistance during this time 
(Figure 5.7).  These responses were not different between treatment groups, and the only 
feature of the experimental protocol introduced at this time which was common between the two 
groups, as previously discussed, was the period of gentle uterine handling. 
This differential effect on two elements of the ‘fetal brain sparing’ response can be explained, as 
this was a non-hypoxic challenge to the fetus (Table 6.5).  Fetal peripheral vasoconstriction, 
although classically understood as part of the fetal brain sparing response to acute hypoxia 
(300), can also result from fetal acidosis in the absence of fetal hypoxia (190), primarily 
mediated by the sympathetic nervous response and maintained by endocrine-mediated fetal 
stress responses (191).  Cerebral vasodilatation in response to acute hypoxia is under 
paracrine, rather than systemic, control, and so functionally separated from the mechanisms of 
peripheral vasoconstriction (300).  Peripheral vasoconstriction has been described in sheep 
fetuses as a response to reduced uterine blood flow in the absence of fetal hypoxia (189).  An 
increase in umbilical arterial vascular resistance, and a redistribution of blood to the fetal brain, 
as a result of uterine surgery in human pregnancy (a non-hypoxic insult) has also been 
described (188). 
Isoflurane sedation does not alter the capacity of fetal sheep to redistribute cerebral and 
systemic blood flow in response to reduced utero-placental flow or the development of acidosis 
(184).  Given that the delivery of oxygen and glucose to the fetal brain by the carotid artery was 
preserved within normal limits for the duration of all experiments in Group A animals, hypoxia-
induced cerebral vasodilatation would not be expected.  Therefore, the increase in the ratio of 
the carotid to femoral blood flow in the fetus is secondary to the fall in femoral blood flow, not an 
indication of a classical brain-sparing redistribution of the fetal cardiac output in response to 
acute fetal hypoxia being represented by cerebral vasodilatation and peripheral vasoconstriction 
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(301).  Therefore, the increased peripheral vascular resistance is most likely as a result of 
increased sympathetic outflow, potentially as a result of the changes in maternal uterine artery 
blood flow.  
Although fetal oxygenation remained within normal limits for the duration of the procedure, there 
was a gradual reduction in the fetal PaO2, the saturation of oxyhaemoglobin, and delivery of 
oxygen to the brain between the baseline and recovery periods.  These changes were not 
different between HIFU and sham groups and most likely represent fetal deterioration under 
anaesthetic rather than an effect of HIFU exposures.  With increasing duration of anaesthesia, a 
mixed respiratory and metabolic fetal acidosis still developed.  Placental transfer of oxygen 
relies on the double Bohr effect, where elimination of CO2 from the fetal circulation drives 
maternal oxyhaemoglobin dissociation and increases the affinity of fetal haemoglobin for 
oxygen (302).  Anything that reduces fetal elimination of CO2, resulting in a fetal respiratory 
acidosis, paradoxically reduces the availability of maternal oxygen at the placental interface.   
Carbon dioxide is generated by the fetus at a steady rate and is eliminated from the fetal 
circulation by diffusion across the placenta (303).  Elevated maternal PaCO2 causes steady 
state equilibration (Fick’s first principle) to reset to a higher baseline, eliminating less CO2 from 
the fetus (303).  Although there was no increase in maternal PaCO2 observed during the 
experimental protocol, the maternal baseline values were above the normal range for non-
anesthetised sheep.  Ventilating sheep in the recumbent position and their increased alveolar 
dead space compared to humans make CO2 elimination from the sheep lungs less effective 
under anaesthesia (304-306), resulting in a mild maternal respiratory acidosis, as previously 
described.  In our animals, mechanical ventilation was used to maintain the ewes in an 
isocapnic state despite the need for periods of breath holding, although as previously 
discussed, the periods of hyperventilation in the HIFU-exposed ewes conferred an advantage in 
this regard, compared to sham-exposed ewes. This likely accounts for the differences in pH 
(and in PaCO2, although this did not reach significance) seen between sham and HIFU exposed 
fetuses during the treatment period of the acute experimental protocol, where the sham fetuses 
experienced a more rapid fall in pH than the HIFU exposed fetuses. 
The placental exchange rate of CO2 is also affected by the supra-physiological PaO2 in the 
mother and fetus.  The Haldane effect describes the increased capacity of deoxygenated 
haemoglobin to buffer CO2 compared to oxygenated haemoglobin (307), and this has been 
calculated to account for 46% of placental CO2 exchange (303). The artificially elevated 
concentrations of oxygenated haemoglobin in both mother and fetus reduce the magnitude of 
the Haldane effect in this setting, and so further reduce the fetal elimination of CO2.  Diffusion of 
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CO2 across the placenta is limited by uterine blood flow (304) because it is highly soluble (307).  
Therefore, the additive effects of reduced uterine artery blood flow during the period of uterine 
manipulation may accelerate the increase in fetal CO2 accumulation.   
Decreases in fetal pH in our results were likely further augmented by the fetal peripheral 
vasoconstriction that they caused.   Lactate is a product of anaerobic respiration and is 
produced in greater quantities by the under-perfused fetal tissues during peripheral 
vasoconstriction, particularly by the muscle bulk of the hind limbs (308, 309).  In our study, it 
increased by the recovery period of the experiment, potentially contributing to a mixed 
respiratory and metabolic acidosis.   
A progressive fetal respiratory acidosis and falling PaO2 has been reported in the anaesthetised 
fetus regardless of concomitant operative or experimental procedures (181, 182), and the 
PaCO2 at the end of our recovery period is comparable to other published values for this 
duration of isoflurane anaesthesia (Appendix I).  It could be suggested that these changes in 
fetal pH, as a result of anaesthesia, are the likely underlying mechanism explaining the trend to 
reduced fetal oxygenation seen in our studies, and the activation of the sympathetic nervous 
system to produce peripheral vasoconstriction.   
Collectively, these findings suggest that the effects of placental HIFU or sham exposures on the 
fetal physiology were the result of responses to a uterine vasospasm and the need for 
mechanical ventilation and general anaesthesia, rather than to a period of acute feta hypoxia, or 
to HIFU exposures themselves.  
 
8.2.1.2 Acute fetal responses to HIFU (Group S) 
On the day preceding HIFU or sham exposures, in un-anaesthetised sheep the mean ± SD 
umbilical artery PI was 1.0 ± 0.2 in the HIFU group and 0.9 ± 0.1 in the sham group.  These 
values are consistent with both expected ranges from published sheep literature and human 
pregnancy at a corresponding gestational age (247, 310).   The mean ± SD of the fetal middle 
cerebral artery PI was 1.7 ± 0.2 in the HIFU group and 1.6 ± 0.1 in the sham group (Figure 5.9).  
These were again consistent with the expected ranges from human pregnancy at a 
corresponding gestational age (222, 226); there is no published data on the expected ranges in 
sheep. 
Following the induction of anaesthesia in Group S animals, there was an increase in UA-PI, 
which reached significance before the application of either HIFU or sham exposures of placental 
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vasculature, and continued to rise for the duration of the general anaesthesia.  There was also a 
decrease in MCA-PI which reached significance at the start of the HIFU or sham exposure 
period and persisted beyond the reversal of anaesthesia.  These responses were equal 
between treatment groups. 
The timing the increase in resistance in the umbilical circulation matches the timing of the 
increase in resistance to flow in the maternal uterine artery seen in Group S ewes, which has 
previously been discussed as a feature of isoflurane anaesthesia.  This response was similar to 
Group A fetus, where changes in maternal uterine vascular resistance produced changes fetal 
femoral vascular resistance. Changes in fetal total peripheral resistance have contributions from 
the systemic vasculature, of which femoral vascular resistance is a measure, as well as from the 
umbilical-placental vascular bed, of which umbilical artery Doppler PI is a non-invasive measure 
(311).  The umbilical and femoral vascular beds are both sensitive to vasoactive hormones of 
the sympatho-adrenal and renin-angiotensin systems (312).  For this reason, it could be 
suggested that in the absence of pre-existing utero-placental dysfunction, invasively measured 
changes in fetal femoral artery vascular resistance should be mirrored by changes in non-
invasively calculated umbilical artery PI, especially if the causative mechanism of the changes is 
circulating vasoactive hormones. 
However, unlike Group A animals, where there was no change in carotid blood flow in response 
to either anaesthesia or HIFU, MCA-PI suggests cerebral redistribution in Group S animals 
during anaesthesia.  While direct observation of arterial oxygenation was not performed in the 
Group S fetuses, extrapolation from the values for arterial oxygen content and tissue delivery in 
the Group A fetuses (Table 6.7) would indicate that this was a non-hypoxic period. Therefore, 
the changes in Group S fetuses appear to simulate classic findings in utero-placental 
dysfunction and fetal redistribution of blood flow preferentially to the central organs, despite 
hypoxia not being the underlying cause.  This pattern of central redistribution of blood in 
response to EXIT surgery, in which the fetus was not hypoxic, has been described in humans 
(188). 
It is possible that these fetal defence mechanisms were a response to the reduction in fetal 
heart rate and depression of cardiac function observed by fetal echocardiography in Group S 
fetuses.  Pre-operatively, in un-anaesthetised fetuses, the values obtained for ductus venosus 
PIV, left ventricular MPI, FS and EF were broadly comparable to expected values of human 
fetuses at a comparable gestation (235, 249-252, 255) and sheep (240).  However, while 
anaesthesia alone did not result in a significant reduction in left ventricular ejection fraction or 
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fractional shortening, it was sufficient to increase left ventricular MPI and ductus venosus PIV 
during anaesthesia, both markers of decompensation and congestive failure of the fetal heart.  
This effect was not different between HIFU or sham treated animals (Figure 5.10), but coupled 
with the reduction in fetal heart rate would reflect a likely reduction in fetal combined cardiac 
output in both treatment groups.  Just as birth asphyxia is recognised to be predominately 
secondary to failure to deliver oxygen to the fetal brain rather than primary deficit in oxygen 
availability (313), a reduction in fetal cardiac function may have been sufficient to initiate 
redistribution of blood flow to the fetal brain.  
Collectively, these findings suggest that the effects of placental HIFU or sham exposures on the 
fetal physiology were the result general anaesthesia, rather than of HIFU exposures 
themselves.  
 
8.2.2 Post-operative recovery 
Fetal physiology was monitored for 20-21 days in Group R and S animals following application 
of transdermal HIFU or sham exposures (Group A animals were not recovered from 
anaesthesia).    
In Group S animals, the umbilical artery, middle cerebral artery and ductus venosus Doppler 
PI(V)s and fetal echocardiography were used to monitor the feto-placental circulation after 
completion HIFU and sham exposures and reversal of anaesthesia.  
In Group R animals, this was achieved by placement of a descending aortic (post-ductal) 
arterial catheter and Transonic femoral arterial flow probe.   Operative time constraints 
prevented the placement of a carotid arterial flow probe and ascending aortic (pre-ductal) 
catheter in Group R animals.   
 
8.2.2.1 Group R fetuses 
The main change in the fetal circulation observed in Group A animals was the increase in fetal 
femoral vascular resistance.  In Group R, fetal femoral vascular resistance was also elevated 
following reversal of anaesthesia (Table 5.2), and remained significantly elevated for the first 24 
hours in HIFU exposed or control Group R fetuses.  After this, femoral vascular resistance fell 
back towards baseline until the fifth postoperative day, and the rate or recovery was not 
different between treatment groups (Figure 5.8).  It then remained stable, and within normal 
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ranges for gestation, while femoral arterial blood flow and amplitude of flow showed increases 
with gestational age in keeping with previous longitudinal studies (269).  It is not possible to 
comment on carotid arterial flow, as flow probes were not placed in Group R animals.  
When the fetal heart rate and blood pressure at the end of the experimental protocol in Group A 
animals was compared to the heart rate in fetuses immediately following the reversal of 
anaesthesia, there are no differences (Table 5.2).  Fetal heart rate and blood pressure were not 
different between treatment groups at any point in Group R animals, and fell within normal 
ranges for gestation.  It is well established that fetal arterial blood pressure and heart rate falls 
with increasing gestational age (314-320), and this occurred in Group R fetuses (Figure 5.6).  
As discussed above, in Group A animals by the end of the recovery period, there was a 
reduction in the partial pressure of fetal arterial oxygen, a mixed respiratory and metabolic 
acidosis, and evidence of haemoconcentration.  Table 6.2 shows that in the Group R fetuses, 
soon after reversal of anaesthesia, that the pH was higher, and the PaCO2 and haematocrit 
were lower.  Fetal PaO2 and saturation of oxyhaemoglobin were not different between groups, 
and both were normal values.  The difference in median duration of anaesthesia in these two 
groups was 10 minutes (Table 5.2) so this is unlikely to account for these differences; similarly, 
the number of placental vessels occluded was comparable between Groups A and R.  It is 
possible the Group R fetuses were in better condition due to the placement of less arterial 
catheters and flow probes than in Group A fetuses, or that these changes represent rapid 
clearance of fetal CO2 following reversal and anaesthesia and re-establishment of spontaneous 
maternal ventilation in the standing position. 
There are still statistically significant differences in fetal pH, PaCO2 and lactate on the first post-
operative day.  These values are not different to baseline and stable from the second day 
onwards.  Fetal PaO2, saturation of oxyhaemoglobin, glucose concentration, and femoral arterial 
delivery of oxygen and glucose are all normal compared to baseline on the first post-operative 
day.  Femoral arterial oxygen and glucose deliveries show gestational age-related increases, in 
line with the increases in femoral arterial blood flow. 
Hence it appears that resolution of the fetal defence responses, and the consequences of 
general anaesthesia, noted in Group A animals were also present in Group R animals following 
the reversal of anaesthesia.  These responses recovered quickly and equally in both HIFU 
exposed and control animals.  The expected ontogenic changes in fetal heart rate, blood 
pressure and femoral blood flow and substrate delivery were seen in both treatment groups, 
indicating.  Hence there is no evidence of chronic fetal cardiovascular compromised or fetal 
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distress.  This is despite the fact that fetuses in the HIFU treated group were exposed to HIFU 
placental vascular occlusion and a longer duration of anaesthesia than fetuses in the control 
group, so could have been expected to have a different recovery profile.   
 
8.2.2.2 Group S fetuses 
The main change in fetal Doppler studies observed intra-operatively in Group S fetuses was an 
elevation of UA-PI and reduction in MCA-PI, leading to a fall in CPR. 
Following the reversal of anaesthesia, the UA-PI remained significantly elevated for the first 24 
hours following HIFU or sham exposures.  It returned to baseline over the next four days at the 
same rate in both treatment groups. Following this, umbilical artery Doppler PI showed a 
tendency to decrease with increasing gestational age following HIFU of sham exposures of 
placental vasculature, but which like other published values did not show a significant fall in PI 
at this stage of gestation (205, 247).  The values themselves agree well with expected values 
for sheep fetuses of a comparable gestational age and human fetuses in the third trimester 
(310).  This suggests that there was no clinically significant utero-placental dysfunction acquired 
as a result of the HIFU occlusion or sham exposures of placental vasculature. These findings 
also suggest that the resolution of increased fetal peripheral resistance occurred in a stepwise 
fashion, over the following three to four days, before stabilising at values typical for this stage of 
gestation in un-anaesthetised sheep (205).  This is in keeping with the resolution of a response 
mediated by vasoactive hormones, rather than progressive fetal deterioration.   
Redistribution of blood to the fetal brain as indicated by the reductions in MCA-PI and CPR also 
continued for 3 days, before they were restored to typical values for human pregnancy at a 
comparable gestational age, and remained stable (222); there are no published longitudinal 
values for sheep against which to compare.  The magnitude or duration of this redistribution 
was not different between treatment groups.  While not directly comparable, there was no 
evidence of fetal hypoxia in Group R animals over this same time period, so the underlying 
cause of this apparent vasodilatation of the cerebral vasculature again appears to be non-
hypoxic, but unknown.  Due to the lack of carotid artery flow probes it was not possible to 
correlate MCA Doppler changes between Group R and S animals. 
While under general anaesthesia, there was also evidence of reduction in fetal cardiac function, 
with a lower LV-MPI and DV-PIV.  DV-PIV was recovered by the first day post procedure, LV-
MPI by the second.  However, for the first 1-4 days post procedure in Group S fetuses, the LV-
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EF and LV-FS were increased (Figure 5.10), without a corresponding increase in fetal heart rate 
(Figure 5.5).  In terms of timescale, these changes match the period during which an increase in 
peripheral resistance and central redistribution of blood is observed in the fetus (Figure 5.7, 
Figure 5.9).  This may represent a cardiac contribution to the maintenance of cardiovascular 
defence mechanisms, although the effectiveness of increasing stroke volume compared to heart 
rate is thought to be minimal (321, 322).  However, recently, two studies of pre-labour cardiac 
function showed that human fetuses with a lower left ventricular cardiac output were more likely 
to develop fetal compromise in response to uterine contractions.  These fetuses also had the 
lowest CPRs (323, 324).  This suggests, at least in principle, a higher left ventricular cardiac 
output is beneficial to a fetus undergoing stress and maintaining cerebral redistribution.  
Regardless, these changes recovered within four days of the exposure to HIFU or sham, and all 
indices of cardiac function remained stable for the remained of the follow-up period. 
Overall, therefore it seems that the fetus can withstand appropriately the challenges of 
anaesthesia, surgery and of HIFU, and recover rapidly from these events without impact on fetal 
cardiovascular function or metabolic status.  It should be noted that the sheep fetuses were 
healthy and that the effects on an already compromised fetus with reduced capacity to tolerate 
intrauterine insults may be different, for example a fetus already affected by TTTS.  However, 
one aim of developing a non-invasive method to divide fetal circulations is to reduce the risks 
associated with the invasive nature of current therapies and to allow earlier intervention before 
such fetal compromise occurs. 
 
8.3 Fetal growth and physiological maturation 
We were able to assess fetal growth velocity in Group S animals by performing non-invasive 
ultrasound measures of fetal biometry.  These studies demonstrated not only consistent growth, 
which did not differ between treatment groups, but also a linear trend in the pattern of growth 
(Figure 7.2).  This is comparable with other invasive and non-invasive measures of fetal growth 
reported which show a linear pattern of growth in sheep towards the end of gestation, rather 
than the curvilinear trends more familiar from human pregnancy (203, 325), a pattern which 
itself has recently been questioned (326).  While standard ultrasound measures of fetal 
biometry in sheep are not commonly used, they are described in sufficient detail for use in a 
reproducible fashion.   
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Furthermore, comparison of post-mortem biometry and ultrasound biometry taken on the same 
day in this study showed a high level of agreement (Figure 7.1).  While there was a tendency to 
underestimate fetal weight by the formulae used, particularly in lower weights, this is a known 
feature of Hadlock fetal weight estimation (200).  Therefore, while a system optimised for 
human use might be expected to perform poorly in sheep, the Hadlock formula still 
outperformed other formulae suggested for specific use in sheep (203). 
The rate of fetal growth in late gestation is known to be affected by under or over production of 
cortisol and its effect on nutrient transfer across the placenta to the fetus (325, 327). Combined, 
the maintenance of normal growth rate with normal gestational changes in fetal plasma cortisol 
(Figure 7.3) and stable glucose availability (Table 6.7) strongly suggests that sufficient nutrient 
transfer across the placenta to meet the fetal requirements was maintained until the time of 
post-mortem.  In addition, there was no evidence of hypoxaemia in the post-ductal circulation 
(Table 6.7) during the follow-up period, again consistent with the conclusion that no utero-
placental dysfunction was induced by HIFU occlusion of placental vessels, or by any other 
experimental procedure performed in Group R or S animals. 
These findings are supported by comparison of post mortem biometry between treatment 
groups in fetus after 20-21 days of follow-up, which showed that there was no difference in fetal 
weight, biometry, fat deposition or asymmetric growth at the time of post-mortem (Table 7.3, 
Table 7.4).  While the onset of adverse intrauterine conditions from early or mid-gestation in 
fetal sheep is well documented to produce a reduction in fetal body weight (328), even 
apparently significant hypoxic insults in late gestation do not always produce this outcome, 
although they are associated with asymmetric growth (268, 328, 329). 
In Group S, the only animals in which this was measured, showed no differences in absolute 
fetal organ weights or organ weights as a proportion of total body weight.  Notably, there was no 
difference in adrenal to body weight ratio (Table 7.5), which has previously been shown as the 
result of short term (3 days) reductions in umbilical artery blood flow (329).  Given the transient 
findings on Doppler ultrasound of redistribution of blood to the fetal brain and an increase in 
utero-placental resistance, these findings suggest that the degree of the fetal insult was not 
sufficient to result in any changes in the growth pattern of the fetus or fetal organs.  This again 
supports the idea that there was adequate placental function to maintain fetal growth and 
development until the time of post mortem.  
In the sheep, placental cotyledonary number reaches its maximum at 40 days of gestation; 
placental weight is maximal at 70 days (330).  After this time, placental weight is maintained 
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until term (331) although remodelling of placentome types can occur to match fetal needs and 
intrauterine events (332). Placentome morphology is assessed with respect to the degree of 
eversion of the fetal portion in respect to maternal tissue, and classified as type A (least 
eversion) to D (most eversion) (160).  Towards term, there is a natural reduction in the 
proportion of type D placentomes resulting from the natural rise in fetal plasma cortisol levels, 
which is thought to increase glucose delivery to the fetus (327). Adverse intrauterine conditions, 
such as maternal under or over nutrition, hypoxaemia, reduction in umbilical blood flow, heat 
exposure and alterations in the activity of cortisol and the renin-angiotensin system have also 
been shown to influence placental weight and morphology at term (329, 333-337) although 
results are contradictory as to whether the proportion of type A or type D placentomes are 
increased by a fetal challenge in late gestation (327, 329).   
Reassuringly in Group S animals, the total placental weights were comparable, and the 
proportion of type A/B and type C/D placentomes were not different between treatment groups, 
either in terms of number or weight (Table 7.6), similar to previously reported findings for this 
sheep breed (329). This is potentially unexpected as ablation of six placentomes and occlusion 
of the blood flow arising here could represent up to a ten percent loss of placental mass, and it 
might be reasonable to expect some degree of compensation for this loss of blood supply and 
surface area within the placentome system.  This is one area where the sheep placental model, 
while a good anatomical model of anastomoses in the human monochorionic placenta, is a 
poorer model of the haemodynamics of twin pregnancy: ideally following occlusion of placental 
anastomoses the circulation of each twin remains intact with no loss of placental supply.  
However, it is reassuring to demonstrate that even in the presence of loss of up to 10% of the 
placental blood supply there is no obvious detrimental effect on fetal growth or placental 
function.  Of course, it should be noted here again, that these were healthy sheep and 
placentae without pre-existing compromise and the situation in a fetus affected with TTTS may 
ultimately be different. 
In addition to monitoring for gross differences in placental morphology, fetal growth and relative 
organ size, we also investigated directly for evidence of fetal stress.  Elevated fetal plasma 
cortisol has been reported in sheep fetuses undergoing chronic stress, such as chronic 
intrauterine hypoxia (338, 339), which is implicated in the persistence of peripheral vascular 
resistance (301).   In Group R animals, we could compare fetal plasma cortisol on day five 
postoperative, after surgical recovery was completed and all cardiovascular and metabolic 
variables were normal and stable.  At this stage of gestation, fetal plasma cortisol 
concentrations would still be low, before the cortisol surge that triggers parturition in sheep had 
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occurred.  Accordingly, fetal plasma cortisol levels at this time were around 10 ng.ml-1, typical 
for this gestation (340) and not different between treatment groups, suggesting good recovery 
from surgery in both groups.  At the time of post mortem, 15 days later, cortisol levels were 
higher, as expected in preparation for delivery, but were again not different between groups.  
The rise in endogenous cortisol levels approaching term underlies the increase in arterial blood 
pressure observed in sheep fetuses in late gestation as the sympathetic nervous system 
matures and begins to establish resting tone (341, 342) and alterations in feta plasma cortisol 
levels or the activity of the renin-angiotensin system disrupt this pattern of change (340).  
Accordingly, we could demonstrate progressive increases in mean arterial blood pressure in 
both treatment groups in fetuses in Groups R (Figure 5.6).  Combined, these findings again 
support the theory that HIFU occlusion of placental vasculature caused no chronic fetal stress in 
the treated group, and that in fact both groups had recovered well from surgery and tolerated 
chronic instrumentation well for the duration of the follow-up period.   
Finally, the presence of arterial catheters and flow probes allowed the examination of beat-to-
beat variation in fetal heart rate to assess the function of the autonomic nervous system in the 
control of the heart rate (139, 140, 343).  Fetuses were predominantly in an active sleep state, 
which was expected from the observed distribution of fetal behaviour states at these gestational 
ages (344).  Fetuses were highly comparable between treatment groups in both active and quiet 
sleep (Table 7.7). 
Overall variability in the fetal heart rate was greater in active sleep, denoted by a higher mean 
SDNN and STV in active sleep.  Active sleep appears to be a sympathetically dominant state 
with elevated absolute and normalised LF power compared to the quiet sleep state; the higher 
ratio of LF to HF power in active sleep also demonstrates this sympathetic dominance.  Quiet 
sleep appears to be a parasympathetically dominant state.  However, this appears to be due to 
withdrawal of sympathetic stimulation rather than parasympathetic nervous system activation, 
as there is no change in normalised HF power between the sleep states.  Given the large 
difference in total power between sleep states, this would be expected to provide a more 
comparable measure of the influence of the parasympathetic nervous system between sleep 
states as it adjusts for the differences in total power (Table 7.7). 
During the follow-up period, there were no significant effects of treatment group for any variable 
of fetal heart rate variability, in either quiet or active sleep states (Figure 7.4, Figure 7.5).  
Appropriate gestational age-related increases were seen in overall variability (SDNN), the 
parasympathetic (nHF) and sympathetic (nLF) nervous systems contribution to fetal heart rate 
variability as both systems matured in the fetuses approaching full term.  The STV also 
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increased in the Group R fetal sheep, in line with expected values from human pregnancy at 
this gestation (132).  These increases can be impaired by fetal growth restriction, and a 
persistent reduction in STV is a strong indicator of fetal compromise (130), with lower heart rate 
variability in FGR fetuses resulting from sympathetic suppression (133, 135-138).  In 
experimental fetal sheep, chronic hypoxia has been suggested to decrease the overall fetal 
heart rate variability, the STV and the sympathetic nervous system contribution to control of 
fetal heart rate variability (345).   
In the present study, there were no changes indicative of chronic stress seen in the animals 
treated with HIFU.  This agrees well with the findings of fetal plasma cortisol and normal 
ontogenic changes in fetal heart rate, fetal arterial blood pressure and regional blood flow.  This 
suggests, in these fetuses, that the normal pattern of neuro-endocrine development was not 
affected by the experimental procedures performed, or the application of HIFU to occlude the 
placental vasculature. 
Together, features of consistent fetal growth, normal fetal body size and organ weights at post 
mortem and an absence of several independent non-invasive and invasive markers of chronic 
fetal stress provide robust evidence to support that HIFU mediated placental vascular 
occlusions did not result in fetal compromise. 
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This thesis demonstrates that it is possible to occlude placental blood vessels in the pregnant 
sheep using non-invasive HIFU.  Using an iterative experimental design, we have developed 
and refined a transuterine, then a transdermal, treatment protocol to deliver HIFU energy into 
the intra-uterine space, and occlude target placental blood vessels.   
This study shows the feasibility of using ultrasound as the imaging modality for vessel targeting 
and monitoring treatment responses.  The final treatment protocol, used in Group R animals, is 
not yet necessarily fully optimised for use in sheep, and is not optimised for use in human 
pregnancy.  However, to date, it is the first reported use of ultrasound-guided HIFU to 
selectively occlude placental blood vessels. 
Table 9.1 summarises the key findings of the study which specifically demonstrate the feasibility 
and efficacy of HIFU as a method of non-invasive placental vascular occlusion.  These points 
align to the first hypothesis of the thesis (section 2.2).  The occlusion rate in placental blood 
vessels when transdermal HIFU was applied (as it would be in any potential human therapy) 
was 97% in the most refined version of the treatment protocol.  There was histological evidence 
that the resultant vascular occlusion persisted for at least 21 days, with changes indicative of 
fibrosis obliterans in 75% of vascular targets. 
Colour flow Doppler ultrasound was also shown to be an accurate method of targeting vascular 
targets, and confirming occlusion non-invasively.  This is of direct clinical relevance, as the only 
imaging modality which has been used to identify vascular anastomoses in the human 
monochorionic placenta is ultrasound.  Therefore, the imaging modality planned for HIFU 
guidance in any potential human treatment is ultrasound.   
While the efficacy off occlusion appears high in this animal model, the nature of the sheep 
placenta allowed a multitude of targets, from which the easiest could be selected.  However, in 
a clinical setting, the AVAs causative of TTTS need to be occluded, not simply the easiest 
vessels to target.  Therefore, there still needs to be prospective evaluation of the feasibility of 
using HIFU to (i) occlude human placental blood vessels, and (ii) occlude selected blood 
vessels in the monochorionic placenta. 
This evaluation will need to include equipment and treatment protocol adaptions to (in outline): 
(i) Improve the quality of the imaging to the expected standard for human obstetric 
applications; 
(ii) Address the bioengineering requirements of the transducer, which will need to have a 
larger central aperture, longer focal length but retain a small and precise focal zone; 
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(iii) Improve the user interface and system control software to be a more robust system with 
introduction of automated safety checks prior to the firing of HIFU; and 
(iv) Use a more adaptive gantry apparatus to stabilise the HIFU and diagnostic transducers, 
which could allow for angulation and rotation integrated head to be introduced into 
treatment protocols. 
This list outlines the minimum amount of work which would be required to create a HIFU system 
suitable for human treatment, and represents a substantial amount of outstanding software and 
hardware development.  As such, while this thesis demonstrates the potential for HIFU to be 
used in the treatment of TTTS, the research has not yet progressed to a point where human 
treatment would be feasible or ethical. 
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Table 9.1: Key findings of the study: feasibility and efficacy. 
The table lists the key findings of the study which align to the first hypothesis, that it is possible to use ultrasound 
guided HIFU to permanently occlude placental blood vessels.  The supporting evidence for the findings is 
summarised in the table, and the section of the thesis where this evidence is presented or discussed further is also 
listed. 
Evidence provided
Thesis section / 
Reference
Blood vessels of clinically relevant 
diameters can be occluded non-invasively 
using HIFU
The diameter of occluded blood vessels in the study 
(measured histologically) was between 0.4 - 2.9 mm.  
The quoted diameter of human placental arterio-
venous anastomoses is 0.9 - 2.1 mm.
Successful occlusion rates:
Group A protocol: 93% (n=28/30)
Group S protocol: 91% (n=31/34)
Group R protocol: 97% (n=58/60)
Lewi et al.  2007 (7)
Section 4.2.2.1
Section 4.4.2.1
Section 4.5.2.1
Sufficient HIFU energy can be delivered 
into the intra-uterine space to cause 
heating effects
Hyperecho (US evidence of tissue heating) observed 
during HIFU exposures:
Group A protocol: 100% (n=28/28)
Group S protocol: 84% (n=26/31)
Group R protocol: 97% (n=56/58)
Section 4.2.2.1
Section 4.4.2.1
Section 4.5.2.1
HIFU mediated vascular occlusion persists 
for at least 21 days post exposure
Evidence of trapped erythrocytes (H&E) after 21 days 
in 88/89 target vessels where colour flow Doppler 
showed occlusion.
Evidence of organised clot (PTAH) after 21 days in 
24/24 target vessels examined.
Evidence of vacuolar degeneration surrounding target 
vessels (H&E) in 73/88 (75%) cases where trapped 
erythrocytes were found.
Section 4.4.2.1
Section 4.5.2.1
Sheep placental blood vessels of clinically 
relevant diameters can be identified with 
colour flow Doppler ultrasound.  
Colour flow Doppler signal can be demonstrated 
arising from the fetal portion of placentomes.
The diameters of the targeted vessels (measured 
histologically) was 0.4 - 2.9 mm.
Figure 4.3
Lewi et al.  2007 (7)
Colour flow Doppler ultrasound is a 
sufficiently accurate method of targeting 
placental blood vessels to allow HIFU 
mediated occlusion.
Identified targeting errors resulted in failed occlusion.
Discrepancy between the target and HIFU focal plane 
> 5 mm was sufficient to result in failed occlusions.
Table 4.7
Colour flow Doppler ultrasound is an 
accurate method of confirming vascular 
occlusion (rather than identifying transient 
vascular spasm).
Absent of preserved colour flow Doppler signal can be 
seen in the target vessel following HIFU exposures.
This correlates well with histological findings of 
entrapped erythrocytes within exposed vessel lumen:
True positives: 130/130
True negatives: 9/9
False positives: 0
False negatives: 0
CFD and histology not correlated: 9/148
Figure 4.5, 4.6 and 4.7
Tissue responses to HIFU exposures can 
be monitored real-time using B-mode 
ultrasound to identify hyperecho
Hyperecho (US evidence of tissue heating) observed 
during HIFU exposures:
Group A protocol: 100% (n=28/28)
Group S protocol: 84% (n=26/31)
Group R protocol: 97% (n=56/58)
Figure 4.9
Finding of the study
Sheep placental blood vessels can be 
occluded using HIFU.
Ultrasound guidance is a feasible modality to 
target and monitor HIFU mediated placental 
vascular occlusion
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Prior to this study, the potential for HIFU to cause direct iatrogenic harm to mother, fetus or 
placenta was suspected based on the known side effect profile of transdermal HIFU.  This study 
has confirmed that maternal, fetal and placental damage can result from the application of HIFU 
to occlude placental blood vessels.  The key points are again summarised in Table 9.2 and 
Table 9.3, which align to hypothesis 2a (section 2.2). 
Overall, the most common adverse event encountered was maternal skin burns in ewes: 6/19 
(32%) of ewes experienced a skin burn.  In the final version of the treatment protocol 1/10 
(10%) experienced a skin burn (2% of HIFU exposure series resulted in burn).  While these 
rates are higher than quoted in retrospective large studies of using a commercially available 
HIFU system and an established treatment protocol (0.26%, 9988 patients, (107), they are 
similar to the rates described in prospective smaller scale studies of using HIFU in novel 
applications (4-10%, 22-80 patients, (108-112, 346, 347).   The maternal skin burns healed well 
with no need for veterinary attention (minor complications (class B) as per SIR guidance (106)), 
and were well tolerated by the ewes with minimal requirements for analgesia. 
The study also reported single instances of a fetal burn (4% fetuses, 1% HIFU exposure series), 
a uterine burn (6% ewes, 1% transdermal HIFU exposure series) and a placental vascular 
haemorrhage (4% ewes, 1% HIFU exposure series).  All three were likely related to operator or 
system error, and so should be preventable, but the fetal and uterine burn did occur in the 
Group R HIFU protocol, i.e. the most refined HIFU treatment protocol.   
There were no indications of injury to the maternal bladder, bowel or problems with maternal 
mobility (nerve or joint injury).  There were no instance or preterm rupture of membranes, 
preterm labour, development of fetal anaemia or intrauterine fetal death related to exposure to 
HIFU. 
Importantly, safety protocols were identified and introduced which reduced the risk of maternal 
and fetal burns and placental vascular haemorrhage.  As previously discussed, there is scope 
for the safety protocols to be developed further and made more rigorous, potentially with the 
introduction of automated checks, which may reduce the rate of adverse events further. 
Regardless, these rates of adverse events could cast doubt on the suitability of this technique to 
be adapted to human pregnancy, or to be the subject of a first in human clinical trial.  However, 
the clinical need to test novel agents or technologies with unknown efficacy and safety in rare 
diseases is a recognised issue in clinical trial methodology.  Accordingly, clinical study designs 
such as the Bryant Day two stage design, are used to evaluate clinical response and toxicity in 
such challenging circumstances.  This study design considers two end-points, both efficacy and 
Chapter 9: Conclusions and future work 
289 
 
safety, and rejects the new agent or technology if the positive response rate is inadequate, or 
there the rate of adverse events is excessive. This limits recruitment to the first stage of the 
study, and prevents recruitment to the larger second stage, until an adequate efficacy and 
safety have been established.  Such a design usually requires one or more positive patient 
response in around 5-10 patients and limits the rate of adverse events to one or less in around 
5-10 patients (348).  This allows testing of a novel agents or technologies in rarer disease 
states, where small numbers of patients are expected to be recruited to the clinical trial.  As 
such, this study design would likely be an ethical way to test HIFU placental vascular occlusion 
in human subjects, while protecting patients from the risk of excessive adverse events.  
 
Table 9.2: Key findings of the study: direct iatrogenic harm (part 1). 
The table lists the key findings of the study which align to the hypothesis 2a: that it is possible to use ultrasound-
guided HIFU to permanently occlude placental blood vessels without significant direct iatrogenic harm to the 
mother or fetus in the pregnant sheep model.  The supporting evidence for the findings is summarised in the table, 
and the section of the thesis where this evidence is presented or discussed further is also listed. 
Evidence provided Thesis section
Maternal skin burns were the most 
common adverse event in the study
Overall, 6/19 (32%) ewes experienced a skin burn.
In Group R animals:
- 1/10 ewes experienced a maternal skin burn; 1/60 
(2%) HIFU exposure series resulted in a maternal skin 
burn.
- 1/10 ewes experiences maternal skin erythema; 6/60 
(10%) HIFU exposure series resulted in maternal skin 
erythema.
Section 4.5.2.3
Careful preparation and cooling of the skin 
and preservation of the acoustic window 
appeared to reduce skin burns
Protocol modifications resulted in a 0.33 relative risk 
(95% CI 0.12-0.94) of maternal skin burns
Section 4.4.2.3
Table 4.6
Healing of maternal skin burns was 
uncomplicated
No additional procedures (analgesia only) were 
necessary to aid healing of maternal skin burns
Figure 4.26
Section 4.4.2.3
The depth of the target vessel can be used 
to determine the drive voltage selected for 
a HIFU exposure series
The estimated in situ intensity required to produce 
successful occlusion in sheep placental vessels 
appears to be between 2.5 - 3.0 kW.cm
2
.
The depth of the target vessel and the attenuation of 
overlying tissue can be used to calculate the estimated 
in situ intensity delivered to the target.  This should 
prevent under- or over- exposure to HIFU energy.
Figure 4.27
Appendix III
The cross sectional area of the region 
containing the target vessel can be used to 
plan the number of HIFU exposures in a 
HIFU exposure series
A C-STAR >1 appears to reduce the risk of failed 
occlusion and placental vascular haemorrhage.
Use of the C-STAR to determine the HIFU treatment 
area, and so the number of HIFU exposures in a 
series, should prevent exposure of too large or small 
an area of placental tissue surrounding the target 
vessel.
Table 4.3
Section 4.2.2.1
Section 4.6.2.3
Section 4.6.3
The delivery of HIFU energy can be modified 
to reduce the risk of iatrogenic harm
The risk of maternal skin burns is moderate
Finding of the study
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Table 9.3: Key findings of the study: direct iatrogenic harm (part 2). 
The table lists the key findings of the study which align to the hypothesis 2a: that it is possible to use ultrasound-
guided HIFU to permanently occlude placental blood vessels without significant direct iatrogenic harm to the 
mother or fetus in the pregnant sheep model.  The supporting evidence for the findings is summarised in the table, 
and the section of the thesis where this evidence is presented or discussed further is also listed. 
Evidence provided Thesis section
Fetal burns did not occur in the absence 
errors in HIFU delivery
1/23 (4%) fetuses experience a fetal burn.
1/153 (1%) HIFU exposure series resulted in a fetal 
burn.
The fetal burn was due to a breach of safety protocols
Section 4.6.2.3
Figure 4.28
A minimum safe separation between the 
fetus and the HIFU focal plane can be 
established
A minimum separation of >25 mm between the 
nearest fetal part and the HIFU focal plane appears to 
be sufficient to prevent fetal injury using this HIFU 
transducer
Figure 4.32
Fetal burns are a survivable event
The Group R fetus with the burn survived for 20 days 
of follow-up with no objective indication of fetal 
compromise until the injury was discovered at post-
mortem examination
Section 4.5.2.2
There was no evidence of injury to the 
maternal bladder, bowel or spine
0/32 animals had bladder, bowel of retroperitoneal 
injury noted at post-mortem examination
0/16 animals recovered from anaesthesia showed 
evidence of mobility difficulties, or alteration in urinary 
or bowel function
Section 4.1.2.3
Section 4.2.2.2
Section 4.4.2.2
Section 4.5.2.2
The risk of uterine burns is low
1/18 (6%) ewes experienced an uterine burn when 
HIFU was applied through intact abdominal skin.
1/103 (1%) transdermal HIFU exposure series 
resulted in an uterine burn.
There was evidence of healing over the course of 20 
days and no evidence of uterine rupture at the site.
Section 4.5.2.3
Figure 4.29
Placental vascular haemorrhage was 
associated with excessive delivery of HIFU 
energy
Rates of haemorrhage seen in allantoic membranes, 
grouped by estimated in situ intensity delivered to the 
target vessel (all groups, C-STAR >1):
≤ 5.0 kW.cm
2
: 0/152
5.0 - 5.9 kW.cm
2
: 0/40
6.0 - 6.9 kW.cm
2
: 1/2
≥ 7.0 kW.cm
2
: 1/1
Section 4.1.2.3
Figure 4.15
Placental vascular haemorrhage did not 
occur in the absence errors in HIFU 
delivery once upper limit for planned in situ 
intensity introduced
1/23 (4%) ewes experienced placental vascular 
haemorrhage.
1/153 (1%) HIFU exposure series resulted in a 
placental vascular haemorrhage.
The placental haemorrhage was due a gantry arm 
movement error.
Section 4.6.2.3
Section 4.6.3
There was no evidence of fetal anaemia 
following HIFU exposures
In the 12 Group S and R fetuses which completed 
follow-up, there were no changes in MCA-PSV or 
haemoglobin noted
Figure 4.24
Table 6.7
Safety protocols to reduce the risk of 
vascular haemorrhage appeared effective.
There were no instances of vascular haemorrhage 
when the C-STAR >1 and the in situ intensity <5.0 
kW.cm
2
Section 4.6.2.3
Section 4.6.3
Vascular haemorrhage was difficult to 
provoke
Attempts to create a reproducible vascular 
haemorrhage model were unsuccessful.  Using a C-
STAR <1 and in situ intensity < 5.0 kW.cm
2
 resulted in 
a 28% rate of haemorrhage (n=5/18).
Section 4.6.2.3
Section 4.6.3
Finding of the study
The risk of fetal burns is low
The risk of significant maternal internal 
injury is low
The risk of placental vascular haemorrhage 
following exposure to HIFU is low
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At the outset of this study, unlike the potential for direct iatrogenic harm, the potential for indirect 
materno-fetal harms as a result of HIFU occlusion of placental vessels was unknown, and 
unreported in published literature.  The key points are summarised below, and in Table 9.4 and 
Table 9.5, which align to hypothesis 2b (section 2.2). 
Reassuringly, there was no evidence of maternal cardiovascular or metabolic compromise as a 
result of HIFU.  The mild reduction in maternal blood pressure and tendency to accumulate CO2 
in the blood stream were effects of general anaesthesia, and in agreement with the previously 
published effects of inhaled isoflurane.  The changes in uterine arterial blood flow were also the 
result of general anaesthesia, with an additive effect of uterine handling in the animals where 
transuterine HIFU was used.  All these effects resolved fully and quickly once uterine handling 
was stopped, and anaesthesia reversed. 
The fetal cardiovascular and metabolic status was similarly unaffected by HIFU, although fetal 
responses to general anaesthesia, uterine handling and the resultant changes in maternal 
physiology were more pronounced.  While under isoflurane anaesthesia there were reversible 
reductions in heart rate and cardiac function, and activation of non-hypoxic fetal cardiovascular 
defence mechanisms, with increases in peripheral vascular resistance and cerebral 
redistribution of blood flow.  Fetuses also became acidotic due to an accumulation of CO2 and 
lactate, with a resultant reduction in oxygen levels (not sufficient to result in hypoxaemia) during 
the period of anaesthesia.  These changes recovered at different rates.  The majority had 
normalised by the first day, but all were fully resolved by five days post procedure.   
Importantly, all these changes were seen in sham exposed or control animals, with no additive 
effect of exposure to HIFU.  As any human application of HIFU to occlude placental blood 
vessels – given that it is planned to be a non-invasive therapy – would not involve uterine 
handling, and is highly unlikely to involve general anaesthesia, these results appear to have 
little direct clinical relevance. 
Maternal and fetal obstetric outcomes were similarly unaltered by HIFU placental vascular 
occlusion compared to sham exposed animals.  Fetal growth and maturation appeared normal, 
as did placental size and morphology.  There was no evidence of chronic stress, from the 
measures taken in this study, affecting either the fetus or the placenta.  While it was not an 
exhaustive survey of all possible obstetric outcomes, the measures used are those commonly 
reported in literature to describe complicated pregnancies and chronic distress in fetuses.  
Given the transient changes in fetal cardiovascular and metabolic status described above, this 
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is an important confirmation that while there were changes in fetal physiology, these did not 
appear to constitute a period of fetal distress sufficient to cause lasting harm. 
There were also no unanticipated indicators of maternal or fetal harm identified beyond those 
measured by the planned experimental procedures and described here.   
Overall, there is no evidence in this study that HIFU placental vascular occlusion causes acute 
or chronic (up to 21 days) maternal or fetal compromise, or alters obstetric outcomes.  It is true 
that fetuses affected by TTTS will have a degree of pre-exiting compromise, and that even 
subtle changes in physiology may have a greater impact on them than the apparently otherwise 
healthy sheep fetuses used in these experiments.  However, currently fetuses showing 
pathological decompensation resulting from the vascular steal effect of TTTS are the ones in 
whom fetoscopy and placental vascular ablation are currently performed, and are able to 
survive this insult.  It is not unreasonable to anticipate that HIFU should be at least equally well 
tolerated, even in a compromised fetus. 
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Table 9.4: Key findings of the study: materno-fetal compromise (part 1). 
The table lists the key findings of the study which align to the hypothesis 2b: that it is possible to use ultrasound 
guided HIFU to permanently occlude placental blood vessels without significant indirect iatrogenic harm to the 
mother or fetus in the pregnant sheep model.  The section of the thesis where this evidence is presented or 
discussed further is also listed. 
Maternal heart rate and blood pressure are stable during the acute 
application of HIFU
Figure 5.1
Maternal heart rate and blood pressure are stable during recovery from 
application of HIFU
Figure 5.2
Maternal uterine artery blood flow decreases due to exposure to isoflurane 
anaesthesia ± uterine handling, not exposure to HIFU
Figure 5.3
Figure 5.4
Maternal uterine artery blood flow is normal and stable during recovery from 
application of HIFU
Figure 5.4
Fetal heart rate and blood pressure are stable during the acute application 
of HIFU
Figure 5.5
There is evidence of a reversible reduction in fetal heart rate and cardiac 
decompensation secondary to isoflurane exposure in both sham and HIFU 
exposed fetuses
Table 5.4
Figure 5.5
Figure 5.10
Fetal heart rate and cardiac function are normal during the recovery period 
in both sham and HIFU exposed fetuses
Figure 5.5
Figure 5.6
Figure 5.10
There is non-hypoxic, reversible, activation of fetal defence mechanisms in 
response to isoflurane exposure ± uterine handling.  There is an increase in 
peripheral vascular resistance and a decrease in cerebral vascular 
resistance, which is equal in sham and HIFU exposed groups
Figure 5.7
Figure 5.9
Table 6.5
Table 6.6
There is no evidence of persistent activation of fetal defence mechanisms or 
cerebral redistribution during the recovery period in either sham or HIFU 
exposed animals
Figure 5.8
Figure 5.9
Maternal oxygenation, glucose availability and pH are stable during the 
acute application of HIFU exposures
Table 6.3
Table 6.8
The accumulation of carbon dioxide in the maternal arterial blood during 
prolonged anaesthesia can be offset by an increased ventilatory rate
Table 6.8
Maternal oxygenation, glucose availability and pH are stable during the 
recovery from application of HIFU exposures
Table 6.4
Table 6.9
Thesis section
Fetal cardiovascular status is unaffected by exposure to HIFU alone
Finding of the study
Maternal cardiovascular status is unaffected by exposure to HIFU alone
Maternal metabolic status is unaffected by exposure to HIFU
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Table 9.5: Key findings of the study: materno-fetal compromise (part 2). 
The table lists the key findings of the study which align to the hypothesis 2b: that it is possible to use ultrasound 
guided HIFU to permanently occlude placental blood vessels without significant indirect iatrogenic harm to the 
mother or fetus in the pregnant sheep model.  The section of the thesis where this evidence is presented or 
discussed further is also listed. 
There is an equal fall in pH and accumulation of PaCO2 and lactate in sham 
and HIFU exposed fetuses, related to the length of anaesthesia and 
activation of fetal cardiovascular defence mechanisms
Table 6.5
Table 6.10
There is a reduction in PaO2 concentrations in both sham and HIFU 
exposed fetuses related to the developing fetal acidosis.  The fall in oxygen 
levels do not reach the level of hypoxaemia.
Table 6.5
Fetal pH, PaCO2, PaO2, lactate are normal and stable during recovery in 
both control and HIFU exposed fetuses
Table 6.7
Table 6.11
Glucose availability and haemoglobin concentration are stable during the 
application of HIFU or sham exposures
Table 6.5
Changes in peripheral oxygen and glucose delivery during the application of 
HIFU or sham exposures are the result of increases in peripheral vascular 
resistance
Table 6.5
Table 6.6
Glucose and oxygen delivery are unaffected by treatment group during the 
recovery period, and show gestational age related increases linked to the 
increase in fetal femoral blood flow
Table 6.7
Figure 5.8
No evidence of preterm rupture of membranes, labour or intrauterine fetal 
death in the 12/12 ewes which completed the 21 d recovery period
Section 4.4.2.2
Section 4.5.2.2
Total placentome number, weight and placentome subtype distribution equal 
between sham and HIFU exposed animals
Table 7.6
Fetal growth was normal in sham and HIFU exposed animals, without 
evidence of asymmetric growth
Figure 7.2
Table 7.2
Table 7.3
Table 7.4
Table 7.5
There was no evidence of a chronic fetal stress (cortisol) response due to 
exposure to HIFU
Figure 7.3
The autonomic control of heart rate variability developed normally in control 
and HIFU exposed fetuses
Table 7.7
Figure 7.4
Figure 7.5
Maternal and fetal obstetric outcomes are unaffected by exposure to HIFU
Fetal metabolic status is unaffected by exposure to HIFU
Finding of the study Thesis section
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Table I.i: Reported maternal cardiovascular parameters in pregnant sheep under isoflurane anaesthesia. 
The table shows the effect of 0.5-2.0% MAC of isoflurane for a duration of between 15 and 240 minutes on 
maternal mean arterial blood pressure, heart rate and uterine blood flow in pregnant sheep, reported in 6 studies. 
The key to the reference is on page 318. 
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
0.5% Isoflurane + 
oxygen
85 21
Okutomi 
2009
Mean of 
quoted values
85.0 21
90 21
Okutomi 
2009
91.8 4
Palahniuk 
1974
93.2 4
Palahniuk 
1974
98.9 4
Palahniuk 
1974
88.8 4
Palahniuk 
1974
Mean of 
quoted values
89.8 25 91.8 4 93.2 4 98.9 4
78 21
Okutomi 
2009
74.5 6
Palahniuk 
1974
81 6 Gaynor 1998 80.3 6
Palahniuk 
1974
82.3 6
Palahniuk 
1974
77.3 6
Palahniuk 
1974
78 10 Gaynor 1998 92 8
McClaine 
2007
65 8
McClaine 
2007
80 10 Gaynor 1998
76 10 Gaynor 1998
Mean of 
quoted values
75.2 45 76.7 16 81.0 6 84.1 24 82.3 6
70 21
Okutomi 
2009
61.1 6
Palahniuk 
1974
89.5 8 Biehl 1983 65.2 6
Palahniuk 
1974
65 6
Palahniuk 
1974
99 8
McClaine 
2007
98 8
McClaine 
2007
94 8
McClaine 
2007
55.1 6
Palahniuk 
1974
86.3 8 Biehl 1983 96 8 Biehl 1983 97.8 8
McClaine 
2007
83 8 Biehl 1983 58.3 10 Gaynor 1998
60.8 6
Bachman 
1986
Mean of 
quoted values
69.0 41 68.3 24 89.5 8 82.8 14 83.7 14 99.0 8 98.0 8 94.0 8
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
0.5% Isoflurane + 
oxygen
120 21
Okutomi 
2009
Mean of 
quoted values
120.0 21
119 21
Okutomi 
2009
113 4
Palahniuk 
1974
116 4
Palahniuk 
1974
131 4
Palahniuk 
1974
72 4
Palahniuk 
1974
Mean of 
quoted values
111.5 25 113 4 116 4 131 4
117 21
Okutomi 
2009
105 6
Palahniuk 
1974
97 10 Gaynor 1998 109 6
Palahniuk 
1974
114 6
Palahniuk 
1974
110 6
Palahniuk 
1974
96 10 Gaynor 1998 108 8
McClaine 
2007
95 10 Gaynor 1998 87 8
McClaine 
2007
98 10 Gaynor 1998
Mean of 
quoted values
109.9 37 95.3 24 97.0 10 104.1 24 114.0 6
115 21
Okutomi 
2009
93.7 6
Palahniuk 
1974
98.1 8 Biehl 1983 93 6
Palahniuk 
1974
96 6
Palahniuk 
1974
112 8
McClaine 
2007
114 8
McClaine 
2007
110 8
McClaine 
2007
91 6
Palahniuk 
1974
93.1 8 Biehl 1983 107.5 8 Biehl 1983 106 8
McClaine 
2007
111 8 Biehl 1983 91 10 Gaynor 1998
102 6
Bachman 
1986
Mean of 
quoted values
108.8 41 92.4 24 98.1 8 101.3 14 101.7 14 112.0 8 114.0 8 110.0 8
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
0.5% Isoflurane + 
oxygen
378 21
Okutomi 
2009
Mean of 
quoted values
378.0 21
390 21
Okutomi 
2009
616 4
Palahniuk 
1974
654 4
Palahniuk 
1974
647 4
Palahniuk 
1974
580 4
Palahniuk 
1974
Mean of 
quoted values
420.4 25 616 4 654 4 647 4
350 21
Okutomi 
2009
406 6
Palahniuk 
1974
434 6
Palahniuk 
1974
464 6
Palahniuk 
1974
400 6
Palahniuk 
1974
Mean of 
quoted values
361.1 27 406.0 6 0.0 0 434.0 6 464.0 6
329 21
Okutomi 
2009
260 6
Palahniuk 
1974
291 6
Palahniuk 
1974
313 6
Palahniuk 
1974
218 6
Palahniuk 
1974
Mean of 
quoted values
304.3 27 260.0 6 291.0 6 313.0 6
C
o
n
te
n
t 
o
f 
in
sp
ir
ed
 g
as
es
1.0% Isoflurane + 
oxygen
1.5% Isoflurane + 
oxygen
2.0% Isoflurane + 
oxygen
Uterine 
Blood Flow 
(ml min-1)
Duration of exposure to inhaled isoflurane
15-16 minutes 30-32 minutes 45-48 minutes 60-64 minutes 90-96 minutes 120 mintues 180 minutes 240 minutes
1.0% Isoflurane + 
oxygen
C
o
n
te
n
t 
o
f 
in
sp
ir
ed
 g
as
es
1.5% Isoflurane + 
oxygen
2.0% Isoflurane + 
oxygen
Maternal 
Heart Rate 
(bpm)
1.5% Isoflurane + 
oxygen
2.0% Isoflurane + 
oxygen
Duration of exposure to inhaled isoflurane
15-16 minutes 30-32 minutes 45-48 minutes 60-64 minutes 90-96 minutes 120 mintues 180 minutes 240 minutes
Duration of exposure to inhaled isoflurane
240 minutes
Maternal Mean Arterial 
Pressure (mmHg)
C
o
n
te
n
t 
o
f 
in
sp
ir
ed
 g
as
es
120 mintues 180 minutes15-16 minutes 30-32 minutes 45-48 minutes 60-64 minutes 90-96 minutes
1.0% Isoflurane + 
oxygen
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Table I.ii: Reported fetal cardiovascular parameters under isoflurane anaesthesia 
The table shows the effect of 0.5-2.0% MAC of isoflurane for a duration of between 15 and 240 minutes on fetal 
mean arterial blood pressure and heart rate, reported in 5 studies.  The key to the reference is on page 318. 
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
0.5% Isoflurane + 
oxygen
53 21
Okutomi 
2009
Mean of 
quoted values
53.0 21
52 21
Okutomi 
2009
47.7 4
Palahniuk 
1974
45.8 4
Palahniuk 
1974
47.9 4
Palahniuk 
1974
45.4 4
Palahniuk 
1974
Mean of 
quoted values
50.9 25 47.7 4 45.8 4 47.9 4
43 21
Okutomi 
2009
44.6 6
Palahniuk 
1974
44.5 6
Palahniuk 
1974
44.9 6
Palahniuk 
1974
44.8 6
Palahniuk 
1974
38 8
McClaine 
2007
38 8
McClaine 
2007
Mean of 
quoted values
42.2 35 44.6 6 40.8 14 44.9 6
41 21
Okutomi 
2009
35.5 6
Palahniuk 
1974
50 8 Biehl 1983 37.8 6
Palahniuk 
1974
35.2 6
Palahniuk 
1974
39 8
McClaine 
2007
41 8
McClaine 
2007
40 8
McClaine 
2007
36.4 6
Palahniuk 
1974
50.5 8 Biehl 1983 49.2 8 Biehl 1983 50.2 8
McClaine 
2007
50 8 Biehl 1983 39.2 6
Bachman 
1986
40.5 6
Bachman 
1986
Mean of 
quoted values
42.0 41 42.6 20 50.0 8 44.3 14 43.8 14 39.0 8 41.0 8 40.0 8
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
Mean 
value
n Reference
0.5% Isoflurane + 
oxygen
164 21
Okutomi 
2009
Mean of 
quoted values
164.0 21
165 21
Okutomi 
2009
170 4
Palahniuk 
1974
160 4
Palahniuk 
1974
166 4
Palahniuk 
1974
160 4
Palahniuk 
1974
Mean of 
quoted values
164.2 25 170 4 160 4 166 4
158 21
Okutomi 
2009
154 6
Palahniuk 
1974
152 6
Palahniuk 
1974
151 6
Palahniuk 
1974
166 6
Palahniuk 
1974
150 8
McClaine 
2007
Mean of 
quoted values
#REF! 27 154.0 6 150.9 14 151.0 6
145 21
Okutomi 
2009
132 6
Palahniuk 
1974
156 8 Biehl 1983 142 6
Palahniuk 
1974
138 6
Palahniuk 
1974
150 8
McClaine 
2007
149 8
McClaine 
2007
147 8
McClaine 
2007
137 6
Palahniuk 
1974
158 8 Biehl 1983 156 8 Biehl 1983 146 8
McClaine 
2007
166 8 Biehl 1983 122 6
Bachman 
1986
142 6
Bachman 
1986
Mean of 
quoted values
147.5 41 139.4 20 156.0 8 150.0 14 142.6 14 150.0 8 149.0 8 147.0 8
C
o
n
te
n
t 
o
f 
in
sp
ir
ed
 g
as
es
1.0% Isoflurane + 
oxygen
1.5% Isoflurane + 
oxygen
2.0% Isoflurane + 
oxygen
Fetal Heart Rate (bpm)
Duration of exposure to inhaled isoflurane
15-16 minutes 30-32 minutes 45-48 minutes 60-64 minutes 90-96 minutes 120 mintues 180 minutes 240 minutes
Duration of exposure to inhaled isoflurane
15-16 minutes 30-32 minutes 45-48 minutes 60-64 minutes 90-96 minutes 120 mintues 180 minutes 240 minutes
C
o
n
te
n
t 
o
f 
in
sp
ir
ed
 g
as
es 1.0% Isoflurane + oxygen
1.5% Isoflurane + 
oxygen
2.0% Isoflurane + 
oxygen
Fetal Mean Arterial 
Pressure (mmHg)
  
 
3
1
6
 
 
 
Table I.iii: Reported maternal acid-base parameters in pregnant sheep under isoflurane anaesthesia 
The table shows the effect of 1.0-2.0% MAC of isoflurane for a duration of between 15 and 240 minutes on maternal pH and PaCO2 in pregnant sheep, reported in 5 
studies.  The key to the reference is on page 318. 
 
 
 
 
Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n
Palahniuk 1974 7.48 0.01 4 7.55 0.04 4 7.54 0.01 4 7.50 0.02 4 7.40 0.02 4
Okutomi 2009 7.52 21 7.48 21
Mean 7.50 0.00160 25 7.52 0.00640 25 7.54 0.01000 4 7.50 0.02000 4 7.40 0.02000 4
Palahniuk 1974 7.47 0.02 6 7.51 6 7.52 6 7.52 6 7.51 6
McClaine 2007 7.50 0.02 8 7.49 8 7.47 8 7.45 8 7.45 8 7.45 8
Okutomi 2009 7.52 0.02 21 7.47 21
Mean 7.50 0.00437 35 7.49 27 7.51 14 7.50 14 7.51 6 7.45 8 7.45 8 7.45 8
Palahniuk 1974 7.53 0.02 6 7.51 6 7.51 6 7.51 6 7.50 6
Biehl 1983 7.48 0.04 8 7.48 0.03 8 7.50 0.02 8 7.50 0.02 8 7.49 0.02 8 7.47 0.03 8
Bachman 1986 7.48 0.03 6 7.51 6 7.53 6
Okutomi 2009 7.52 0.02 21 7.46 0.02 21
Mean 7.50 0.00411 41 7.49 0.00089 41 7.51 0.00029 20 7.50 0.00113 8 7.50 0.00049 14 7.49 0.00110 14
Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n
Palahniuk 1974 31.10 1.30 4 29.10 3.40 4 30.20 2.20 4 33.50 1.50 4 34.50 0.02 4
Okutomi 2009 29.00 0.80 21 33.00 21
Mean 30.05 2.46592 25 31.05 0.54400 25 30.20 2.20000 4 33.50 1.50000 4 34.50 0.02000 4
Palahniuk 1974 28.70 1.10 6 32.3 6 32.20 6 32.80 6 34.20 6
McClaine 2007 29.00 1.40 8 32.90 8 36.10 8 36.10 8 38.20 8 36.90 8
Okutomi 2009 29.00 0.80 21 34 21
Mean 28.90 2.00599 35 33.15 27 32.55 0.00000 14 34.45 14 34.20 6 36.10 8 38.20 8 36.90 8
Palahniuk 1974 29.00 1.00 6 32.90 6 31.80 6 33.20 6 33.20 6
Biehl 1983 33.30 4.50 8 36.00 0.03 8 28.00 0.02 8 30.00 8 29.00 0.02 8 34.00 0.03 8
Bachman 1986 34.00 1.50 6 32.00 6 32.00 6
Okutomi 2009 29.00 0.80 21 35.50 21
Mean 31.33 6.46658 41 34.10 0.00022 41 30.60 0.00029 20 30.00 8 31.10 0.00049 14 33.60 0.00110 14
60 min 90 min 120 min 180 min 240 min
Maternal PaCO2
Isoflurane 2.0%
Baseline (pre-ox) 15 min 30 min 45 min
Isoflurane 1.0%
Isoflurane 1.5%
Isoflurane 2.0%
120 min 180 min 240 min
Isoflurane 1.0%
90 min60 min
Maternal pH
Isoflurane 1.5%
Baseline (pre-ox) 15 min 30 min 45 min
  
 
3
1
7
 
 
Table I.iv: Reported fetal acid-base and oxygenation parameters under isoflurane anaesthesia. 
The table shows the effect of 1.0-2.0% MAC of isoflurane for a duration of between 15 and 240 minutes on fetal mean arterial blood pressure and heart rate, 
reported in 5 studies.  The key to the reference is on page 318. 
Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n
Palahniuk 1974 7.34 0.04 4 7.35 0.03 4 7.37 0.02 4 7.33 0.03 4 7.32 0.04 4
Okutomi 2009 7.35 0.01 21 7.33 21
Mean 7.35 0.00675 25 7.33 0.00480 25 7.37 0.02000 4 7.33 0.03000 4 7.32 0.04000 4
Palahniuk 1974 7.38 0.03 6 7.31 6 7.33 6 7.32 6 7.33 6
McClaine 2007 7.39 8 7.31 8 7.29 8 7.28 8 7.26 8 7.26 8
Okutomi 2009 7.35 0.01 21 7.33 21
Mean 7.36 0.00536 35 7.33 27 7.32 14 7.30 14 7.33 6 7.28 8 7.26 8 7.26 8
Palahniuk 1974 7.38 0.02 6 7.29 6 7.30 6 7.29 6 7.26 6
Biehl 1983 7.35 0.04 8 7.38 8 7.35 8 7.34 8 7.33 8 7.26 8
Bachman 1986 7.34 0.02 6 7.32 6 7.33 6
Okutomi 2009 7.35 0.01 21 7.33 21
Mean 7.35 0.03 41 7.33 41 7.33 20 7.34 8 7.31 14 7.26 14
Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n
Palahniuk 1974 41.40 0.60 4 43.10 4.00 4 41.20 1.80 4 46.20 2.30 4 50.40 4.10 4
Okutomi 2009 43.00 1.40 21 45.00 21
Mean 42.74 7.01088 25 44.70 0.64000 25 41.20 1.80000 4 46.20 2.30000 4 50.40 4.10000 4
Palahniuk 1974 37.30 1.30 6 44.7 6 44.50 6 44.80 6 43.00 6
McClaine 2007 37.00 1.20 8 52.40 8 54.30 8 56.90 8 61.60 8 64.00 8
Okutomi 2009 43.00 1.40 21 46 21
Mean 40.65 4.73105 35 45.71 27 49.01 14 50.23 14 43.00 6 56.90 8 61.60 8 64.00 8
Palahniuk 1974 37.30 1.40 6 43.30 6 42.50 6 41.20 6 44.40 6
Biehl 1983 37.00 1.00 8 42.00 8 39.00 8 40.00 8 41.00 8 44.00 8
Bachman 1986 37.30 1.10 6 46.80 6 45.10 6
Okutomi 2009 43.00 1.40 21 47.00 21
Mean 40.16 2.58 41 45.45 41 41.88 20 40.00 8 41.09 14 44.17 14
Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n
Palahniuk 1974 -1.20 2.40 4 -1.90 1.70 4 -1.40 1.40 4 -2.20 1.40 4 -0.90 0.02 4
Mean -1.20 2.40000 4 -1.90 1.70000 4 -1.40 1.40000 4 -2.20 1.40000 4 -3.70 0.02000 4
Palahniuk 1974 -2.50 1.40 6 -4 6 -2.50 6 -3.20 6 -3.70 6
Mean -2.50 1.40000 6 -4.00 2.4 -2.50 6 -3.20 6 -7.00 0.00000 6
Palahniuk 1974 -2.70 1.80 6 -5.60 -0.6 -5.80 6 -6.50 6 -7.10 6
Biehl 1983 -1.10 1.50 8 0.10 8 -2.40 8 -2.60 8 -3.20 8 -6.20 0.03 8
Bachman 1986 -0.60 6 0.30 6 -0.60 6
Mean -1.47 1.74748 20 -1.73 13 -2.93 20 -2.60 8 -4.85 14 -6.65 14
Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n Mean SEM n
Palahniuk 1974 20.90 2.90 4 18.60 3.20 4 17.70 2.00 4 20.20 2.10 4 19.20 2.60 4
Okutomi 2009 17.00 1.00 21 24.00 21
Mean 17.62 3.99200 25 23.14 0.51200 25 17.70 2.00000 4 20.20 2.10000 4 19.20 2.60000 4
Palahniuk 1974 20.50 1.30 6 21.2 1.4 6 21.50 6 22.10 6 21.70 6
McClaine 2007 20.00 1.20 8
Okutomi 2009 17.00 1.00 21 25 21
Mean 18.29 2.68646 35 24.16 1.40000 27 21.50 6 22.10 6 21.70 6
Palahniuk 1974 21.80 1.50 6 19.40 6 20.50 6 18.20 6 17.70 6
Biehl 1983 20.50 1.30 8 26.00 8 24.00 8 24.00 8 24.00 8 25.00 8
Bachman 1986 22.20 0.83 6 24.00 6 22.30 6
Okutomi 2009 17.00 1.00 21 24.00 21
Mean 19.15 1.85 41 23.72 41 22.44 20 24.00 8 21.51 14 21.87 14
Fetal PaCO2
Fetal ABE
Fetal PaO2
Isoflurane 1.0%
Isoflurane 1.5%
Isoflurane 2.0%
30 min 45 min 60 min 90 min
Isoflurane 1.0%
Isoflurane 1.5%
Isoflurane 2.0%
Baseline (pre-ox) 15 min
60 min 90 min
Isoflurane 2.0%
Baseline (pre-ox) 15 min 30 min 45 min
Isoflurane 1.0%
Isoflurane 1.5%
Baseline (pre-ox) 15 min 30 min 45 min 60 min 90 min 120 min 180 min 240 min
Isoflurane 2.0%
90 min 120 min 180 min 240 min
Isoflurane 1.0%
Isoflurane 1.5%
60 min
Fetal pH
Baseline (pre-ox) 15 min 30 min 45 min
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APPENDIX II: TRANSONIC FLOW PROBE PRINCIPALS OF 
ACTION 
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Time-transit ultrasonic flow probes make use of upstream and downstream transducers, a 
known distance apart, with a predefined angle of insonation (R series 45o; S series 65o (349)) 
and an acoustic reflector in a fixed orientation to calculate the volume of flow through their 
acoustic window (Figure II). This measurement is independent of the diameter, shape and 
angulation of the vessel as well as the flow profile of the blood within (271). 
 
Figure II: Transonic flow probe. 
The diagram shows the of path of ultrasound pulse from the up- to the downstream transducer and back, passing 
through blood vessel in which absolute blood flow will be determined. 
The downstream transducer emits and ultrasound pulse which passes through the vessel, 
before being reflected by the acoustic reflector, passing through the vessel a second time and 
sensed by the upstream transducer.  The time for the ultrasound wave to travel this distance is 
measured as the downstream transit time (tdown).  As the ultrasound wave propagates in the 
same direction as the flow in the vessel it undergoes a phase shift, and the transit time is less 
than it would be without any flow in the vessel by an amount proportional to the average blood 
velocity multiplied by the path length over which the velocity is measured.  The upstream 
transducer also emits an ultrasound pulse that is reflected, transects the vessel twice and is 
sensed by the downstream transducer.  In this case, the wave propagates against the direction 
of blood flow, and so the upstream transit time (tup) is increased from the time without flow in the 
vessel.  Alternating signals are produced by the upstream and downstream transducer at 1ms 
intervals.  The difference between upstream and downstream integrated transit times is 
therefore a measure of volume flow (reported as ml.min-1) through the length of the vessel 
insonated.  Ultrasonic beams which do not intersect the vessel do not contribute to the flow 
integral (271). 
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Time-transit ultrasonic flow probes have some advantages over other methods of flow 
measurement. As each ultrasound signal passes through the vessel twice, angulation of the 
vessel has negligible effect on the calculation of volume flow, as the increase in one flow vector 
in the outward path is offset by the corresponding decrease in the flow vector of the return path 
(unlike Doppler velocimetry where angle of insonation needs to be corrected for).  As phase and 
not frequency shift (unlike Doppler ultrasound velocimetry) is calculated, the flow of liquid, not 
the passage of erythrocytes is measured, meaning time transit flow probes are unaffected by 
changes in haematocrit or cell content of the blood (350).  They are also able to zero calibrate 
themselves by sending two consecutive upstream phase measurements without the need for 
clamping of the vessel to create a situation of no-flow prior to measurement (like 
electromagnetic flow probes) which reduces the handling of vessels and subsequent 
vasospasm (280). 
When used with a suitable acoustic coupling agent (351) to exclude air from the acoustic 
window they can be used in the acute setting to monitor arterial flow; for chronic measurement 
the development of fibrous encapsulation within 7 days of implantation creates a stable pocket 
filled with tissue fluid which ensures air-free coupling (352). This means they can be implanted 
loosely around blood vessels, avoiding irritation or constraint of blood vessels and allowing 
vessel growth in the fetus (280). 
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APPENDIX III: CRITERIA USED TO IDENTIFY 
ARTEFACTUAL PHYSIOLOGICAL DATA 
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Table III: Exclusion criteria for artefactual data. 
The table lists the exclusion criteria for maternal and fetal blood pressure and blood flow readings in Group R animals which were determined to be there result of 
equipment malfunction or incorrect calibration.  
If above If below Other
Maternal systolic blood pressure (mmHg) 300 0
If < 5 mmHg different from 
diastolic blood pressure
Maternal diastolic blood pressure (mmHg) 300 0
If < 5 mmHg different from 
systolic blood pressure
Maternal heart rate (bpm) 200 0 n/a
Catheter blocked 
(non pulsatile flow)
Fetal systolic blood pressure (mmHg) 300 0
If < 5 mmHg different from 
diastolic blood pressure
Fetal diastolic blood pressure (mmHg) 300 0
If < 5 mmHg different from 
systolic blood pressure
Fetal heart rate (bpm) 300 0
If > 20 bpm difference 
between FHR derived from 
catheter and flow probe
Fetal maximum femoral blood flow (ml.min
-1
) 500 0
If < 5 ml.min-1 different 
from minimum blood flow
Fetal minimum femoral blood flow (ml.min
-1
) 500 0
If < 5 ml.min-1 different 
from minimum blood flow
Fetal mean femoral blood flow (ml.min
-1
) 500 0
If < 5 ml.min-1 difference 
between maximum and 
minimum blood flow
Fetal femoral blood flow amplitude (ml.min
-1
) 1000 0
If < 5 ml.min-1 difference 
between maximum and 
minimum blood flow
Amniotic pressure (mmHg) 100 0
If > fetal diastolic blood 
pressure
Catheter blocked or displaced
Exclusion criteria
Flow probe transmitting non-pulsatile 
data (calibration error, data cable 
damage, poor acoustic window, 
probe displacement).
Catheter blocked (non pulsatile flow), 
calibration incorrect, or data cable pin 
damaged
Catheter blocked (non pulsatile flow), 
calibration incorrect, or data cable pin 
damaged
Variable Reason for artefactual data
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APPENDIX IV: HIFU TRANSDUCER CALIBRATION AND 
ESTIMATION OF IN SITU INTENSITY 
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Introduction 
In situ intensity is an estimate of the actual acoustic energy delivered to the focus per second, 
accounting for losses (attenuation) in the overlying tissues.  It can be estimated by subtracting 
predicted energy losses (derived from tissue characterisation studies of relevant overlying 
tissues) from the amount of acoustic energy a HIFU transducer produces at a given drive 
voltage, the free field intensity.  Use of in situ intensity rather than free field intensity essentially 
corrects for depth of the target tissue and type(s) of overlying tissue, allowing outcomes of 
individual exposure series to be more readily compared to one-another. 
Every HIFU transducer is unique and therefore requires individual calibration to calculate the 
free-field intensity (a measure of the maximum acoustic energy delivered per second to the 
focus through a lossless medium) generated by the transducer.  Calibration of the transducer 
and calculation of free-field intensities for a given drive voltage (the actual setting used 
on the signal generator to select power level) for the transducer used in this study was 
performed by Drs Rivens and Civale at the Institute of Cancer Research, and the final 
results were supplied to me in order to estimate in situ intensity, as described in the methods 
section below.  The tissue characterisation studies were performed by me, using a pre-
prepared experimental protocol provided by Dr Civale. 
 
Methods: Calculation of free field intensity from drive voltage 
Free-field spatial peak temporal average intensity (ISPTA), measured in W.cm-2, was calculated 
from pressure measured at the focal peak in degassed, deionised water using a calibrated (at 
the National Physical Laboratories, Teddington) membrane hydrophone (Precision Acoustics, 
Dorset, UK).  Measurements were made over a range of relatively low drive voltages, Vdrive 
quantified on a logarithmic dBm scale in order to avoid acoustic cavitation damage to the 
piezoelectric hydrophone element. An exponential fit to the calculated ISPTA values was used to 
extrapolate to the free field intensities at the higher drive levels used in the in vivo studies. 
 
Methods: Tissue characterisation 
A finite amplitude insertion substitution (FAIS) tissue characterisation system (Figure IV.i) was 
used to determine the ultrasonic attenuation of relevant tissues for planning of HIFU exposure 
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conditions and interpretation of vascular occlusion outcomes relative to acoustic energy used. 
The FAIS system uses a pair of 2.5 MHz weakly focused (20 mm diameter, 100 mm focal 
length) transducers (Imasonic SA, France) co-axially aligned as a transmitter-receiver pair.  
Pulsed ultrasound energy was transmitted through water (reference medium) and samples held 
within a pair of flat, parallel 19 µm thick Melinex membranes (the sample holder windows) and 
detected by either the “receiver” transducer or, after reflection, by the transmitter.  The sample 
holder position in three orthogonal directions was determined by a motion controller able to 
move in x, y and z.  The offset of the sample from the centre of the sample holder window, the 
size of the region of tissue to be sampled and of the spacing between measurement points were 
manually inputted into a custom written tissue characterisation Matlab script GUI (MathWorks, 
USA).  This Matlab interface controlled the FAIS system’s motion controller and ultrasonic 
pulser/receiver (JSR DPR300, Imaginant Inc., USA) and recorded data from a thermocouple 
(TC01, National Instruments, USA) placed in the water tank adjacent to the sample and the 
oscilloscope (3205A, PicoTechnology, USA) which measured the reflected and transmitted 
ultrasound pulses.  The software also performed post processing of data acquired to calculate 
sample thickness, speed of sound, attenuation coefficient (dB.cm-1.MHz-1) and frequency 
dependence of the attenuation coefficient.  The software included filters to remove unreliable 
measurements by ensuring correct echo detection for thickness and therefore sound speed 
measurements, by filtering out frequency dependent data which were too noisy.  It also allowed 
attenuation level filtering to allow removal of data from the tissue maps which was obtained 
through water or through the outer edges of the sample where interface effects produced 
artificially high results. The remaining data in the characterisation maps were used to produce 
average and standard deviation values for the quantities listed above.  
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Figure IV.i: FAIS system setup.  
The illustration shows the arrangement of a pair of 2.5 MHz transducers co-axially aligned to direct ultrasound 
energy through the tissue sample, held in degassed water between two 19 µm thick Melinex membranes by the 
sample holder placed between the transmitter-receiver pair of transducers. 
Measurement of the attenuation coefficient, speed of sound and sample thickness were 
determined in (i) fresh ovine skin with wool and lanolin removed, subcutaneous adipose tissue, 
rectus sheath and muscles as a composite of layers, (ii) uterus, (iii) placental tissue, and (iv) 
amniotic fluid.  Samples from the maternal abdomen were taken from positions defined as the 
central, axial or lateral aspects (defined in Figure IV.ii).   
 
Figure IV.ii: Sheep abdominal regions.   
The “central” area of the sheep abdomen is shown demarcated by green lines overlaid on the photographic image.  
The “axial” area falls between the green and orange lines on both sides (only show on right) and the “lateral” area 
falls between the orange and red lines on both sides (only shown on right).  The sheep abdominal skin has been 
exposed by shaving with clippers, then 24-48h later washed with iodine to remove dirt and lanolin, chemical 
depilated to remove short hairs, then washed again with plain water.  The upper border of the photo is caudal. 
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Maternal skin was shaved, washed with iodine, chemically depilated and washed in water to 
reduce the risk of trapping air bubbles on its surface, which can cause reflection or scattering of 
HIFU energy, and so introduce measurement artefacts in this setting. Layers of skin, adipose 
tissue and between one and three layers of muscle (dependant on the location on the maternal 
abdomen from which the sample was taken) were not separated before testing.   
As we needed to know the attenuation of the maternal skin, fat and recuts overlying the uterus 
to plan in vivo HIFU exposures, measuring the overlying tissue as a composite structure was 
the most directly relevant way to perform these measurements.  Additionally, measuring 
attenuation in thicker structures is more reproducible than thinner structures, and not separating 
layers also reduces the risk of trapping air bubble at any of the interfaces, from which air was 
otherwise excluded, so reducing measurement artefacts.   
Each abdominal sample was cut into a rectangular shaped area of even thickness.  
Placentomes were separated from the uterine tissues prior to measuring; placentomes were 
categorised by type and their allantoic membranes were removed to reduce the risk of the 
formation of air pockets, but tested whole.  The time between euthanasia of the ewes and the 
start of tissue characterisation was less than 60 minutes in all cases; however, in some cases 
tissue samples could not be used due to hardening of the rectus sheath post-mortem. 
 
Results: Free field intensity 
Free field intensities were calculated at drive voltages between -22 and -11 dBm.  These values 
are plotted with black symbols in Figure IV.iii, and a line of best fit was applied to them.  This 
equation was then used to extrapolate the free field intensity of drive voltages selected during in 
vivo studies (-4 to -9 dBm).  The degree of uncertainty associated with this was reported as 
±10%.  For this reason, free field intensities, when reported, are given to 2 significant figures 
only. 
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Figure IV.iii: Measured and calculated free field intensities.   
The graph shows free field intensities measured by a membrane hydrophone in a deionised, degassed water tank 
at given drive voltages (n=12, black circles) and the extrapolated values for free field intensity at higher drive 
voltages based on the curve of best fit (n=7, red circles). 
 
Results: Tissue characterisation 
Samples were obtained immediately following euthanasia in nine adult pregnant sheep during 
the last third of gestation.  There were two central, at least two axial and at least one lateral wall 
tissue sample contributed from each animal (Figure IV.ii).  The mean weight of the ewes was 39 
kg (SD 8 kg) and ranged from 29 – 54 kg.  The results of tissue characterisation of these 
samples are shown in Table IV. 
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Table IV: Tissue characterisation results.    
Values represent the mean ± standard deviation of the attenuation coefficient, exponent of the attenuation 
coefficient and measured thickness of the types of tissue and fluid samples listed.  Attenuation at 1.66 MHz is given 
by α1.66N, for the HIFU transducer used in this study.  
 
Based on this, for transuterine exposures, a weighted average of the calculated attenuation 
coefficient of the uterus and placental tissues of 0.8 ± 0.2 dB.cm-1 (at 1.66 MHz) was used to 
estimate total energy loss (in dB) between the skin and target region.  As the attenuation of 
water and amniotic fluid were treated as negligible, the following equation was used to estimate 
energy losses as a result of passing through maternal uterine tissue: 
Transuterine energy loss = 0.8 x target depth 
However, it should be noted that the error in this calculation arising from the tissue 
characterisation studies was effectively ±25%, compounded on the ±10% error from conversion 
of drive voltage to free field intensity.  Hence, while estimated in situ intensity is quoted to 2 
significant figures, this may still represent a greater degree of accuracy than actually merited.  
However, quoting to 1 significant figure did not allow sufficient discrimination between the 
energy levels delivered to tissue. 
  
Attenuation 
Coefficient (α) 
(dB.(cm*MHz)-1) 
Exponent of 
the attenuation 
coefficient (N) 
Attenuation 
at 1.66 MHz 
(dBm.cm-1) 
Measured 
thickness 
(cm) 
Number 
of 
samples 
Skin, subcutaneous adipose 
tissue, rectus sheath and 
muscles (central) 
0.96 ± 0.20 1.36 ± 0.11 1.91 ± 0.51 0.93 ± 0.09 18 
Skin, subcutaneous adipose 
tissue, rectus sheath and 
muscles (axial) 
1.91 ± 0.53 1.09 ± 0.21 3.32 ± 1.28 1.58 ± 0.10 19 
Skin, subcutaneous adipose 
tissue, rectus sheath and 
muscles (lateral) 
3.05 ± 0.72 0.98 ± 0.40 5.01 ± 2.23 2.28 ± 0.27 11 
Uterus 0.29 ± 0.06 1.75 ± 0.17 0.70 ± 0.17 - 24 
Placentome (type A/B) 0.34 ± 0.06 1.75 ± 0.22 0.83 ± 0.20 - 28 
Placentome (type C/D) 0.30 ± 0.05 1.88 ± 0.32 0.78 ± 0.21 - 16 
Amniotic fluid 0.02 ± 0.01 1.05 ± 0.2 0.03 ± 0.01 - 5 
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Tissue characterisation results show that for transdermal exposures, the additional thickness of 
the rectus sheath and muscles away from the central portion of the sheep abdomen would 
result in much higher energy losses.  If exposures were constrained to the central region only 
(demarcated in green, Figure IV.ii) a standard value of total attenuation of skin, adipose tissue 
and rectus sheath and muscle of 1.9 ± 0.5 dB.cm-1 (at 1.66 MHz) could be anticipated in 
addition to the attenuation from the uterus and placentomes. Again, this shows a degree of 
uncertainty in this result of ±25%.  However, using the value of 1.9 dB.cm-1 for the attenuation of 
skin, fat and rectus and a value of 0.8 dB.cm-1 for the attenuation of uterus and placental tissue, 
the following equation can be used to estimate energy losses in transdermal exposures: 
Trans-dermal energy losses = 0.8(target depth – 0.9) + (1.9 x 0.9) 
 
 
